<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><style scope="figure-callout">figure-callout:not([filenames=""]) a.figure-callout {
  cursor: zoom-in;
  text-decoration: underline;
  text-decoration-color: #ddd;
}</style><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><style scope="image-carousel">image-carousel {
  display: block;
}

.thumbnails.image-carousel {
  display: block;
        background-color: transparent;
        padding: 7px;
        white-space: nowrap;
        overflow: auto;
        font-size: 0;
}

.thumbnails.image-carousel img.image-carousel {
  margin-right: 7px;
        cursor: zoom-in;
}

.thumbnails.image-carousel img[selected].image-carousel {
  outline: solid 3px #4285f4;
}

.thumbnails.image-carousel img.image-carousel:last-of-type {
  margin-right: 0;
}</style><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: ""
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>RU2725292C2 - Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/RU2725292C2/en">
    <meta name="description" content="
     FIELD: medicine.SUBSTANCE: invention can be used for treating Trop-2-positive cancer in a patient. That is ensured by administering an antibody-drug conjugate (ADC) to a human patient with Trop-2-positive cancer. Patient has relapsed after treatment with a control point inhibitor or refractory treatment to a control point inhibitor. Said ADC contains SN-38 conjugated with linker fragment attached to antibody to Trop-2 or its antigen-binding fragment. Antibody is the hRS7 antibody. Said linker is CL2A. ADC has structure MAb-CL2A-SN-38.EFFECT: invention provides treating the patients with Trop-2-positive cancer resistant to the control point inhibitors treatment.21 cl, 11 tbl, 5 dwg, 18 ex 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point 
       ">
    <meta name="DC.date" content="2017-04-18" scheme="dateSubmitted">
    <meta name="DC.description" content="
     FIELD: medicine.SUBSTANCE: invention can be used for treating Trop-2-positive cancer in a patient. That is ensured by administering an antibody-drug conjugate (ADC) to a human patient with Trop-2-positive cancer. Patient has relapsed after treatment with a control point inhibitor or refractory treatment to a control point inhibitor. Said ADC contains SN-38 conjugated with linker fragment attached to antibody to Trop-2 or its antigen-binding fragment. Antibody is the hRS7 antibody. Said linker is CL2A. ADC has structure MAb-CL2A-SN-38.EFFECT: invention provides treating the patients with Trop-2-positive cancer resistant to the control point inhibitors treatment.21 cl, 11 tbl, 5 dwg, 18 ex 
   
   ">
    <meta name="citation_patent_application_number" content="RU:2018139610A">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/53/a4/61/23e08d6e2363b8/RU2725292C2.pdf">
    <meta name="citation_patent_number" content="RU:2725292:C2">
    <meta name="DC.date" content="2020-06-30" scheme="issue">
    <meta name="DC.contributor" content=" . " scheme="inventor">
    <meta name="DC.contributor" content=" . " scheme="inventor">
    <meta name="DC.contributor" content=", ." scheme="assignee">
    <meta name="DC.relation" content="US:20150132217:A1" scheme="references">
    <meta name="DC.relation" content="US:20150366988:A1" scheme="references">
    <meta name="citation_reference" content="BARDIA A. et al., Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552), DOI: 10.1158/1538-7445.SABCS14-P5-19-27" scheme="references">
    <meta name="citation_reference" content="BARDIA A. et al., Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552), DOI: 10.1158/1538-7445.SABCS14-P5-19-27. GOLDENBERG D. M. et al., Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC), Oncotarget, 2015,Vol. 6, No. 26, P. 22496-22512." scheme="references">
    <meta name="citation_reference" content="GOLDENBERG D. M. et al., Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC), Oncotarget, 2015,Vol. 6, No. 26, P. 22496-22512." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point 
       </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result" hidden="">translated from </div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA405531869" lang="EN" source="national office" load-source="docdb" class="style-scope patent-text">
    <div class="abstract style-scope patent-text">FIELD: medicine.SUBSTANCE: invention can be used for treating Trop-2-positive cancer in a patient. That is ensured by administering an antibody-drug conjugate (ADC) to a human patient with Trop-2-positive cancer. Patient has relapsed after treatment with a control point inhibitor or refractory treatment to a control point inhibitor. Said ADC contains SN-38 conjugated with linker fragment attached to antibody to Trop-2 or its antigen-binding fragment. Antibody is the hRS7 antibody. Said linker is CL2A. ADC has structure MAb-CL2A-SN-38.EFFECT: invention provides treating the patients with Trop-2-positive cancer resistant to the control point inhibitors treatment.21 cl, 11 tbl, 5 dwg, 18 ex</div>
  </abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              
                <section id="thumbnails" class="style-scope patent-result">
                  <h3 class="style-scope patent-result">Images (<span class="style-scope patent-result">13</span>)</h3>
                  <image-carousel id="figures" class="style-scope patent-result">
    
    
      <div class="thumbnails style-scope image-carousel">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/56/d4/50/1f3e0beb1780b5/00000044.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/81/64/ac/a8b3e23dbfb8fe/00000045.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/bc/a9/97/59ab07be05be4c/00000046.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/9a/0e/50/80185a1db42252/00000047.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/9c/16/47/9d4c3ab665508d/00000048.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/3a/2b/62/d8a9901edb089a/00000049.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/45/d1/a3/1557ca5ce7d367/00000050.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/da/3b/7c/76407da958df30/00000051.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/dc/16/1e/d5e32eb7384b84/00000052.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/a8/f1/97/f293f728c37fb2/00000053.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/34/17/1f/1a732b0b3d356d/00000054.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/96/81/e4/ec32bdb8f9d1eb/00000055.png">
        
          <img class="style-scope image-carousel" src="https://patentimages.storage.googleapis.com/ef/52/83/0c120673d1854e/00000056.png">
        <template is="dom-repeat" as="img" class="style-scope image-carousel"></template>
      </div>
    <template is="dom-if" class="style-scope image-carousel"></template>
  </image-carousel>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/30"><a id="link" href="#" class="style-scope state-modifier">C07K16/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/335"><a id="link" href="#" class="style-scope state-modifier">A61K31/335</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/337"><a id="link" href="#" class="style-scope state-modifier">A61K31/337</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K45/00"><a id="link" href="#" class="style-scope state-modifier">A61K45/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing active ingredients not provided for in groups A61K31/00&nbsp;-&nbsp;A61K41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K45/06"><a id="link" href="#" class="style-scope state-modifier">A61K45/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6801"><a id="link" href="#" class="style-scope state-modifier">A61K47/6801</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6855"><a id="link" href="#" class="style-scope state-modifier">A61K47/6855</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6857"><a id="link" href="#" class="style-scope state-modifier">A61K47/6857</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6859"><a id="link" href="#" class="style-scope state-modifier">A61K47/6859</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6863"><a id="link" href="#" class="style-scope state-modifier">A61K47/6863</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6865"><a id="link" href="#" class="style-scope state-modifier">A61K47/6865</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6867"><a id="link" href="#" class="style-scope state-modifier">A61K47/6867</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6869"><a id="link" href="#" class="style-scope state-modifier">A61K47/6869</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/04"><a id="link" href="#" class="style-scope state-modifier">A61P1/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/18"><a id="link" href="#" class="style-scope state-modifier">A61P1/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/00"><a id="link" href="#" class="style-scope state-modifier">A61P13/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/08"><a id="link" href="#" class="style-scope state-modifier">A61P13/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system of the prostate</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/00"><a id="link" href="#" class="style-scope state-modifier">A61P13/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/10"><a id="link" href="#" class="style-scope state-modifier">A61P13/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system of the bladder</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/00"><a id="link" href="#" class="style-scope state-modifier">A61P13/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P13/12"><a id="link" href="#" class="style-scope state-modifier">A61P13/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the urinary system of the kidneys</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P15/00"><a id="link" href="#" class="style-scope state-modifier">A61P15/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for genital or sexual disorders; Contraceptives</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/04"><a id="link" href="#" class="style-scope state-modifier">A61P35/04</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents specific for metastasis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 22 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">RU2725292C2</h2>
                  <p class="tagline style-scope patent-result">Russia</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Patent for an invention or claims of a patent for an invention (second level)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/53/a4/61/23e08d6e2363b8/RU2725292C2.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;cancer&quot;,&quot;antibody&quot;,&quot;antibodies&quot;,&quot;trop&quot;,&quot;adc&quot;]" data-before="20160427"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/RU2725292C2"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2725292C2/ru"><a id="link" href="#" class="style-scope state-modifier">Russian</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor=" . "><a id="link" href="#" class="style-scope state-modifier"> . </a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor=" . "><a id="link" href="#" class="style-scope state-modifier"> . </a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2017</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2017257254B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2017257254A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN109310385A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201780038812.7A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2725292C2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">RU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RU2018139610A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2017189279A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US2017/028137</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US10266605B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US15/490,535</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP7379795B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2018556311A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3016917A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3016917A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3448260A4/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP17790120.4A</div>
                <div class="style-scope application-timeline">Filing date: 2017-04-18</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US11192955B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US16/279,520</div>
                <div class="style-scope application-timeline">Filing date: 2019-02-19</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2021</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20210395385A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/338,327</div>
                <div class="style-scope application-timeline">Filing date: 2021-06-03</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022046678A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2021212229A</div>
                <div class="style-scope application-timeline">Filing date: 2021-12-27</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application RU2018139610A events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2017-04-18</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee=", ."><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by , .</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2020-05-27</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2018139610A3/ru"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of RU2018139610A3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2020-05-27</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2018139610A/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of RU2018139610A</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2020-06-30</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2020-06-30</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2725292C2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of RU2725292C2</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (125)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#nplCitations" class="style-scope patent-result">Non-patent citations (3)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (26)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=RU&amp;NR=2725292C2&amp;KC=C2&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/RU/2725292/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/RU2725292C2">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Russian</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES269381420" lang="EN" load-source="google" class="style-scope patent-text">
  <p num="1" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>RELATED APPLICATIONS</span>
  </p>
  <p num="2" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[01]      119()  35          62/328289,  4  2016 .,         .</span>[01] This application claims priority pursuant to 119 (e) of <figure-callout id="35" label="Section" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Section</a></figure-callout> 35 of the United States Code of Provisional Application for US Patent No. 62/328289, filed April 4, 2016, the entire contents of which are incorporated herein by reference.</span>
  </p>
  <p num="3" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>LIST OF SEQUENCES</span>
  </p>
  <p num="4" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[02]     ,    ASCII  EFS-Web        .     ASCII,  5  2017 .,   IMM366WO2_SL.txt.   13 002 .</span>[02] This application includes a sequence listing filed in ASCII format via EFS-Web and incorporated herein by reference in its entirety. The specified ASCII copy created on April 5, 2017 is named IMM366WO2_SL.txt. and the size is 13,002 bytes.</span>
  </p>
  <p num="5" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>FIELD OF TECHNOLOGY</span>
  </p>
  <p num="6" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[03]            (ADC),    Trop-2    ,  ,   SN-38,           -.             ,    .       ADC     /    ,    .  ,        SN-38 ,    ,     ,            ,      ,    -   ,   , , , , , ,   .      ADC   -  Trop-2-     3  18 /,    4  12 /,    8  10 /.  ,       (ADC) -Trop-2-SN38    Trop-2-    ,                 ,     ,       ,   ,  ,      .</span>[03] The present invention relates to the therapeutic use of antibody-drug conjugates (ADCs) containing anti-Trop-2 antibodies or antigen-binding fragments thereof, and camptothecins, such as SN-38, with improved ability to target various cancer cells in subjects people. In preferred embodiments, said antibodies and therapeutic fragments are linked by a cleavable intracellular bond, which increases therapeutic efficacy. In more preferred embodiments, said ADCs are administered at specific dosages and / or according to specific administration schemes that optimize the therapeutic effect. Unexpectedly, optimized dosages and regimens for administering SN-38 conjugated antibodies, such as gamitecan sacituzumab, demonstrate unexpected higher efficacy, which could not be predicted from studies in animal models, allowing for the effective treatment of cancer-resistant antibodies - control point inhibitors such as atezolizumab, pembrolizumab, nivolumab, pidilizumab, durvalumab, atesolizumab, ipilimumab or trelimumumab. In particular embodiments, said ADC can be administered to a human subject with Trop-2 positive cancer in a dosage of 3 to 18 mg / kg, more preferably 4 to 12 mg / kg, most preferably 8 to 10 mg / kg. Surprisingly, these anti-Trop-2-SN38 drug-antibody conjugates (ADCs) are effective in treating Trop-2-positive cancers in patients who have recurred after treatment with a checkpoint inhibitor or who have demonstrated resistance to therapy with a checkpoint inhibitor, such as cancer of the pancreas, breast cancer with a triple negative phenotype, small cell lung cancer, endometrial cancer, urothelial cancer and non-small cell lung cancer.</span>
  </p>
  <p num="7" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>BACKGROUND</span>
  </p>
  <p num="8" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[04]          ()        (MAb)         .     MAb    ,          ,        ,      .         ,    ,     ,    MAb,  ,    (Sharkey, Goldenberg, CA Cancer J Clin. 2006 Jul-Aug; 56(4):226-243) , ,         (Dadachova, Casadevall, Q J Nucl Med Mol Imaging 2006; 50(3):193-204).</span>[04] Over the years, scientists in the field of specific targeted drug therapy have worked on the use of monoclonal antibodies (MAb) for the specific delivery of toxic agents to human cancers. Conjugates of tumor-associated MAb and suitable toxic agents have been developed, however, they have had varying success in the treatment of cancer in humans, and have hardly been used in other diseases such as infectious and autoimmune diseases. The toxic agent is most often a chemotherapeutic drug, although particles emitting radionuclides, or bacterial or plant toxins, have also been conjugated to MAb, in particular for cancer therapy (Sharkey, Goldenberg, CA Cancer J Clin. 2006 Jul-Aug; 56 (4 ): 226-243) and, recently, with radio immunoconjugates for preclinical treatment of certain infectious diseases (Dadachova, Casadevall, QJ Nucl Med Mol Imaging 2006; 50 (3): 193-204).</span>
  </p>
  <p num="9" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[05]    MAb       ,  ()        ; (b)        MAb         ,    ,      MAb; ()  MAb               ,   ,  MAb     , ,  ,          ;  (d)  MAb                 MAb,  ,   -  .</span>[05] The advantages of using MAb conjugates with a chemotherapeutic drug are that (a) the structure of the indicated chemotherapeutic drug itself is well defined; (b) said chemotherapeutic drug is coupled to a MAb protein using very well defined chemical conjugate formation agents, often at specific sites remote from the antigen binding regions of said MAb; (c) MAb conjugates with chemotherapeutic drug can be obtained with greater reproducibility and they usually have less immunogenicity than chemical conjugates containing MAb and bacterial or plant toxins, and thus are more suitable for the commercial development and approval of regulatory authorities; and (d) MAb chemotherapeutic drug conjugates have orders of magnitude lower systemic toxicity compared to radionuclide conjugates with MAb, in particular with respect to radiation-sensitive bone marrow.</span>
  </p>
  <p num="10" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[06]  ()         .  (  -11)      ,        (Iyer, Ratain, Cancer Chemother. Phamacol. 42: S31-S43 (1998)).       I,    I   (Liu, et al.,  : The Camptothecins: Unfolding Their Anticancer Potential, Liehr J.G., Giovanella, B.C., Verschraegen (eds), NY Acad Sci., NY 922:1-10 (2000)).        .           . -,       (..  )     . ,          .            ,      ;     ,   SN-38,     -11,    -10- ,     10--,      -10    -20-. -,      5-         . ,     ,       7  ,     .     ,   ,     ,  ,    8  . -,       /,    ,     .</span>[06] Camptothecin (CPT) and its derivatives are a class of potent antitumor agents. Irinotecan (also called CPT-11) and topotecan are analogs of CPT approved as anti-cancer therapies (Iyer, Ratain, Cancer Chemother. Phamacol. 42: S31-S43 (1998)). CPTs act by inhibiting the enzyme topoisomerase I, stabilizing the complex of topoisomerase I with DNA (Liu, et al., Source: The Camptothecins: Unfolding Their Anticancer Potential, Liehr JG, Giovanella, BC, Verschraegen (eds), NY Acad Sci., NY 922: 1-10 (2000)). When receiving conjugates with CPT there are specific problems. One of the problems is the insolubility of most derivatives of CPT in aqueous buffers. Secondly, in the structural modification of CPT for conjugation (i.e., the formation of conjugates) with macromolecules, specific difficulties arise. For example, CPT itself contains only a tertiary hydroxyl group in ring E. The specified hydroxyl functional group in the case of CPT should be linked to a linker suitable for subsequent conjugation with a protein; and in powerful derivatives of CPT, such as SN-38, the active metabolite of the chemotherapeutic agent CPT-11, and other C-10-hydroxyl derivatives, such as topotecan and 10-hydroxy-CPT, the presence of phenolic hydroxyl at position C-10 complicates the necessary derivatization of C-20-hydroxyl. Thirdly, the lability under physiological conditions of the fragment of the 5-lactone of the E ring of camptothecin leads to a significant decrease in antitumor power. Accordingly, the conjugation protocol is carried out so that the pH value is 7 or less in order to avoid the opening of the lactone ring. However, the conjugation of a bifunctional CPT containing an amino reactive group, such as an active ester, typically requires a pH of 8 or more. Fourth, it is preferable to incorporate a cleavable intracellular fragment into a linker / spacer connecting CPT to antibodies, or other binding fragments.</span>
  </p>
  <p num="11" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[07]             ,    -Trop-2-SN-38 (,  ).           ,     ,      Trop-2- ,     -   ,     -   .</span>[07] There is a need for more effective methods for the preparation and administration of conjugates of antibodies with CPT, such as conjugates of anti-Trop-2-SN-38 (eg, sacituzumab govitecan). In a preferred embodiment, such methods include optimized dosing and administration regimens that maximize efficacy and minimize toxicity, for use in patients with Trop-2-positive cancer recurring after treatment with antibody-checkpoint inhibitors or resistant to antibody-checkpoint inhibitors.</span>
  </p>
  <p num="12" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>SUMMARY OF THE INVENTION</span>
  </p>
  <p num="13" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[08]              ,   SN-38,      .         ,          ADC -.       SN-38,       Trop-2 (,  ).        ,        ,    Trop-2+ ,     -   ,      -   .</span>[08] As used herein, the abbreviation "CPT" may refer to camptothecin or any of its derivatives, such as SN-38, unless expressly indicated otherwise. The present invention satisfies an existing need in the art by providing improved methods and compositions for the preparation and administration of an ADC CPT antibody. In a preferred embodiment, camptothecin is SN-38, and the antibody is an anti-Trop-2 antibody (for example, sacituzumab govitecan). The disclosed methods and compositions are suitable for treating diseases that are refractory or less responsive to other forms of therapy, such as Trop-2 + cancers that are resistant to treatment with antibodies - checkpoint inhibitors, or that recur after treatment with antibodies - checkpoint inhibitors.</span>
  </p>
  <p num="14" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[09]       ADC    ,  ,     ,        .       ,  -IgG1, IgG2, IgG3  IgG4 ,   -       IgG1 .           -,   -,   (     (CDR) ),    ,    ,    IgG4 ( ),    : Van der Neut Kolfschoten et al., Science 2007; 317:1554-1557.            ()  ()  ,      ,    ,          ADC -.      ,    G1m1 (nG1m1),   G1m3, G1m3,1, G1m3,2  G1m3,1,2.        ,    nG1m1, G1m3, nG1m1,2  Km3.</span>[09] In a preferred embodiment, the antibody fragment in the ADC is a monoclonal antibody, an antibody fragment, a bispecific or other multivalent antibody, or another antibody-based molecule or compound. The specified antibody may belong to various isotypes, preferably human IgG1, IgG2, IgG3 or IgG4, more preferably it contains sequences of hinge and constant regions of human IgG1. The indicated antibody or fragment thereof may be a human-mouse chimeric antibody, a human primate chimeric antibody, a humanized antibody (human framework and mouse hypervariable regions (CDRs)), or a fully human antibody, as well as variants of the above, such as IgG4 semi-antibodies (called "Uniters"), as described in the source: Van der Neut Kolfschoten et al., Science 2007; 317: 1554-1557. In a more preferred embodiment, the indicated antibody or fragment thereof can be constructed (o) or selected (o) so as to contain human constant region sequences belonging to specific allotypes, which can lead to reduced immunogenicity when the specified ADC is administered to a human subject. Preferred allotypes for administration include a non-allotype G1m1 (nG1m1) allotype, such as G1m3, G1m3,1, G1m3,2 or G1m3,1,2. In a more preferred embodiment, the allotype is selected from the group consisting of allotypes nG1m1, G1m3, nG1m1,2 and Km3.</span>
  </p>
  <p num="15" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[010]    Trop-2    RS7 (hRS7),   CDR   CDR1 (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2);  CDR3 (QQHYITPLT, SEQ ID NO: 3),   CDR   CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5)  CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>[010] An example of an anti-Trop-2 antibody is a humanized RS7 antibody (hRS7) comprising CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2); and CDR3 (QQHYITPLT, SEQ ID NO: 3), and CDR1 sequences of the heavy chain CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>
  </p>
  <p num="16" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[011]          ()     ;        SN-38.        ,    (,  III, ), ,  (,  (DOX), ,  (-DOX), - (-DOX), 2- (2-PDOX)  2-PDOX    (-2-PDOX); ., , : Priebe W (ed.), ACS Symposium Series 574, .    (American Chemical Society, Washington D.C., 1995 (332pp))  Nagy et al., Proc. Natl. Acad. Sci. USA 93:2464-2469, 1996),  ,     (DeBoer et al., Journal of Antibiotics 23:442-447, 1970; Neckers et al., Invest. New Drugs 17:361-373, 1999);  ..         ()       ; ,       1   5;      6    ,       6 -   12  .</span>[011] According to a preferred embodiment, the chemotherapeutic fragment is selected from camptothecin (CPT) and its analogs and derivatives; in a more preferred embodiment, it is SN-38. However, other chemotherapeutic fragments can be used, which include taxanes (e.g., baccatin III, taxol), epothilones, anthracyclines (e.g., doxorubicin (DOX), epirubicin, morpholinodoxorubicin (morpholino-DOX), cyanomorpholino-doxorubicin (cyanomorphine, DO) 2-pyrrolinodoxorubicin (2-PDOX) or 2-PDOX in the form of a prodrug (pro-2-PDOX); see, for example, sources: Priebe W (ed.), ACS Symposium Series 574, publ. American Chemical Society (American Chemical Society, Washington DC, 1995 (332pp)) and Nagy et al., Proc. Natl. Acad. Sci. USA 93: 2464-2469, 1996), benzoquinoid ansamycins, for example geldanamycin (DeBoer et al., Journal of Antibiotics 23: 442-447, 1970; Neckers et al., Invest. New Drugs 17: 361-373, 1999); etc. In a preferred embodiment, said antibody or fragment thereof is coupled (o) to at least one chemotherapeutic fragment; preferably with chemotherapeutic fragments in an amount of from 1 to about 5; in a more preferred embodiment with 6 or more chemotherapeutic fragments, in a more preferred embodiment with about 6 to about 12 chemotherapeutic fragments.</span>
  </p>
  <p num="17" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[012]             ,  Trop-2 ,   ,    , ,    ,  , , ,     ,  ,  , , , ,    .</span>[012] Various implementation options may include the use of the claimed methods and compositions for the treatment of cancer expressing human Trop-2, including, but not limited to, carcinomas, such as carcinomas of the esophagus, pancreas, lung, stomach, colon and rectum intestines, bladder, breast, ovaries, uterus, kidney, urothelium and prostate.</span>
  </p>
  <p num="18" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[013]    ,    ,          ,  , ,   , , ,   ..                 ,        ,       .                   .      ADC      , -  ,   ,  PI3K,  PARP   ,   .</span>[013] In some embodiments, including the treatment of cancer, drug conjugates may be used in combination with surgery, radiation therapy, chemotherapy, immunotherapy with naked antibodies, radioimmunotherapy, immunomodulators, vaccines, and the like. These types of combination therapy may allow the introduction of lower doses of each of the therapeutic agents in such combinations, with a reduction in certain serious side effects, and a potential reduction in the required duration of treatment. In the absence of overlapping toxicity or with minimal overlapping toxicity, full doses of each therapeutic agent may also be administered. In alternative embodiments, said ADCs may be administered in combination with interferon, a checkpoint antibody inhibitor, a Bruton tyrosine kinase inhibitor, a PI3K inhibitor, a PARP inhibitor, or a microtubule inhibitor, as discussed below.</span>
  </p>
  <p num="19" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[014]    ADC   /   3 /  18 /,    ,     ,      .       ,        , ,     ,      ,       ,     ,       , ,     ,       , ,     ,       , , ,     ,       ,          .        , ,    2,    4,    6,    8,    10,    12,    14     16 .      4 /, 5 /, 6 /, 7 /, 8 /, 9 /, 10 /, 11 /, 12 /, 13 /, 14 /, 15 /, 16 /, 17 /  18 /.    4, 6, 8, 9, 10,  12 /.</span>[014] Preferred optimal dosage of ADC may include an iv dosage of 3 mg / kg to 18 mg / kg, preferably administered either weekly, or twice a week, or once every two weeks. An optimal dosing regimen may include treatment cycles that include two consecutive weeks of therapy followed by one, two, three or four weeks of rest, or alternating weeks of therapy and rest, or one week of therapy with subsequent two, three or four weeks of rest, or three weeks of therapy followed by one, two, three or four weeks of rest, or four weeks of therapy, followed by one, two, three or four weeks of rest, or five weeks of therapy, followed by one, two, three, four or five weeks of rest, or once two weeks, once every three weeks or once a month. Treatment may be extended for any number of cycles, preferably at least 2, at least 4, at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 cycles. Examples of suitable dosages may include 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg and 18 mg / kg. Dosages of 4, 6, 8, 9, 10, or 12 mg / kg are preferred.</span>
  </p>
  <p num="20" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[015]         ADC  ADC, ,   (IMMU-132)      ADC    ,    ,     (, 1, 2  3 ,  ). ,       1,5  4 / ADC,    1 ,  3      2 ,         ,   .     /      8 /.   ADC   /  /   -      .  ,      -  /    8-10 / (    ADC  1  8   21- ,  1-  ),   /          ,     .  ()         /   Trop-2-  .</span>[015] According to some alternative embodiments, for subcutaneous administration of ADC, dosages of ADC, for example, govitecan sacituzumab (IMMU-132), may be limited by the possibility of ADC concentration without precipitation or aggregation, as well as by the volume of administration that can be administered subcutaneously (preferably 1, 2 or 3 ml or less). Therefore, with subcutaneous administration, 1.5 to 4 mg / kg of ADC can be administered daily for 1 week, or 3 times a week for 2 weeks, or twice a week for two weeks, followed by rest. When using multiple sites of SC injection, dosages of up to 8 mg / kg can be used. Maintenance doses of ADC may be given iv or sc every two to three weeks or monthly after induction. Alternatively, induction can be carried out in the form of two to four cycles of iv administration at a dose of 8-10 mg / kg (each cycle includes the administration of ADC on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of two 21-day cycles separated by a 1-week rest period), s subsequent s / c administration as an active dosage one or more times a week, or as maintenance therapy. Dosing (administration) can be adjusted based on an intermediate scan of the tumor and / or analysis of circulating Trop-2-positive tumor cells.</span>
  </p>
  <p num="21" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[016]        ,      ADC    ,   ,   ,      ,          (,  ),    /           .      ,        4-8 .     ,    ,         -,            .  ,       ,            ,        .</span>[016] A person of ordinary skill in the art will understand that when choosing the optimal dosage of ADC, various factors can be considered, such as age, general health, the functioning of a specific organ or body weight, as well as the effects of prior therapy on specific organ systems (for example, bone marrow), and that the dosage and / or frequency of administration can be increased or decreased during the course of therapy. If necessary, dosing can be repeated, and the reduction in tumor size is observed after 4-8 doses. The optimized dosages and administration regimens described herein unexpectedly demonstrate superior efficacy and reduced toxicity in human subjects, which could not be predicted from studies in animal models. Surprisingly, this superior efficacy allows the treatment of tumors that were previously considered resistant to one or more standard types of anticancer therapy, including control point inhibitor therapy.</span>
  </p>
  <p num="22" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[017]       / -,  ,        .       ,    ( ), 19-9, ,  15.3  ,  .  /             /    .</span>[017] The claimed methods may include the use of CT and / or PET-CT, or MRI, to measure the response of tumors at regular intervals. Can also monitor the levels of tumor markers, such as CEA (carcinoembryonic antigen), CA19-9, AFP, CA 15.3 or PSA, in the blood. Dosages and / or regimens can be adjusted if necessary in accordance with the results of imaging and / or marker levels in the blood.</span>
  </p>
  <p num="23" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[018]                 ,    ,            ,   .           ,     ,  SN-38,   ,    .                 .         ,       .                15%  , ,  20%  , ,  30%  ,   -  40%   (     ).        ,          , ,     ,            .        ,    ,  / - .     ,         ADC, ,    .</span>[018] Unexpected for the claimed compositions and methods, the result is the unanticipated tolerance of high doses of the conjugate of the antibody to the drug, even with repeated infusions accompanied by observed toxicity of only relatively low degrees in the form of nausea and vomiting, or controlled neutropenia. An additional unexpected result is the lack of accumulation of the conjugate of the antibody with the drug, unlike other products containing SN-38, conjugated with albumin, PEG or other carriers. The lack of accumulation is associated with improved tolerance and the absence of serious toxicity even after repeated administration or increase in dose. These unexpected results allow you to optimize the dosage and delivery schemes, providing unexpectedly high efficiency and low toxicity. The claimed methods provide a reduction in the size of solid tumors in individuals with previously demonstrated cancer resistance by 15% or more, preferably 20% or more, preferably 30% or more, more preferably 40% or more (estimated based on the maximum diameter). One of ordinary skill in the art will understand that tumor size can be measured using a variety of techniques, for example, by measuring the total volume of tumors, the maximum size of the tumors in any dimension, or a combination of sizes in several dimensions. This can be done by standard radiological procedures, such as computed tomography, ultrasonography and / or positron emission tomography. Measurement methods are less important than the observed trend in tumor size reduction in the treatment of ADC, preferably leading to tumor elimination.</span>
  </p>
  <p num="24" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[019]  ADC       ,      ADC          .   Cmax    ADC      , ,   .       ,    HICKMAN, BROVIAC  PORT-A-CATH (., , Skolnik et al., Ther Drug Monit 32:741-48, 2010),         .           ,         .         0,1  3,0 /  .      ADC            2-5 ,   - 2-3 .</span>[019] Although ADC may be administered as a periodic bolus injection, in alternative embodiments, said ADC may be administered by continuous infusion of antibody-drug conjugates. To increase Cmax and prolong the ADF in the blood, a continuous infusion can be carried out, for example, through a permanent catheter. Such devices are known in the art, such as HICKMAN, BROVIAC or PORT-A-CATH catheters (see, for example, Skolnik et al., Ther Drug Monit 32: 741-48, 2010), and can be used any such well-known permanent catheter. Also various sediment for continuous infusion are known in the art, and any such known infusion pump can be used. The dosage range for continuous infusion may be from 0.1 to 3.0 mg / kg per day. More preferably, said ADCs may be administered by intravenous infusion over relatively short periods of 2-5 hours, more preferably 2-3 hours.</span>
  </p>
  <p num="25" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[020]      ADC        ,  ()    . ,   Trop-2     ,      , ,    SN-38.  ,               .  ADC                    . ADC      /          , ,   -   .</span>[020] According to specific preferred embodiments, ADCs and dosing regimens may be effective in patients who are resistant to standard therapies. For example, an anti-Trop-2 antibody, sacituzumab govitecan, may be administered to a patient who has not responded to prior irinotecan therapy, the agent from which SN-38 originates. Surprisingly, in a patient resistant to irinotecan, a partial or even complete response to sacituzumab govitecan may be observed. The ability of ADC to specifically target tumor tissue can overcome tumor resistance through improved targeting and improved delivery of a therapeutic agent. ADCs may exhibit similar improved efficacy and / or reduced toxicity compared to alternative standard therapies, for example, treatment with control point antibody inhibitors.</span>
  </p>
  <p num="26" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[021]              ,      ,         ,   HER- (HER+), - (ER+), -   ,       (),      ,     ,     ,     ,      ,           .</span>[021] A specific preferred subject may be a patient with metastatic colon and rectal cancer, a patient with metastatic pancreatic cancer, a patient with triple negative phenotype cancer, a patient with HER-positive (HER +), estrogen-positive (ER +) , progesterone-positive breast cancer, a patient with metastatic non-small cell lung cancer (NSCLC), a patient with metastatic small cell lung cancer, a patient with metastatic gastric cancer, a patient with metastatic kidney cancer, a patient with metastatic urothelial cancer, a patient with metastatic urinary cancer, a patient with metastatic ovarian cancer or a patient with metastatic uterine cancer.</span>
  </p>
  <p num="27" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>BRIEF DESCRIPTION OF THE DRAWINGS</span>
  </p>
  <p num="28" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[022] . 1.   -          ,   10 /  .</span>[022] FIG. 1. Overview of CT scan results for a patient with metastatic TNBC resistant to control point inhibitors treated with 10 mg / kg of sacituzumab govitecan.</span>
  </p>
  <p num="29" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[023] . 2.  -          ,    ( )      ( ).   .</span>[023] FIG. 2. Basic CT images for a patient with metastatic TNRMC resistant to control point inhibitors; axial images (upper row) and sagittal images (lower row) are shown. Tumors are indicated by arrows.</span>
  </p>
  <p num="30" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[024] . 3.   -     1  2,     10 /   (IMMU-132).    ,         .      ,  IMMU-132.</span>[024] FIG. 3. Comparison of CT scan results for <figure-callout id="1" label="target lesions" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="2" label="target lesions" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">target lesions</a></figure-callout></a></figure-callout> 1 and 2, before and after treatment with 10 mg / kg of govitecan sacituzumab (IMMU-132). The initial image is shown above, the second assessment of the response after therapy with satsituzumab govitekan is presented below. There was a pronounced reduction in tumor size induced by IMMU-132.</span>
  </p>
  <p num="31" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[025] . 4.   -     3,     10 /   (IMMU-132).    ,          .      ,  IMMU-132.</span>[025] FIG. 4. Comparison of CT scan results for the <figure-callout id="3" label="target lesion" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">target lesion</a></figure-callout> 3, before and after treatment with 10 mg / kg of govitecan sacituzumab (IMMU-132). The initial image is shown above, and the second assessment of the response after therapy with satsituzumab govitekan shown below. There was a pronounced reduction in tumor size induced by IMMU-132.</span>
  </p>
  <p num="32" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[026] . 5.            ,   IMMU-132.</span>[026] FIG. 5. Generalized results for patients with resistant to treatment with a reference point inhibitor tumors treated with IMMU-132.</span>
  </p>
  <p num="33" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>DETAILED DESCRIPTION OF THE INVENTION</span>
  </p>
  <p num="34" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Definitions</span>
  </p>
  <p num="35" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[027]      ,          . ,       ,        .</span>[027] The description below uses a number of terms, and to facilitate understanding of the claimed subject matter, their definitions are given. Terms not expressly defined herein are used in accordance with their usual accepted meaning.</span>
  </p>
  <p num="36" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[028]    ,        .</span>[028] Unless otherwise indicated, the terms in the singular mean "one or more."</span>
  </p>
  <p num="37" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[029]            (10%)  . ,  100      90  110.</span>[029] The term approximately herein means plus or minus ten percent (10%) of the value. For example, about 100 refers to any number from 90 to 110.</span>
  </p>
  <p num="38" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[030]        (..             )   (,  IgG)     ,    .           ,       .   ,   , IgG1, IgG2, IgG3, IgG4 (  IgG4),    IgA.      MAb      ,  ,     .</span>[030] An antibody herein refers to a full-sized (ie naturally-occurring or formed during normal recombination of fragments of immunoglobulin genes) immunoglobulin molecule (eg, IgG antibody) or an antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody or antibody fragment may be conjugated or otherwise derivatized, which is within the scope of the claimed subject matter. Such antibodies include, but are not limited to, IgG1, IgG2, IgG3, IgG4 (and IgG4 subforms), as well as IgA isotypes. Hereinafter, the abbreviation "MAb" may be used interchangeably with the terms antibody, antibody fragment, monoclonal antibody or multispecific antibody.</span>
  </p>
  <p num="39" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[031]      ,   (ab')<sub class="style-scope patent-text">2</sub>, F(ab)<sub class="style-scope patent-text">2</sub>, Fab', Fab, Fv, scFv ( Fv),   (DAB  VHH)  ..,     IgG4,   (van der Neut Kolfschoten et al. (Science 2007; 317(14 Sept): 1554-1557).   ,          ,    .          ,             . ,     ,    ,    Fv,        ,     ,           ( scFv).           /   .</span>[031] An antibody fragment is a portion of an antibody, such as P (ab ') <sub class="style-scope patent-text">2</sub> , F (ab) <sub class="style-scope patent-text">2</sub> , Fab', Fab, Fv, scFv (single chain Fv), single domain antibodies (DAB or VHH), and the like. , including the IgG4 half-molecule mentioned above (van der Neut Kolfschoten et al. (Science 2007; 317 (14 Sept): 1554-1557). Regardless of the structure, an antibody fragment suitable for use binds to the same antigen that recognizes the intact antibody. The term "antibody fragment" also includes synthetic or genetically engineered proteins that act as an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of variable regions, such as "Fv" fragments consisting from the variable regions of the heavy and light chains, and recombinant single-chain polypeptide molecules in which the light and heavy variable regions are connected by a peptide linker (scFv proteins). These fragments can be sk constructed in different ways to produce multivalent and / or multispecific binding forms.</span>
  </p>
  <p num="40" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[032]       ,     .      /  , ,   Fe- ,     ()   (  ).        ,   , ,  ,  ,     ,    .       ,      ,    ,     ,    .            .                   .</span>[032] A naked antibody is usually a whole antibody that is not conjugated to a therapeutic agent. A naked antibody can exhibit therapeutic and / or cytotoxic effects, for example, due to Fe-dependent functions, such as complement fixation (SCC) and ADCC (antibody-dependent cellular cytotoxicity). However, other mechanisms may also provide a therapeutic effect, such as apoptosis, anti-angiogenesis, anti-metastatic activity, anti-adhesive activity, inhibition of heterotypic or homotypic adhesion, and signaling pathway interference. Naked antibodies include polyclonal and monoclonal antibodies, naturally occurring or recombinant antibodies, such as chimeric antibodies, humanized antibodies or human antibodies, as well as fragments thereof. In some cases, a naked antibody may also refer to a naked fragment of an antibody. As defined herein, naked is synonymous with unconjugated and means unconnected or not conjugated to a therapeutic agent.</span>
  </p>
  <p num="41" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[033]      ,      ,     ,       (CDR) ,    , ,   ,   -   ,             .               , , ,   .</span>[033] A chimeric antibody is a recombinant protein that contains the variable domains of both the heavy and light chains of antibodies, including the complementarity determining region (CDR) of an antibody, originating from one species, preferably from a rodent antibody, more preferably from an antibody mice, while the constant domains of the indicated antibody molecules are derived from the constant domains of a human antibody. For use in veterinary medicine, the constant domains of a chimeric antibody can be derived from the constant domains of other species, for example, primate, cat or dog.</span>
  </p>
  <p num="42" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[034]      ,    CDR    ; ,  ,              ( )     .           .         ,  ,    CDR     ,   , ,          , ,    ..</span>[034] A humanized antibody is a recombinant protein in which CDR regions from an antibody of the same species; for example, mouse antibodies are transferred from the variable heavy and light chains of the indicated mouse antibody to the variable domains (frame regions) of human heavy and light chains. The constant domains of said antibody molecule are derived from the constant domains of a human antibody. In some cases, specific residues of the framework region of a humanized antibody, in particular, in contact with or located close to the CDR sequences, can be modified, for example, by replacing the residues with the corresponding residues from the original antibody of a mouse, rodent, ape, or the like.</span>
  </p>
  <p num="43" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[035]     , , ,   ,            .             ,      ,             .       ,     ,         .           : Green et al., Nature Genet. 7:13 (1994), Lonberg et al., Nature 368:856 (1994)  Taylor et al., Int. Immun. 6:579 (1994).              ,     ,        . . ,        in vitro         McCafferty et al., Nature 348:552-553 (1990).               ,      ,           .          , ,     ,     ,  ,   .  ,     -.        ,   , ,  : Johnson, Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993).       in vitro  -. .   5567610  5229275,           .</span>[035] A human antibody is an antibody obtained, for example, from transgenic mice that have been engineered to produce human antibodies in response to antigenic stimulation. In this method, elements of the loci of the human heavy and light chains are introduced into mice of lines originating from lines of embryonic stem cells in which endogenous loci of the heavy chains and light chains were targeted. These transgenic mice can synthesize human antibodies specific for different antigens and can be used to produce human antibody-secreting hybridomas. Methods for producing human antibodies using transgenic mice are described in sources: Green et al., Nature Genet. 7:13 (1994), Lonberg et al., Nature 368: 856 (1994) and Taylor et al., Int. Immun. 6: 579 (1994). A fully human antibody can also be constructed using genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art. See, for example, a description of the production of human antibodies and their fragments in vitro from the repertoires of the immunoglobulin variable domain genes of immunized donors McCafferty et al., Nature 348: 552-553 (1990). In this methodology, the genes of the variable domains of human antibodies are cloned inside the frame into the gene of either the main or small protein of the membrane of the filamentous bacteriophage, with the display in the form of functional fragments of antibodies on the surface of the phage particle. Since the filamentous particle contains a copy of the single-stranded DNA of the phage genome, selection based on the functional properties of the antibody also leads to the selection of a gene encoding an antibody exhibiting these properties. Thus, the phage mimics some of the properties of b cells. Phage display can be implemented in various formats, an overview of which is given, for example, in the source: Johnson, Chiswell, Current Opinion in Structural Biology 3: 5564-571 (1993). Human antibodies can also be produced in vitro by activated B cells. See US Pat. Nos. 5,567,610 and 5,229,275, sections of the examples of each of which are incorporated herein by reference.</span>
  </p>
  <p num="44" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[036]     ,   ,    .    ,   , ,  , ,  ,  ,  , ,  (     ), , , ,  ,    , , ,  , , -,  ,  , , , , ,    ,   .</span>[036] A therapeutic agent is an atom, molecule or compound suitable for treating a disease. Examples of therapeutic agents include, but are not limited to, antibodies, antibody fragments, immunoconjugates, drugs, cytotoxic agents, proapoptotic agents, toxins, nucleases (including DNases and RNases), hormones, immunomodulators, chelators, boron compounds, photoactive agents or dyes , radionuclides, oligonucleotides, interference RNA, siRNA, RNA interference, antiangiogenic agents, chemotherapeutic agents, cytokines, chemokines, prodrugs, protein or peptide binding enzymes, or combinations thereof.</span>
  </p>
  <p num="45" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[037]    ,   ,       ,    .      .      .   ,        ,         ,  ADC.</span>[037] An immunoconjugate is an antibody, an antigen binding fragment of an antibody, an antibody complex, or an antibody fusion protein conjugated to a therapeutic agent. Conjugation can be covalent or non-covalent. In a preferred embodiment, the conjugation is covalent. In cases where the specified therapeutic agent is a drug, the resulting immunoconjugate is a conjugate of an antibody with a drug, or ADC.</span>
  </p>
  <p num="46" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[038]              ,        ,         ,     , , ,   ..                 ,     ,    ,         ,        ,    .</span>[038] As used herein, the term antibody fusion protein means a recombinantly produced antigen binding molecule in which one or more naturally occurring antibodies, single chain antibodies or antibody fragments are connected to another fragment, such as a protein or peptide, toxin, cytokine, hormone, etc. .P. In some preferred embodiments, said fusion protein may comprise two or more of the same or different antibodies, antibody fragments or single chain antibodies fused to each other, which can bind to the same epitope, different epitopes on the same antigen, or different antigens.</span>
  </p>
  <p num="47" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[039]     ,   ,      .  ,              ,   ,  , - / -.            .  ,    ,  ,         5-20 ,      (,  -)     ,        .    ,    , ,      ,      ()  .     .       ,    -    .    -, -, -  -.</span>[039] An immunomodulator is a therapeutic agent whose presence modifies, suppresses, or stimulates the body's immune system. In general, an immunomodulator suitable for use stimulates the proliferation or activation of immune cells in the cascade of the immune response, such as macrophages, dendritic cells, B cells and / or T cells. However, in some cases, an immunomodulator can suppress the proliferation or activation of immune cells. An example of an immunomodulator described herein is a cytokine, which is a soluble small protein weighing approximately 5-20 kDa, which is released by a single population of cells (e.g., primed T-lymphocytes) upon contact with specific antigens, and acts as an intercellular mediator for cells. As will be appreciated by one skilled in the art, examples of cytokines include lymphokines, monokines, interleukins, and a number of related signaling molecules, such as tumor necrosis factor (FIO) and interferons. Chemokines are a subset of cytokines. Certain interleukins and interferons are examples of cytokines that stimulate the proliferation of T cells or other immune cells. Examples of interferons include interferon-, interferon-, interferon- and interferon-.</span>
  </p>
  <p num="48" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[040]      ,         ,      , , SN-38.      ,    ,   -,    1   1 .</span>[040] CPT is an abbreviation for camptothecin, and as used herein, CPT means both camptothecin itself and an analogue or derivative of camptothecin, for example SN-38. The structures of camptothecin and some of its analogues, with the numbering and rings indicated by the symbols AE, are shown in <figure-callout id="1" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 1 in <figure-callout id="1" label="scheme" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">scheme</a></figure-callout> 1 below.</span>
  </p>
  <p num="49" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[041]  1</span>[041] <figure-callout id="1" label="Scheme" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Scheme</a></figure-callout> 1</span>
  </p>
  <p num="50" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/a2/1e/5e8fa4234afb3d/00000001.png" class="style-scope patent-text"><img file="00000001.jpg" he="36" wi="135" img-format="jpg" img-content="undefined" width="540" height="144" alt="Figure 00000001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/a2/1e/5e8fa4234afb3d/00000001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/a2/1e/5e8fa4234afb3d/00000001.png" class="style-scope patent-text"><img file="00000001.jpg" he="36" wi="135" img-format="jpg" img-content="undefined" width="540" height="144" alt="Figure 00000001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/a2/1e/5e8fa4234afb3d/00000001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="51" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  Trop-2</span>Antibodies against Trop-2</span>
  </p>
  <p num="52" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[042]         ,    Trop-2.        Trop-2      RS7 (., ,   7238785,       ),   CDR   CDR1 (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2);  CDR3 (QQHYITPLT, SEQ ID NO: 3),   CDR   CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5)  CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>[042] Various embodiments provide for the use of antibodies or fragments thereof that bind to Trop-2. According to a specific preferred embodiment, the anti-Trop-2 antibody may be a humanized RS7 antibody (see, for example, US Pat. No. 7,238,785, incorporated herein by reference in its entirety) containing CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO: 1 ); CDR2 (SASYRYT, SEQ ID NO: 2); and CDR3 (QQHYITPLT, SEQ ID NO: 3), and CDR1 sequences of the heavy chain CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>
  </p>
  <p num="53" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[043]  RS7   IgG<sub class="style-scope patent-text">1</sub>           . (Stein et al., Cancer Res. 50: 1330, 1990)  RS7    46-48 ,      13. (Stein et al., Int. J. Cancer Supp. 8:98-102, 1994).    EGP-1 ( -1),     Trop-2.</span>[043] The RS7 antibody was mouse IgG <sub class="style-scope patent-text">1</sub> against a composition with untreated membranes of primary human squamous cell carcinoma of the lung. (Stein et al., Cancer Res. 50: 1330, 1990) The RS7 antibody recognizes a 46-48 kDa glycoprotein characterized as belonging to <figure-callout id="13" label="cluster" filenames="00000047.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cluster</a></figure-callout> 13. (Stein et al., Int. J. Cancer Supp. 8: 98-102 , 1994). The antigen was designated as EGP-1 (epithelial glycoprotein-1), however it is also called Trop-2.</span>
  </p>
  <p num="54" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[044] Trop-2     I ,        (Fornaro et al., Int J Cancer 1995; 62:610-8),      (Sewedy et al., Int J Cancer 1998; 75:324-30).   Trop-2   (., ,    NCBI P09758.3).         (Ripani et al., Int J Cancer 1998; 76:671-6)  Trop-2 ,   ,          ,             Trop-2 (Wang et al., Mol Cancer Ther 2008; 7:280-5).</span>[044] Trop-2 is a type I transmembrane protein that has been cloned from both human cells (Fornaro et al., Int J Cancer 1995; 62: 610-8) and mouse cells (Sewedy et al., Int J Cancer 1998; 75: 324-30). The human Trop-2 amino acid sequence is well known (see, for example, Accession No. in NCBI P09758.3). In addition to its role as a tumor-associated calcium signal carrier (Ripani et al., Int J Cancer 1998; 76: 671-6), human Trop-2 expression has been shown to be necessary for tumorigenesis and for the invasiveness of colon cancer cells that can be effective reduced when applying a polyclonal antibody to the extracellular domain of Trop-2 (Wang et al., Mol Cancer Ther 2008; 7: 280-5).</span>
  </p>
  <p num="55" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[045]    Trop-2         (Cubas et al., Biochim Biophys Acta 2009; 1796:309-14)   ,      Trop-2     (Huang et al., Clin Cancer Res 2005; 11:4357-64),     (Ohmachi et al., Clin Cancer Res 2006; 12:3057-63; Fang et al., Int J Colorectal Dis 2009; 24:875-84)      (Fong et al., Modem Pathol 2008; 21:186-91).  ,        in vitro  in vivo ,     ,    ,    Trop-2 (Goldstein et al., Proc Natl Acad Sci USA 2008; 105:20882-7).</span>[045] The growing interest in Trop-2 as a therapeutic target in the treatment of solid cancer (Cubas et al., Biochim Biophys Acta 2009; 1796: 309-14) is supported by additional reports documenting the clinical significance of overexpressed Trop-2 in breast carcinomas (Huang et al., Clin Cancer Res 2005; 11: 4357-64), colon and rectum (Ohmachi et al., Clin Cancer Res 2006; 12: 3057-63; Fang et al., Int J Colorectal Dis 2009; 24: 875-84) and squamous cell carcinoma of the oral cavity (Fong et al., Modem Pathol 2008; 21: 186-91). In particular, recent data on elevated levels of in vitro and in vivo activity similar to that of stem cells, prostate basal cells expressing high levels of Trop-2 (Goldstein et al., Proc Natl Acad Sci USA 2008; 105: 20882 -7).</span>
  </p>
  <p num="56" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[046]         ,  MAb RS7      ,        (Stein et al., 1990). Trop-2    ,    , ,  ,  , ,    .          MAb RS7             (Stein et al., 1990; Stein et al., 1991).</span>[046] Studies using flow cytometry and immunohistochemical staining showed that MAb RS7 detects antigen on various types of tumors, with limited binding to normal human tissues (Stein et al., 1990). Trop-2 is mainly expressed by carcinomas, such as carcinomas of the lung, stomach, bladder, breast, ovary, uterus, and prostate. Studies of localization and therapy using radiolabeled MAb RS7 mice in animal models have shown tumor targeting and therapeutic efficacy (Stein et al., 1990; Stein et al., 1991).</span>
  </p>
  <p num="57" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[047]   RS7      ,  ,  , , ,    . (Stein et al., Int. J. Cancer 55:938, 1993).       ,  . (Stein et al., Int. J. Cancer 55:938, 1993).       ,   ,    RS7         .</span>[047] Severe RS7 staining has been demonstrated in tumors from the lungs, breast, bladder, ovaries, uterus, stomach, and prostate. (Stein et al., Int. J. Cancer 55: 938, 1993). Cases of lung cancer include both squamous cell carcinomas and adenocarcinomas. (Stein et al., Int. J. Cancer 55: 938, 1993). Marked staining was observed in both types of cells, indicating that for the RS7 antibody the differences in the histological classes of non-small cell lung carcinomas are not significant.</span>
  </p>
  <p num="58" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[048] MAb RS7     (Stein et al., 1993).    MAb RS7            MAb, ,   ,    ADC ().  ,   ADC        (Pastan et al., Cell 47:641, 1986).  ADC           (Yang et al., Proc. Nat'l Acad. Sci. USA 85: 1189, 1988). ,  RS7   ,    .</span>[048] MAb RS7 is rapidly internalized by target cells (Stein et al., 1993). The internalization rate constant of RS7 MAb takes an intermediate value between the internalization rate constants of two other rapidly internalizing MAb, which, as shown, are suitable for obtaining ADC (above). It is well known that the internalization of ADC is a prerequisite for antitumor activity (Pastan et al., Cell 47: 641, 1986). The internalization of ADC with drugs has been described as a major factor in antitumor efficacy (Yang et al., Proc. Nat'l Acad. Sci. USA 85: 1189, 1988). Accordingly, the RS7 antibody exhibits a number of qualities important for therapeutic use.</span>
  </p>
  <p num="59" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[049]   hRS7  ,   /          Trop-2,         ADC    .           ,          .   ,                        .</span>[049] Although the hRS7 antibody is preferred, information about other anti-Trop-2 antibodies is also known and / or publicly available, and such antibodies can be used in the claimed ADC according to alternative embodiments. Although humanized antibodies or human antibodies are preferred due to reduced immunogenicity, a chimeric antibody may be suitable for use in alternative embodiments. As discussed below, methods for humanizing antibodies are well known in the art and can be used to convert an available mouse antibody or chimeric antibody into a humanized form.</span>
  </p>
  <p num="60" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[050]   Trop-2        LS-C126418, LS-C178765, LS-C126416, LS-C126417 (LifeSpan BioSciences, Inc., , ); 10428-01, 10428-02, 10428-R001, 10428-R030 (Sino Biological Inc., , ); MR54 (eBioscience, -, ); sc-376181, sc-376746, Santa Cruz Biotechnology (-, ); MM0588-49D6, (Novus Biologicals, , ); ab79976  ab89928 (ABCAM, , ).</span>[050] Anti-Trop-2 antibodies are commercially available from a variety of sources and include LS-C126418, LS-C178765, LS-C126416, LS-C126417 (LifeSpan BioSciences, Inc., Seattle, Washington); 10428-MM01, 10428-MM02, 10428-R001, 10428-R030 (Sino Biological Inc., Beijing, China); MR54 (eBioscience, San Diego, California); sc-376181, sc-376746, Santa Cruz Biotechnology (Santa Cruz, California); MM0588-49D6, (Novus Biologicals, Littleton, Colorado); ab79976 and ab89928 (ABCAM, Cambridge, Mass.).</span>
  </p>
  <p num="61" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[051]    Trop-2     . ,    2013/0089872    Trop-2 K5-70 (  FERM -11251), K5-107 (  FERM -11252), K5-116-2-1 (  FERM -11253), 6-16 (  FERM -11346)  5-86 (  FERM -11254),       (International Patent Organism Depositary), , .    5840854     Trop-2 BR110 (  11698).    7420040    Trop-2,     AR47A6.4.2,      , IDAC (International Depository Authority of Canada, , )    141205-05.    7420041    Trop-2,     AR52A301.5,   IDAC    141205-03.    2013/0122020    Trop-2 39, 6G11, 76, 152, 181. ,   ,        ()    -12871  -12872. ADC PF 06263507,    54 ( Trop-2),      F (MMAF),   Pfizer, Inc. (, ) (., , Sapra et al., 2013, Mol Cancer Ther 12:38-47).    8715662    Trop-2,  ,   AID-ICLC (, )   PD 08019, PD 08020  PD 08021.       20120237518    Trop-2 77220, KM4097  KM4590.    8309094 (Wyeth)   A1  A3,    .          ,     ,      .    Lipinski   (Lipinski et al., 1981, Proc Natl. Acad Sci USA, 78:5147-50)    Trop-2 162-25.3  162-46.2.</span>[051] Other anti-Trop-2 antibodies have been described in the patent literature. For example, US publication No. 2013/0089872 describes antibodies against Trop-2 K5-70 (access number FERM BP-11251), K5-107 (access number FERM BP-11252), K5-116-2-1 (access number FERM BP-11253), T6-16 (access number FERM BP-11346) and T5-86 (access number FERM BP-11254) deposited at the International Patent Organism Depositary, Tsukuba, Japan. US Pat. No. 5,840,854 describes a monoclonal antibody against Trop-2 BR110 (ATCC No. HB11698). US 7,400,040 describes an anti-Trop-2 antibody produced by the AR47A6.4.2 hybridoma cell line, deposited with the International Depository Authority of Canada, IDAC (International Depository Authority of Canada, Winnipeg, Canada) under accession number 141205-05. US Pat. No. 7420041 describes an anti-Trop-2 antibody produced by the AR52A301.5 hybridoma cell line, deposited in IDAC under accession number 141205-03. US Publication No. 2013/0122020 describes antibodies against Trop-2 3E9, 6G11, 7E6, 15E2, 18B1. Hybridomas encoding a representative antibody were deposited with the American Type Culture Collection (ATCC) under accession numbers PTA-12871 and PTA-12872. ADC PF 06263507 containing an anti-5T4 antibody (anti-Trop-2) attached to a tubulin inhibitor monomethylauristatin F (MMAF) is available from Pfizer, Inc. (Groton, Connecticut) (see, for example, Sapra et al., 2013, Mol Cancer Ther 12: 38-47). US patent No. 8715662 describes antibodies against Trop-2 produced by hybridomas deposited in AID-ICLC (Genoa, Italy) under the numbers PD 08019, PD 08020 and PD 08021. In published patent application US No. 20120237518 describes antibodies against Trop-2 77220, KM4097 and KM4590. US Pat. No. 8,309,094 (Wyeth) describes antibodies A1 and A3, identified by a sequence listing. Sections of examples of each of the patents or each of the patent applications cited above in this paragraph are incorporated herein by reference. The non-patent publication Lipinski et al. (Lipinski et al., 1981, Proc Natl. Acad Sci USA, 78: 5147-50) describes antibodies against Trop-2 162-25.3 and 162-46.2.</span>
  </p>
  <p num="62" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[052]    Trop-2      /       .   ,            .    ,        .          ,       ,        Trop-2   ADC.</span>[052] Numerous anti-Trop-2 antibodies are known in the art and / or their information is publicly available. As discussed below, methods for producing antibodies against known antigens are routine in the art. Methods for making humanized antibodies, human antibodies, or chimeric antibodies have also been known. An average person skilled in the art, after reading the present description, guided by well-known in the art Information, will be able to obtain and use the genus of antibodies against Trop-2 for the declared ADC.</span>
  </p>
  <p num="63" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[053]    ,  Trop-2,      ,   ADC.   IgG2a  Trop-1,  (PANOREX),        ,             (Baeuerle &amp; Gires, 2007, Br. J Cancer 96:417-423). ,              (Baeuerle &amp; Gires, 2007).  (201),     Trop-1,             , ,  ,     -  - (Baeuerle &amp; Gires, 2007). ,  110,        Trop-1/ CD3,  ,     (Baeuerle &amp; Gires, 2007). , ,     Trop-1,    Pseudomonas,      ,      (Baeuerle &amp; Gires, 2007).         -   ADC  Trop-2,  ,        -   .</span>[053] The use of antibodies against targets related to Trop-2 has been described in the context of immunotherapeutic agents other than ADC. The anti-Trop-1 mouse IgG2a antibody, edrecolomab (PANOREX), has been used to treat colorectal cancer, although the mouse antibody is not well suited for clinical use in humans (Baeuerle &amp; Gires, 2007, Br. J Cancer 96: 417- 423). Subcutaneous administration of low doses of edrecolomab has been reported to induce a humoral immune response against vaccine antigen (Baeuerle &amp; Gires, 2007). Adecatumumab (MT201), a fully human anti-Trop-1 antibody, has been used in metastatic breast cancer and in the early stages of prostate cancer, and it has been reported to act due to ADCC and ACC activity (Baeuerle &amp; Gires, 2007). MT110, a single chain bispecific bispecific anti-Trop-1 / anti-CD3 antibody construct, has been reported to be effective against ovarian cancer (Baeuerle &amp; Gires, 2007). Proxinium, an immunotoxin containing a single chain anti-Trop-1 antibody fused to Pseudomonas exotoxin, was tested for head and neck cancer, as well as bladder cancer (Baeuerle &amp; Gires, 2007). None of these studies contain any description of the use of ADC against Trop-2, in particular, in patients with resistance to treatment with antibodies - control point inhibitors.</span>
  </p>
  <p num="64" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Camptothecin conjugates</span>
  </p>
  <p num="65" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[054]       ADC,    ,       ,  .              () (.. ,     )     ,            ,   1-30  ,      1-12  .</span>[054] Non-limiting methods and compositions for producing ADC containing the camptothecin therapeutic agent attached to an antibody or antigen binding fragment of an antibody are described below. According to preferred embodiments, the solubility of the drug is improved by introducing a fragment of a certain polyethylene glycol (PEG) (i.e., PEG containing a certain number of monomer units) between the drug and the antibody, wherein said specific PEG is a low molecular weight PEG, preferably containing 1-30 monomer units, more preferably containing 1-12 monomer units.</span>
  </p>
  <p num="66" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[055]                      .                    ,       ,   .          ,                .  ,  ( )         N- L-  ,   -    ,               , .</span>[055] In a preferred embodiment, the first linker is connected to the drug at one end and can end with an acetylene or azide group at the other end. Said first linker may comprise a fragment of a specific PEG with an azide or acetylene group at one end and another reactive group, such as a carboxylic acid or hydroxyl group, at the other end. The specified bifunctional specific PEG can be attached to the amino group of the amino alcohol, and the hydroxyl group of the latter can be attached to the hydroxyl group on the drug in the form of a carbonate. Alternatively, a non-azide (or acetylene) fragment of the specified specific bifunctional PEG is optionally attached to the N-terminus of the L-amino acid or polypeptide, the C-terminus being attached to the amino group of the amino alcohol, and the hydroxyl group of the latter attached to the hydroxyl group of the drug in the form of carbonate or carbamate , respectively.</span>
  </p>
  <p num="67" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[056]  ,         ,   ( )   ,  ,  ( ),                   ,      ,         .          ,      .</span>[056] A second linker containing a group for coupling to an antibody and a reactive group complementary to the azide (or acetylene) group of the first linker, namely, the acetylene (or azide) group, can react with the conjugate of the drug and the first linker due to the cycloaddition reaction between acetylene and azide to give a final bifunctional drug product that is suitable for conjugation with disease-targeted antibodies. The group for combining with the antibody is preferably either a thiol or a thiol reactive group.</span>
  </p>
  <p num="68" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[057]    10-    -20-    ,     ,   ,   SN-38,  .             ,      SN-38, , -  -;                  . 10-   ,  ,      ,    ,  ,             .             .</span>[057] Methods for the selective regeneration of a 10-hydroxyl group in the presence of C-20 carbonate in formulations with a precursor containing a drug and a linker, including CPT analogs such as SN-38, are presented below. Other protecting groups for reactive hydroxyl groups in drugs, such as phenolic hydroxyl in SN-38, for example tert-butyldimethylsilyl or tert-butyldiphenylsilyl; deprotection is carried out using tetrabutylammonium fluoride before combining the derivatized drug with a fragment for combining with the antibody. The 10-hydroxyl group of CPT analogs is optionally protected as an ester or carbonate in a manner different from the BOC, so that the bifunctional CPT is conjugated to the antibody without first deprotecting the said protecting group. Deprotection easily occurs under physiological pH values after administration of the bioconjugate.</span>
  </p>
  <p num="69" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[058]  - ,  -,      L2,    -  L3.  , L2   ,  L3 - . -     (+1)         (Kolb , Sharpless KB, Drug Discov Today 2003; 8: 1128-37),        -. -        ,   , , ,     .  -            ,   - .</span>[058] With an acetylene-azide compound called click chemistry, the azide part can be on L2, and the acetylene part can be on L3. Alternatively, L2 may contain acetylene and L3 may contain azide. Click chemistry refers to the copper-catalyzed (+1) cycloaddition reaction between the acetylene moiety and the azide moiety (Kolb HC, Sharpless KB, Drug Discov Today 2003; 8: 1128-37), although alternative forms of click chemistry are known and may be used. . Click chemistry occurs in an aqueous solution under conditions of pH close to neutral, and, accordingly, is suitable for conjugation of drugs. The advantage of click chemistry lies in its chemoselectivity and complement other well-known conjugation chemistry reactions, such as the thiol-maleimide reaction.</span>
  </p>
  <p num="70" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[059]                ,   ,    ,       ,       , , , ,    .</span>[059] Although this document focuses on the use of antibodies or antibody fragments as targeting fragments, one skilled in the art will appreciate that in cases where the conjugate contains an antibody or antibody fragment, another type of targeting fragment may be used, for example, an aptamer, an avimer , affinity or peptide ligand.</span>
  </p>
  <p num="71" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[060]               2,</span>[060] An example of a preferred embodiment relates to a conjugate of a drug derivative and an antibody of <figure-callout id="2" label="general formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">general formula</a></figure-callout> 2,</span>
  </p>
  <p num="72" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MAb-[b2]-[L1]-[]<sub class="style-scope patent-text">m</sub>-['] -   (2)</span>MAb- [b2] - [L1] - [AK] <sub class="style-scope patent-text">m</sub> - [A '] - Drug (2)</span>
  </p>
  <p num="73" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> MAb      ; L2    -,            ( ) ; L1      ( )   ,   ( )   L2,   ,       ,   ;    L-; m    ,   0, 1, 2, 3  4;  '    ,   ,  , 4- , 4- ,     . L-    , , ,  , , ,  , , , , , , , , , , , ,   .   '  ,              , .</span>where MAb is a disease-targeted antibody; L2 is a cross-linker component containing a fragment for connection with an antibody and one or more acetylene (or azide) groups; L1 contains the desired PEG with an azide (or acetylene) at one end, complementary to the acetylene (or azide) moiety in L2, and a reactive group such as a carboxylic acid or hydroxyl group at the other end; AK is an L-amino acid; m is an integer taking the <figure-callout id="0" label="values" filenames="00000052.png,00000053.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="1" label="values" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="2" label="values" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="3" label="values" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="4" label="values" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">values</a></figure-callout></a></figure-callout></a></figure-callout></a></figure-callout></a></figure-callout> 0, 1, 2, 3 or 4; and A  is an additional spacer selected from the group consisting of ethanolamine, 4-hydroxybenzyl alcohol, 4-aminobenzyl alcohol, or substituted or unsubstituted ethylenediamine. AK L-amino acids are selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. If group A  contains hydroxyl, it is connected to the hydroxyl group or amino group of the drug in the form of a carbonate or carbamate, respectively.</span>
  </p>
  <p num="74" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[061]      2 '    ,   L-,         . '       L-: , , ,  , , ,  , , , , , , , , , , , ,   .</span>[061] According to a preferred embodiment of <figure-callout id="2" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 2, A  is a substituted ethanolamine derived from an L-amino acid, wherein the carboxylic acid group of the amino acid is replaced by a hydroxymethyl moiety. A 'can be derived from any of the following L-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, series, threonine, tryptophan, tyrosine and valine.</span>
  </p>
  <p num="75" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[062]         2 m  0, '   L-,     , , SN-38.     3.</span>[062] In an example conjugate according to a preferred embodiment of <figure-callout id="2" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 2, m is 0, A 'is L-valinol, and the drug is, for example, SN-38. The resulting structure is represented by <figure-callout id="3" label="formula" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 3.</span>
  </p>
  <p num="76" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/dd/39/c7/3cdb89e186693e/00000002.png" class="style-scope patent-text"><img file="00000002.jpg" he="31" wi="143" img-format="jpg" img-content="undefined" width="572" height="124" alt="Figure 00000002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/dd/39/c7/3cdb89e186693e/00000002.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/dd/39/c7/3cdb89e186693e/00000002.png" class="style-scope patent-text"><img file="00000002.jpg" he="31" wi="143" img-format="jpg" img-content="undefined" width="572" height="124" alt="Figure 00000002" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/dd/39/c7/3cdb89e186693e/00000002.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="77" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[063]          2, m  1    L-, '   L-,     , , SN-38.     4.</span>[063] In another example of a conjugate according to a preferred embodiment of <figure-callout id="2" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 2, m is 1 and is derivatized L-lysine, A 'is L-valinol, and the drug is, for example, SN-38. The specified structure is represented by <figure-callout id="4" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 4.</span>
  </p>
  <p num="78" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7a/92/37/45cf5d38491a52/00000003.png" class="style-scope patent-text"><img file="00000003.jpg" he="45" wi="160" img-format="jpg" img-content="undefined" width="640" height="180" alt="Figure 00000003" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7a/92/37/45cf5d38491a52/00000003.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7a/92/37/45cf5d38491a52/00000003.png" class="style-scope patent-text"><img file="00000003.jpg" he="45" wi="160" img-format="jpg" img-content="undefined" width="640" height="180" alt="Figure 00000003" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7a/92/37/45cf5d38491a52/00000003.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="79" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[064]            ,   ,   ,        .    N-  ,        ,  N-          ( )   .       20-  10-- SN-38,        L2,    ,     ( ) ,    -. ,        ,    SN-38      ,   3.</span>[064] According to this embodiment, an amide bond is first formed between the carboxylic acid of an amino acid such as lysine and the amino group of valinol using orthogonal protecting groups for the amino groups of lysine. The protective group at the N-terminus of lysine is removed while maintaining the intact protective group on the side chain of lysine, and the N-terminus is conjugated to a carboxyl group on a specific PEG with azide (or acetylene) at the other end. Then, the hydroxyl group of valinol is attached to the 20-chloroformate derivative of 10-hydroxy-protected SN-38, and the intermediate is conjugated to component L2 carrying the antibody binding fragment, as well as to the complementary acetylene (or azide) group involved in click chemistry cycloaddition. Finally, the removal of protective groups from both the side chain of lysine and SN-38 provides the product according to the specified example represented by <figure-callout id="3" label="formula" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 3.</span>
  </p>
  <p num="80" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[065]  - ,  SN-38     (MW),  ,  -SN-38,    ,      SN-38    ,      .</span>[065] Regardless of any theory, the low molecular weight (MW) SN-38 product, namely, valynol-SN-38 carbonate formed after intracellular proteolysis, provides an additional pathway for the isolation of intact SN-38 due to intramolecular cyclization involving the amino group of valinol and carbonyl carbonate.</span>
  </p>
  <p num="81" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[066]      '   2   -,  -    ,   4-    4- ,  C<sub class="style-scope patent-text">1</sub>-<sub class="style-scope patent-text">10</sub>     ,  ,  ,   L-  ,     L-;   N-   -,     .</span>[066] According to another preferred embodiment, A  of <figure-callout id="2" label="general formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">general formula</a></figure-callout> 2 is A-OH, where A-OH is a deformable moiety such as 4-aminobenzyl alcohol or substituted 4-aminobenzyl alcohol substituted with a C <sub class="style-scope patent-text">1</sub> -C <sub class="style-scope patent-text">10</sub> alkyl group in the position of benzyl, and the latter, by means of an amino group, is attached to an L-amino acid or polypeptide containing up to four fragments of an L-amino acid; wherein the N-terminus is attached to a cross-linker terminating in an antibody binding group.</span>
  </p>
  <p num="82" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[067]      ,       -,  '   (2),    4- ,      L-  m  1    (2);    , , SN-38.     ( 5,  MAb-CLX-SN-38).         L-: , , ,  , , ,  , , , , , , , , , , , ,   .  R   4-  (  ' -)     ,   C1-10  .</span>[067] An example of a preferred embodiment is given below, wherein in the indicated embodiment, A-OH corresponding to A  of general formula (2) is derived from substituted 4-aminobenzyl alcohol, and AK consists of a single L-amino acid with m equal to 1 in the general formula (2); the drug is, for example, SN-38. The specified structure is presented below (<figure-callout id="5" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 5, called MAb-CLX-SN-38). A single amino acid "AK" is selected from any of the following L-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, series, threonine, tryptophan, tyrosine and valine. The substituent R on the 4-aminobenzyl alcohol fragment (Embodiment A  A-OH) is hydrogen or an alkyl group selected from C1-C10 alkyl groups.</span>
  </p>
  <p num="83" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/81/2b/0c0b58c1fb0170/00000004.png" class="style-scope patent-text"><img file="00000004.jpg" he="39" wi="134" img-format="jpg" img-content="undefined" width="536" height="156" alt="Figure 00000004" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/81/2b/0c0b58c1fb0170/00000004.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e4/81/2b/0c0b58c1fb0170/00000004.png" class="style-scope patent-text"><img file="00000004.jpg" he="39" wi="134" img-format="jpg" img-content="undefined" width="536" height="156" alt="Figure 00000004" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e4/81/2b/0c0b58c1fb0170/00000004.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="84" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[068]      MAb-CLX-SN-38  5,       L-, R=,     , , SN-38 ( 6;  MAb-CL2A-SN-38).      MAb-CL2-SN-38       Phe-Lys,    CL2.  Phe-Lys        ,  ,         .  ,      , ADC,   CL2A,        ,      in vivo,    CL2.</span>[068] A particular preferred embodiment is MAb-CLX-SN-38 of <figure-callout id="5" label="formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 5, wherein the single amino acid AK is L-lysine, R = H, and the drug is, for example, SN-38 (<figure-callout id="6" label="formula" filenames="00000045.png,00000049.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">formula</a></figure-callout> 6; referred to as MAb- CL2A-SN-38). This structure differs from the MAb-CL2-SN-38 linker by the replacement of a single lysine residue with the Phe-Lys dipeptide found in the CL2 linker. The Phe-Lys dipeptide was designed as a cathepsin B cleavage site, a lysosomal enzyme, which was considered important for the intracellular release of the bound drug. Surprisingly, despite the elimination of the cathepsin cleavage site, ADCs containing the CL2A linker are at least as effective and may be more effective in vivo than those containing the CL2 linker.</span>
  </p>
  <p num="85" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c8/b6/d1/af70a070168485/00000005.png" class="style-scope patent-text"><img file="00000005.jpg" he="41" wi="152" img-format="jpg" img-content="undefined" width="608" height="164" alt="Figure 00000005" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c8/b6/d1/af70a070168485/00000005.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c8/b6/d1/af70a070168485/00000005.png" class="style-scope patent-text"><img file="00000005.jpg" he="41" wi="152" img-format="jpg" img-content="undefined" width="608" height="164" alt="Figure 00000005" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c8/b6/d1/af70a070168485/00000005.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="86" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[069]       10-- ,   SN-38.    SN-38       10-     ,   20- .    2 '    .       7 ,     SN-38     ,         4- ,       Phe-Lys.    ( 7) R  R'      .    MAb-CL17-SN-38  MAb-CL2E-SN-38,  R=R'=.</span>[069] Other embodiments are possible in the context of 10-hydroxy-containing camptothecins, such as SN-38. In the example of SN-38, as a medicine, the more reactive 10-hydroxyl group of said drug is derivatized without involving the 20-hydroxyl group. In <figure-callout id="2" label="general formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">general formula</a></figure-callout> 2, A  is substituted ethylenediamine. An example of this embodiment is represented by the formula 7 below, where the phenolic hydroxyl group of SN-38 is derivatized as carbamate with substituted ethylenediamine, while the other amine of the diamine is derivatized as carbamate with 4-aminobenzyl alcohol, and the amino group of the latter is attached to the Phe-Lys dipeptide. In this structure (Formula 7), R and R 'are independently hydrogen or methyl. It is called MAb-CL17-SN-38 or MAb-CL2E-SN-38, where R = R '= methyl.</span>
  </p>
  <p num="87" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b8/12/93/7ee755ddc04de0/00000006.png" class="style-scope patent-text"><img file="00000006.jpg" he="44" wi="126" img-format="jpg" img-content="undefined" width="504" height="176" alt="Figure 00000006" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b8/12/93/7ee755ddc04de0/00000006.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/b8/12/93/7ee755ddc04de0/00000006.png" class="style-scope patent-text"><img file="00000006.jpg" he="44" wi="126" img-format="jpg" img-content="undefined" width="504" height="176" alt="Figure 00000006" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/b8/12/93/7ee755ddc04de0/00000006.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="88" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[070]        , , -, -  ,   .  : Ala-Leu, Leu-Ala-Leu  Ala-Leu-Ala-Leu (SEQ ID NO: 20) (Trouet et al., 1982).     Phe-Lys,   .</span>[070] In some embodiments, the AK contains a polypeptide fragment, preferably a di-, tri- or tetrapeptide cleaved by intracellular peptidase. Examples are: Ala-Leu, Leu-Ala-Leu and Ala-Leu-Ala-Leu (SEQ ID NO: 20) (Trouet et al., 1982). Another example is represented by a Phe-Lys fragment cleaved by lysosomal cathepsin.</span>
  </p>
  <p num="89" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[071]      L1     ()   1-30   .            1-12   .        ,   .         .    ,  8   ,  NHS   ,     8:</span>[071] According to a preferred embodiment, the conjugate component L1 comprises a specific polyethylene glycol (PEG) spacer with 1-30 repeating monomer units. According to a further preferred embodiment, the PEG is a specific PEG with 1-12 repeating monomer units. The introduction of PEG may include the use of heterobifunctional derivatives of PEG, which are commercially available. Said heterobifunctional PEG may contain an azide or acetylene group. An example of a heterobifunctional specific PEG containing 8 repeating monomer units, where "NHS" is succinimidyl, is presented below in formula 8:</span>
  </p>
  <p num="90" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/34/5e/6d/8c6cd6136d58df/00000007.png" class="style-scope patent-text"><img file="00000007.jpg" he="27" wi="106" img-format="jpg" img-content="undefined" width="424" height="108" alt="Figure 00000007" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/34/5e/6d/8c6cd6136d58df/00000007.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/34/5e/6d/8c6cd6136d58df/00000007.png" class="style-scope patent-text"><img file="00000007.jpg" he="27" wi="106" img-format="jpg" img-content="undefined" width="424" height="108" alt="Figure 00000007" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/34/5e/6d/8c6cd6136d58df/00000007.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="91" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[072]     L2    ( ) ,    2  40,   -  2  20,    -  2  5,     .</span>[072] According to a preferred embodiment, L2 contains a plurality of acetylene (or azide) groups in the range of 2 to 40, however, preferably 2 to 20, and more preferably 2 to 5, and a single antibody binding fragment.</span>
  </p>
  <p num="92" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[073]   SN-38  ,          ,  .  L2     2  ,          SN-38.   MAb    .</span>[073] A representative conjugate of SN-38 with an antibody comprising several drug molecules and a single antibody binding fragment is shown below. Component "L2" of the indicated structure is attached to 2 acetylene groups, which leads to the attachment of two SN-38 molecules attached to the azide. Communication with MAb is presented in the form of succinimide.</span>
  </p>
  <p num="93" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/e5/f1/602494cd1d3b2f/00000008.png" class="style-scope patent-text"><img file="00000008.jpg" he="30" wi="55" img-format="jpg" img-content="undefined" width="220" height="120" alt="Figure 00000008" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/e5/f1/602494cd1d3b2f/00000008.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/25/e5/f1/602494cd1d3b2f/00000008.png" class="style-scope patent-text"><img file="00000008.jpg" he="30" wi="55" img-format="jpg" img-content="undefined" width="220" height="120" alt="Figure 00000008" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/25/e5/f1/602494cd1d3b2f/00000008.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="94" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  R  :</span>Where the remainder R is:</span>
  </p>
  <p num="95" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6f/c8/a1/359303fbf3fbca/00000009.png" class="style-scope patent-text"><img file="00000009.jpg" he="41" wi="115" img-format="jpg" img-content="undefined" width="460" height="164" alt="Figure 00000009" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6f/c8/a1/359303fbf3fbca/00000009.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/6f/c8/a1/359303fbf3fbca/00000009.png" class="style-scope patent-text"><img file="00000009.jpg" he="41" wi="115" img-format="jpg" img-content="undefined" width="460" height="164" alt="Figure 00000009" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/6f/c8/a1/359303fbf3fbca/00000009.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="96" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[074]       ,               ,              .           MAb       (Wong,  : Chemistry of protein conjugation and cross-linking, CRC Press, Inc., Boca Raton, FL (1991), pp 20-22).  ,        (Willner et al., Bioconjugate Chem. 4:521-527 (1993))    ,    (DTT),   7-10   ;   ,          MAb     .       SN-38   -     ADC /SN-38  6  SN-38,     .              ,        (.   7521541,         ).</span>[074] According to preferred embodiments, when the bifunctional drug contains a thiol reactive fragment as an antibody binding group, thiols on said antibody are prepared on the lysine groups of said antibody using a thiolating reagent. Methods for introducing thiol groups into antibodies by modifying MAb lysine groups are well known in the art (Wong, source: Chemistry of protein conjugation and cross-linking, CRC Press, Inc., Boca Raton, FL (1991), pp 20-22 ) Alternatively, mild reduction of the interchain disulfide bonds on an antibody (Willner et al., Bioconjugate Chem. 4: 521-527 (1993)) using reducing agents such as dithiothreitol (DTT) can produce 7-10 thiols on the antibody; which provides the advantage of incorporating several drug fragments into the interchain region of the MAb away from the antigen binding region. In a more preferred embodiment, the attachment of SN-38 to reduced disulfide-sulfhydryl groups results in the formation of an ADC antibody / SN-38 with 6 SN-38 fragments covalently attached to the antibody molecule. Other methods are known for providing cysteine residues for the attachment of drugs or other therapeutic agents, such as the use of engineered antibodies with cysteine (see US Pat. No. 7,521,541, a section of the examples of which is incorporated herein by reference).</span>
  </p>
  <p num="97" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[075]          ,    (DOX), ,  (-DOX),  (-DOX), 2- (2-PDOX), -2PDOX, , 10-, SN-38, , , 9-, 9-, , ,   .           SN-38.                  ; ,       1   12;     6 -   12  .</span>[075] According to alternative preferred embodiments, the chemotherapeutic fragment is selected from the group consisting of doxorubicin (DOX), epirubicin, morpholinodoxorubicin (morpholino-DOX), cyanomorpholinodoxorubicin (cyanomorpholino-DOX), 2-pyrrolinodoxorubicin-2, (2) pyrrolinodoxorubicin (2) CPT, 10-hydroxycamptothecin, SN-38, topotecan, lurtotecan, 9-aminocamptothecin, 9-nitrocamptothecin, taxanes, geldanamycin, ansamycins and epothilones. According to a more preferred embodiment, said chemotherapeutic fragment is SN-38. In a preferred embodiment, in conjugates in preferred embodiments, the antibody is coupled to at least one chemotherapeutic fragment; preferably with chemotherapeutic fragments in an amount of from 1 to about 12; most preferably with about 6 to about 12 chemotherapeutic fragments.</span>
  </p>
  <p num="98" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[076]  ,        L2   ,          ,           .           ,   , ,   ,  ,      .</span>[076] In addition, according to a preferred embodiment, said linker component L2 contains a thiol group that reacts with a thiol-reactive residue introduced into one or more amino groups of the lysine side chain of said antibody. In such cases, the antibody is pre-derivatized with a thiol-reactive group, such as maleimide, vinyl sulfonic, bromoacetamide or iodoacetamide, by procedures well described in the art.</span>
  </p>
  <p num="99" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[077]         ,          ,      10- .   ,   ,  10-   - ()            .    -    ,     ().      20-0-,   ,   ,         . ,        ()       ,      ,       (Walker et al., 2002).  ,      -       ,  -  3  5 .     ,     10--  ,      20  .</span>[077] In the context of this study, a method was unexpectedly discovered by which medicinal CPT with linkers in which CPT additionally contains a 10-hydroxyl group can be obtained. Said method includes, but is not limited to, protecting a 10-hydroxyl group as a tert-butyloxycarbonyl (BOC) derivative, followed by preparation of the penultimate intermediate of a drug conjugate with a linker. Typically, removal of the BOC group requires treatment with a strong acid such as trifluoroacetic acid (TFA). Under these conditions, the carbonate of CPT of the 20-0 linker, containing the protective groups to be removed, is also prone to cleavage to thereby form an unmodified CPT. In fact, the rationale for using the moderately easily removable methoxytrityl (MMT) protecting group of the lysine side chain of the linker molecule, as is known in the art, was to eliminate this possibility (Walker et al., 2002). It was found that the selective removal of the phenolic protective BOC group can be accomplished by conducting reactions of short duration, optimally from 3 to 5 minutes. Under these conditions, a product prevailed in which the BOC at the 10-hydroxy position was removed, while the carbonate at <figure-callout id="20" label="position" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">position</a></figure-callout> 20 remained intact.</span>
  </p>
  <p num="100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[078]     10--   ,   ,  ,              10-- . 10-- ,   10-       ,               in vivo.        10      20 10-         ( et al., Bioorganic &amp; Medicinal Chemistry 12: 4003-4008 (2004)). 10--   SN-38    COR,  R     ,   N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>-(CH<sub class="style-scope patent-text">2</sub>)<sub class="style-scope patent-text">n</sub>-,  n   1-10,            ,    ,   <sub class="style-scope patent-text">3</sub>-(<sub class="style-scope patent-text">2</sub>)<sub class="style-scope patent-text">n</sub>-,  n   0-10,       ,   <sub class="style-scope patent-text">3</sub>-(<sub class="style-scope patent-text">2</sub>)n-O-,  n   0-10,  N(CH<sub class="style-scope patent-text">3</sub>)<sub class="style-scope patent-text">2</sub>-(CH<sub class="style-scope patent-text">2</sub>)<sub class="style-scope patent-text">n</sub>-O-,  n   2-10,  R<sub class="style-scope patent-text">1</sub>O-(CH<sub class="style-scope patent-text">2</sub>-CH<sub class="style-scope patent-text">2</sub>-O)<sub class="style-scope patent-text">n</sub>-CH<sub class="style-scope patent-text">2</sub>-CH<sub class="style-scope patent-text">2</sub>-O-,  R<sub class="style-scope patent-text">1</sub>     ,  n    ,   0-10.  10-       ,       .  , 10-- ,   SN-38,            .     20-  .    10-O-    .</span>[078] An alternative approach involves protecting the 10-hydroxy position of the CPT analogue with a group other than BOC, so that the final product is ready for conjugation with antibodies without the need to deprotect the 10-OH protecting group. The 10-hydroxy protecting group, which converts 10-OH to a phenolic carbonate or phenolic ester, is readily removed by physiological pH or esterases after conjugate administration in vivo. Faster removal of phenolic carbonate at <figure-callout id="10" label="position" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">position</a></figure-callout> 10 relative to tertiary carbonate at <figure-callout id="20" label="position" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">position</a></figure-callout> 20 of 10-hydroxycamptothecin under physiological conditions was described by He et al. (He et al., Bioorganic &amp; Medicinal Chemistry 12: 4003-4008 (2004)). The 10-hydroxy protecting group on SN-38 may be COR, where R may be substituted alkyl, such as N (CH <sub class="style-scope patent-text">3</sub> ) <sub class="style-scope patent-text">2</sub> - (CH <sub class="style-scope patent-text">2</sub> ) <sub class="style-scope patent-text">n</sub> -, where n is 1-10 and the terminal amino group is optionally in the form of a quaternary salt to improve water solubility, or a simple alkyl residue, such as CH <sub class="style-scope patent-text">3</sub> - (CH <sub class="style-scope patent-text">2</sub> ) <sub class="style-scope patent-text">n</sub> -, where n is 0-10, or it can be a fragment of an alkoxy group, such as "CH <sub class="style-scope patent-text">3</sub> - (CH <sub class="style-scope patent-text">2</sub> ) nO-", where n represents 0-10, or "N (CH <sub class="style-scope patent-text">3</sub> ) <sub class="style-scope patent-text">2</sub> - (CH <sub class="style-scope patent-text">2</sub> ) <sub class="style-scope patent-text">n</sub> -O-", where n represents 2-10, or " R <sub class="style-scope patent-text">1</sub> O- (CH <sub class="style-scope patent-text">2</sub> CH <sub class="style-scope patent-text">2</sub> O) <sub class="style-scope patent-text">n</sub> CH <sub class="style-scope patent-text">2</sub> CH <sub class="style-scope patent-text">2</sub> O , wherein R <sub class="style-scope patent-text">1</sub> is ethyl or methyl, and n is an integer of 0-10. These 10-hydroxy derivatives are readily prepared by treating the selected reagent with chloroformate if the resulting derivative is to be carbonate. Typically, a 10-hydroxy-containing camptothecin, such as SN-38, is treated with the molar equivalent of chloroformate in dimethylformamide using triethylamine as the base. Under these conditions, provision 20-OH is not affected. To obtain 10-O-esters, the acid chloride of the selected reagent is used.</span>
  </p>
  <p num="101" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[079]             2,   L2, L1,   -     ,     , [L2]-[L1]-[A]<sub class="style-scope patent-text">m</sub>-[-] -  ,          (    MAb).</span>[079] According to a preferred method for producing a conjugate of a derivative drug and an antibody of <figure-callout id="2" label="general formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">general formula</a></figure-callout> 2, wherein the symbols L2, L1, AK and AX are as described in the sections above, a bifunctional drug fragment is first obtained, [L2] - [L1] - [AK ] <sub class="style-scope patent-text">m</sub> - [AX] - The drug, and then conjugated bifunctional fragment of the drug with the antibody (referred to in this document "MAb").</span>
  </p>
  <p num="102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[080]             2,   L2, L1,   -     ,        -  -    ,         L1.    (.. m=0), -    L1   . -, [L1]-[A]<sub class="style-scope patent-text">m</sub>-[A-OH],        ,      L1,      ( )   ( )  L  L2   -.</span>[080] According to a preferred method for producing a conjugate of a drug derivative and an antibody of <figure-callout id="2" label="general formula" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">general formula</a></figure-callout> 2, wherein the symbols L2, L1, AK and A-OH are as described in the sections above, a bifunctional drug fragment is first obtained by connecting A-OH to the C-terminus of AK by amide bond, followed by the connection of the amino terminus of AK with the carboxylic acid group L1. If AK is absent (i.e., m = 0), A-OH is directly attached to L1 via an amide bond. The cross-linker, [L1] - [AK] <sub class="style-scope patent-text">m</sub> - [A-OH], is attached to the hydroxyl group or amino group of the drug, followed by attachment to the L1 fragment, using the reaction between the azide (or acetylene) and acetylene (or azide) L and L2 groups using click chemistry.</span>
  </p>
  <p num="103" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[081]           (MAb).           /  MAb.        ,  ,     ;        ,  (Fab, Fab, F(ab)<sub class="style-scope patent-text">2</sub>, (ab')<sub class="style-scope patent-text">2</sub>),   ( ),    IgG1, IgG2a, IgG3, IgG4, IgA,    .</span>[081] In one embodiment, said antibody is a monoclonal antibody (MAb). In other embodiments, said antibody may be a multivalent and / or multispecific MAb. The specified antibody may be a monoclonal antibody of a mouse, a chimeric antibody, a humanized antibody or a human antibody; said antibody may be in the form of an intact antibody, fragment (Fab, Fab, F (ab) <sub class="style-scope patent-text">2</sub> , P (ab ') <sub class="style-scope patent-text">2</sub> ), or a sub-fragment (single chain constructs), or isotype antibodies IgG1, IgG2a, IgG3, IgG4, IgA, or their corresponding submolecules.</span>
  </p>
  <p num="104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[082]            ,      ,   -  Trop-2.         , , ,    .   ,       ,        .</span>[082] In a preferred embodiment, said antibody binds to an antigen or epitope of an antigen expressed on a cancer or cancer cell, most preferably Trop-2. Said cancer cell is preferably a hematopoietic tumor, carcinoma, sarcoma, melanoma or glial tumor cell. A preferred malignant disease to be treated in accordance with the present invention is a solid malignant tumor or hematopoietic neoplasm.</span>
  </p>
  <p num="105" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[083]                 MAb      .</span>[083] According to a preferred embodiment, the cleaved intracellular fragment can be cleaved after internalization by the cell by binding the MAb conjugate to the drug with its receptor.</span>
  </p>
  <p num="106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> -   </span>Antibodies - Control Point Inhibitors</span>
  </p>
  <p num="107" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[084]    -             ,        (., , Ott &amp; Bhardwaj, 2013, Frontiers in Immunology 4:346; Menzies &amp; Long, 2013, Ther Adv Med Oncol 5:278-85; Pardoll, 2012, Nature Reviews 12:252-264; Mavilio &amp; Lugli,).        CTLA-4, PD-1  PD-L1             .      ,         ,        ,       (Pardoll, 2012, Nature Reviews 12:252-264).              ,   ,         , ,      (ADC),      ADC.</span>[084] Studies with cancer control point antibody inhibitors have provided unprecedented response rates for cancers that were previously considered resistant to anti-cancer treatment (see, for example, Ott &amp; Bhardwaj, 2013, Frontiers in Immunology 4: 346; Menzies &amp; Long , 2013, Ther Adv Med Oncol 5: 278-85; Pardoll, 2012, Nature Reviews 12: 252-264; Mavilio &amp; Lugli,). Therapy with antagonistic anti-CTLA-4, PD-1, and PD-L1 antibody blocking control points is one of the most promising new ways of immunotherapy for cancer and other diseases. Unlike most anticancer agents, the control point inhibitor does not directly target tumor cells, but targets lymphocyte receptors or their ligands, enhancing the endogenous antitumor activity of the immune system (Pardoll, 2012, Nature Reviews 12: 252-264). Since such antibodies act primarily by regulating the immune response to diseased cells, tissues, or pathogens, they can be used in combination with other therapeutic methods, for example, drug-antibody conjugates (ADCs), to enhance the antitumor effect of these ADCs.</span>
  </p>
  <p num="108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[085]     1 (PD-1,    CD279)        ,    -  NK- (Shinohara et al., 1995, Genomics 23:704-6; Blank et al., 2007, Cancer Immunol Immunother 56:739-45; Finger et al., 1997, Gene 197:177-87; Pardoll, 2012, Nature Reviews 12:252-264).   PD1    ,   ,   ,   ,     ,    ,       , ,   -  (Topalian et al., 2012, N Engi J Med 366:2443-54; Lipson et al., 2013, Clin Cancer Res 19:462-8; Berger et al., 2008, Clin Cancer Res 14:3044-51; Gildener-Leapman et al., 2013, Oral Oncol 49:1089-96; Menzies &amp; Long, 2013, Ther Adv Med Oncol 5:278-85).</span>[085] The programmed cell death protein 1 (PD-1, also known as CD279) encodes a cell surface membrane protein from the immunoglobulin superfamily that is expressed in B cells and NK cells (Shinohara et al., 1995, Genomics 23: 704- 6; Blank et al., 2007, Cancer Immunol Immunother 56: 739-45; Finger et al., 1997, Gene 197: 177-87; Pardoll, 2012, Nature Reviews 12: 252-264). Antibodies against PD1 have been used to treat melanoma, non-small cell lung cancer, bladder cancer, prostate cancer, colorectal cancer, head and neck cancer, breast cancer with a triple negative phenotype, leukemia, lymphoma, and renal cell cancer (Topalian et al., 2012, N Engi J Med 366: 2443-54; Lipson et al., 2013, Clin Cancer Res 19: 462-8; Berger et al., 2008, Clin Cancer Res 14: 3044-51; Gildener-Leapman et al., 2013, Oral Oncol 49: 1089-96; Menzies &amp; Long, 2013, Ther Adv Med Oncol 5: 278-85).</span>
  </p>
  <p num="109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[086]    PD1   (-3475, MERCK),  (BMS-936558, BRISTOL-MYERS SQUIBB)   (-011, CURETECH LTD.).   PD 1  , ,   (137132), BIOLEGEND (EH12.2H7, RMP1-14)  AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4).</span>[086] Examples of antibodies against PD1 include pembrolizumab (MK-3475, MERCK), nivolumab (BMS-936558, BRISTOL-MYERS SQUIBB), and pidilizumab (CT-011, CURETECH LTD.). Antibodies against <figure-callout id="1" label="PD" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">PD</a></figure-callout> 1 are commercially available, for example, from ABCAM (AB137132), BIOLEGEND (EH12.2H7, RMP1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4).</span>
  </p>
  <p num="110" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[087]  1    1 (PD-L1,    CD274)    PD-1,    -, -,    .  PD-1  PD-L1   CD8+ -     (Topalian et al., 2012, N Engi J Med 366:2443-54; Brahmer et al., 2012, N Eng J Med 366:2455-65).   PDL1      , ,     , - ,   ,  ,  ,        (Brahmer et al., N Eng J Med 366:2455-65; Ott et al., 2013, Clin Cancer Res 19:5300-9; Radvanyi et al., 2013, Clin Cancer Res 19:5541; Menzies &amp; Long, 2013, Ther Adv Med Oncol 5:278-85; Berger et al., 2008, Clin Cancer Res 14:13044-51).</span>[087] <figure-callout id="1" label="Ligand" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Ligand</a></figure-callout> 1 of programmed cell death 1 (PD-L1, also known as CD274) is a PD-1 ligand found on activated T cells, B cells, myeloid cells and macrophages. The PD-1 and PD-L1 complex inhibits the proliferation of CD8 + T cells and reduces the immune response (Topalian et al., 2012, N Engi J Med 366: 2443-54; Brahmer et al., 2012, N Eng J Med 366: 2455 -65). Anti-PDL1 antibodies have been used to treat non-small cell lung cancer, melanoma, colorectal cancer, renal cell cancer, pancreatic cancer, stomach cancer, ovarian cancer, breast cancer, and hematologic malignancies (Brahmer et al., N Eng J Med 366: 2455-65; Ott et al., 2013, Clin Cancer Res 19: 5300-9; Radvanyi et al., 2013, Clin Cancer Res 19: 5541; Menzies &amp; Long, 2013, Ther Adv Med Oncol 5: 278- 85; Berger et al., 2008, Clin Cancer Res 14: 13044-51).</span>
  </p>
  <p num="111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[088]    PDL1  MDX-1105 (MEDAREX),  (MEDI4736, MEDIMMUNE),  (TECENTRIQ, MPDL3280A, GENENTECH)  BMS-936559 (BRISTOL-MYERS SQUIBB).   PDL1   , ,  AFFYMETRIX EBIOSCIENCE (MIH1).</span>[088] Examples of antibodies against PDL1 include MDX-1105 (MEDAREX), durvalumab (MEDI4736, MEDIMMUNE), atesolizumab (TECENTRIQ, MPDL3280A, GENENTECH) and BMS-936559 (BRISTOL-MYERS SQUIBB). Antibodies against PDL1 are also commercially available, for example, from AFFYMETRIX EBIOSCIENCE (MIH1).</span>
  </p>
  <p num="112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[089]  4  - (CTLA-4,    CD152)     ,    -.  CTLA-4     - ,  ,     -      - (Pardoll, 2012, Nature Reviews 12:252-264).   CTL4A       ,   ,   ,    (Robert &amp; Ghiringhelli, 2009, Oncologist 14:848-61; Ott et al., 2013, Clin Cancer Res 19:5300; Weber, 2007, Oncologist 12:864-72; Wada et al., 2013, J Transl Med 11:89).</span>[089] <figure-callout id="4" label="Antigen" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Antigen</a></figure-callout> 4 of cytotoxic T lymphocytes (CTLA-4, also known as CD152) is also a member of the immunoglobulin superfamily expressed exclusively on T cells. The effect of CTLA-4 is to inhibit T-cell activation and, according to reports, it inhibits the activity of helper T cells and enhances the immunosuppressive activity of regulatory T cells (Pardoll, 2012, Nature Reviews 12: 252-264). Anti-CTL4A antibodies have been used in clinical trials to treat melanoma, prostate cancer, small cell lung cancer, non-small cell lung cancer (Robert &amp; Ghiringhelli, 2009, Oncologist 14: 848-61; Ott et al., 2013, Clin Cancer Res 19: 5300; Weber, 2007, Oncologist 12: 864-72; Wada et al., 2013, J Transl Med 11:89).</span>
  </p>
  <p num="113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[090]    CTLA4   (Bristol-Myers Squibb)   (PFIZER).   PD1  , ,   (134090), SINO BIOLOGICAL INC. (11159-03, 11159-08)  THERMO SCIENTIFIC PIERCE (PA5-29572, PA5-23967, PA5-26465, MA1-12205, MA1-35914).     FDA     (Wada et al., 2013, J Transl Med 11:89).</span>[090] Examples of antibodies against CTLA4 include ipilimumab (Bristol-Myers Squibb) and trelimumumab (PFIZER). Antibodies against PD1 are commercially available, for example, from ABCAM (AB134090), SINO BIOLOGICAL INC. (11159-H03H, 11159-H08H) and THERMO SCIENTIFIC PIERCE (PA5-29572, PA5-23967, PA5-26465, MA1-12205, MA1-35914). Ipilimumab has recently received FDA approval for the treatment of metastatic melanoma (Wada et al., 2013, J Transl Med 11:89).</span>
  </p>
  <p num="114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[091]      -         IMMU-132.     IMMU-132,     ,       ,    -       .</span>[091] These and other known reference point inhibitor antibodies can be used in combination with IMMU-132. According to preferred embodiments, IMMU-132, individually or in combination, is effective for treating patients with cancers that are refractory to control point inhibitor antibodies when used separately.</span>
  </p>
  <p num="115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    </span>General antibody techniques</span>
  </p>
  <p num="116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[092]               . ., , : </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a1/9b/32/d778785a28d49f/00000010.png" class="style-scope patent-text"><img file="00000010.jpg" he="5" wi="14" img-format="jpg" img-content="undefined" width="56" height="20" alt="Figure 00000010" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a1/9b/32/d778785a28d49f/00000010.png"></a></div> Milstein, Nature 256: 495 (1975),  Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley &amp; Sons 1991). ,         ,  ,     -,  -      ,   ,   ,      ,  ,      ,       .        ,    ,      -,      .[092] Techniques for producing monoclonal antibodies against virtually any target antigen are well known in the art. See, for example, sources: <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a1/9b/32/d778785a28d49f/00000010.png" class="style-scope patent-text"><img file="00000010.jpg" he="5" wi="14" img-format="jpg" img-content="undefined" width="56" height="20" alt="Figure 00000010" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a1/9b/32/d778785a28d49f/00000010.png"></a></div> Milstein, Nature 256: 495 (1975), and Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley &amp; Sons 1991). Briefly, monoclonal antibodies can be obtained by injecting mice with a composition containing an antigen, extracting a spleen to obtain B lymphocytes, fusing B lymphocytes with myeloma cells to produce hybridomas, cloning these hybridomas, selecting positive clones that produce antibodies to the specified antigen, culturing clones that produce antibodies to the specified antigen, and the selection of these antibodies from hybridoma cultures. It will be clear to one of ordinary skill in the art that when antibodies are intended to be administered to human subjects, these antibodies bind to human antigens.
  <p class="style-scope patent-text"></p>
  <p num="117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[093] MAb              .              G,     . ., , Coligan, . 2.7.1-2.7.12  . 2.9.1-2.9.3.  . : Baines et al., "Purification of Immunoglobulin G (IgG)",      (METHODS IN MOLECULAR BIOLOGY),  10, . 79-104 (The Humana Press, Inc. 1992)).</span>[093] MAb can be isolated and purified from hybridoma cultures using various well-developed techniques. Such isolation techniques include Sepharose affinity chromatography with protein A or protein G, size exclusion chromatography, and ion exchange chromatography. See, for example, Coligan, pp. 2.7.1-2.7.12 and pp. 2.9.1-2.9.3. Also see source: Baines et al., "Purification of Immunoglobulin G (IgG)," in Methods of Molecular Biology (METHODS IN MOLECULAR BIOLOGY), <figure-callout id="10" label="Volume" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Volume</a></figure-callout> 10, pp. 79-104 (The Humana Press, Inc. 1992 )).</span>
  </p>
  <p num="118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[094]           ,       .               ,   .</span>[094] After the initial production of antibodies to the immunogen, these antibodies can be sequenced and then processed using recombinant techniques. Humanization and chimerization of antibodies and mouse antibody fragments are well known to those skilled in the art, as discussed below.</span>
  </p>
  <p num="119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[095]   ,              ,     . ,   ,          . ,            (, , ).         ,   ,    ,  ,    , /      ,          . ., ,   7312318, 7282567, 7151164, 7074403, 7060802, 7056509, 7049060, 7045132, 7041803, 7041802, 7041293, 7038018, 7037498, 7012133, 7001598, 6998468, 6994976, 6994852, 6989241, 6974863, 6965018, 6964854, 6962981, 6962813, 6956107, 6951924, 6949244, 6946129, 6943020, 6939547, 6921645, 6921645, 6921533, 6919433, 6919078, 6916475, 6905681, 6899879, 6893625, 6887468, 6887466, 6884594, 6881405, 6878812, 6875580, 6872568, 6867006, 6864062, 6861511, 6861227, 6861226, 6838282, 6835549, 6835370, 6824780, 6824778, 6812206, 6793924, 6783758, 6770450, 6767711, 6764688, 6764681, 6764679, 6743898, 6733981, 6730307, 6720155, 6716966, 6709653, 6693176, 6692908, 6689607, 6689362, 6689355, 6682737, 6682736, 6682734, 6673344, 6653104, 6652852, 6635482, 6630144, 6610833, 6610294, 6605441, 6605279, 6596852, 6592868, 6576745, 6572,856, 6566076, 6562618, 6545130, 6544749, 6534058, 6528625, 6528269, 6521227, 6518404, 6511665, 6491915, 6488930, 6482598, 6482408, 6479247, 6468531, 6468529, 6465173, 6461823, 6458356, 6455044, 6455040 6451310, 6444206, 6441143, 6432404, 6432402, 6419928, 6413726, 6406694, 6403770, 6403091, 6395276, 6395274, 6387350, 6383759, 6383484, 6376654, 6372215, 6359126, 6355481, 6355444, 6355245, 6355244, 6346246, 6344198, 6340571, 6340459, 6331175, 6306393, 6254868, 6187287, 6183744, 6129914, 6120767, 6096289, 6077499, 5922302, 5874540, 5814440, 5798229, 5789554, 5776456, 5736119, 5716595, 5677136, 5587459, 5443953, 5525338,           .     ,             .   ,                        , NCBI / USPTO         .       , ,    ,   -     ,    ,      .        ,   ,   ,    .</span>[095] One skilled in the art will appreciate that any of a wide variety of antibodies known in the art may be employed in the claimed methods and compositions. Antibodies suitable for use can be obtained commercially from a wide variety of known sources. For example, secreting various antibodies of the hybridoma line are available in the American Type Culture Collection (ATCC, Manassas, Virginia). A significant number of antibodies against various disease-related targets, including, but not limited to, tumor-associated antigens, have been deposited in ATCC and / or sequences of their variable regions have been published and are available for use in the claimed methods and compositions. See, for example, US patents No. 7312318, No. 7282567, No. 7151164, No. 7074403, No. 7060802, No. 7056509, No. 7049060, No. 7045132, No. 7041803, No. 7041802, No. 7041293, No. 7038018, No. 7037498, No. 7012133, No. 7012133 7001598, No. 6998468, No. 6994976, No. 6994852, No. 6989241, No. 6974863, No. 6965018, No. 6964854, No. 6962981, No. 6962813, No. 6956107, No. 6951924, No. 6949244, No. 6946129, No. 6943020, No. 6939547, No. 6939547, 69 No. 6921645, No. 6921533, No. 6919433, No. 6919078, No. 6916475, No. 6905681, No. 6899879, No. 6893625, No. 6887468, No. 6887466, No. 6884594, No. 6881405, No. 6878812, No. 6875580, No. 6872568, No. 6867006 No. 6861511, No. 6861227, No. 6861226, No. 6838282, No. 6835549, No. 6835370, No. 6824780, No. 6824778, No. 6812206, No. 6793924, No. 6783758, No. 6770450, No. 6767711, No. 6764688, No. 6764681, No. 6764679, 6743898, No. 6733981, No. 6730307, No. 6720155, No. 6716966, No. 6709653, No. 6693176, No. 6692908, No. 6689607, No. 6689362, No. 6689355, No. 6682737, No. 6682736, No. 6682734, No. 6673344, No. 6653284, No. 6635482, No. 6630144, No. 6610833, No. 6610294, No. 6605441, No. 6605279, No. 6596852, No. 6592868, No. 6576745, No. 6572,856, No. 6566076, No. 6562618, No. 6545130, No. 6544749, No. 6534058, No. 652862525, Number 6 528269, No. 6521227, No. 6518404, No. 6511665, No. 6491915, No. 6488930, No. 6482598, No. 6482408, No. 6479247, No. 6468531, No. 6468529, No. 6465173, No. 6461823, No. 6458356, No. 6455044, No. 6456440 64513 , No. 6441143, No. 6432404, No. 6432402, No. 6419928, No. 6413726, No. 6406694, No. 6403770, No. 6403091, No. 6395276, No. 6395274, No. 6387350, No. 6383759, No. 6383484, No. 6376654, No. 6372215, No. 6372656, No. 6372215, 6355481, No. 6355444, No. 6355245, No. 6355244, No. 6346246, No. 6344198, No. 6340571, No. 6340459, No. 6331175, No. 6306393, No. 6254868, No. 6187287, No. 6183744, No. 6129914, No. 6128797, No. 6,606,767, No. 6,606,767, No. 6,628,767 No. 5922302, No. 5874540, No. 5814440, No. 5798229, No. 5798554, No. 5776456, No. 5736119, No. 5716595, No. 5677136, No. 5587459, No. 54443953, No. 5525338, a section of examples of each of which is incorporated herein by reference. These antibodies are solely examples, and a wide range of other antibodies and their hybridomas are known in the art. One skilled in the art will recognize that sequences of antibodies or antibody-secreting antibodies against almost any disease-associated antigen can be obtained by simply searching the ATCC, NCBI, and / or USPTO databases of antibodies against the selected disease-associated target of interest. The antigen binding domains of the cloned antibodies can be amplified, excised, dotted into an expression vector, transfected with an adapted host cell and used to produce the protein using standard techniques well known in the art. Isolated antibodies can be conjugated to therapeutic agents, such as camptothecins, using the techniques described herein.</span>
  </p>
  <p num="120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">   </span>Chimeric and humanized antibodies</span>
  </p>
  <p num="121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[096]      ,           , ,  ,     (CDR)  .           .           (, Leung et al., 1994, Hybridoma 13:469).</span>[096] A chimeric antibody is a recombinant protein in which the variable regions of a human antibody have been replaced by variable regions, for example, mouse antibodies, including the complementarity determining regions (CDRs) of a mouse antibody. Chimeric antibodies exhibit reduced immunogenicity and increased stability when administered to a subject. Methods for constructing chimeric antibodies are well known in the art (e.g., Leung et al., 1994, Hybridoma 13: 469).</span>
  </p>
  <p num="122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[097]          CDR               .   (FR)         FR .              FR        .         .           . (., , Jones et al., 1986, Nature, 321:522; Riechmann et al., Nature, 1988, 332:323; Verhoeyen et al., 1988, Science, 239:1534; Carter et al., 1992, Proc. Nat'l Acad. Sci. USA, 89:4285; Sandhu, Crit. Rev. Biotech., 1992, 12:437; Tempest et al., 1991, Biotechnology 9:266; Singer et al., J. Immun., 1993, 150:2844.)</span>[097] The chimeric monoclonal antibody can be humanized by transferring mouse CDR regions from the mouse immunoglobulin variable heavy and light chains to the corresponding variable domains of a human antibody. Mouse framework regions (FR) in a chimeric monoclonal antibody are also replaced by human FR sequences. To maintain the stability and antigenic specificity of the humanized monoclonal antibody, one or more human FR residues can be replaced with corresponding mouse residues. Humanized monoclonal antibodies can be used for therapeutic treatment of subjects. Techniques for making humanized monoclonal antibodies are well known in the art. (See, for example, Jones et al., 1986, Nature, 321: 522; Riechmann et al., Nature, 1988, 332: 323; Verhoeyen et al., 1988, Science, 239: 1534; Carter et al., 1992, Proc. Nat'l Acad. Sci. USA, 89: 4285; Sandhu, Crit. Rev. Biotech., 1992, 12: 437; Tempest et al., 1991, Biotechnology 9: 266; Singer et al., J . Immun., 1993, 150: 2844.)</span>
  </p>
  <p num="123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[098]          .         , ,  : Goldenberg et al., WO 91/11465 (1991)  Losman et al., Int. J. Cancer 46: 310 (1990).           .        ,            ,   .</span>[098] Other implementations may include antibodies to non-human primates. General techniques for producing therapeutically useful antibodies in baboons are described, for example, in Goldenberg et al., WO 91/11465 (1991) and Losman et al., Int. J. Cancer 46: 310 (1990). In another embodiment, the antibody may be a human monoclonal antibody. Such antibodies can be obtained from transgenic mice that are designed to produce specific human antibodies in response to antigenic stimulation, as discussed below.</span>
  </p>
  <p num="124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Human antibodies</span>
  </p>
  <p num="125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[099]          ,   ,    ,      (., , : Mancini et 1 2004, New Microbiol. 27:315-28; Conrad, Scheller, 2005, Comb. Chem. High Throughput Screen. 8:117-26; Brekke, Loset, 2003, Curr. Opin. Phamacol. 3:544-50;         ).    ,  ,      ,     ,   in vivo    ,     .            ,     .</span>[099] Methods for producing fully human antibodies using either combinatorial approaches or transgenic animals transformed with human immunoglobulin loci are known in the art (see, for example, sources: Mancini et a1, 2004, New Microbiol. 27: 315-28 ; Conrad, Scheller, 2005, Comb. Chem. High Throughput Screen. 8: 117-26; Brekke, Loset, 2003, Curr. Opin. Phamacol. 3: 544-50; each of which is incorporated herein by reference). Such fully human antibodies are expected to show even fewer side effects than chimeric or humanized antibodies, and function in vivo essentially in the same way as endogenous human antibodies. In some embodiments, the claimed methods and procedure may involve human antibodies obtained using such techniques.</span>
  </p>
  <p num="126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0100]              (., , : Dantas-Barbosa et al., 2005, Genet. Mol. Res. 4:126-40,      ).        ,   ,      , ,  (Dantas-Barbosa et al., 2005).             ,               .</span>[0100] In one alternative, phage display techniques can be used to produce human antibodies (see, for example, source: Dantas-Barbosa et al., 2005, Genet. Mol. Res. 4: 126-40, incorporated herein by links). Human antibodies can be obtained from healthy people, or from people who have a specific disease state, such as cancer (Dantas-Barbosa et al., 2005). An advantage of constructing human antibodies based on antibodies of a diseased individual is that the repertoire of circulating antibodies can be biased toward antibodies against disease-associated antigens.</span>
  </p>
  <p num="127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0101]       Dantas-Barbosa   (2005)     Fab-      .  ,         ().  Fab    ,   -        ().           Fab            (. : Marks et al., 1991, J. Mol. Biol. 222:581-97,      ).       : Andris-Widhopf et al., 2000,   Phage Display Laboratory Manual, Barbas et al. (eds), 1<sup class="style-scope patent-text">st</sup> edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 9.1-9.22,      ).  Fab-             .            .   ,      ,                  .</span>[0101] According to one non-limiting example of this methodology, Dantas-Barbosa et al. (2005) constructed a phage display library of Fab fragments of human antibodies from patients with osteosarcoma. As a rule, total RNA was obtained from circulating lymphocytes (above). Recombinant Fab was cloned from the repertoires of , , and  chains of antibodies and built into the phage display library (above). RNA was converted to cDNA and used to obtain Fab cDNA libraries using specific primers against the heavy and light chains of immunoglobulin sequences (see source: Marks et al., 1991, J. Mol. Biol. 222: 581-97, incorporated herein by reference). The construction of the library was carried out in accordance with the source: Andris-Widhopf et al., 2000, in the manual Phage Display Laboratory Manual, Barbas et al. (eds), 1 <sup class="style-scope patent-text">st</sup> edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 9.1-9.22, incorporated herein by reference). The resulting Fab fragments were digested with restriction endonucleases and inserted into the bacteriophage genome to obtain a phage display library. Such libraries can be screened using standard phage display methods. One skilled in the art will understand that this technique is an example only, and any known method for producing and screening antibodies or fragments of human antibodies by means of phage display can be used.</span>
  </p>
  <p num="128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0102]         ,        ,                 .          : Green et al., Nature Genet. 7:13 (1994), Lonberg et al., Nature 368:856 (1994)  Taylor et al., Int. Immun. 6:579 (1994).      XENOMOUSE (., , : Green et al., 1999, J. Immunol. Methods 231:11-23,      )  Abgenix (, ),            ,        .</span>[0102] In another alternative, transgenic animals that have been genetically engineered to produce human antibodies can be used to produce antibodies against essentially any immunogenic target using standard immunization protocols as discussed above. Methods for producing human antibodies in transgenic mice are described in sources: Green et al., Nature Genet. 7:13 (1994), Lonberg et al., Nature 368: 856 (1994) and Taylor et al., Int. Immun. 6: 579 (1994). A non-limiting example of such a system is XENOMOUSE (see, for example, source: Green et al., 1999, J. Immunol. Methods 231: 11-23, incorporated herein by reference) from Abgenix (Fremont, California), where the genes mouse antibodies are inactivated and replaced with the functional genes of human antibodies, while the rest of the immune system of mice remains intact.</span>
  </p>
  <p num="129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0103]    YAC (  )    ,    IgH  - Ig ,       ,       .           -,          .  XENOMOUSE,   ,        ,     /     ,   .      ,        .  ,                 (Green et al., 1999).   ,          XENOMOUSE,       ,        .</span>[0103] Transgenic mice were transformed with YAC (artificial yeast chromosomes) in a germline configuration containing fragments of IgH loci and human IgG kappa chains, including most variable region sequences, as well as auxiliary genes and regulatory sequences. The repertoire of human variable regions can be used to produce antibody-producing B cells that can be transformed into hybridomas using known techniques. XENOMOUSE mice immunized with the target antigen, as a result of a normal immune response, produce human antibodies that can be assembled and / or prepared using standard techniques, as discussed above. Various lines of genetically engineered mice are available, each of which is capable of producing a separate class of antibodies. It has been shown that human antibodies obtained by the transgenic method have therapeutic potential while maintaining the pharmacokinetic properties of normal human antibodies (Green et al., 1999). One skilled in the art will understand that the claimed compositions and methods are not limited to the use of the XENOMOUSE system, and may involve the use of any transgenic animals that have been genetically engineered to produce human antibodies.</span>
  </p>
  <p num="130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Obtaining antibody fragments</span>
  </p>
  <p num="131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0104]      /     .      , ,           . ,             5S-,  F(ab')<sub class="style-scope patent-text">2</sub>.         -  , ,     ,     ,    3,5S Fab'-.  ,         Fab-  Fc-.          4036945;   4331647;  : Nisonoff et al., 1960, Arch. Biochem. Biophys., 89:230; Porter, 1959, Biochem. J., 73:119; Edelman et al., 1967, METHODS IN ENZYMOLOGY, page 422 (Academic Press);  Coligan et al. (eds.), 1991, CURRENT PROTOCOLS IN IMMUNOLOGY, (John Wiley &amp; Sons).</span>[0104] Some embodiments of the claimed methods and / or compositions may include antibody fragments. Such antibody fragments can be obtained, for example, by pepsin or papain cleavage of whole antibodies using standard methods. For example, antibody fragments can be obtained by enzymatically cleaving antibodies with pepsin to provide a 5S fragment denoted by F (ab ') <sub class="style-scope patent-text">2</sub> . The indicated fragment can be further cleaved using a thiol reducing agent and, optionally, blocking groups for sulfhydryl groups formed by cleavage of disulfide bonds to obtain monovalent 3,5S Fab'-fragments. Alternatively, enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment. Examples of methods for producing antibody fragments are described in US Pat. No. 4,036,945; U.S. Patent No. 4,331,647; Sources: Nisonoff et al., 1960, Arch. Biochem. Biophys., 89: 230; Porter, 1959, Biochem. J. 73: 119; Edelman et al., 1967, METHODS IN ENZYMOLOGY, page 422 (Academic Press); and Coligan et al. (eds.), 1991, CURRENT PROTOCOLS IN IMMUNOLOGY, (John Wiley &amp; Sons).</span>
  </p>
  <p num="132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0105]       ,          / ,      ,    ,  ,      ,   . , Fv-     V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>.     ,    : Inbar et al., 1972, Proc. Nat'l. Acad. Sci. USA, 69:2659.  ,          -  ,   . . Sandhu, 1992, Crit. Rev. Biotech., 12:437.</span>[0105] Other antibody cleavage methods can also be used, such as heavy chain separation to form monovalent light / heavy chain fragments, additional fragment cleavage, or other enzymatic, chemical, or genetic techniques, provided that these fragments bind to an antigen recognized by the intact antibody . For example, Fv fragments include a bond between V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> chains. The specified connection may be non-covalent, as described in the source: Inbar et al., 1972, Proc. Nat'l. Acad Sci. USA 69: 2659. Alternatively, the variable chains can be joined by an intermolecular disulfide bond or cross-linked with chemicals, such as glutaraldehyde. See Sandhu, 1992, Crit. Rev. Biotech., 12: 437.</span>
  </p>
  <p num="133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0106]    Fv-   V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>,   .     (scFv)     ,   ,   V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>,    .      ,     -, , . coli.  -       ,     V-.   scFv      . . : Whitlow et al., 1991, Methods: A Companion to Methods in Enzymology 2:97; Bird et al., 1988, Science, 242:423;   4946778; Pack et al., 1993, Bio/Technology, 11:1271;  Sandhu, 1992, Crit. Rev. Biotech., 12:437.</span>[0106] In a preferred embodiment, the Fv fragments comprise V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> chains linked by a peptide linker. These single chain antigen binding proteins (scFvs) are obtained by constructing a structural gene containing DNA sequences encoding the V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> domains connected by an oligonucleotide linker sequence. The structural gene is inserted into the expression vector, which is then introduced into the host cell, for example, E. coli. Recombinant host cells synthesize a single polypeptide chain with a linker peptide forming a bridge between two V domains. Methods for producing scFv are well known in the art. See sources: Whitlow et al., 1991, Methods: A Companion to Methods in Enzymology 2:97; Bird et al., 1988, Science, 242: 423; U.S. Patent No. 4,946,778; Pack et al., 1993, Bio / Technology, 11: 1271; and Sandhu, 1992, Crit. Rev. Biotech., 12: 437.</span>
  </p>
  <p num="134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0107]        (dAb),    .           (., , Cossins et al., Protein Expression and Purification, 2007, 51:253-59; Shuntao et al., Molec Immunol 2006, 43:1912-19; Tanha et al., J. Biol. Chem. 2001, 276:24774-780).             (CDR). CDR- (  )      ,  CDR   .   , ,              . . : Larrick et al., 1991, Methods: A Companion to Methods in Enzymology 2:106; Ritter et al. (eds.), 1995, MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, pages 166-179 (Cambridge University Press); Birch et al., (eds.), 1995, MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, pages 137-185 (Wiley-Liss, Inc.)</span>[0107] Another form of an antibody fragment is a single domain antibody (dAb), sometimes called a single chain antibody. Single domain antibody production techniques are well known in the art (see, for example, Cossins et al., Protein Expression and Purification, 2007, 51: 253-59; Shuntao et al., Molec Immunol 2006, 43: 1912-19; Tanha et al., J. Biol. Chem. 2001, 276: 24774-780). Other types of antibody fragments may contain one or more complementarity determining regions (CDRs). CDR peptides (minimal recognition units) can be obtained by constructing genes encoding the CDRs of an antibody of interest. Such genes are obtained, for example, using the polymerase chain reaction for the synthesis of the variable region with RNA producing antibody cells. See sources: Larrick et al., 1991, Methods: A Companion to Methods in Enzymology 2: 106; Ritter et al. (eds.), 1995, MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, pages 166-179 (Cambridge University Press); Birch et al., (Eds.), 1995, MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, pages 137-185 (Wiley-Liss, Inc.)</span>
  </p>
  <p num="135" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Antibody Options</span>
  </p>
  <p num="136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0108]      ,   Fc- ,       ,      .            ,   -  (., , Sambrook et al., Molecular Cloning, A laboratory manual, 2<sup class="style-scope patent-text">nd</sup> Ed, 1989).                  Fc (., ,   6254868,         ).              Fc (., , : Hornick et al., 2000, J Nucl Med 41:355-62; Hinton et al., 2006, J Immunol 176:346-56; Petkova et al. 2006, Int Immunol 18:1759-69;   7217797;         ).</span>[0108] In some embodiments, antibody sequences, such as Fc portions of antibodies, may be varied to optimize physiological characteristics of conjugates, such as serum half-lives. Methods for replacing amino acid sequences in proteins, such as site-specific mutagenesis, are widely known in the art (see, for example, Sambrook et al., Molecular Cloning, A laboratory manual, 2 <sup class="style-scope patent-text">nd</sup> Ed, 1989). In preferred embodiments, the variant may include adding or removing one or more glycosylation sites in the Fc sequence (see, for example, US Pat. No. 6,254,868, an example section of which is incorporated herein by reference). In other preferred embodiments, specific amino acid substitutions in the Fc sequence can be made (see, for example, Sources: Hornick et al., 2000, J Nucl Med 41: 355-62; Hinton et al., 2006, J Immunol 176: 346 -56; Petkova et al. 2006, Int Immunol 18: 1759-69; US Patent No. 7217797; each of which is incorporated herein by reference).</span>
  </p>
  <p num="137" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    </span>Target antigens and antibody examples</span>
  </p>
  <p num="138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0109]      ,    /   ,        ,          ,     .          .       LL1 ( CD74),      810<sup class="style-scope patent-text">6</sup>       (., , Hansen et al., 1996, Biochem J. 320:293-300). ,       ,       110<sup class="style-scope patent-text">6</sup>   110<sup class="style-scope patent-text">7</sup>      . ,           MAb,  ,  .  ,     , , , ,   ,  LL1 ( CD74), LL2  RFB4 ( CD22),  (hA20,  CD20),  ( CD20),  (GA101,  CD20),  (  PD-1),  (  PD-1),  ( CTLA-4), RS7 (  -1 (EGP-1,    TROP-2)), PAM4  4 (  ), MN-14 (   (,    CD66e,  5), MN-15  MN-3 ( 6), -9 (     -), Immu 31 ( -), R1 ( -IR),  19 ( CD 19), TAG-72 (, 49), Tn, J591  HuJ591 (  (    )), AB-PG1-XG1-026 (  ), D2/B ( ), G250 (MAb   IX), L243 ( HLA-DR),  ( CD52),  ( ),  ( EGFR),  ( CD33),   ( CD20);  ( EGFR);  ( CD20); PAM4 ( ,  )   ( ErbB2).        (., , :   5686072; 5874540; 6107090; 6183744; 6306393; 6653104; 6730.300; 6899864; 6926893; 6962702; 7074403; 7230084; 7238785; 7238786; 7256004; 7282567; 7300655; 7312318; 7585491; 7612180; 7642239;       20050271671; 20060193865; 20060210475; 20070087001;           .)   ,   ,  hPAM4 (  7282567), hA20 (  7251164), hA19 (  7109304), hIMMU-31 (  7300655), hLL1 (  7312318), hLL2 (  7074403), hMu-9 (  7387773), hL243 (  7612180), hMN-14 (  6676924), hMN-15 (  7541440), hR1 (    12/772645), hRS7 (  7238785), hMN-3 (  7541440), AB-PG1-XG1-026 (    11/983372,      -4405  -4406)  D2/B (WO 2009/130575);                ,      .          hRS7.       , ,    ,      Trop-2      ,  Trop-2.</span>[0109] In a preferred embodiment, antibodies are used that recognize antigens and / or bind to antigens that are expressed at high levels on the target cells, and are mainly or exclusively expressed on diseased cells, and not in normal tissues. In a more preferred embodiment, said antibodies are rapidly internalized after binding. An example of a rapidly internalizing antibody is the LL1 antibody (anti-CD74), the internalization rate of which is approximately 8  10 <sup class="style-scope patent-text">6</sup> antibody molecules per cell per day (see, for example, Hansen et al., 1996, Biochem J. 320: 293-300). Accordingly, a rapidly internalizing antibody can be represented by an antibody whose internalization index is from about 1  10 <sup class="style-scope patent-text">6</sup> to about 1  10 <sup class="style-scope patent-text">7</sup> antibody molecules per cell per day. Antibodies suitable for use in the claimed compositions and methods may include MAb having the properties described above. Examples of antibodies suitable for use in the treatment of, for example, cancer include, but are not limited to, antibodies LL1 (against CD74), LL2 or RFB4 (against CD22), veltuzumab (hA20, against CD20), rituximab (against CD20), obinutuzumab ( GA101, against CD20), lambrolizumab (against the PD-1 receptor), nivolumab (against the PD-1 receptor), ipilimumab (against CTLA-4), RS7 (against epithelial glycoprotein-1 (EGP-1, also known as TROP-2 )), PAM4 or KC4 (both against mucin), MN-14 (against carcinoembryonic antigen (KEA, also known as CD66e, or CEACAM5), MN-15 or MN-3 (against CEACAM6), Mi-9 (against specific for antigen-p colon), Immu 31 (against alpha-fetoprotein), R1 (against IGF-IR), A 19 (against CD 19), TAG-72 (e.g. CC49), Tn, J591 or HuJ591 (against PSMA ( specific prostate membrane antigen)), AB-PG1-XG1-026 (against PSMA dimer), D2 / B (against PSMA), G250 (MAb against carbonic anhydrase IX), L243 (against HLA-DR), alemtuzumab (against CD52), bevacizumab (against VEGF), cetuximab (against EGFR), gemtuzumab (against CD33), ibritutomab tiuxetan (against CD20); panitumumab (against EGFR); tositumomab (against CD20); PAM4 (or clivatuzumab, against mucin) and trastuzumab (against ErbB2). Such antibodies are known in the art (see, for example, sources: US Pat. ; 7300655; 7312318; 7585491; 7612180; 7642239; and published U.S. patent applications No. 2005271671; No. 20060193865; No. 2006210475; No. 20070087001; examples of each of which are incorporated herein by reference.) Specific known antibodies suitable for use, include hPAM4 (US patent No. 7282567), hA20 (US patent No. 7251164), hA19 (US patent No. 7109304), hIMMU-31 (US patent No. 7300655), hLL1 (US patent No. 7312318), hLL2 (US patent No. 7074403) , hMu-9 (US patent No. 7387773), hL243 (US patent No. 7612180), hMN-14 (US patent No. 6676924), hMN-15 (US patent No. 7541440), hR1 (application for <figure-callout id="12" label="US patent" filenames="00000045.png,00000047.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">US patent</a></figure-callout> 12/772645), hRS7 (US patent No. 7238785), hMN-3 (US patent No. 7541440), AB-PG1-XG1-026 (<figure-callout id="11" label="patent application US" filenames="00000046.png,00000047.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patent application US</a></figure-callout> 11/983372, deposited in ATCC under the numbers PT A-4405 and PTA-4406) and D2 / B (WO 2009/130575); the text of each of the mentioned patents and each of the mentioned applications is incorporated into this document by reference, with reference to the sections of the drawings and examples. According to a particular preferred embodiment, said antibody is hRS7. One of ordinary skill in the art will understand that, according to some embodiments, antibodies against TAAs other than Trop-2 can be used in combination with an anti-Trop-2 antibody.</span>
  </p>
  <p num="139" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0110]   ,    ,   IX, 7, CCL19, CCL21, CSAp, HER-2/neu, BrE3, CD1, CD1a, CD2, CD3, CD4, CD5. CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20 (. 2 8, MAb hA20, 1F5), CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD44, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, CTLA-4, - (),  (, ,   ),  ED-B (, L19), EGP-1 (TROP-2), EGP-2 (, 17-1),  EGF (ErbB1) (, ), ErbB2, ErbB3,  , FHL-1, Flt-3,  , Ga733, GRO-, HMGB-1,    (HIF), HM1.24, HER-2/neu,    (), -, -, -, -, -2R, -4R, -6R, -13R, -15R, -17R, -18R, -2, -6, -8, -12, -15, -17, -18, -25, IP-10, -1R, Ia, HM1.24, , HCG,  HLA-DR,    L243,  CD66, .. CD66a-d   , MAGE, mCRP, MCP-1, MIP-1A, MIP-1B,     (MIF), MUC1, MUC2, MUC3, MUC4, MUC5ac,    (),  (  ), ,  4,  PD-1, NCA-95, NCA-90, A3, 22, -, KS-1, Le(y), , S100, , ,  Tn,  -,   ,   , -,  TRAIL (R1  R2), TROP-2, , RANTES, 101,      ,   3, 3, C3b, 5, 5   .</span>[0110] Other suitable antigens that may be targeted include carbonic anhydrase IX, B7, CCL19, CCL21, CSAp, HER-2 / neu, BrE3, CD1, CD1a, CD2, CD3, CD4, CD5. CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20 (e.g. C2 B8, MAb hA20, 1F5), CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L , CD44, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, CTLA-4, alpha -fetoprotein (AFP), VEGF (e.g., bevacizumab, fibronectin splicing variant), ED-B fibronectin (e.g. L19), EGP-1 (TROP-2), EGP-2 (e.g. 17-1A), EGF receptor ( ErbB1) (e.g. cetuximab), ErbB2, ErbB3, factor H, FHL-1, Flt-3, folate receptor, Ga733, GRO-, HMGB-1, hypoxia-induced factor (HIF), HM1.24, HER-2 / neu, insulin-like growth factor (IGF), IFN-, IFN-, IFN-, IFN-, IL-2R, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, IFR-1R, Ia, HM1.24, gangliosides, HCG, the HLA-DR antigen that L243 binds to, CD66 antigens, i.e. CD66a-d or a combination thereof, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, macrophage migration inhibition factor (MIF), MUC1, MUC2, MUC3, MUC4, MUC5ac, placental growth factor (PFR), PSA ( prostate specific antigen), PSMA, PAM4 antigen, PD-1 receptor, NCA-95, NCA-90, A3, A22, Ep-CAM, KS-1, Le (y), mesothelin, S100, tenascin, TAC, Tn antigen , Thomson-Friedenreich antigens, tumor necrosis antigens, tumor angiogenesis antigens, TNF-, TRAIL receptor (R1 and R2), TROP-2, rRFES, RANTES, T101, as well as cancer stem cell antigens, complement factors C3, C3a, C3b , C5a, C5 and oncogen product.</span>
  </p>
  <p num="140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0111]     (Cluster Designation,  CD)     ,      ,             ,   : Craig, Foon, Blood,     15  2008 .; DOL 10.1182/blood-2007-11-120535.</span>[0111] A comprehensive analysis of suitable antigenic (Cluster Designation, or CD) targets on hematopoietic malignant cells, as shown by flow cytometry, which can guide the selection of suitable antibodies for conjugated drug immunotherapy, is described in: Craig, Foon, Blood , preliminary publication on the network January 15, 2008; DOL 10.1182 / blood-2007-11-120535.</span>
  </p>
  <p num="141" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0112]  CD66        , CD66a-e,       (), BCG, CGM6, NCA, CGM1  , .   CD66 (, 6)     ,          .          ,   NY-ESO-1 (Theurillat et al., Int. J. Cancer 2007; 120(11):2411-7),  CD79a    (Kozlov et al., Cancer Genet. Cytogenet. 2005; 163(1):62-7),   - ,  CD79b    (Poison et al., Blood 110(2):616-623).           . 60/426379,   Use of Multi-specific, Non-covalent Complexes for Targeted Delivery of Therapeutics (        ),  15  2002 ..   ,         - (Hill, Perris, J. Natl. Cancer Inst. 2007; 99:1435-40),  ,        ,   CD 133     (Maitland et al., Ernst Schering Found. Sympos. Proc. 2006; 5:155-79),    (Donnenberg et al., J. Control Release 2007; 122(3):385-91)   (Beier et al., Cancer Res. 2007; 67(9):4010-5),  CD44       (Dalerba et al., Proc. Natl. Acad. Sci. USA 2007; 104(24)10158-63),    (Li et al., Cancer Res. 2007; 67(3):1030-7)        (Prince et al., Proc. Natl. Acad. Sci. USA 2007; 104(3)973-8).           LIV-1,  Taylor   (Taylor et al., Biochem. J. 2003; 375:51-9).  CD47          (., , Naujokat et al., 2014, Immunotherapy 6:290-308; Goto et al., 2014, Eur J Cancer 50:1836-46; Unanue, 2013, Proc Natl Acad Sci USA 110:10886-7).</span>[0112] CD66 antigens are composed of five different glycoproteins with a similar structure, CD66a-e, encoded by members of the gene family of carcinoembryonic antigens (CEA), BCG, CGM6, NCA, CGM1 and CEA, respectively. These CD66 antigens (e.g. CEACAM6) are expressed mainly in granulocytes, normal epithelial cells of the digestive tract and tumor cells of various tissues. Test cancer antigens such as NY-ESO-1 (Theurillat et al., Int. J. Cancer 2007; 120 (11): 2411-7) and CD79a for myeloid leukemia (Kozlov et al) are also suitable cancer targets. ., Cancer Genet. Cytogenet. 2005; 163 (1): 62-7), as well as B-cell diseases, and CD79b for non-Hodgkin's lymphoma (Poison et al., Blood 110 (2): 616-623). A number of the above antigens are described in provisional patent application US Ser. No. 60/426379, entitled Use of Multi-specific, Non-covalent Complexes for Targeted Delivery of Therapeutics, filed on November 15, 2002. Cancer stem cells that considered more resistant to therapy by populations of malignant progenitor cells (Hill, Perris, J. Natl. Cancer Inst. 2007; 99: 1435-40), contain antigens that can be targeted in certain types of cancer, such as CD 133 in prostate cancer glands (Maitland et al., Ernst Schering Found. Sympos. Proc. 2006; 5: 155-79), non-small cell lung cancer (Donnenberg et al., J. Control Release 2007; 122 (3): 385-91) and glioblastoma (Beier et al., Cancer Res. 2007; 67 (9): 4010-5), and CD44 for colorectal cancer (Dalerba et al., Proc. Natl. Acad. Sci. USA 2007; 104 (24) 10158-63), pancreatic cancer (Li et al., Cancer Res. 2007; 67 (3): 1030-7) and with squamous cell carcinoma of the head and neck (Prince et al., Proc. Natl. Acad Sci. USA 2007; 104 (3) 973-8). Another suitable target for the treatment of breast cancer is the LIV-1 antigen described by Taylor et al. (Taylor et al., Biochem. J. 2003; 375: 51-9). The CD47 antigen is an additional suitable target for cancer stem cells (see, for example, Naujokat et al., 2014, Immunotherapy 6: 290-308; Goto et al., 2014, Eur J Cancer 50: 1836-46; Unanue, 2013 , Proc Natl Acad Sci USA 110: 10886-7).</span>
  </p>
  <p num="142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0113]          , , CD38  CD 138 (Stevenson, Mol Med 2006; 12(11-12):345-346; Tassone et al., Blood 2004; 104(12):3688-96), CD74 (Stein et al.,  ), CS1 (Tai et al., Blood 2008; 112(4):1329-37)  CD40 (Tai et al., 2005; Cancer Res. 65(13):5898-5906).</span>[0113] For the treatment of multiple myeloma, suitable targeting antibodies have been described, for example, CD38 and CD 138 (Stevenson, Mol Med 2006; 12 (11-12): 345-346; Tassone et al., Blood 2004; 104 (12) : 3688-96), CD74 (Stein et al., Ibid.), CS1 (Tai et al., Blood 2008; 112 (4): 1329-37) and CD40 (Tai et al., 2005; Cancer Res. 65 (13): 5898-5906).</span>
  </p>
  <p num="143" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0114]     (MIF)          . CD74      MIF (Leng et al., 2003, J Exp Med 197:1467-76).      CD74   MIF            ,     ,  ,  , ,       (, Meyer-Siegler et al., 2004,  Cancer 12:34; Shachar &amp; Haran, 2011, Leuk Lymphoma 52:1446-54);  ,         (Morand &amp; Leech, 2005, Front Biosci 10:12-22; Shachar &amp; Haran, 2011, Leuk Lymphoma 52:1446-54);  ,      (Lan, 2008, Nephron Exp Nephrol. 109:e79-83);     (Meyer-Siegler et al., 2009, Mediators Inflamm epub March 22, 2009; Takahashi et al., 2009, Respir Res 10:33.  (hLL1)      CD74,        MIF .</span>[0114] Inhibition of macrophage migration (MIF) is an important regulator of innate and adaptive immunity and apoptosis. CD74 has been described as an endogenous MIF receptor (Leng et al., 2003, J Exp Med 197: 1467-76). The therapeutic effect of antagonistic antibodies against CD74 on MIF-mediated intracellular pathways may be suitable for use in the treatment of a wide range of disease conditions such as cancer of the bladder, prostate, breast, lung, colon and chronic lymphocytic leukemia (e.g., Meyer-Siegler et al ., 2004, Navy Cancer 12:34; Shachar &amp; Haran, 2011, Leuk Lymphoma 52: 1446-54); autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (Morand &amp; Leech, 2005, Front Biosci 10: 12-22; Shachar &amp; Haran, 2011, Leuk Lymphoma 52: 1446-54); kidney diseases such as kidney allograft rejection (Lan, 2008, Nephron Exp Nephrol. 109: e79-83); and numerous inflammatory diseases (Meyer-Siegler et al., 2009, Mediators Inflamm epub March 22, 2009; Takahashi et al., 2009, Respir Res 10:33. Milatuzumab (hLL1) is an example of an anti-CD74 antibody suitable for therapeutic use in the treatment of MIF-mediated diseases.</span>
  </p>
  <p num="144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0115]   -              ,    ,   (,    ,   )  .    -    CDP571 (Ofei et al., 2011, Diabetes 45:881-85);   MTNFAI, M2TNFAI, M3TNFAI, M3TNFABI, 302   33 (Thermo Scientific, , );  (Centocor, , );   (UCB, , );   (Abbott, -, ).        -       .  ,          , ,   ,   -,   , ,   hL243;  (  -6);  ( CD25);  ( CD25);  ( CD 11); -CD3 (  CD3);   CD40L (UCB, , );  (  4)   ( IgE).</span>[0115] Antibodies against TNF- are known in the art and may be suitable for use in the treatment of immune diseases such as autoimmune disease, immune dysfunction (eg, graft versus host disease, organ transplant rejection) or diabetes. Known anti-TNF- antibodies include the human CDP571 antibody (Ofei et al., 2011, Diabetes 45: 881-85); mouse antibodies MTNFAI, M2TNFAI, M3TNFAI, M3TNFABI, M302 B and M3O3 (Thermo Scientific, Rockford, Illinois); infliximab (Centocor, Malvern, PA); certolizumab pegol (UCB, Brussels, Belgium); and adalimumab (Abbott, Abbott Park, Illinois). These and many other known antibodies against TNF- can be used in the claimed methods and compositions. Other antibodies suitable for use in the treatment of immune dysregulation or autoimmune diseases include, but are not limited to, anti-B cell antibodies such as veltuzumab, epratuzumab, milatuzumab, or hL243; tocilizumab (against IL-6 receptor); basiliximab (against CD25); daclizumab (against CD25); efalizumab (against CD 11a); muromonab-CD3 (against the CD3 receptor); anti-CD40L antibody (UCB, Brussels, Belgium); natalizumab (against integrin 4) and omalizumab (against IgE).</span>
  </p>
  <p num="145" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0116]       ,      ,      ,        .     /  LL1, MAb  CD74 ( ,    II . Ii) (., ,   6653104; 7312318;           ).  CD74      -  (    )  ,  - , ,   ,   ,       (Ong et al., Immunology 98:296-302 (1999)).    CD74     : Stein et al., Clin Cancer Res. 2007 Sep 15; 13(18 Pt 2):5556s-5563s,      .</span>[0116] According to another preferred embodiment, antibodies are used that are rapidly internalized and then re-expressed, processed and presented on the surface of the cells, providing continuous uptake and accumulation of the circulating conjugate by the cell. An example of the most preferred antibody / antigen pair is LL1, anti-CD74 MAb (Class II chaperone invariant chain. Ii) (see, for example, US Pat. No. 6,653,104; No. 7,312,318; examples of each of which are incorporated herein by reference ) The CD74 antigen is highly expressed in B-cell lymphomas (including multiple myeloma) and leukemia, certain T-cell lymphomas, melanomas, colon cancer, lung and kidney cancer, glioblastomas and some other cancers (Ong et al., Immunology 98: 296-302 (1999)). A review of the use of CD74 antibodies in cancer is provided in the source: Stein et al., Clin Cancer Res. 2007 <figure-callout id="15" label="Sep" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Sep</a></figure-callout> 15; 13 (18 Pt 2): 5556s-5563s, incorporated herein by reference.</span>
  </p>
  <p num="146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0117] ,       CD74, ,   ,  ,  , ,  , ,  ,  , ,     .     CD74                     LL1     ,   .   ,   ,   LL1    ,    .   LL1          ,          .</span>[0117] Diseases that are preferably treated with anti-CD74 antibodies include, but are not limited to, non-Hodgkins lymphoma, Hodgkins disease, melanoma, cancer of the lung, kidney, colon, glioblastoma multiforme, histiocytomas, myeloid leukemia, and multiple myeloma. Constantly renewing expression of the CD74 antigen over short periods of time on the surface of the target cells, followed by internalization of the indicated antigen and re-expression of the antigen, allows the targeting antibody LL1 to be internalized along with any chemotherapeutic fragment that it carries. This provides a high, also therapeutic, concentration of the LL1 conjugate with a chemotherapeutic drug that accumulates inside such cells. The internalized conjugates of LL1 with a chemotherapeutic drug cyclically pass through lysosomes and endosomes, and the chemotherapeutic fragment is released in active form in the target cells.</span>
  </p>
  <p num="147" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">   </span>Bispecific and multispecific antibodies</span>
  </p>
  <p num="148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0118]        . ,           -         -.  ,     CD3  -,         - (Nitta, et al. Lancet. 1990; 355:368-371).        CD3   CD 19.       CD3                - ,  , ,   CD3   Trop-2,  CD3   CD20,  CD3   CD22,  CD3   HLA-DR;   CD3   CD74.         ADC-,    ,         . ,   (bsAb)  Trop-2   CD3   ,    ADC  Trop-2.</span>[0118] Bispecific antibodies are suitable for some biomedical applications. For example, a bispecific antibody with binding sites for cell surface tumor antigen and cell surface T receptor can direct lysis of specific tumor cells with T cells. Bespecific antibodies recognizing gliomas and the CD3 epitope on T cells have been successfully used to treat brain tumors in human patients (Nitta, et al. Lancet. 1990; 355: 368-371). A preferred bispecific antibody is an anti-CD3  anti-CD19 antibody. In alternative embodiments, an anti-CD3 antibody or fragment thereof may be attached to an antibody or antibody fragment of another B-cell-associated antigen to produce, for example, an anti-CD3  anti Trop-2, against CD3  against CD20, against CD3  against CD22, against CD3  against HLA-DR; or against CD3  against CD74. In some embodiments, the methods and compositions for the ADC therapy described herein can be used in combination with bispecific or multispecific antibodies. For example, an anti-Trop-2  anti-CD3 bispecific antibody (bsAb) can be administered before, simultaneously with, or after anti-Trop-2 ADC.</span>
  </p>
  <p num="149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0119]        , ,      7405320,         .       ,     ,      ,     (Milstein, Cuello, Nature, 1983; 305:537-540).</span>[0119] Numerous methods are known for producing bispecific or multispecific antibodies, for example, as described in US Pat. No. 7,405,320, a section of the examples of which are incorporated herein by reference. Bespecifically antibodies can be obtained in a quadratic manner involving the fusion of two different hybridomas, each of which produces a monoclonal antibody that recognizes an excellent antigenic site (Milstein, Cuello, Nature, 1983; 305: 537-540).</span>
  </p>
  <p num="150" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0120]         -        (Staerz, et al. Nature, 1985; 314:628-631; Perez, et al. Nature, 1985; 316:354-356).                 ,             (Staerz, Bevan. Proc Natl Acad Sci USA. 1986; 83:1453-1457).              Fab'-    . (., ,     0453082).</span>[0120] In another method for producing bispecific antibodies, heterobifunctional cross-linkers are used to chemically couple two different monoclonal antibodies (Staerz, et al. Nature, 1985; 314: 628-631; Perez, et al. Nature, 1985; 316: 354- 356). Bespecifically antibodies can also be obtained by reducing each of the two starting monoclonal antibodies to the corresponding semimolecules, which are then mixed and allowed to re-oxidize to give a hybrid structure (Staerz, Bevan. Proc Natl Acad Sci USA. 1986; 83: 1453-1457). Another alternative involves the chemical crosslinking of two or three individually purified Fab'fragments using suitable linkers. (See, for example, European Patent Application 0453082).</span>
  </p>
  <p num="151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0121]                        ,    (DeMonte, et al. Proc Natl Acad Sci USA. 1990, 87:2941-2945);        ,        .</span>[0121] Other methods include increasing the efficiency of producing hybrid hybridomas by transferring genes of different breeding markers through retrovirus-derived shuttle vectors to the corresponding parent hybridomas, which are then fused (DeMonte, et al. Proc Natl Acad Sci USA. 1990, 87: 2941-2945 ); or by transfection of the hybridoma cell line with expression plasmids containing the heavy and light chain genes of another antibody.</span>
  </p>
  <p num="152" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0122]   V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>           (     12  )    Fv (scFv)   .   scFv     4946778    5132405,           .        12      V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>        V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>      ,      .    V<sub class="style-scope patent-text">H</sub>  V<sub class="style-scope patent-text">L</sub>,     3-12  ,     ( ).     0-2  ,    ( )   ( ),    , -,   ,    V- (V<sub class="style-scope patent-text">H</sub>--V<sub class="style-scope patent-text">L</sub>,  V<sub class="style-scope patent-text">L</sub>--V<sub class="style-scope patent-text">H</sub>),   .</span>[0122] The cognate domains V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> can be connected to a peptide linker of suitable composition and length (usually consisting of more than 12 amino acid residues) to form single chain Fv (scFv) with binding activity. Methods for producing scFv are described in US patent No. 4946778 and US patent No. 5132405, sections of examples of each of which are incorporated herein by reference. Reducing the length of the peptide linker to less than 12 amino acid residues prevents pairing of the V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> domains on one chain and stimulates the pairing of the V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> domains with complementary domains on other chains, which leads to the formation of functional multimers. The polypeptide chains of the V <sub class="style-scope patent-text">H</sub> and V <sub class="style-scope patent-text">L</sub> domains connected to linkers with a length of 3-12 amino acid residues form mainly dimers (called diabodies). In the case of linkers with a length of 0-2 amino acid residues, trimers (called triates) and tetramers (called tetrales) are predominantly formed, however, the exact oligomerization patterns seem to depend on the composition and orientation of the V domains (V <sub class="style-scope patent-text">H</sub> -linker-V <sub class="style-scope patent-text">L</sub> , or V <sub class="style-scope patent-text">L</sub> -linker-V <sub class="style-scope patent-text">H</sub> ), in addition to the length of the linker.</span>
  </p>
  <p num="153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0123]           ,  ,  ,  ,     .  ,   dock and lock (DNL),         ,       (., ,   7521056; 7527787; 7534866; 7550143; 7666400; 7858070; 7871622; 7906121; 7906118; 8163291; 7901680; 7981398; 8003111  8034352,           ).       ,    (anchoring domains, AD),      (dimerization and docking domains, DDD),          ,  ,  , , ,   .       ,    .  DNL    ,    .                        .</span>[0123] These methods for producing multispecific or bispecific antibodies are fraught with various difficulties, namely, low yield, the need for purification, low stability or the complexity of the method. Recently, a technique known as dock and lock (DNL) has been used to obtain combinations of virtually any desired antibody, antibody fragments, and other effector molecules (see, for example, US Pat. Nos. 7,521,056; 7,572,787; 7,534,866; 7,554,843; No. 7666400; No. 7858070; No. 7871622; No. 7906121; No. 7906118; No. 8163291; No. 7901680; No. 7981398; No. 8003111 and No. 8034352, examples of each of which are incorporated herein by reference). The specified technique involves complementary protein binding domains called anchoring domains (AD) and dimerization and docking domains (DDD), which bind to each other and provide assembly of complex structures in the range including dimers, trimers, tetramers, pentamers and hexamers. They form stable complexes with a high yield, without the need for significant purification. The DNL technique allows the assembly of monospecific, bispecific or multispecific antibodies. For the practical implementation of the methods claimed herein, any of the techniques known in the art for producing bispecific or multispecific antibodies can be used.</span>
  </p>
  <p num="154" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0124]     ,    ,       .           ,   .            ,  ,      .</span>[0124] In various embodiments, the conjugate described herein may be part of a multispecific composite antibody. Such antibodies may contain two or more different antigen binding sites, with varying specificity. Said multispecific composite antibody may bind to different epitopes of the same antigen or, alternatively, may bind to two different antigens.</span>
  </p>
  <p num="155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DOCK-AND-LOCK (DNL)</span>DOCK-AND-LOCK  (DNL )</span>
  </p>
  <p num="156" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0125]            DOCK-AND-LOCK (DNL) (., ,   7521056; 7527787; 7534866; 7550143; 7666400; 7858070; 7871622; 7906121; 7906118; 8163291; 7901680; 7981398; 8003111  8034352,           .)          ,        (DDD)  (R)  -  ()     (AD),        (Baillie et al., FEBS Letters. 2005; 579: 3264. Wong, Scott, Nat. Rev. Mol. Cell Biol. 2004; 5:959).  DDD  AD      ,    .   DDD       AD,        ,       DDD  AD.</span>[0125] According to preferred embodiments, a bivalent or multivalent antibody is formed as a DOCK-AND-LOCK  complex (DNL ) (see, for example, US Pat. Nos. 7,521,056; 7,527,787; 7,534,866; 7,551,043; 7,566,400; 7,858,070; No. 7871622; No. 7906121; No. 7906118; No. 8163291; No. 7901680; No. 7981398; No. 8003111 and No. 8034352, sections of examples of each of which are incorporated herein by reference.) Typically, this technique takes advantage of the specific and high-affinity binding interactions occurring between the sequence of the dimerization and docking domain (DDD) of the regulatory (R) subunits of the camp-dependent protein kinase (PKA) and the sequence of the anchor domain (AD) originating from any of a number of AKAP proteins (Baillie et al., FEBS Letters. 2005; 579: 3264. Wong, Scott, Nat. Rev. Mol. Cell Biol. 2004; 5: 959). The DDD and AD peptides can be attached to any protein, peptide or other molecule. Since the DDD sequences spontaneously dimerize and bind to the AD sequence, this technique allows the preparation of complexes of any selected molecules that can be attached to the DDD or AD sequences.</span>
  </p>
  <p num="157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0126]    DNL     DDD- ,    AD- ,      , , , ,    .      DNL      ,     ,                .  DNL        ,   , , , , , ,  ,  , -, , ,   ,  ,   ,   , ,   , ,  , ,  ,  ,        .</span>[0126] Although the standard DNL  complex contains a trimer with two DDD-linked molecules attached to one AD-linked molecule, complex structure options allow the formation of dimers, trimers, tetramers, pentamers, hexamers and other multimers. In some embodiments, the DNL  complex may contain two or more antibodies, antibody fragments, or fusion proteins that bind to the same antigenic determinant or to two or more different antigens. The DNL  complex may also contain one or more other effectors, such as proteins, peptides, immunomodulators, cytokines, interleukins, interferons, binding proteins, peptide ligands, carrier proteins, toxins, ribonuclease, such as onconase, inhibitory oligonucleotides, such as siRNA , antigens or xenoantigens, polymers such as PEG, enzymes, therapeutic agents, hormones, cytotoxic agents, antiangiogenic agents, proapoptotic agents, or any other molecule or aggregate.</span>
  </p>
  <p num="158" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0127] ,             ,    , ,   R,         1968  (Walsh et al., J. Biol. Chem. 1968;243:3763).       ,      R (Taylor, J. Biol. Chem. 1989; 264:8443).        R (RI  RII),      </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>  <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> (Scott, Pharmacol. Ther. 1991; 50:123). ,       RI<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>, RI<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>, RII<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>  RII<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>.  R       ,   ,   ,    44   RII (Newlon et al., Nat. Struct. Biol. 1999; 6:222).   ,            ,      N-  .     R          / ,            AKAP (Scott et al., J. Biol. Chem. 1990; 265; 21561)[0127] A PKA, which plays a central role in one of the best-studied signaling pathways triggered by the binding of a secondary messenger, cAMP, to the R subunits, was first isolated from rabbit skeletal muscle in 1968 (Walsh et al., J. Biol. Chem. 1968; 243: 3763). The holoenzyme structure consists of two catalytic subunits held inactive by the R subunits (Taylor, J. Biol. Chem. 1989; 264: 8443). Two types of R subunits (RI and RII) are found in PKA isoenzymes, and each type has isoforms <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> and <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> (Scott, Pharmacol. Ther. 1991; 50: 123). Accordingly, four isoforms of regulatory subunits of PKA are represented by RI <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> RI <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> RII <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> and RII <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> . R subunits were isolated only as stable dimers, and the dimerization domain was shown to consist of the first 44 amino terminal residues of RII (Newlon et al., Nat. Struct. Biol. 1999; 6: 222). According to the discussion below, similar parts of amino acid sequences of other regulatory subunits are involved in dimerization and docking, each of which is localized near the N-terminus of the regulatory subunit. The binding of cAMP to R subunits leads to the release of active catalytic subunits for a wide range of serine / threonine kinase activity, targeting selected substrates by compartmentalization of PCA by docking with AKAP proteins (Scott et al., J. Biol. Chem. 1990; 265; 21561)
  <p class="style-scope patent-text"></p>
  <p num="159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0128]      1984     ,    -2 (Lohmann et al., Proc. Natl. Acad. Sci USA. 1984; 81:6723),    50 AKAP      ,     ,  , ,    ,   ,         (Wong, Scott, Nat. Rev. Mol. Cell Biol. 2004; 5:959). AD  AKAP        14-18  (Carr et al., J. Biol. Chem. 1991; 266:14188).   AD  AKAP   ,   ,    RII,     2  90  (Alto et al., Proc. Natl. Acad. Sci. USA. 2003; 100:4445). AKAP      R.   RII</span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>  AD    ,  23   (Colledge, Scott, Trends Cell Biol. 1999; 6:216). ,   ,   AKAP  RII<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>      N-   44  (Newlon et al., Nat. Struct. Biol. 1999; 6:222; Newlon et al., EMBO J. 2001; 20:1651),     DDD.[0128] Since the first AKAR associated with microtubule protein-2 was characterized in 1984 (Lohmann et al., Proc. Natl. Acad. Sci USA. 1984; 81: 6723), more than 50 AKAPs with localization have been identified at various subcellular sites, including the plasma membrane, actin cytoskeleton, nucleus, mitochondria, and endoplasmic reticulum, with diverse structures belonging to species ranging from yeast to humans (Wong, Scott, Nat. Rev. Mol. Cell Biol. 2004; 5; : 959). AKAP AD proteins for PKA is an amphipathic helix with a length of 14-18 residues (Carr et al., J. Biol. Chem. 1991; 266: 14188). The amino acid sequences of ADs of individual AKAPs vary widely, and the binding affinity recorded for RII dimers is in the range of 2 to 90 nM (Alto et al., Proc. Natl. Acad. Sci. USA. 2003; 100: 4445). AKAP binds only to the dimeric subunits of R. In the case of RII <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> Human AD binds to a hydrophobic surface formed by 23 amino-terminal residues (Colledge, Scott, Trends Cell Biol. 1999; 6: 216). Accordingly, both the dimerization domain and the AKAP binding domain RII <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> humans are located within the same N-terminal sequence of 44 amino acids (Newlon et al., Nat. Struct. Biol. 1999; 6: 222; Newlon et al., EMBO J. 2001; 20: 1651), referred to herein as DDD .
  <p class="style-scope patent-text"></p>
  <p num="160" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0129]       DDD      AD  AKAP           ,       ,    ,         DNL       DDD,    AD        .       .       DDD   ,      ,     .   DDD    ,  , ,   <sub class="style-scope patent-text">2</sub>.       AD   ,      ,     b.   DDD,   <sub class="style-scope patent-text">2</sub>,        AD,   b,       <sub class="style-scope patent-text">2</sub>  b     ,   a<sub class="style-scope patent-text">2</sub>b.              </span>[0129] The inventors developed a platform technology for using the DDD regulatory subunits of human PKA and AKAP AD protein as an excellent pair of linker modules for docking any two objects, hereinafter referred to as A and B, to obtain a non-covalent complex, which can be further locked In the DNL  complex by introducing cysteine residues in both DDD and AD in strategic positions to facilitate the formation of disulfide bonds. The general methodology of this approach is as follows. Object A is constructed by attaching a DDD sequence to predecessor A, which results in the first component, hereinafter referred to as a. Since the DDD sequence provides spontaneous dimer formation, A will accordingly consist of a <sub class="style-scope patent-text">2</sub> . Object B is constructed by attaching an AD sequence to predecessor B, which results in a second component, hereinafter referred to as b. The dimeric DDD motif contained in a <sub class="style-scope patent-text">2</sub> creates a docking site for binding to the AD sequence contained in b, thereby facilitating the unimpeded formation of a <sub class="style-scope patent-text">2</sub> and b bonds to form a binary trimeric complex consisting of a <sub class="style-scope patent-text">2</sub> b. Said binding is made irreversible by a subsequent reaction to covalently anchor said two objects</span>
  </p>
  <p num="161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  ,          ,        ,    DDD,    AD (Chmura et al., Proc. Natl. Acad. Sci. USA. 2001; 98:8480),  - .     ,             DNL     (., ,   7550143; 7521056; 7534866; 7527787  7666400).</span>through disulfide bridges, which occurs very efficiently based on the principle of effective local concentration, since the initial binding interactions bring together the reactive thiol groups located on both DDD and AD (Chmura et al., Proc. Natl. Acad. Sci. USA. 2001 ; 98: 8480), for site-specific ligation. Using various combinations of linkers, adapter modules, and precursors, a wide range of DNL  designs with different stoichiometric compositions can be obtained and used (see, for example, US Patent Nos. 7550143; No. 7521056; No. 7534866; No. 7527787 and No. 7666400).</span>
  </p>
  <p num="162" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0130]   DDD  AD       ,  - , ,       .           , -  ,   ,    , , ,          .         AD  DDD ,     ,          DNL.      ,       .</span>[0130] By attaching DDD and AD away from the functional groups of the two precursors, such site-specific ligation is expected to preserve the original activity of these two precursors. This approach has a modular nature and can potentially be used for compounds, site-specific and covalent, a wide range of substances, including peptides, proteins, antibodies, antibody fragments and other effector fragments with a wide spectrum of activity. Using the fusion protein-involving method for constructing AD and DDD conjugated effectors described in the Examples section below allows the incorporation of virtually any protein or peptide in the DNL  construct. However, this technique is not limiting, and other conjugation methods may be used.</span>
  </p>
  <p num="163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0131]      ,    ,  /         ,     .                     (., , Sambrook et al., Molecular Cloning, A laboratory manual, 2<sup class="style-scope patent-text">nd</sup> Ed, 1989).       AD / DDD      N-,   -    .    ,     AD  DDD                ( )   ,     . -          ,     ,     -  /    .</span>[0131] Various methods are known for producing fusion proteins, including synthesis, hybridization, and / or amplification of nucleic acids to produce a synthetic double-stranded nucleic acid encoding a fusion protein of interest. Such double-stranded nucleic acids can be inserted into expression vectors to produce a fusion protein using standard molecular biology techniques (see, for example, Sambrook et al., Molecular Cloning, A laboratory manual, 2 <sup class="style-scope patent-text">nd</sup> Ed, 1989). In such preferred embodiments, an AD and / or DDD fragment can be attached either to the N-terminus or to the C-terminus of an effector protein or peptide. However, one skilled in the art will understand that the site of attachment of an AD or DDD fragment to an effector fragment may vary depending on the chemical nature of said effector fragment and part (or parts) of said effector fragment involved in its physiological activity. Site-specific attachment of various effector fragments can be performed using techniques known in the art, such as the use of bivalent cross-linking reagents and / or other chemical conjugation techniques.</span>
  </p>
  <p num="164" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0132]              DNL , ,   DDD  AD  -   ,    .       DDD  AD,   -  AD,     -    (., ,     . 13/901737,  24  2013 .,         .) -   AD  DDD</span>[0132] In various embodiments, an antibody or antibody fragment can be incorporated into a DNL  complex by, for example, attaching a DDD or AD fragment to the C-terminus of the antibody heavy chain, as described in more detail below. In more preferred embodiments, a DDD or AD fragment, more preferably an AD fragment, can be attached to the C-terminus of the antibody light chain (see, for example, U.S. Patent Application Ser. No. 13/901737, filed May 24, 2013, a section of examples of which is incorporated herein by reference.) Structural and functional relationships of fragments AD and DDD</span>
  </p>
  <p num="165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0133]   DNL        AD  DDD.   DDD  AD  .</span>[0133] For different types of DNL  constructs, different AD or DDD sequences can be used. Examples of DDD and AD sequences are given below.</span>
  </p>
  <p num="166" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ea/f7/31/fd5bcf1763b90d/00000012.png" class="style-scope patent-text"><img file="00000012.jpg" he="69" wi="149" img-format="jpg" img-content="undefined" width="596" height="276" alt="Figure 00000012" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ea/f7/31/fd5bcf1763b90d/00000012.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ea/f7/31/fd5bcf1763b90d/00000012.png" class="style-scope patent-text"><img file="00000012.jpg" he="69" wi="149" img-format="jpg" img-content="undefined" width="596" height="276" alt="Figure 00000012" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ea/f7/31/fd5bcf1763b90d/00000012.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="167" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0134]   ,  DDD1  DDD2    DDD  RII</span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>D   .        DDD  AD      DDD  RI<div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div>D       AKAP,    DDD3, DDD3C  AD3,  .[0134] One skilled in the art will appreciate that DDD1 and DDD2 are based on the DDD sequence of the RII isoform <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> D human protein kinase A However, in alternative embodiments, said DDD and AD fragments may be based on a DDD sequence of form RI <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png" class="style-scope patent-text"><img file="00000011.jpg" he="6" wi="6" img-format="jpg" img-content="undefined" width="24" height="24" alt="Figure 00000011" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/a7/3c/f4b739ca084191/00000011.png"></a></div> D human protein kinase A and the corresponding AKAP sequence, according to the illustrative examples DDD3, DDD3C and AD3 below.
  <p class="style-scope patent-text"></p>
  <p num="168" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f5/cb/90/eea453d32daecb/00000013.png" class="style-scope patent-text"><img file="00000013.jpg" he="63" wi="160" img-format="jpg" img-content="undefined" width="640" height="252" alt="Figure 00000013" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f5/cb/90/eea453d32daecb/00000013.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f5/cb/90/eea453d32daecb/00000013.png" class="style-scope patent-text"><img file="00000013.jpg" he="63" wi="160" img-format="jpg" img-content="undefined" width="640" height="252" alt="Figure 00000013" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f5/cb/90/eea453d32daecb/00000013.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="169" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0135]             AD / DDD    DNL. ,      DDD  ,   DDD  RI, RII, RI  RII.   DDD RII  DDD1  DDD2,  .    DDD    .  DDD    1-44 RII, 1-44 RII, 12-61 RI  13-66 RI. (,   DDD1     DDD RII  .)</span>[0135] According to other alternative embodiments, other variant sequences of AD and / or DDD fragments can be used in the construction of DNL  complexes. For example, there are only four variants of the human DDD PKA sequences corresponding to the DDD fragments of PKA RI, RII, RI and RII. The DDD RII sequence is based on DDD1 and DDD2 above. These four sequences of DDD human PKA are given below. The DDD sequence is residues 1-44 RII, 1-44 RII, 12-61 RI and 13-66 RI. (Note that the DDD1 sequence is slightly modified relative to the DDD RII fragment of human PKA.)</span>
  </p>
  <p num="170" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f9/9e/08/0a4999fd9ee251/00000014.png" class="style-scope patent-text"><img file="00000014.jpg" he="72" wi="160" img-format="jpg" img-content="undefined" width="640" height="288" alt="Figure 00000014" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f9/9e/08/0a4999fd9ee251/00000014.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/f9/9e/08/0a4999fd9ee251/00000014.png" class="style-scope patent-text"><img file="00000014.jpg" he="72" wi="160" img-format="jpg" img-content="undefined" width="640" height="288" alt="Figure 00000014" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/f9/9e/08/0a4999fd9ee251/00000014.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="171" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bf/c3/33/5978c4aa4b8eb6/00000015.png" class="style-scope patent-text"><img file="00000015.jpg" he="16" wi="146" img-format="jpg" img-content="undefined" width="584" height="64" alt="Figure 00000015" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bf/c3/33/5978c4aa4b8eb6/00000015.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/bf/c3/33/5978c4aa4b8eb6/00000015.png" class="style-scope patent-text"><img file="00000015.jpg" he="16" wi="146" img-format="jpg" img-content="undefined" width="584" height="64" alt="Figure 00000015" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/bf/c3/33/5978c4aa4b8eb6/00000015.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="172" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0136] -   AD  DDD   . (., , : Burns-Hamuro et al., 2005, Protein Sci 14:2982-92; Carr et al., 2001, J Biol Chem 276:17332-38; Alto et al., 2003, Proc Natl Acad Sci USA 100:4445-50; Hundsrucker et al., 2006, Biochem J 396:297-306; Stokka et al., 2006, Biochem J 400:493-99; Gold et al., 2006, Mol Cell 24:383-95; Kinderman et al., 2006, Mol Cell 24:397-408,          .)</span>[0136] The structural and functional relationships of the AD and DDD domains have been studied. (See, for example, sources: Burns-Hamuro et al., 2005, Protein Sci 14: 2982-92; Carr et al., 2001, J Biol Chem 276: 17332-38; Alto et al., 2003, Proc Natl Acad Sci USA 100: 4445-50; Hundsrucker et al., 2006, Biochem J 396: 297-306; Stokka et al., 2006, Biochem J 400: 493-99; Gold et al., 2006, Mol Cell 24: 383-95; Kinderman et al., 2006, Mol Cell 24: 397-408, each of which is incorporated herein by reference.)</span>
  </p>
  <p num="173" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Antibody Allotypes</span>
  </p>
  <p num="174" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0137]               (Baert et al., 2003, N Engl J Med 348:602-08).             (Stickler et al., 2011, Genes and Immunity 12:213-21).              .  IgG-,      -  Gm- (1976, J Immunol 117:1056-59).</span>[0137] The immunogenicity of therapeutic antibodies is associated with an increased risk of infusion reactions and a decrease in the duration of the therapeutic response (Baert et al., 2003, N Engl J Med 348: 602-08). The degree of induction by the therapeutic antibodies of the host immune response can be determined in part by the antibody allotype (Stickler et al., 2011, Genes and Immunity 12: 213-21). An antibody allotype is associated with variations in amino acid sequences at specific locations in the sequences of constant regions of the antibody. Allotypes of IgG antibodies containing a constant region of heavy type  chains are called Gm allotypes (1976, J Immunol 117: 1056-59).</span>
  </p>
  <p num="175" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0138]   IgG1-      G1m1 (Stickler et al., 2011, Genes and Immunity 12:213-21).   G1m3        (). G1m1-,   ,   ,            G1m1  (nG1m1),   G1m3- (). ,    G1m1 ,      G1m1- ().</span>[0138] Among the common human IgG1 antibodies, the most common allotype is G1m1 (Stickler et al., 2011, Genes and Immunity 12: 213-21). However, the G1m3 allotype is also often found in representatives of the Caucasoid race (above). G1m1 antibodies have been described to contain allotypic sequences that tend to induce an immune response when administered to recipients other than G1m1 allotype (nG1m1), such as G1m3 patients (above). Antibodies having a different allotype from G1m1 are not so immunogenic when administered to G1m1 patients (above).</span>
  </p>
  <p num="176" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0139]  G1m1         Kabat 356      Kabat 358   3   IgG1.  nG1m1        Kabat 356      Kabat 358.  , G1m1  nG1m1,        Kabat 357;      DEL  .           G1m1  nG1m1      (SEQ ID NO: 18)   (SEQ ID NO:19).</span>[0139] The human G1m1 allotype contains the amino acids aspartic acid at the Kabat 356 position and leucine at the Kabat 358 position in the CH3 sequence of the IgG1 heavy chain. The nG1m1 allotype contains the amino acids glutamic acid at the Kabat 356 position and methionine at the Kabat 358 position. Both allotypes, G1m1 and nG1m1, contain the glutamic acid residue at the Kabat 357 position; these allotypes are sometimes referred to as DEL and EEM allotypes. A non-limiting example of heavy chain constant region sequences for antibodies of the G1m1 and nG1m1 allotypes is shown for the illustrative antibodies of rituximab (SEQ ID NO: 18) and veltuzumab (SEQ ID NO: 19).</span>
  </p>
  <p num="177" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">      (SEQ ID NO: 18)</span>The sequence of the variable region of the heavy chain of rituximab (SEQ ID NO: 18)</span>
  </p>
  <p num="178" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e7/a3/6c/63da301b108e09/00000016.png" class="style-scope patent-text"><img file="00000016.jpg" he="41" wi="160" img-format="jpg" img-content="undefined" width="640" height="164" alt="Figure 00000016" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e7/a3/6c/63da301b108e09/00000016.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/e7/a3/6c/63da301b108e09/00000016.png" class="style-scope patent-text"><img file="00000016.jpg" he="41" wi="160" img-format="jpg" img-content="undefined" width="640" height="164" alt="Figure 00000016" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/e7/a3/6c/63da301b108e09/00000016.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">     (SEQ ID NO: 19)</span>The variable region of the heavy chain of veltuzumab (SEQ ID NO: 19)</span>
  </p>
  <p num="180" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/71/52/39e6c9724a3dd0/00000017.png" class="style-scope patent-text"><img file="00000017.jpg" he="41" wi="160" img-format="jpg" img-content="undefined" width="640" height="164" alt="Figure 00000017" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/71/52/39e6c9724a3dd0/00000017.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/28/71/52/39e6c9724a3dd0/00000017.png" class="style-scope patent-text"><img file="00000017.jpg" he="41" wi="160" img-format="jpg" img-content="undefined" width="640" height="164" alt="Figure 00000017" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/28/71/52/39e6c9724a3dd0/00000017.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="181" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0140] Jefferis  Lefranc (2009, mAb 1:1-7)   </span>[0140] Jefferis and Lefranc (2009, mAb 1: 1-7) provide an overview of options</span>
  </p>
  <p num="182" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">,    IgG     .  ,   G1m3       Kabat 214,     G1m17    Kabat 214   .   nG1m1,2       Kabat 356,     Kabat 358      Kabat 431.   G1m1,2       Kabat 356,     Kabat 358      Kabat 431.       , Jefferis  Lefranc (2009)        ,    Kml       Kabat 153      Kabat 191,  Kml, 2      Kabat 153      Kabat 191,   Km3      Kabat 153      Kabat 191.</span>sequences characteristic of IgG allotypes and their effect on immunogenicity. They report that the G1m3 allotype is characterized by an arginine residue in the Kabat 214 position, while with the G1m17 allotype in the Kabat 214 position, the lysine residue is located. The nG1m1,2 allotype is characterized by glutamic acid in the Kabat 356 position, methionine in the Kabat 358 position and the alanine in the Kabat 431 position. The G1m1,2 allotype is characterized by aspartic acid in the Kabat 356 position, leucine in the Kabat 358 position and glycine in the Kabat position 431. In addition to the heavy chain constant region sequence variants, Jefferis and Lefranc (2009) described allotypic variants of the kappa light chain constant region, wherein the Kml allotype is characterized by a shaft in the Kabat 153 position and leucine in the Kabat 191 position, allotype Kml, 2 is characterized by alanine in the Kabat 153 position and leucine in the Kabat 191 position, and the Km3 allotype is characterized by alanine in the Kabat 153 position and valine in the Kabat 191 position.</span>
  </p>
  <p num="183" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0141]    ,     , ,    IgG1-  CD20,          .   1       .     1,  (G1m17,1)    DEL IgG1,    ,            Kabat 214 (CH1  ).   ,      ,   (., , Morchhauser et al., 2009, J Clin Oncol 27:3346-53; Goldenberg et al., 2009, Blood 113:1062-70; Robak &amp; Robak, 2011, BioDrugs 25:13-25);        .      DEL, ,       .</span>[0141] With regard to therapeutic antibodies, veltuzumab and rituximab are, respectively, humanized and chimeric anti-CD20 IgG1 antibodies suitable for use in the treatment of a wide range of hematologic malignancies. Table 1 shows a comparison of the sequences of the allotypes of rituximab and veltuzumab. As shown in table 1, rituximab (G1m17.1) is an DEL IgG1 allotype, with an additional sequence variant, with lysine in rituximab and arginine in veltuzumab at the Kabat 214 position (heavy chain CH1). As described, veltuzumab is less immunogenic in subjects than rituximab (see, for example, Morchhauser et al., 2009, J Clin Oncol 27: 3346-53; Goldenberg et al., 2009, Blood 113: 1062-70; Robak &amp; Robak, 2011, BioDrugs 25: 13-25); this effect was explained by the difference between humanized and chimeric antibodies. However, the difference in the allotypes of EEM and DEL probably also contributes to the lower immunogenicity of veltuzumab.</span>
  </p>
  <p num="184" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0f/b6/fe/8b2994062d10e5/00000018.png" class="style-scope patent-text"><img file="00000018.jpg" he="69" wi="160" img-format="jpg" img-content="undefined" width="640" height="276" alt="Figure 00000018" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0f/b6/fe/8b2994062d10e5/00000018.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0f/b6/fe/8b2994062d10e5/00000018.png" class="style-scope patent-text"><img file="00000018.jpg" he="69" wi="160" img-format="jpg" img-content="undefined" width="640" height="276" alt="Figure 00000018" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0f/b6/fe/8b2994062d10e5/00000018.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0142]          nG1m1,    ,   G1m3,      Kabat 214,    nG1m1,2,       Kabat 356,     Kabat 358      Kabat 431.  ,  ,     C1m3-           .       IgG4 ,  ,    G1m3,      Kabat 214,      Kabat 356,     Kabat 359      Kabat 431.  , -,          ,       IgG4          .   G1m3-IgG1   IgG4      .</span>[0142] In order to reduce the immunogenicity of therapeutic antibodies in individuals with the nG1m1 genotype, it is desirable to select an allotype antibody corresponding to the G1m3 allotype characterized by arginine at the Kabat position 214, and a null allotype of the nG1m1,2 characteristic characterized by glutamic acid at the Kabat position at the Kabat position 356, methion position at Kabat position 356, methion according to Kabat 358 and alanine in the position according to Kabat 431. Unexpectedly, it was found that repeated subcutaneous administration of C1m3 antibodies over a long period of time did not lead to a significant immune response. In alternative embodiments, the human IgG4 heavy chain, like the allotype G1m3, contains arginine in the Kabat position 214, glutamic acid in the Kabat position 356, methionine in the Kabat position 359, and alanine in the Kabat position 431. Since immunogenicity, apparently associated, at least in part, with residues at these positions, the use of a sequence of constant regions of heavy IgG4 chains of human antibodies for therapeutic antibodies is also a preferred implementation option. Combinations of G1m3-IgG1 antibodies with IgG4 antibodies may also be suitable for therapeutic administration.</span>
  </p>
  <p num="186" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Avimera</span>
  </p>
  <p num="187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0143]      ,    ,       .      ,               .              in vitro    (Silverman et al., 2005, Nat. Biotechnol. 23:1493-94; Silverman et al., 2006, Nat. Biotechnol. 24:220).         ,      (   - )          ().        , ,   DDD / AD       .  ,       , ,       20040175756, 20050048512, 20050053973, 20050089932  20050221384,           .</span>[0143] In some embodiments, the binding fragments described herein may contain one or more avimer sequences. Avimeres are a class of binding proteins that are somewhat analogous to antibodies in terms of affinity and specificity for various target molecules. They were developed based on human extracellular receptor domains using in vitro exon permutation and phage display (Silverman et al., 2005, Nat. Biotechnol. 23: 1493-94; Silverman et al., 2006, Nat. Biotechnol. 24: 220 ) The resulting multi-domain proteins may contain several independent binding domains, which may exhibit improved affinity (in some cases, subnanomolar) and specificity compared to single epitope binding proteins (above). In various embodiments, the avimers can be attached, for example, to DDD and / or AD sequences for use in the claimed methods and compositions. Further details regarding the methods for constructing and using the avimera are described, for example, in published US patent applications No. 20040175756, No. 200550048512, No. 20050053973, No. 20050089932 and No. 2005250221384, examples of each of which are incorporated herein by reference.</span>
  </p>
  <p num="188" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Phage display</span>
  </p>
  <p num="189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0144]      /      /    ,   .         ,     ,   ,    ,   .                . ,    5223409; 5622699  6068829     .        ,         (Smith, Scott, 1985, Science 228:1315-1317; Smith  Scott, 1993, Meth. Enzymol. 21:228-257).  ,             ,     (Arap et al., 1998, Science 279:377-380).</span>[0144] Certain embodiments of the claimed compositions and / or methods may include binding peptides and / or peptidomimetics of various target molecules, cells or tissues. Binding peptides can be identified using any method known in the art, including but not limited to phage display techniques. Various phage display methods and techniques for producing diverse populations of peptides are well known in the art. For example, in US patents No. 5,223,409; No. 5622699 and No. 6068829 describes methods for producing a phage library. The phage display technique employs genetic manipulations with bacteriophages that allow small peptides to be expressed on their surface (Smith, Scott, 1985, Science 228: 1315-1317; Smith and Scott, 1993, Meth. Enzymol. 21: 228-257). In addition to peptides, larger protein domains, such as single chain antibodies (Arap et al., 1998, Science 279: 377-380) can also be displayed on the surface of phage particles.</span>
  </p>
  <p num="190" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0145]   ,     , ,           (Pasqualini, Ruoslahti, 1996, Nature 380:364-366; Pasqualini, 1999, The Quart. J. Nucl. Med. 43:159-162). ,  ,            , ,     ,   ,   . ,    ,      , ,     ,       -.</span>[0145] Targeting amino acid sequences selective for a particular organ, tissue, cell type, or target molecule can be isolated by panning (Pasqualini, Ruoslahti, 1996, Nature 380: 364-366; Pasqualini, 1999, The Quart. J. Nucl. Med. 43: 159-162). Briefly, a phage library containing the putative targeting peptides is introduced into an intact organism or into isolated organs, tissues, cell types or target molecules, and samples containing bound phage are collected. A phage that binds to the target can be eluted from the target organ, tissue, cell type or target molecule, and then amplified by culturing in the host bacteria.</span>
  </p>
  <p num="191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0146]           -   .  ,   ,         .            , ,            .              .          ,       .                  (Arap et al., 1998, Smith et al., 1985).</span>[0146] According to some embodiments, said phage can be propagated in host bacteria between panning rounds. These bacteria, instead of phage lysis, can secrete several copies of the phage with a display of a particular insert. If necessary, repeated exposure to the amplified phage on target organs, tissues, cell types or the target molecule can be carried out and phage collection for additional rounds of panning. Prior to obtaining a population of selective or specific binding agents, several rounds of panning can be performed. The amino acid sequence of these peptides can be determined by DNA sequencing corresponding to the insertion of the target peptide in the phage genome. The identified targeting peptide can then be obtained as a synthetic peptide using standard protein chemistry techniques (Arap et al., 1998, Smith et al., 1985).</span>
  </p>
  <p num="192" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0147]              .       ,    ,   ,  .              ,   . ,                 .            , ,   .               , ,      5840841, 5705610, 5670312  5492807.</span>[0147] In some embodiments, a subtraction protocol can be used to further reduce background phage binding. The purpose of the subtraction is to remove phages from the library that bind to targets other than the target of interest. In alternative embodiments, a preliminary screening of a phage library with a control cell, tissue, or organ can be performed. For example, tumor-binding peptides can be identified after preliminary screening of the library with a control line of normal cells. After subtraction, a screening of the indicated library with a molecule, cell, tissue or organ of interest can be performed. Other methods of using subtraction protocols are known and can be applied in the practical implementation of the claimed methods, for example, as described in US patents No. 5840841, No. 5705610, No. 5670312 and No. 5492807.</span>
  </p>
  <p num="193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Aptamers</span>
  </p>
  <p num="194" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0148]      ,   ,    .             . ,       5582981, 5595877  5637459,           .     ,       ,  , ., ,   5475096    5270163,           .</span>[0148] In some embodiments, the targeting fragment suitable for use may be an aptamer. Methods of constructing and determining the binding characteristics of aptamers are well known in the art. For example, such techniques are described in US patent No. 5582981, No. 5595877 and No. 5637459, sections of examples of each of which are incorporated herein by reference. Methods for preparing and screening aptamers that bind to specific targets of interest are well known, see, for example, US Pat. No. 5,447,096 and US Pat.</span>
  </p>
  <p num="195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0149]       ,       ,     ,           ,      .  ,        3 ,  -    5 .      10    ,       10, 20, 30  40 .</span>[0149] Aptamers can be obtained by any known method, including using synthetic methods, recombinant methods and purification methods, and can be used individually or in combination with other ligands specific for the same target. In general, specific binding requires a minimum of approximately 3 nucleotides, preferably at least 5 nucleotides. Aptamers with sequences of less than 10 bases in length may be suitable, although aptamers of 10, 20, 30, or 40 nucleotides in length may be preferred.</span>
  </p>
  <p num="196" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0150]    ,  / ,         .  ,       .    ,    ,      ,  ,    ,         ,       .            , , (O)O   P(O)S, P(O)NR<sub class="style-scope patent-text">2</sub>, P(O)R, P(O)OR', CO  CNR<sub class="style-scope patent-text">2</sub>,   R      (1-20), a R'    (1-20);  ,            S.         .</span>[0150] Aptamers can be isolated, sequenced and / or amplified, or synthesized as standard DNA or RNA molecules. Alternatively, the aptamers of interest may contain modified oligomers. Any of the hydroxyl groups typically present in aptamers can be replaced by phosphonate groups, phosphate groups, protected by a standard protecting group, or activated to provide additional bonds to other nucleotides, or can be conjugated to solid supports. One or more phosphodiester bonds can be replaced by alternative linking groups, for example, P (O) O is replaced by P (O) S, P (O) NR <sub class="style-scope patent-text">2</sub> , P (O) R, P (O) OR ', CO or CNR <sub class="style-scope patent-text">2</sub> , wherein R is H or alkyl (1-20C), and R 'is alkyl (1-20C); in addition, this group can be attached to adjacent nucleotides through O or S. Not all bonds in the oligomer must necessarily be identical.</span>
  </p>
  <p num="197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Affiliates and finomers</span>
  </p>
  <p num="198" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0151]         .     Affibody  (, ).      ,    ,       .        -   (Nord et al., 1995, Protein Eng 8:601-8; Nord et al., 1997, Nat Biotechnol 15:772-77).       ,   IgG   A (Nord et al., 1995; 1997).            13 ,   Fc-    A (Nord et al., 1995; 1997).   -             .           ,        (, Pasqualini, Ruoslahti, 1996, Nature 380:364-366; Pasqualini, 1999, Quart. J. Nucl. Med. 43:159-162),         .</span>[0151] Certain alternative implementations may involve affiliates instead of antibodies. Affiliates are commercially available from Affibody AB (Solna, Sweden). Affiliates are small proteins that function as antibody mimetics and are suitable for binding to target molecules. Affiliates were developed by combinatorial construction on an alpha-helical protein scaffold (Nord et al., 1995, Protein Eng 8: 601-8; Nord et al., 1997, Nat Biotechnol 15: 772-77). Affiliate design is based on a three-helix bundle structure containing the IgG binding domain of protein A (Nord et al., 1995; 1997). Affiliates with a wide range of binding affinities can be obtained by randomizing 13 amino acids involved in the Fc-binding activity of bacterial protein A (Nord et al., 1995; 1997). After randomization, the PCR-amplified library was cloned into a phagemid vector for screening mutant proteins using phage display. The phage display library can be screened with any known antigen using standard phage display screening techniques (e.g., Pasqualini, Ruoslahti, 1996, Nature 380: 364-366; Pasqualini, 1999, Quart. J. Nucl. Med. 43: 159 -162), to identify one or more antibodies against the target antigen.</span>
  </p>
  <p num="199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0152]    <sup class="style-scope patent-text">177</sup>Lu- ,    HER2/neu,  2-  in vivo (Tolmachev et al., 2007, Cancer Res 67:2773-82).   ,       ,    ,        ,         ().</span>[0152] The targeting of <sup class="style-scope patent-text">177</sup> Lu-labeled HER2 / neu specific antibodies to HEK2 expressing xenografts in vivo has been demonstrated (Tolmachev et al., 2007, Cancer Res 67: 2773-82). Although renal toxicity due to the accumulation of a low molecular weight radiolabeled compound was initially a problem, reversible binding to albumin reduced accumulation in the kidneys, allowing radiolabeled-based radiolabeled affinity therapy (above).</span>
  </p>
  <p num="200" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0153]             in vivo (Tolmachev et al., 2011, Bioconjugate Chem 22:894-902).   NOTA     HER2     <sup class="style-scope patent-text">111</sup>In ().  ,  HER2-  DU-145,      -,    ().</span>[0153] The feasibility of using radiolabeled affinity antibodies to visualize tumors in vivo has recently been demonstrated (Tolmachev et al., 2011, Bioconjugate Chem 22: 894-902). Maleimide derivatized NOTA was conjugated to anti-HER2 affinity and labeled with a radioactive label <sup class="style-scope patent-text">111</sup> In (above). The introduction of mice carrying the HER2-expressing xenograft DU-145, followed by registration of images in the gamma camera, allowed visualization of the xenograft (above).</span>
  </p>
  <p num="201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0154]             .     SH3 Fyn ,         .  SH3 Fyn       63 ,        .                     .     COVAGEN AG (, ).</span>[0154] Finomers can also bind to target antigens with antibody similar affinity and specificity. Finomers are based on the human SH3 Fyn domain, which is used as a scaffold for the assembly of binding molecules. The SH3 Fyn domain is a fully human 63 amino acid length protein that can be produced by bacteria in high yield. Finomers can be interconnected to form a multispecific binding protein with affinity for two or more different antigenic targets. Finomers are commercially available from COVAGEN AG (Zurich, Switzerland).</span>
  </p>
  <p num="202" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0155]   ,                 .</span>[0155] One skilled in the art will recognize that affiniters or finomers can be used as targeting molecules in the practical implementation of the claimed methods and compositions.</span>
  </p>
  <p num="203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Immunoconjugates</span>
  </p>
  <p num="204" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0156]                         .                  -. -   , ,   SH- /    . -              .  ,         -,   --3-(2-) (SPDP). Yu et al., Int. J. Cancer 56: 244 (1994).          . ., , Wong, CHEMISTRY OF CHEMISTRY OF PROTEIN CONJUGATION AND CROSS-LINKING (CRC Press 1991); Upeslacis et al., "Modification of Antibodies by Chemical Methods,  : MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, Birch et al. (eds.), pp. 187-230 (Wiley-Liss, Inc. 1995); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies,  : MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, Ritter et al. (eds.), pp. 60-84 (Cambridge University Press 1995).  , -        Fc- .</span>[0156] In some embodiments, a cytotoxic drug or other therapeutic or diagnostic agent may be covalently attached to an antibody or antibody fragment to form an immunoconjugate. In some embodiments, the drug or other agent may be coupled to the antibody or fragment thereof with a carrier moiety. Carrier fragments can be attached, for example, to reduced SH groups and / or to carbohydrate side chains. The carrier fragment can be attached in the hinge region of the restored component of the antibody due to the formation of a disulfide bond. Alternatively, such agents may be attached using a heterobifunctional cross-linker, such as M-succinyl-3- (2-pyridyldithio) propionate (SPDP). Yu et al., Int. J. Cancer 56: 244 (1994). General techniques for such conjugation are well known in the art. See, for example, Wong, CHEMISTRY OF CHEMISTRY OF PROTEIN CONJUGATION AND CROSS-LINKING (CRC Press 1991); Upeslacis et al., "Modification of Antibodies by Chemical Methods", source: MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, Birch et al. (Eds.), Pp. 187-230 (Wiley-Liss, Inc. 1995); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies", source: MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, Ritter et al. (eds.), pp. 60-84 (Cambridge University Press 1995). Alternatively, the carrier fragment may be conjugated by a carbohydrate fragment in the Fc region of an antibody.</span>
  </p>
  <p num="205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0157]                 . ., , Shih et al., Int. J. Cancer 41: 832 (1988); Shih et al., Int. J. Cancer 46: 1101 (1990);  Shih et al.,   5057313,         .      ,    ,  -,         .</span>[0157] Methods of conjugating functional groups to antibodies via a carbohydrate fragment of an antibody are well known to those skilled in the art. See, for example, Shih et al., Int. J. Cancer 41: 832 (1988); Shih et al., Int. J. Cancer 46: 1101 (1990); and Shih et al., US patent No. 5057313, a section of examples of which is incorporated herein by reference. A general method involves reacting an antibody containing an oxidized carbohydrate moiety with a carrier polymer containing at least one free amine functional group.</span>
  </p>
  <p num="206" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">        ( ),             .</span>This reaction leads to the formation of Schiff base (imine bond), which can be stabilized by reduction to a secondary amine with the formation of the final conjugate.</span>
  </p>
  <p num="207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0158] Fc-  ,     ADC    .             ,    . ., , Leung et al., J. Immunol. 154: 5919 (1995);   5443953  6254868,         .          .</span>[0158] The Fc region may be absent if the antibody component in the ADC is an antibody fragment. However, the introduction of a carbohydrate fragment is possible in the variable region of the light chain of both a full-sized antibody and an antibody fragment. See, for example, Leung et al., J. Immunol. 154: 5919 (1995); US patent No. 5443953 and No. 6254868, sections of examples of which are incorporated herein by reference. The engineered carbohydrate moiety is used to attach a therapeutic or diagnostic agent.</span>
  </p>
  <p num="208" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0159]    -       -.  -                . (., , Kolb et al., 2004, Angew Chem Int Ed 40:3004-31; Evans, 2007, Aust J Chem 60:384-95.).         -,   1,3-      (Tornoe et al., 2002, J Organic Chem 67:3057-64),    -.     ,    -,    ( ,    ,   -   ),       ;  ,  -  , ,   - .</span>[0159] An alternative method of attaching carrier fragments to a targeting molecule involves the use of click chemistry reactions. The click chemistry approach was originally proposed as a way to quickly obtain complex substances by combining small subunits in a modular manner. (See, for example, Kolb et al., 2004, Angew Chem Int Ed 40: 3004-31; Evans, 2007, Aust J Chem 60: 384-95.). Various forms of click chemistry reactions are known in the art, such as the 1,3-dipolar copper-catalyzed Huysgen cycloaddition reaction (Tornoe et al., 2002, J Organic Chem 67: 3057-64), which is often referred to as the click reaction . Other alternatives include cycloaddition reactions, such as the Diels-Alder reaction, nucleophilic substitution reactions (in particular, in low stress cycles, such as epoxy and aziridine compounds), the preparation of urea compounds using carbonyl chemistry; and reactions involving carbon-carbon double bonds, for example alkynes in thiol-inine reactions.</span>
  </p>
  <p num="209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0160]   -               ,    .    ,   ,           1,4- 1,2,3-.          ,         . (Rostovstev et al., 2002, Angew Chem Int Ed 41:2596; Tornoe et al., 2002, J Org Chem 67:3057.)                ,       .         ,      -   .       ,     -   in vitro   ADC.</span>[0160] In the Hughesgen azide-alkynyl cycloaddition reaction, a copper catalyst is used in the presence of a reducing agent to catalyze the reaction of the terminal alkynyl group attached to the first molecule. In the presence of a second molecule containing an azide moiety, said azide reacts with activated alkyne to form 1,4-disubstituted 1,2,3-triazole. The reaction catalyzed by copper occurs at room temperature and is quite specific, so that often the purification of the reaction product is not necessary. (Rostovstev et al., 2002, Angew Chem Int Ed 41: 2596; Tornoe et al., 2002, J Org Chem 67: 3057.) The azide and alkyne functional groups are significantly inert with respect to biomolecules in an aqueous medium, which allows carry out the reaction in complex solutions. The resulting triazole is chemically stable and does not undergo enzymatic cleavage, which ensures high stability of the click chemistry product in biological systems. Although a copper catalyst is toxic to living cells, a copper-based click chemistry reaction can be used in vitro to produce ADC.</span>
  </p>
  <p num="210" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0161]       -   . (., , Agard et al., 2004, J Am Chem Soc 126:15046-47.)           ,  [3+2]  -  (). ,    8-      .         ,         ,  . ,      -    ().</span>[0161] For a covalent modification of biomolecules, a click reaction without the use of copper has been proposed. (See, for example, Agard et al., 2004, J Am Chem Soc 126: 15046-47.) In a copper-free reaction, ring stress is used instead of a copper catalyst, stimulating [3 + 2] azide-alkynyl cycloaddition reactions (above) . For example, cyclooctin is an 8-carbon ring structure with an internal alkine bond. The specified cyclic structure induces a significant deformation of the bond angle of acetylene, which has a high reactivity with respect to azide groups, forming a triazole. Accordingly, cyclooctin derivatives can be used for click reactions without the use of copper (above).</span>
  </p>
  <p num="211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0162] Ning   (Ning et al., 2010, Angew Chem Int Ed 49:3065-68)    -   ,       .                ().       , 4-   ().               N-  (). ,                    -     ().        N-,           ().      -     -   in vitro.</span>[0162] Ning et al. (Ning et al., 2010, Angew Chem Int Ed 49: 3065-68) described another type of copper-free click reaction involving stress-stimulated cycloaddition of alkynes and nitrons. To overcome the slow reaction rate with the starting cyclooctin, electron-withdrawing groups (above) are attached next to the triple bond. Examples of such substituted cyclooctins include difluorinated cyclooctins, 4-dibenzocyclooctinol, and azacyclooctin (above). An alternative reaction without the use of copper involved a voltage-stimulated cycloaddition of alkynes and nitrons to produce N-alkylated isoxazolines (above). It was reported that the reaction had extremely fast reaction kinetics and was used in a three-step reaction protocol in one reaction vessel for site-specific modification of peptides and proteins (above). Nitrons were obtained by condensation of the appropriate aldehydes with N-methylhydroxylamine, and this cycloaddition reaction proceeded in a mixture of acetonitrile and water (above). These and other known click chemistry reactions can be used to attach carrier fragments to antibodies in vitro.</span>
  </p>
  <p num="212" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0163] Agard   (Agard et al., 2004, J Am Chem Soc 126:15046-47) ,           N-     N-     . -            ,          (). Laughlin   (Laughlin et al., 2008, Science 320:664-667)            -,    N-. -        (DIFO) ,    in vivo.</span>[0163] Agard et al. (Agard et al., 2004, J Am Chem Soc 126: 15046-47) demonstrated that expression of recombinant glycoprotein in CHO cells in the presence of peracetylated N-azidoacetylmannosamine led to the bio-incorporation of the corresponding N-azidoacetyl sialic acid glycoprotein. The azido-derivatized glycoprotein reacted specifically with biotinylated cyclooctin to form biotinylated glycoprotein, while the control glycoprotein without the azide fragment remained unlabeled (above). Laughlin et al. (Laughlin et al., 2008, Science 320: 664-667) used a similar technique for the metabolic labeling of cell surface glycans in zebrafish embryos incubated with peracetylated N-azidoacetylgalactosamine. Azido-derivatized glycans reacted with difluorinated cyclooctin (DIFO) reagents, allowing visualization of glycans in vivo.</span>
  </p>
  <p num="213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0164]  -      in vivo. Rossin   (Rossin et al., 2010, Angew Chem Int Ed 49:3375-78)   52%  in vivo        TAG72 (49),  - ()  ,  <sup class="style-scope patent-text">111</sup>In-   DOTA. -  49  ,     ,    1   <sup class="style-scope patent-text">111</sup>In-   ().                  ,    -           ,   :,  13:1 ().           in vivo.</span>[0164] The Diels-Alder reaction was also used to label molecules in vivo. Rossin et al. (Rossin et al., 2010, Angew Chem Int Ed 49: 3375-78) reported a 52% in vivo response between a tumor localized anti-TAG72 antibody (CC49) carrying a trans-cyclooctene (TCO) reactive fragment, and <sup class="style-scope patent-text">111</sup> In-labeled tetrazine derivative of DOTA. The TCO-labeled CC49 antibody was administered to mice bearing colon cancer xenografts, after which <sup class="style-scope patent-text">111</sup> In-labeled tetrazine probe (above) was injected after 1 day. The reaction between the radiolabeled probe and the antibody localized in the tumor resulted in pronounced localization of the radioactivity in the tumor, as demonstrated by SPECT imaging of live mice three hours after injection of the radiolabeled probe, with a tumor: muscle ratio of 13: 1 (above) . These results confirmed the chemical reaction of TCO and tetrazine-labeled molecules in vivo.</span>
  </p>
  <p num="214" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0165]                6953675 (        ).    ,       .     ,   ,        N-   CHl  V,   ,       .       N-  N-.        ,      ,   , ,    ,     .  ,    ,   ,   DTPA,    ,   -,   - .       ,   ,         -,   ,   ,      .</span>[0165] Techniques for labeling antibodies using the biological inclusion of tagging fragments are further described in US Pat. No. 6,953,675 (a section of examples of which is incorporated herein by reference). Received such "labeled" antibodies containing reactive ketone groups at glycosylated sites. The method included the expression of cells transfected with an expression vector encoding an antibody with one or more N-glycosylation sites in the CHl or V domain in a culture medium containing a ketone derivative of a saccharide or saccharide precursor. Ketone-derivatized saccharides or precursors include N-levulinoylmannosamine and N-levulinoylfucose. The labeled antibodies were then reacted with agents containing a ketone reactive fragment, such as hydrazide, hydrazine, hydroxylamino groups or thiosemicarbazide groups, to form a labeled targeting molecule. Examples of agents attached to labeled antibodies include chelating agents such as DTPA, large drug molecules such as doxorubicin-dextran, and acyl hydrazide-containing peptides. The indicated labeling technique is not limited to the production of antibodies containing ketone fragments, and can also be used to introduce a reactive group of click chemistry, such as nitron, azide or cyclooctin, onto an antibody or other biological molecule.</span>
  </p>
  <p num="215" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0166]   -    in vitro  in vivo.          ,    .  ,      ,     ,     ,   .        ,         ,  .            ,   .</span>[0166] Modified click chemistry reactions are suitable for in vitro or in vivo use. A reactive targeting molecule can be formed either by chemical conjugation or by biological incorporation. A targeting molecule, such as an antibody or antibody fragment, may be activated by an azide fragment substituted by a cyclooctin or alkynyl group, or a nitron fragment. If the targeting molecule contains an azide or nitron group, the corresponding targeting structure contains a substituted cyclooctin or alkyne group, and vice versa. Such activated molecules can be obtained by metabolic incorporation into living cells, as discussed above.</span>
  </p>
  <p num="216" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0167]  ,             ,        .    ADC , ,    4699784; 4824659; 5525338; 5677427; 5697902; 5716595; 6071490; 6187284; 6306393; 6548275; 6653104; 6962702; 7033572; 7147856;  7259240,           .</span>[0167] Alternatively, chemical conjugation of such fragments with biomolecules is well known in the art, and any such known method can be used. General methods for producing ADC are described, for example, in US patent No. 4699784; No. 4824659; No. 5525338; No. 5677427; No. 5697902; No. 5716595; No. 6071490; No. 6187284; No. 6306393; No. 6,548,275; No. 6653104; No. 6962702; No. 7033572; No. 7,147,856; and No. 7259240, sections of examples of each of which are incorporated herein by reference.</span>
  </p>
  <p num="217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0168]      -, -, -  - ,        .           , , ,      .  ,    ,     .</span>[0168] The preferred conjugation protocol is based on a thiol-maleimide, thiol-vinyl sulfone, thiol-bromoacetamide or thiol-iodoacetamide reaction, which proceeds easily at neutral or acidic pH values. This eliminates the need for conditions with higher pH values for conjugation, which, for example, is necessary when using active esters. Further information regarding examples of conjugation protocols is provided in the examples section below.</span>
  </p>
  <p num="218" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Therapeutic treatment</span>
  </p>
  <p num="219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0169]          ,            (ADC),   IMMU-132,    .      Trop-2- ,     -   . ADC     ,        ,   , ,       ,    ,  , , , ,  ,    -,    ..        , ,     ,   ,   .</span>[0169] According to another aspect, the present invention relates to a method for treating a subject, comprising administering to the subject a therapeutically effective amount of an antibody-drug conjugate (ADC), such as IMMU-132, described herein. In a preferred embodiment, the subject suffers from Trop-2-positive cancer resistant to control points antibody inhibitors. ADC can be administered once or repeatedly, depending on the disease state and tolerability of the conjugate, and can also be optionally used in combination with other types of therapy, such as surgery, external radiation, radioimmunotherapy, immunotherapy, chemotherapy, antisense therapy, therapy with RNA interference, gene therapy, etc. Each combination is adapted according to the type of tumor, stage, condition of the patient and previous therapy, and other factors considered by the managing physician.</span>
  </p>
  <p num="220" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0170]          (..   ),   ,    ,  ,     .          . ,       ,   ,  ,    . ,    ,   ,         ,   ,           ..</span>[0170] As used herein, the term subject refers to any animal (ie, vertebrates and invertebrates), including, but not limited to, mammals, including humans. The term does not imply specific restrictions on age or gender. Accordingly, this term encompasses adult and newborn subjects, as well as fetuses, both male and female. The doses indicated in this document are intended for humans, but can be adjusted to fit the sizes of other mammals, as well as children, according to body weight or body surface area in sq.m.</span>
  </p>
  <p num="221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0171]      ,    Trop-2,   MAb hRS7,     ,    ,  , , ,     ,  ,  , , ,    ,      7238785; 7517964  8084583,         .  hRS7    ,       (CDR)   CDR1 (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2);  CDR3 (QQHYITPLT, SEQ ID NO: 3);   CDR   CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5)  CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>[0171] According to a preferred embodiment, therapeutic conjugates comprising an anti-Trop-2 antibody, such as hRS7 MAb, can be used to treat carcinomas such as carcinomas of the esophagus, pancreas, lung, stomach, colon and rectum, bladder, and mammary glands, ovaries, uterus, kidneys and prostate, as described in US patent No. 7238785; No. 7517964 and No. 8084583, sections of examples of which are incorporated herein by reference. An hRS7 antibody is a humanized antibody that contains a sequence of complementarity determining regions (CDRs) of CDR1 light chains (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2); and CDR3 (QQHYITPLT, SEQ ID NO: 3); and CDR sequences of the heavy chains of CDR1 (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6).</span>
  </p>
  <p num="222" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0172]     ,      ,      (  CDR)  ;         .    IgG           . ,  ,     .     IgG-    IgG-        IgG  .  ,  hLL1  hLL2,          ,  ,          .         ,    .</span>[0172] According to a preferred embodiment, the antibodies that are used in the treatment of human diseases are human antibodies or humanized (with CDR grafted) antibody variants; although mouse antibodies and chimeric antibody variants may be used. Some types of IgG molecules as delivery agents are most preferred to minimize the immune response. This, in particular, is important when the planned treatment is repeated. When used in humans, a human IgG antibody or a humanized IgG antibody is less likely to elicit an immune response against IgG in patients. Antibodies such as hLL1 and hLL2 quickly internalize after binding to the internalizing antigen on the target cells, which means that the chemotherapeutic drug they carry is also rapidly internalized by the cells. However, antibodies that have a lower internalization rate can also be used to perform selective therapy.</span>
  </p>
  <p num="223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0173]                   .            7387772; 7300655; 7238785;  7282567,           .     ,  ,           (),            ,          , -           .                    ,        ,    .</span>[0173] According to a preferred embodiment, more efficient incorporation into cells can be accomplished using multivalent multispecific or multivalent monospecific antibodies. Examples of such bivalent and bispecific antibodies can be found in US patent No. 7387772; No. 7300655; No. 7238785; and No. 7282567, sections of examples of each of which are incorporated herein by reference. These multivalent or multispecific antibodies, in particular, are preferred for targeting cancers and infectious organisms (pathogens) that express several antigenic targets and even several epitopes of a single antigenic target, but antibody targeting and sufficient binding for immunotherapy are often avoided due to insufficient expression or availability of a single antigenic target on a cell or pathogen. By targeting multiple antigens or epitopes, these antibodies exhibit higher levels of binding and retention time on the target, thereby providing higher saturation with the drug targeted according to the present invention.</span>
  </p>
  <p num="224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0174]       ,         ,      .  ,      ,  <sup class="style-scope patent-text">111</sup>In, <sup class="style-scope patent-text">177</sup>Lu, <sup class="style-scope patent-text">212</sup>Bi, <sup class="style-scope patent-text">213</sup>Bi, <sup class="style-scope patent-text">211</sup>At, <sup class="style-scope patent-text">62</sup>Cu, <sup class="style-scope patent-text">67</sup>Cu, <sup class="style-scope patent-text">90</sup>Y, <sup class="style-scope patent-text">125</sup>I, <sup class="style-scope patent-text">131</sup>I, <sup class="style-scope patent-text">32</sup>P, <sup class="style-scope patent-text">33</sup>P, <sup class="style-scope patent-text">47</sup>Sc, <sup class="style-scope patent-text">111</sup>Ag, <sup class="style-scope patent-text">67</sup>Ga, <sup class="style-scope patent-text">142</sup>Pr, <sup class="style-scope patent-text">153</sup>Sm, <sup class="style-scope patent-text">161</sup>Tb, <sup class="style-scope patent-text">166</sup>Dy, <sup class="style-scope patent-text">166</sup>Ho, <sup class="style-scope patent-text">186</sup>Re, <sup class="style-scope patent-text">188</sup>Re, <sup class="style-scope patent-text">189</sup>Re, <sup class="style-scope patent-text">212</sup>Pb, <sup class="style-scope patent-text">223</sup>Ra, <sup class="style-scope patent-text">225</sup>Ac, <sup class="style-scope patent-text">59</sup>Fe, <sup class="style-scope patent-text">75</sup>Se, <sup class="style-scope patent-text">77</sup>As, <sup class="style-scope patent-text">89</sup>Sr, <sup class="style-scope patent-text">99</sup>Mo, <sup class="style-scope patent-text">105</sup>Rh, <sup class="style-scope patent-text">109</sup>Pd, <sup class="style-scope patent-text">143</sup>Pr, <sup class="style-scope patent-text">149</sup>Pm, <sup class="style-scope patent-text">169</sup>Er, <sup class="style-scope patent-text">194</sup>Ir, <sup class="style-scope patent-text">198</sup>Au, <sup class="style-scope patent-text">199</sup>Au, <sup class="style-scope patent-text">227</sup>Th  <sup class="style-scope patent-text">211</sup>Pb,    .          20  6000 ,     60  200   -, 100-2500   -  4000-6000   -.        -    20-5,000 ,   - 100-4000 ,    - 500-2500 .    ,       . , -58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt-109, In-111, Sb-119, I-125, Ho-161, Os-189m  Ir-192.       -     1,000 ,   -  100 ,    -  70 .    ,       -.   ,    Dy-152, At-211, Bi-212, Ra-223, Rn-219, Po-215, Bi-211, Ac-225, Fr-221, At-217, Bi-213, Th-227  Fm-255.       -    2000-10000 ,   - 3000-8000 ,    - 4000-7000 .        <sup class="style-scope patent-text">11</sup>C, <sup class="style-scope patent-text">13</sup>N, <sup class="style-scope patent-text">15</sup>O, <sup class="style-scope patent-text">75</sup>Br, <sup class="style-scope patent-text">198</sup>Au, <sup class="style-scope patent-text">224</sup>, <sup class="style-scope patent-text">126</sup>I, <sup class="style-scope patent-text">133</sup>I, <sup class="style-scope patent-text">77</sup>Br, <sup class="style-scope patent-text">113m</sup>In, <sup class="style-scope patent-text">95</sup>Ru, <sup class="style-scope patent-text">97</sup>Ru, <sup class="style-scope patent-text">103</sup>Ru, <sup class="style-scope patent-text">105</sup>Ru, <sup class="style-scope patent-text">107</sup>Hg, <sup class="style-scope patent-text">203</sup>Hg, <sup class="style-scope patent-text">121m</sup>Te, <sup class="style-scope patent-text">122m</sup>Te, <sup class="style-scope patent-text">125m</sup>Te, <sup class="style-scope patent-text">165</sup>Tm, <sup class="style-scope patent-text">167</sup>Tm, <sup class="style-scope patent-text">168</sup>Tm, <sup class="style-scope patent-text">197</sup>Pt, <sup class="style-scope patent-text">109</sup>Pd, <sup class="style-scope patent-text">105</sup>Rh, <sup class="style-scope patent-text">142</sup>Pr, <sup class="style-scope patent-text">143</sup>Pr, <sup class="style-scope patent-text">161</sup>Tb, <sup class="style-scope patent-text">166</sup>Ho, <sup class="style-scope patent-text">199</sup>Au, <sup class="style-scope patent-text">57</sup>Co, <sup class="style-scope patent-text">58</sup>Co, <sup class="style-scope patent-text">51</sup>Cr, <sup class="style-scope patent-text">59</sup>Fe, <sup class="style-scope patent-text">75</sup>Se, <sup class="style-scope patent-text">201</sup>Tl, <sup class="style-scope patent-text">225</sup>Ac, <sup class="style-scope patent-text">76</sup>Br, <sup class="style-scope patent-text">169</sup>Yb  ..</span>[0174] According to another preferred embodiment, the therapeutic agent used in combination with the camptothecin conjugate of the present invention may contain one or more isotopes. Radioactive isotopes suitable for treating diseased tissue include <sup class="style-scope patent-text">111</sup> In, <sup class="style-scope patent-text">177</sup> Lu, <sup class="style-scope patent-text">212</sup> Bi, <sup class="style-scope patent-text">213</sup> Bi, <sup class="style-scope patent-text">211</sup> At, <sup class="style-scope patent-text">62</sup> Cu, <sup class="style-scope patent-text">67</sup> Cu, <sup class="style-scope patent-text">90</sup> Y, <sup class="style-scope patent-text">125</sup> I, <sup class="style-scope patent-text">131</sup> I, <sup class="style-scope patent-text">32</sup> P, <sup class="style-scope patent-text">33</sup> P, <sup class="style-scope patent-text">47</sup> Sc, <sup class="style-scope patent-text">111</sup> Ag, <sup class="style-scope patent-text">67</sup> Ga, <sup class="style-scope patent-text">142</sup> Pr, <sup class="style-scope patent-text">153</sup> Sm, <sup class="style-scope patent-text">161</sup> Tb, <sup class="style-scope patent-text">166</sup> Dy, <sup class="style-scope patent-text">166</sup> Ho, <sup class="style-scope patent-text">186</sup> Re, <sup class="style-scope patent-text">188</sup> Re, <sup class="style-scope patent-text">189</sup> Re, <sup class="style-scope patent-text">212</sup> Pb, <sup class="style-scope patent-text">223</sup> Ra, <sup class="style-scope patent-text">225</sup> Ac, <sup class="style-scope patent-text">59</sup> Fe, <sup class="style-scope patent-text">75</sup> Se, <sup class="style-scope patent-text">77</sup> As, <sup class="style-scope patent-text">89</sup> Sr , <sup class="style-scope patent-text">99</sup> Mo, <sup class="style-scope patent-text">105</sup> Rh, <sup class="style-scope patent-text">109</sup> Pd, <sup class="style-scope patent-text">143</sup> Pr, <sup class="style-scope patent-text">149</sup> Pm, <sup class="style-scope patent-text">169</sup> Er, <sup class="style-scope patent-text">194</sup> Ir, <sup class="style-scope patent-text">198</sup> Au, <sup class="style-scope patent-text">199</sup> Au, <sup class="style-scope patent-text">227</sup> Th and <sup class="style-scope patent-text">211</sup> Pb, but are not limited to the above. The decay energy of the therapeutic radionuclide is preferably in the range of 20 to 6000 keV, preferably in the range of 60 to 200 keV for the Auger emitter, 100-2500 keV for the beta emitter and 4000-6000 keV for the alpha emitter. The maximum decay energy of suitable nuclide emitting beta particles is preferably 20-5,000 keV, more preferably 100-4000 keV, and most preferably 500-2500 keV. Also preferred are radionuclides that decay essentially emitting Auger particles. For example, Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt-109, In-111, Sb-119, I-125, Ho-161, Os-189m and Ir-192. The decay energy of suitable nuclide emitting beta particles is preferably less than 1,000 keV, more preferably less than 100 keV, and most preferably less than 70 keV. Also preferred are radionuclides, which decay essentially to produce alpha particles. Such radionuclides include, but are not limited to, Dy-152, At-211, Bi-212, Ra-223, Rn-219, Po-215, Bi-211, Ac-225, Fr-221, At-217, Bi-213 , Th-227 and Fm-255. The decay energy of suitable alpha-emitting radionuclides is preferably 2000-10000 keV, more preferably 3000-8000 keV, and most preferably 4000-7000 keV. Additional potentially suitable radioisotopes for use include <sup class="style-scope patent-text">11</sup> C, <sup class="style-scope patent-text">13</sup> N, <sup class="style-scope patent-text">15</sup> O, <sup class="style-scope patent-text">75</sup> Br, <sup class="style-scope patent-text">198</sup> Au, <sup class="style-scope patent-text">224</sup> Ac, <sup class="style-scope patent-text">126</sup> I, <sup class="style-scope patent-text">133</sup> I, <sup class="style-scope patent-text">77</sup> Br, <sup class="style-scope patent-text">113m</sup> In, <sup class="style-scope patent-text">95</sup> Ru, <sup class="style-scope patent-text">97</sup> Ru, <sup class="style-scope patent-text">103</sup> Ru, <sup class="style-scope patent-text">105</sup> Ru, <sup class="style-scope patent-text">107</sup> Hg, <sup class="style-scope patent-text">203</sup> Hg, <sup class="style-scope patent-text">121m</sup> Te, <sup class="style-scope patent-text">122m</sup> Te, <sup class="style-scope patent-text">125m</sup> Te, <sup class="style-scope patent-text">165</sup> Tm, <sup class="style-scope patent-text">167</sup> Tm, <sup class="style-scope patent-text">168</sup> Tm, <sup class="style-scope patent-text">197</sup> Pt, <sup class="style-scope patent-text">109</sup> Pd, <sup class="style-scope patent-text">105</sup> Rh, <sup class="style-scope patent-text">142</sup> Pr, <sup class="style-scope patent-text">143</sup> Pr, <sup class="style-scope patent-text">161</sup> Tb, <sup class="style-scope patent-text">166</sup> Ho, <sup class="style-scope patent-text">199</sup> Au, <sup class="style-scope patent-text">57</sup> Co, <sup class="style-scope patent-text">58</sup> Co, <sup class="style-scope patent-text">51</sup> Cr, <sup class="style-scope patent-text">59</sup> Fe, <sup class="style-scope patent-text">75</sup> Se, <sup class="style-scope patent-text">201</sup> Tl, <sup class="style-scope patent-text">225</sup> Ac, <sup class="style-scope patent-text">76</sup> Br, <sup class="style-scope patent-text">169</sup> Yb, etc.</span>
  </p>
  <p num="225" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0175]       , ,    ,     .  ,   NOTA, DOTA          ,  ,   ,   , .                  .       ,     ,    <sup class="style-scope patent-text">223</sup>Ra.</span>[0175] Radionuclides and other metals can be delivered, for example, using chelating groups attached to an antibody or conjugate. Macrocyclic chelates such as NOTA, DOTA and TETA are suitable for use with various metals and radio metals, in particular with gallium, yttrium and copper radionuclides, respectively. Such chelate complexes with metals can be given high stability by adapting the size of the ring to the metal of interest. Other cyclic chelates, such as macrocyclic polyethers, can be used to produce <sup class="style-scope patent-text">223</sup> Ra complexes.</span>
  </p>
  <p num="226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0176]  ,        ,    ,  , ,   ,    , , , , ,  ,  , ,  -2, ,    ,  , , , ,  ,           ,  ..       , , , ,   ,  ,  ,   ,   ..     : REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (Mack Publishing Co. 1995)  GOODMAN AND </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5d/e5/ea/70ef4608b84bf1/00000019.png" class="style-scope patent-text"><img file="00000019.jpg" he="4" wi="20" img-format="jpg" img-content="undefined" width="80" height="16" alt="Figure 00000019" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5d/e5/ea/70ef4608b84bf1/00000019.png"></a></div> THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7th Ed. (MacMillan Publishing Co. 1985),       .    ,     ,      .[0176] Therapeutic agents suitable for use in combination with camptothecin conjugates described herein also include, for example, chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxins, taxanes, antimetabolites, tyrosine kinase inhibitors, alkylating agents, antibiotics Cox-2 inhibitors, antimitotics, antiangiogenic and proapoptotic agents, in particular, doxorubicin, methotrexate, taxol, other camptothecins, as well as other agents from these and other classes of anti-cancer agents, etc. Other anti-cancer chemotherapeutic drugs include mustargens, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogues, pyrimidine analogues, purine analogues, platinum coordination complexes, hormones, etc. Suitable chemotherapeutic agents are described in REMINGTON'S PHARMACEUTICAL SCIENC. (Mack Publishing Co. 1995) and GOODMAN AND <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5d/e5/ea/70ef4608b84bf1/00000019.png" class="style-scope patent-text"><img file="00000019.jpg" he="4" wi="20" img-format="jpg" img-content="undefined" width="80" height="16" alt="Figure 00000019" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5d/e5/ea/70ef4608b84bf1/00000019.png"></a></div> THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7th Ed. (MacMillan Publishing Co. 1985), as well as their revised and revised editions. Other suitable chemotherapeutic agents, such as experimental drugs, are known to those skilled in the art.
  <p class="style-scope patent-text"></p>
  <p num="227" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0177]       ,   , 5-, , , , , , , AVL-101, AVL-291, , , , , -1, , , , , 10-, , , ,  (CDDP),  -2,  (-11), SN-38, , , , , , , , , , , , , , 2- (2P-DOX), -,  ,  , , , , , ,    ,  (VP16),  ,  , , ,  (FUdR), 3',5'-O--FudR. (FUdR-dO), , ,  -, , , , GDC-0834, GS-1101, , , , , , , , , L-, , , , LFM-A13, , , , , 6-, , , , , , , , , , , , , , PCI-32765, , PSI-341, , , , , SU11248, , , , , , , , , , , , , , ,    ZD 1839.      ,    ,  ,  ,      ,  ,       .</span>[0177] Examples of suitable medicaments include, but are not limited to, 5-fluorouracil, afatinib, aplidine, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bozutinib, bryostatin-1 , busulfan, calicheamicin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothephan, cyclis, cytarabine, dacarbazine, dasatinib, dinatsiklib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolino (2P-DOX), cyano-morfolinodoksorubitsin, doxorubicin glucuronide, epirubicin glucuronide, erlotinib, estramustine, epidofillotoksin, erlotinib, entinostat linking estrogen receptor agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, phloxuridine (FUdR), 3 ', 5'-O-dioleoyl-FudR. (FUdR-dO), fludarabine, flutamide, farnesyl protein transferase inhibitors, flavopiridol, fostamatinib, ganethespib, GDC-0834, GS-1101, gefinitib, gemcitabine, hydroxyurea, ibrutinibicin, ididezinibicib, idibinibisibate, , lenalidomide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mitramycin, mitomycin, mitotan, navelbin, neratinib, nilotinibec, plicinazaricin, plycazolebicaricin, nylrosinazaricin, , pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temozolomide, transplatin, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uramustine, vatalanibin viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, viniborin, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibinib, vinibininvin Such agents may be part of the conjugates described herein, or may, alternatively, be administered in combination with the conjugates described, prior to administration, simultaneously with or after administration to onyugate.</span>
  </p>
  <p num="228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0178]  ,        ,    ,    . ,     ,  , ,  (),  I,   ,   , ,  ,  Pseudomonas   Pseudomonas. (., , Pastan. et al., Cell (1986), 47:641,  Sharkey, Goldenberg, CA Cancer J Clin. 2006 Jul-Aug; 56(4):226-43.)  ,      ,            6077499.</span>[0178] Therapeutic agents that can be used in combination with camptothecin conjugates may also contain toxins conjugated to targeting fragments. Toxins that can be used in this way include ricin, abrin, ribonuclease (RNase), DNase I, staphylococcal enterotoxin A, antiviral pacifier protein, gelonin, diphtheria toxin, Pseudomonas exotoxin and Pseudomonas endotoxin. (See, for example, Pastan. Et al., Cell (1986), 47: 641, and Sharkey, Goldenberg, CA Cancer J Clin. 2006 Jul-Aug; 56 (4): 226-43.) Additional toxins suitable for use herein are known to those skilled in the art and are described in US Pat. No. 6,077,499.</span>
  </p>
  <p num="229" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0179]           . ,   ,     ,    , ,  ,   (),  (), ,    .  ,    ,      (),  ,    (),  ,      (-)  -   (-), ,    , ,   ,     ,     S1.     ,     , N-   ,    ;  ; ; ; ; ; ;  ,     (),   ()    ();   ; ,   ; ;  ,  ;   -  - ;   ; -  ; ; ;    ; ;  ();   ,   -;   ;    ()   -  -;    I  II;  ();  ; ,    ,   ;   (),     (-);  (),   -1, -1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12; -13, -14, -15, -16, -17, -18, -21, -25, -  (), Kit-  FLT-3, , , ,      (LT).              ,       .</span>[0179] Another class of therapeutic agents may contain one or more immunomodulators. Immunomodulators suitable for use may be selected from a cytokine, stem cell growth factor, lymphotoxin, hematopoietic factor, colony stimulating factor (CSF), interferon (IFN), erythropoietin, thrombopoietin, and combinations thereof. In particular, lymphotoxins such as tumor necrosis factor (TNF), hematopoietic factors such as interleukin (IL), colony stimulating factor such as granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) are suitable for use ), interferon, such as interferons , ,  or , and stem cell growth factor, such as denoted by "factor S1". Cytokines include growth hormones, such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH) and luteinizing hormone (LH); liver growth factor; prostaglandin, fibroblast growth factor; prolactin; placental lactogen, protein OB; tumor necrosis factor- and ; Mueller inhibitory substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-; platelet growth factor; transforming growth factors (TGF) such as TGF- and TGF-; insulin-like growth factors I and II; erythropoietin (EPO); osteinductive factors; interferons, such as interferon ,  and ; colony stimulating factors (CSF), such as macrophage CSF (M-CSF); interleukins (IL), such as IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10 , IL-11, IL-12; IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, leukemia inhibiting factor (LIF), Kit ligand or FLT-3, angiostatin, thrombospondin, endostatin, tumor necrosis factor and lymphotoxin (LT). As used herein, the term cytokine includes proteins from natural sources or recombinant cell cultures, and biologically active equivalents of natural cytokine sequences.</span>
  </p>
  <p num="230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0180] ,   ,  RANTES, MCAF, MIP1-, MIP1 -  IP-10.</span>[0180] Chemokines suitable for use include RANTES, MCAF, MIP1 alpha, MIP1 beta, and IP-10.</span>
  </p>
  <p num="231" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0181]            ADC  Trop-2    ,    , ,   .      , , , , , , , , , CI-980, , , , 2-, 7010, , , , , , , , , , ,  52,    .</span>[0181] In certain embodiments, the Therapeutic Agent for use in combination with anti-Trop-2 ADC is a microtubule inhibitor such as vinca alkaloid, taxanes, maytansinoid or auristatin. Examples of known microtubule inhibitors include paclitaxel, vincristine, vinblastine, mertansine, epothilone, docetaxel, discodermolide, combrestatin, podophyllotoxin, CI-980, phenylagistins, steganacins, curacins, 2-methoxyestradiol, E701enofininofinamides, vinibenofinamide, vinibinofinamide, vinibinofinamide, vinibinonefinamine, vinibinonefinamide, vinibinonefinamide, vininonefinamine, vininonefinaminfin, , rhizoxin, tasidotine, halichondrins, hemiasterelins, cryptophycin 52, MMAE and eribulin mesylate.</span>
  </p>
  <p num="232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0182]            ADC    PARP,   ,  (BMN-673), , ,  9722,  4827, BGB-290, -888, AG014699, BSI-201, -8983  3-.</span>[0182] In an alternative embodiment, the therapeutic agent for use in combination with ADC is a PARP inhibitor such as olaparib, talazoparib (BMN-673), rukaparib, veliparib, SER 9722, MK 4827, BGB-290, ABT-888, AG014699 , BSI-201, SER-8983 or 3-aminobenzamide.</span>
  </p>
  <p num="233" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0183]      ,     ADC,     ,    (PCI-32765), PCI-45292, -292 (AVL-292), ONO-4059, GDC-0834, LFM-A13  RN486.</span>[0183] In another alternative, the therapeutic agent used in combination with ADC is a Bruton tyrosine kinase inhibitor such as ibrutinib (PCI-32765), PCI-45292, CC-292 (AVL-292), ONO-4059, GDC- 0834, LFM-A13 or RN486.</span>
  </p>
  <p num="234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0184]       ,     ADC,    PI3K,   , , , , -866, IPI-145 (), BAY 80-6946, BEZ235, RP6530, TGR1202, SF1126, INK1117, GDC-0941, 120, XL147, XL765,  529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE477, CUDC-907, AEZS-136  LY294002.</span>[0184] According to yet another alternative, the therapeutic agent used in combination with ADC is a PI3K inhibitor such as Idealisib, Wortmannin, Demethoxyviridine, Periposin, PX-866, IPI-145 (Duvelisib), BAY 80-6946, BEZ235, RP6530, TGR1202, SF1126, INK1117, GDC-0941, VKM120, XL147, XL765, Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE477, CUDS-907, 907 .</span>
  </p>
  <p num="235" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0185]        ,   ADC,  ,      ,              ,    ,   ,  , , ,  ,  ,  , , , , , , , -  .        ,     ADC,      ADC    .</span>[0185] One of ordinary skill in the art will understand that the claimed ADCs containing camptothecin conjugated to an antibody or antibody fragment can be used alone or in combination with one or more other therapeutic agents, such as a second antibody, a second antibody fragment, second immunoconjugate, radionuclide, toxin, drug, chemotherapeutic agent, radiation therapy, chemokine, cytokine, immunomodulator, enzyme, hormone, oligonucleotide, RNA interference or siRNA. Such additional therapeutic agents may be administered alone, in combination with the claimed ADC, or be coupled to the claimed ADC antibody with a drug.</span>
  </p>
  <p num="236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Composition and Introduction</span>
  </p>
  <p num="237" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0186]     ,  , , , , , ,  , , , ,  , , , ,    .     .  ,     ,   , ,       .</span>[0186] Suitable routes for administration of conjugates include, without limitation, oral, parenteral, subcutaneous, rectal, transmucosal, intestinal administration, intramuscular, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal or intraocular injection. Preferred routes of administration are parenteral. Alternatively, the compound may be administered topically and not systemically, for example, by injecting the compound directly into a solid tumor.</span>
  </p>
  <p num="238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0187]   ADC              ,   ADC        .                .           . ., , : Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea &amp; Febiger 1990),  Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990),      .</span>[0187] Compositions with ADC can be prepared according to known methods for preparing pharmaceutically acceptable compositions in which ADC is mixed with a pharmaceutically acceptable adjuvant. Sterile phosphate buffered saline is one example of an excipient suitable for pharmaceutical use. Other suitable excipients are well known to those skilled in the art. See, for example, sources: Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea &amp; Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), and their revised and revised editions.</span>
  </p>
  <p num="239" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0188]     ADC       ( 6-7)   ,   ,   N(2-)-2-  (ACES); N-(2-)  (ADA); N,N-(2-)-2-  (BES); 4-(2-)-1-  (HEPES); 2-(N-)  (MES); 3-(N-)  (MOPS); 3-(N-)-2-  (MOPSO);  -N,N'-(2- ) [Pipes].     MES  MOPS, ,     20  100 ,   -  25 .   25  MES,  6,5.      25    0,01%    80    ,        22,25      .        ,       -20  2,   -  2-8.</span>[0188] According to a preferred embodiment, the ADCs are formulated in Good's biological buffer (pH 6-7) using a buffer selected from the group consisting of N (2-acetamido) -2-aminoethanesulfonic acid (ACES); N- (2-acetamido) iminodiacetic acid (ADA); N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid (BES); 4- (2-hydroxyethyl) piperazin-1-ethanesulfonic acid (HEPES); 2- (N-morpholino) ethanesulfonic acid (MES); 3- (N-morpholino) propanesulfonic acid (MOPS); 3- (N-morpholinyl) -2-hydroxypropanesulfonic acid (MOPSO); and piperazine-N, N'-bis (2-ethanesulfonic acid) [Pipes]. More preferred buffers are MES or MOPS, preferably in a concentration range of 20 to 100 mM, more preferably about 25 mM. Most preferred is 25 mM MES, pH 6.5. The specified composition may additionally contain 25 mm trehalose and 0.01% by volume of polysorbate 80 as excipients, while the final buffer concentration is modified to 22.25 mm as a result of the addition of excipients. A preferred storage method is represented by a lyophilized composition with conjugates stored at temperatures ranging from -20  C to 2  C, most preferably at 2-8  C.</span>
  </p>
  <p num="240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0189] ADC         , ,  ,     .                4 ,   -        3 . ,  25-50         30 ,   15 ,        2-3 .    ,     , ,      9180205,         .        1, 2  3 ,            .  ,  ,   1,5  4 /  ADC.</span>[0189] ADC can be formulated for intravenous administration by, for example, bolus injection, slow infusion, or continuous infusion. In a preferred embodiment, the antibody of the present invention is infused over a period of less than about 4 hours, more preferably over a period of less than about 3 hours. For example, the first 25-50 mg can be infused over a period of 30 minutes, preferably even 15 minutes, and the remainder is infused over the next 2-3 hours. If subcutaneous administration is required, the antibody may be concentrated, for example, as described in US Pat. No. 9,180,205, a section of the examples of which is incorporated herein by reference. Subcutaneous injections can be represented by 1, 2 or 3 ml injections, which can be administered at one site or at two or more sites. Each injection typically contains 1.5 to 4 mg / kg of concentrated ADC.</span>
  </p>
  <p num="241" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0190]         , ,     ,   .     , , ,        ,     ,   ,  /  .  ,       ,    , ,   ,  .</span>[0190] Formulations for injection may be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with the addition of a preservative. These compositions may take the form of, for example, suspensions, solutions or emulsions in an oil or water base, and may contain prescription agents, such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient may be in powder form, requiring reconstitution with a suitable base, for example, sterile pyrogen-free water, before use.</span>
  </p>
  <p num="242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0191]           .                ADC   . ,      (--)           . Sherwood et al., Bio/Technology 10: 1446 (1992).   ADC        ADC,  ADC       . Saltzman et al., Biophys. J. 55: 163 (1989); Sherwood et al., .       : Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea &amp; Febiger 1990),  Gennaro (ed.), </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4a/11/c6/bdd82f4f828ec2/00000020.png" class="style-scope patent-text"><img file="00000020.jpg" he="4" wi="30" img-format="jpg" img-content="undefined" width="120" height="16" alt="Figure 00000020" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4a/11/c6/bdd82f4f828ec2/00000020.png"></a></div> PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990),       .[0191] Additional pharmaceutical methods can be used to control the duration of action of the therapeutic conjugate. Controlled release formulations can be prepared by using polymers to complex with the indicated ADC or adsorb it. For example, biocompatible polymers include matrices from poly (ethylene-co-vinyl acetate) and matrices from a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood et al., Bio / Technology 10: 1446 (1992). The rate of release of ADC from such a matrix depends on the molecular weight of ADC, the amount of ADC in the matrix, and the size of the dispersed particles. Saltzman et al., Biophys. J. 55: 163 (1989); Sherwood et al., Supra. Other solid dosage forms are described in sources: Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th Edition (Lea &amp; Febiger 1990), and Gennaro (ed.), <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/4a/11/c6/bdd82f4f828ec2/00000020.png" class="style-scope patent-text"><img file="00000020.jpg" he="4" wi="30" img-format="jpg" img-content="undefined" width="120" height="16" alt="Figure 00000020" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/4a/11/c6/bdd82f4f828ec2/00000020.png"></a></div> PHARMACEUTICAL SCIENCES, 18th Edition (Mack Publishing Company 1990), as well as their revised and revised editions.
  <p class="style-scope patent-text"></p>
  <p num="243" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0192]   ADC         ,  ,  , , ,       .       ADC  ,       1 /  24 /     , ,    ,          .  1-20 /      70 , ,  70-1400 ,  41-824 /<sup class="style-scope patent-text">2</sup>    1,7 .      , ,       4-10 ,       8 ,        4 .       , ,         ,        ,     .    ,   , 1 /, 2 /, 3 /, 4 /, 5 /, 6 /, 7 /, 8 /, 9 /, 10 /, 11 /, 12 /, 13 /, 14 /, 15 /, 16 /, 17 /, 18 /, 19 /, 20 /, 22 /  24 /.        1  24 /.     ,      .       4 ,   - 8 ,   - 16   .           ,   ,   ,  : (i)  ; (ii)      ; (iii)      ,     ; (iv)      , ,     ; (v)      , , ,     ; (vi)      , , ,     ; (vii)      , , ,     ;  (viii)  .      4, 6, 8, 10, 12, 16  20   .</span>[0192] Typically, the dosage of ADC for administration to a person varies depending on factors such as age, body weight, height, gender, general medical condition, and the patients previous medical history. It may be desirable to ensure that the recipient receives the ADC in a dosage that ranges from about 1 mg / kg to 24 mg / kg as a single intravenous infusion, however, a lower or higher dosage may also be used, depending on the circumstances. The dosage of 1-20 mg / kg for a patient weighing 70 kg, for example, is 70-1400 mg, or 41-824 mg / m <sup class="style-scope patent-text">2</sup> for a patient with a height of 1.7 m. Dosing can be repeated, for example, once per week for 4-10 weeks, once a week for 8 weeks, or once a week for 4 weeks. Administration can also be carried out at a lower frequency, for example, once every two weeks for several months, or monthly or quarterly for many months, if necessary for maintenance therapy. Preferred dosages may include, but are not limited to, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 22 mg / kg and 24 mg / kg. Any amount in the range of 1 to 24 mg / kg may be used. Dosing is preferably carried out several times, once or twice a week. A minimum dosing schedule of 4 weeks may be used, more preferably 8 weeks, more preferably 16 weeks or more. The administration schedule may include administration once or twice a week, over a cycle selected from the group consisting of: (i) weekly administration; (ii) once every two weeks; (iii) one week of therapy followed by two, three or four weeks of rest; (iv) two weeks of therapy followed by one, two, three or four weeks of rest; (v) three weeks of therapy followed by one, two, three, four or five weeks of rest; (vi) four weeks of therapy followed by one, two, three, four or five weeks of rest; (vii) five weeks of therapy followed by one, two, three, four or five weeks of rest; and (viii) monthly administration. The specified cycle can be repeated 4, 6, 8, 10, 12, 16 or 20 times or more.</span>
  </p>
  <p num="244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0193]  , ADC        2  3 ,       3 ,        4-6 .      200-300 /<sup class="style-scope patent-text">2</sup> (340       1,7   4,9 /      70 )             4-10 .  ,     ,  ,     2  3    2-3 .  , ,     ,   12 /         2-3 ,     / ,     .         ;        ,       .</span>[0193] Alternatively, ADC may be administered in a single dose every 2 or 3 weeks, for a total of at least 3 times, or twice a week for 4-6 weeks. If the dosage is reduced to approximately 200-300 mg / m <sup class="style-scope patent-text">2</sup> (340 mg per dose for a patient with a height of 1.7 m or 4.9 mg / kg for a patient weighing 70 kg), dosing can be carried out once or even twice a week for 4-10 weeks. Alternatively, the dosing schedule can be reduced, namely, dosing can be carried out every 2 or 3 weeks for 2-3 months. It has been determined, however, that even higher doses, such as 12 mg / kg once a week or once every 2-3 weeks, can be administered by slow iv infusion, over multiple dosing cycles. The dosage schedule may optionally be repeated at other intervals; dosing can be carried out using various parenteral routes, with appropriate dose adjustments and dosing regimens.</span>
  </p>
  <p num="245" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0194]      ADC    .    ,   , , , , ,   , ,    .          :   (,   ),  ,  , ,  ,      ,   ,      ,  ,      ,     ,   ,  ,   ,  ,  ,   , ,  ,  ,    ,    ,   ,  ,   ,   ,     ,   ,     ,   ,  ,   ,   ,      .         (, ,        ,        ),       (,    ,         ,     ).</span>[0194] In preferred embodiments, said ADCs are suitable for cancer therapy. Examples of cancers include, but are not limited to, carcinoma, lymphoma, glioblastoma, melanoma, sarcoma and leukemia, myeloma, or lymphoid malignancies. More specific examples of such cancers are listed below and include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), Ewing's sarcoma, Wilms tumor, astrocytoma, lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and squamous cell carcinoma, peritoneal cancer, gastric tract or stomach cancer, including gastrointestinal cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, hepatocellular carcinoma, neuroendocrine tumors, medullary thyroid cancer, differentiated thyroid carcinoma, breast cancer, ovarian cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary carcinoma, kidney or renal cancer, prostate cancer, vulvar cancer, anal canal carcinoma, penile carcinoma as well as head and neck cancer. The term cancer includes primary malignant cells or tumors (for example, tumors whose cells have not migrated to the sites of the subjects body other than the site of the original malignant formation or tumor), and secondary malignant cells or tumors (for example, resulting from metastasis, migration of malignant cells or tumor cells to secondary sites other than the site of the original tumor).</span>
  </p>
  <p num="246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0195]       ,    :     ,   ,   ,   ,  , ()    , ()    ,     ,     ,    ,    ,    ,     ,     , - , -  ,   , ,   ,   ,  ,    ,   ,   ,     , ()    ,    ,  ,  ,   , ()    , ()    ,     ,     ,      ,    ,    ,       ,    ,    ,       ,    ,   ,    ,          ,     ,   ,     ,       ,   ,   ,   ,  - ,      ,  , ,  ,  ,     ,    ,    ,    ,    ,  ,    ,  ,   ,  ,   ,  ,    ,   ,   ,    ,  ,  , ,  ,   ,  ,   ,     ,  ,  ,  ,     ,  ,  ,  , ,    ,  ,  , , , ,      ,     ,    ,  ,  / ,  ,  ,  ,  ,      ,  , ,  ,   ,   ,      ,  , -/   , /  , /   ,   ,    ,      ,   , ,  ,   ,   , ,  ,     ,   ,   ,   , - ,     , , ,   ,  ,  ,  ,   ,   ,   ,   ,  ,        , - ,  , ,   , -     , -     ,  ,      ,  ,  ,  ,  ,     ,  ,  ,       ,  ,    ,  .</span>[0195] Other examples of cancer or malignancies include, but are not limited to: acute lymphoblastic leukemia of childhood, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, (primary) hepatocellular carcinoma of the adult, (primary) liver cancer adulthood, adult acute lymphocytic leukemia, adult acute myeloid leukemia, adult Hodgkins lymphoma, adult lymphocytic leukemia, adult non-Hodgkins lymphoma, primary adult liver cancer, adult soft tissue sarcoma, AIDS-associated lymphoma, AIDS-related malignant tumors, anal canal cancer, astrocytoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumors, breast cancer, renal pelvis and ureter cancer, (primary) lymphoma of the central nervous system, lymphoma in the central nervous system, cerebellar astrocytoma, cerebral astrocytoma, cervical cancer, childhood (primary) hepatocellular cancer in childhood, (primary) childhood liver cancer, acute childhood lymphoblastic leukemia, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, childhood extracranial tumors of germ line cells, childhood Hodgkins disease, childhood Hodgkins lymphoma, hypothalamic glioma and visual pathway of childhood, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkins tumors of the pineal body and supratentorial primitive neuroectodermal tumors of childhood, primary childhood cancer of the liver, childhood rhabdomyosarcoma, childhood soft tissue sarcoma, hypothalamic glioma and visual pathway of children age, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, cutaneous T-cell lymphoma, pancreatic islet cell carcinoma of the pancreas, endometrial cancer, ependymoma, epithelial cancer, esophageal cancer, Ewing's sarcoma and associated tumors, exocrine pancreatic cancer germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, female breast cancer, Gaucher disease, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal tumor, germ line tumor, gestational trophoblastic tumor, fleecy leukemia cells, head and neck cancer, hepatocellular cancer, Hodgkins lymphoma, hypergammaglobulinemia, hypopharyngial cancer, gastrointestinal cancers, intraocular melanoma, islet cell carcinoma, pancreatic islet cell cancer, Kaposis sarcoma, kidney cancer, laryngeal cancer, lip and oral cancer liver cancer, l cancer lung, lymphoproliferative disorders, macroglobulinemia, male breast cancer, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, mesothelioma, metastatic occult primary squamous cell carcinoma of the neck, metastatic primary squamous cell carcinoma of the neck, metastatic squamous cell squamous cell carcinoma , myelodysplastic syndrome, myelogenous leukemia, myeloid leukemia, myeloproliferative disorders, cancer of the nasal cavity and paranasal sinuses, cancer of the nasopharynx, neuroblastoma, non-Hodgkins lymphoma, non-melanoma skin cancer, non-small cell lung cancer, occult primary metastatic cancer, squamous cell fibrotic sarcoma, osteosarcoma / malignant fibrous histiocytoma, osteosarcoma / malignant fibrous histiocytoma, epithelial ovarian cancer, ovarian germ cell tumor, low potential ovarian tumor m malignancy, pancreatic cancer, paraproteinemia, true polycythemia, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, primary lymphoma of the central nervous system, primary liver cancer, prostate cancer, colorectal cancer, renal cell carcinoma, renal cell carcinoma pelvis and ureter, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoidosis sarcomas, Cesari syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous neck cancer, gastric cancer, supratentorial primitive neuroectoderm tumors, body tumors, -cellular lymphoma, testicular cancer, thymoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumors, cancer of the ureter and renal pelvis, ureter cancer, uterine cancer, uterine sarcoma, cancer of the vagina, glioma of the optic pathway and hypothalamus, cancer of the vulva, macroglo Waldenstrom bulminemia, Wilms tumor and any other hyperproliferative disease, in addition to the neoplasm localized in the organ systems listed above.</span>
  </p>
  <p num="247" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0196]   ,      ,        ,         ,   ,    , ,  .      , ,     ,     ,  ,       ,   ,  ,  ,  (.         : Robbins, Angell, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79 (1976)).</span>[0196] The methods and compositions described and claimed herein can be used to treat malignant or pre-malignant conditions, and to prevent progression to a neoplastic or malignant status, including, but not limited to, the disorders described above. Such applications are indicated for conditions preceding, according to available data or presumably, progression to a neoplasm or cancer, in particular, when there is the growth of non-neoplastic cells selected from hyperplasia, metaplasia or, in particular, dysplasia (see the review of such abnormal growth of states in the source: Robbins, Angell, Basic Pathology, 2d Ed., WB Saunders Co., Philadelphia, pp. 68-79 (1976)).</span>
  </p>
  <p num="248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0197]     ,      .           ,         .         .  ,     , ,   ,   , - ,   , - ,  ,  ,  ,  , - ,   , - , - , - ,  ,  ,  ,  ,  ,   ,   ,   ,  , -- ,    ,    , - ,   ,   ,     ,   ,   ,   ,   , - ,  ,  ,   ,  ,   , -- ,  ,  ,  ,  ,   ,   ,   ,  ,  ,    - .</span>[0197] Dysplasia is often a harbinger of cancer, and is mainly found in the epithelium. It represents the most disordered form of growth of non-neoplastic cells, including the loss by individual cells of homogeneity and structural orientation of cells. The occurrence of dysplasia in areas of chronic irritation or inflammation is characteristic. Dysplastic disorders that can be treated include, but are not limited to, anhydrotic ectodermal dysplasia, anterior facies dysplasia, asphyxial thoracic dysplasia, atrial-digital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondrodectomy, chondrodectomy congenital ectodermal dysplasia, cranial-diaphyseal dysplasia, cranial-carpotarsal dysplasia, cranial-metaphysaric dysplasia, dentin dysplasia, diaphyseal dysplasia, ectodermal dysplasia, enamel dysplasia, encephaloophthalmic dysplasia, hemimerrhizal dysplasia, epimelic dysplasia dysplasia epileptic epileptic dysplasia, epimelic dysplasia epileptic dysplasia, epimelic dysplasia epileptic dysplasia, epimelic dysplasia dysplasia epileptic epileptic dysplasia, epimelic dysplasia - finger-genital dysplasia, familial fibrous jaw dysplasia, familial white folded dysplasia, muscular fibro-muscular dysplasia, fibrous bone dysplasia, florid bone dysplasia, hereditary renal dysplasia and retinas, hydrotic ectodermal dysplasia, hypohydrotic ectodermal dysplasia, lymphocytopenic dysplasia of the thymus, dysplasia of the mammary gland, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic dysplasia, mucoeipulosis dysplasia, mucoeipulosis dysplasia, mucoeipulosis dysplasia , oculovertebral dysplasia, odontogenic dysplasia, ophthalmandomibulomelic dysplasia, periapical cement dysplasia, polyossal fibrous dysplasia, pseudo-chondroplastic spondyloepiphysar dysplasia, retinal dysplasia, and spondyloperipydephysis dysplasia dysplasia.</span>
  </p>
  <p num="249" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0198]   ,     , ,   ,    (,  , - ,  ,    ,   ), , ,  ,  ,  ,   .</span>[0198] Additional preneoplastic disorders that can be treated include, but are not limited to, benign dysproliferative disorders (eg, benign tumors, fibrocystic states, tissue hypertrophy, intestinal polyps or adenomas, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, "farmer's skin", solar cheilitis, and solar keratosis.</span>
  </p>
  <p num="250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0199]            ,  /  ,  ,    .</span>[0199] According to preferred embodiments, the method of the present invention is used to inhibit the growth, progression and / or metastasis of cancer, in particular the above types of cancer.</span>
  </p>
  <p num="251" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0200]   ,  /  ,   ,  /      ,    (    ; ,   ,    [   , , ,    ])    (,   []     ),  ,  (,     ),  ,  ,      ,   ,    ,   ,   , , , ,  , , , , , , , ,  , , ,   ,   ,   ,  ,   ,  , - , ,   ,   ,  ,  , ,  ,  ,  , ,   , , ,  ,  ,   ,  ,  ,   ,   ,  , , , , , , , ,  , , , ,   .</span>[0200] Additional hyperproliferative diseases, disorders and / or conditions include, but are not limited to, the progression and / or metastases of malignant tumors and associated disorders such as leukemia (including acute leukemia; for example, acute lymphocytic leukemia, acute myelocytic leukemia [in including myeloblastic, promyelocytic, myelomonocytic, monocytic leukemia and erythroleukemia]) and chronic leukemia (for example, chronic myelocytic [granulocytic] leukemia and chronic lymphocytic leukemia), true polycythemia, lymphomas (eg, Hodgkins lymphoma, necrosis), Waldenstrom, heavy chain disease and solid tumors, including, but not limited to, sarcomas and carcinomas, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphoma sarcoma, lymphotherosarcoma, lymphoma ioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous carcinoma, papillary carcinoma adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonic carcinoma, Wilms tumor, cervical cancer, testicular tumor, pulmonary carcinoma, pulmonary carcinoma, small cell carcinoma, small cell carcinoma glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma and retinoblastoma.</span>
  </p>
  <p num="252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0201]  ,        ADC,       , ,  ,  ,   ,  ,  ,  ,  ,  ,  -,  ,  ,  , ANCA- ,  ,  ,  , ,  ,  , IgA-,  ,  ,  ,  ,  ,   ,  , , ,   , /, ,  ,  ,  ,  ,   ,   ,  /,  ,   ,    .</span>[0201] Autoimmune diseases that can be treated with ADC may include acute and chronic immune thrombocytopenia, dermatomyositis, Sydenham chorea, severe myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, and pulmonary diabetes mellitus Shenlein-Genoch purpura, post-streptococcal nephritis, erythema nodosum, Takayasu arteritis, ANCA-associated vasculitis, Addisons disease, rheumatoid arthritis, multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis splerosis, nodular polyarteritis, ankyl arteriitis, angiitis arteriitis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splerosis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis arteritis, splenitis, thromboangiitis, Sjgrens syndrome, primary biliary cirrhosis, Hashimotos thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis / dermatomyositis, polychondritis, bullous pemphigoid, common pemphigus, amyotrophic granulomatosis, spinal cord neurogenesis, spinal cord neurogenesis, spinal cord neurogenesis, neurogenesis, Igantocellular arteritis / polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, psoriasis or fibrosing alveolitis.</span>
  </p>
  <p num="253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Sets</span>
  </p>
  <p num="254" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0202]      ,  ,       .         ADC        .  ,  ,  ,         , ,  ,    ,     -  .       , , ,  ,   ,        .      .</span>[0202] Various implementation options may include kits containing components suitable for the treatment of diseased tissue of a patient. Examples of kits may contain at least one ADC or other targeting fragment described herein. If the composition containing the components for administration is not formulated for delivery through the digestive tract, for example, oral delivery, a device may be included that allows the components of the kit to be delivered in any other way. One type of device for use cases involving, for example, parenteral delivery, is a syringe that is used to inject the composition into the subject's body. Inhalation devices may also be used.</span>
  </p>
  <p num="255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0203]             .                ,    .        ,    /   .  ,   , ,   , , , ,   ..            .  ,    ,       .</span>[0203] The components of the kit may be packaged together or divided into two or more containers. In some embodiments, said containers may be vials of sterile lyophilized formulations with a composition that are suitable for reconstitution. A kit may also contain one or more buffers suitable for reconstituting and / or diluting other reagents. Other containers that may be used include, but are not limited to, a bag, tray, box, test tube, or the like. Kit components may be packaged and stored in a sterile condition inside said containers. Another component that may be included is provided by user instructions for using the kit.</span>
  </p>
  <p num="256" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>EXAMPLES</span>
  </p>
  <p num="257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0204]         ,     .</span>[0204] Various embodiments of the present invention are illustrated by the following non-limiting examples.</span>
  </p>
  <p num="258" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 1.         -Trop-2-SN-38</span>Example 1. The preparation and use of the conjugate of the antibody with the drug anti-Trop-2-SN-38</span>
  </p>
  <p num="259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0205]   RS7 (hRS7)  Trop-2       7238785,           .  SN-38,    CL2A,     hRS7 ( Trop-2), hPAM4 ( MUC5ac), hA20 ( CD20)  hMN-14 ( 5)      7999083 ( 10  12        ).      6  SN-38   .</span>[0205] A humanized RS7 antibody (hRS7) against Trop-2 was prepared as described in US Pat. No. 7,238,785, sections of the drawings and examples of which are incorporated herein by reference. Received SN-38, attached to the CL2A linker, and conjugated with antibodies hRS7 (against Trop-2), hPAM4 (against MUC5ac), hA20 (against CD20) or hMN-14 (against CEACAM5) in accordance with US patent No. 7999083 (examples 10 and 12 of which are incorporated herein by reference). The conjugation protocol affixed approximately 6 SN-38 molecules per antibody molecule.</span>
  </p>
  <p num="260" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0206]   Nude ()   ,          ,      CL2A-SN-38,   ,     .     .      Capan 1   CL2A-SN-38  hRS7 (  Trop-2), hPAM4 (  MUC-5ac)  hMN-14 (  5)         hA20-CL2A-SN-38 (  CD20)     ( ).  ,       3  hRS7-CL2A-SN-38          ( ).</span>[0206] Nude nude mice (females) with immune deficiency carrying subcutaneous xenografts of human pancreatic or colon tumors were treated with either specific CL2A-SN-38 conjugate, control conjugate, or received no treatment. The therapeutic efficacy of specific conjugates has been observed. In the <figure-callout id="1" label="Capan" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">Capan</a></figure-callout> 1 pancreatic tumor model, specific conjugates of CL2A-SN-38 antibodies hRS7 (anti-Trop-2 antibody), hPAM4 (anti-MUC-5ac antibody) and hMN-14 (anti-CEACAM5 antibody) showed better efficacy compared to the control hA20 conjugate -CL2A-SN-38 (anti-CD20 antibody) and untreated control (not shown). Similarly, in the human pancreatic cancer model BXPC3, specific hRS7-CL2A-SN-38 showed better therapeutic efficacy compared to control treatment (not shown).</span>
  </p>
  <p num="261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 2.   ADC  Trop-2 ( )  ,      </span>Example 2. The therapeutic use of ADC against Trop-2 (satsituzumab govitecan) in patients refractory to therapy with checkpoint inhibitors</span>
  </p>
  <p num="262" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Short description</span>
  </p>
  <p num="263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0207] IMMU-132 ( ,  hRS7-CL2A-SN-38)       II                ,     (ClinicalTrials.gov, NCT01631552),      Trop-2.     Trop-2     7,6  SN-38,   ,  CL2A,  ,     in vivo    ,          ,    .</span>[0207] IMMU-132 (satsituzumab govitecan, or hRS7-CL2A-SN-38) has shown promising therapeutic results in phase II trials in patients with metastatic breast cancer with a triple negative phenotype and other cancers that have undergone serious treatment (ClinicalTrials. gov, NCT01631552) in which high levels of Trop-2 are expressed. This new Trop-2-targeted humanized antibody is conjugated to 7.6 moles of SN-38, the active form of irinotecan, the CL2A linker described above, and undergoes less in vivo glucuronidation compared to irinotecan, which causes a significantly lower incidence of diarrhea in patients treated with the indicated agent.</span>
  </p>
  <p num="264" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0208]  , IMMU-132     ,               ,       .    ,     ,         4  - (CTLA-4),     (PD-1)   1    (PD-L1).     , IMMU-132     ,   , /    ,     .</span>[0208] Unexpectedly, IMMU-132 has been shown to be highly effective in patients who have previously experienced relapse after use or resistance to many standard types of anti-cancer therapies, including the parent irinotecan compound. A new class of anticancer agents known as checkpoint inhibitors include antibodies or other inhibitory agents against cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein (PD-1), and programmed cell death ligand 1 (PD-L1) . As described herein, IMMU-132 exhibits unexpected and unanticipated efficacy against tumors recurring / refractory to control point inhibitors, as well as other anti-cancer agents.</span>
  </p>
  <p num="265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0209]            (255-029),    IMMU-132      PD-L1.</span>[0209] The following data summarizes the results for a practical use case in a patient (255-029) responding to IMMU-132 therapy after demonstrated resistance to a PD-L1 inhibitor.</span>
  </p>
  <p num="266" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">:  (    PD-L1)</span>Cancer: TNBC (patient progressed after PD-L1 therapy)</span>
  </p>
  <p num="267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> :  ,  (   54%)</span>Best answer: Partial answer, confirmed (54% reduction in size)</span>
  </p>
  <p num="268" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  IMMU-132: 10 /</span>Starting dose IMMU-132: 10 mg / kg</span>
  </p>
  <p num="269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    IMMU-132: 40+</span>The number of treatment procedures with IMMU-132: 40+</span>
  </p>
  <p num="270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  : 12,4 +  ( )</span>Time to progression: 12.4 + months (not achieved)</span>
  </p>
  <p num="271" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> :  </span>Study end: Continuation of treatment.</span>
  </p>
  <p num="272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0210]  - :   47 ,   2007 .     1,8     .         (   ).  ,      ER, PR  Her-2 (..   ).    4    (  ),        (12).   2008 .  -            ;    .        ,    XRT ( )    2009 .   2010 .        .          (),  (,     )   (),      2013 .,   ,              () .   2014 .   6     PD-L1 (MPDL3280A),    2015 .  .          IMMU-132.</span>[0210] Anamnesis - Patient: 47-year-old woman, in October 2007, a neoplasm of 1.8 cm in the right breast was first diagnosed. The patient underwent a right-sided mastectomy with a signal lymph node biopsy (there was no malignancy in the nodes). It was determined that the tumor is negative for ER, PR, and Her-2 (i.e., it is TNBC). Then the patient underwent 4 cycles of AS therapy (doxorubicin and cyclophosphamide), followed by weekly administration of low doses of paclitaxel ( 12). In October 2008, a CT scan revealed a previously unnoticed pulmonary nodule and an enlarged node in the mammary gland; the specified node was cancerous. The patient underwent local surgery to remove the node, after which she received XRT (radiation therapy) during March 2009. In June 2010, with CT, a recurrent lesion of the lungs and bones was recorded. The patient was included in a clinical trial using Avastin (bevacizumab), Metmab (onartuzumab, an antibody against hepatocyte growth factor) and Taxol (paclitaxel), in which she participated until March 2013, demonstrating a complete response, but was ultimately observed progression of the peripheral pulmonary nodule and node in the AP (aortopulmonary) window. In September 2014, the patient began 6 cycles of treatment with the anti-PD-L1 antibody (MPDL3280A), but progression began in January 2015. After that, the patient was transferred to participate in the IMMU-132 trial.</span>
  </p>
  <p num="273" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0211]   IMMU-132 -     6  2015 .   10 /,           ,    40 + .</span>[0211] Treatment at IMMU-132 - Treatment of the patient was started on February 6, 2015 with a dose of 10 mg / kg, administration of the indicated dose continued without reduction or delays according to the planned schedule, 40 + doses were already administered.</span>
  </p>
  <p num="274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>results</span>
  </p>
  <p num="275" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0212]     3    (1  , 2     )    60 ,      (    ) (. 2).    (7  2015 .)          33%,       RECIST 1.1.    -,    5  (18  2015 .)   ,     48% (. 3, . 4). 19  2015 . -      ,  50%  . 13  2015 . -     52%  ,  - 15  15 .  54%  .  -,  25  2016 .,     46%  .</span>[0212] Initially, the patient had 3 target lesions (1 in the lung, 2 in the lymph nodes of the chest) with a total diameter of 60 mm, and an additional non-target lesion (other lymph node of the chest) (Fig. 2). At the first assessment (April 7, 2015), the total diameter of the target lesions in the patient decreased by 33%, which corresponds to a partial response according to the RECIST 1.1 criteria. A subsequent confirmatory CT study conducted approximately 5 weeks later (May 18, 2015) showed an improvement in response, with an overall decrease of 48% (Fig. 3, Fig. 4). On July 19, 2015, a CT study showed the continuation of a partial response in the patient, with a 50% reduction in size. On September 13, 2015, a CT study showed a continuation of HO with a 52% reduction in size, and a CT study on November 15, 15, showed a 54% reduction in size. The latest CT study, conducted on February 25, 2016, showed a continuation of HO with a 46% reduction in size.</span>
  </p>
  <p num="276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0213]      . 1.   -   . 2,      ,         (  ).        . 3  . 4.  . 3     , 1  2,   .   (29  2015 .)  .     L1,   L2       (19  2015 .),   .  . 4        3,         .   ,         IMMU-132       .</span>[0213] The generalized CT results are shown in FIG. 1. The results of basic CT scans are presented in FIG. 2, axial images are shown in the upper row, and images in a sagittal projection in the lower row (tumors are indicated by arrows). A direct comparison of the target lesions is shown in FIG. 3 and FIG. 4. In FIG. 3 shows both target lesions, 1 and 2, in the same plane. The basic snapshot (January 29, 2015) is shown above. A significant reduction in the size of both L1 and L2 was evident in the second assessment of the answer (May 19, 2015), the pictures are shown below. In FIG. Figure 4 shows equivalent images for the <figure-callout id="3" label="target lesion" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">target lesion</a></figure-callout> 3, with a basic image on top and a second assessment of the response from below. The patient continues treatment, and he continues to have a partial response to IMMU-132 after a previous unsuccessful checkpoint inhibitor therapy.</span>
  </p>
  <p num="277" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0214]    Trop-2         2 + (  ).</span>[0214] An immunohistochemical analysis of Trop-2 expression in patient tumors confirms expression with a 2+ stain level (data not shown).</span>
  </p>
  <p num="278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0215]  -             3  (G3) (   ),            2 (G2) (2  2015 .;  6),  (G1),  (G1),   (G1),  (G2)   (G1).</span>[0215] Toxicity - At the time of writing this report, the most serious adverse event was <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 hypophosphatemia (G3) (not related to treatment), with toxicity associated with treatment being class 2 (G2) neutropenia (April 2, 2015). ; dose 6), fatigue (G1), nausea (G1), maculopapular rash (G1), alopecia (G2) and rhinorrhea (G1).</span>
  </p>
  <p num="279" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0216]   ,  IMMU-132     ,               .     IMMU-132      .     IMMU-132    Trop-2-  ,          ().</span>[0216] These results demonstrate that IMMU-132 is highly effective in patients who have previously experienced relapse after treatment with a control point inhibitor or resistance to the specified therapy. When using a therapeutic dosage of IMMU-132, only controlled toxicity was observed in the patient. These results demonstrate the usefulness of IMMU-132 for use in Trop-2-positive cancers, such as triple negative phenotype breast cancer (TNBC).</span>
  </p>
  <p num="280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 3. - ADC  Trop-2</span>Example 3. ADCC activity of ADC against Trop-2</span>
  </p>
  <p num="281" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0217]   -  ADC -   hRS7  IgG hRS7 ( ). ,   ,     -.  Trop-2-      (-3)      ,       100:1. ,  IgG hRS7   ,  hRS7-Pro-2-PDox, hRS7-CL2A-SN-38     hRS7-NEM.      33,3 .</span>[0217] The comparative ADCC activity of various ADC conjugates with hRS7 and IgG hRS7 (not shown) was determined. MCPCs purified from blood were purchased at the New Jersey Blood Center. A line of Trop-2-positive human pancreatic adenocarcinoma cells (BxRS-3) was used as the target cell line, with a ratio of effector to target cells of 100: 1. ADCC mediated by hRS7 IgG was compared with ADCC mediated by hRS7-Pro-2-PDox, hRS7-CL2A-SN-38 and reduced and capped hRS7-NEM. All antibodies were used at a concentration of 33.3 nM.</span>
  </p>
  <p num="282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0218]    ,   ( ).  8,5%    IgG hRS7,        hRS7-Pro-2-PDox.     ,     hLL2  hRS7-NEM    (  0,02,  t-).   hRS7-NEM    .</span>[0218] The overall activity was low, but significant (not shown). There was 8.5% specific lysis for hRS7 IgG, which did not significantly differ from the results for hRS7-Pro-2-PDox. Both results were significantly better than the results for the control hLL2 and hRS7-NEM and sacituzumab govitecan (P less than 0.02, two-sided t-test). There were no differences between hRS7-NEM and satsituzumab govitecan.</span>
  </p>
  <p num="283" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 4.  ADC -Trop-2-SN-38      in vivo</span>Example 4. The effectiveness of ADC anti-Trop-2-SN-38 against various types of epithelial cancer in vivo</span>
  </p>
  <p num="284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Short review</span>
  </p>
  <p num="285" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0219]       ADC SN-38    Trop-2 (hRS7),       ,        ,          hRS7,    .   SN-38, CL2-SN-38  CL2A-SN-38,      Trop-2, hRS7.  ADC  in vitro   ,   .           ,    -2.        .</span>[0219] The aim of this study was to evaluate the effectiveness of ADC SN-38 and anti-Trop-2 antibody (hRS7) directed against several types of solid human tumors, and to evaluate its tolerance in mice and monkeys, and tissue cross-reactivity against hRS7 was evaluated in the latter. similar to that observed in humans. Two derivatives of SN-38, CL2-SN-38 and CL2A-SN-38, were conjugated to a humanized anti-Trop-2 antibody, hRS7. These ADCs were characterized in vitro with respect to stability, binding and cytotoxicity. Efficacy was tested in five different models with xenografts of solid human tumors that express the Tcor-2 antigen. Toxicity was evaluated in mice and cynomolgus monkeys.</span>
  </p>
  <p num="286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0220]  hRS7    SN-38         (~6),   (K<sub class="style-scope patent-text">d</sub> ~ 1,2 /),  (IC<sub class="style-scope patent-text">50</sub> ~ 2,2 /)     in vitro (t/</span></span></p><div class="patent-image small-patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7a/3a/36/8c6ad9d3aad8aa/00000021.png" class="style-scope patent-text"><img file="00000021.jpg" he="2" wi="3" img-format="jpg" img-content="undefined" width="12" height="8" alt="Figure 00000021" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7a/3a/36/8c6ad9d3aad8aa/00000021.png"></a></div> ~ 20 ).   ADC     ,    PARP,       53  21   SN-38.           ,   Calu-3 (    0,05), Capan-1 (  0,018), -3 (  0,005)  COLO 205 (  0,033)      ADC.    212 / ( SN-38)          ACT.   ,   20,96 /,       ,  ,  ,      .[0220] hRS7 conjugates with two derivatives of SN-38 were equivalent in terms of drug substitution rate (~ 6), cell binding (K <sub class="style-scope patent-text">d</sub> ~ 1.2 nmol / L), cytotoxicity (IC <sub class="style-scope patent-text">50</sub> ~ 2.2 nmol / L) and in vitro serum stability (t / <div class="patent-image small-patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7a/3a/36/8c6ad9d3aad8aa/00000021.png" class="style-scope patent-text"><img file="00000021.jpg" he="2" wi="3" img-format="jpg" img-content="undefined" width="12" height="8" alt="Figure 00000021" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7a/3a/36/8c6ad9d3aad8aa/00000021.png"></a></div> ~ 20 hours). Under the influence of ADC on cells, signaling pathways were observed leading to PARP cleavage, however, differences in the positive regulation of p53 and p21 relative to free SN-38 were noted. Sacituzumab govitecan provided significant antitumor effects at non-toxic doses in mice bearing tumors of Calu-3 (P less than or equal to 0.05), Capan-1 (P less than 0.018), BhRS-3 (P less than 0.005) and COLO 205 (P less 0.033) compared with non-targeting control ADCs. Mice tolerated a dose of 2  12 mg / kg (SN-38 equivalents) with only a short-term increase in liver enzyme ALT and ACT levels. In cynomolgus monkeys, which were infused with 2  0.96 mg / kg, there was only a transient decrease in the number of blood elements, while, importantly, the values did not fall below normal ranges.
  <p class="style-scope patent-text"></p>
  <p num="287" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0221]  , ADC  Trop-2 hRS7-CL2A-SN-38           .     ,  Trop-2        ,    .</span>[0221] Summarizing the above, Trop-2 hRS7-CL2A-SN-38 ADC provided significant specific antitumor effects against a number of types of solid human tumors. It was well tolerated in monkeys whose expression of Trop-2 in tissues is similar to that in humans at clinically relevant doses.</span>
  </p>
  <p num="288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Introduction</span>
  </p>
  <p num="289" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0222]                  -11    SN-38.      SN-38            SN-38  .      SN-38     Trop-2, hRS7.               /   ,      ,   ,    ,    ,       (,     SN-38    3,2 /). Trop-2       ,       ;               .   24   SN-38/        .           ,          .</span>[0222] Successful treatment of solid tumor tumors with irinotecan has been limited for the most part due to the low conversion rate of the CPT-11 prodrug to the active metabolite SN-38. Other researchers have studied non-targeting forms of SN-38 as a way to avoid the need for this conversion and for passive delivery of SN-38 to tumors. The present inventors covalently conjugated SN-38 with a humanized anti-Trop-2 antibody, hRS7. The indicated conjugate of the antibody with the drug has specific antitumor effects in a number of models with subcutaneous xenografts of human cancer, including non-small cell lung carcinoma, pancreatic cancer, colon and rectum, and squamous cell carcinoma of the lung, in all cases in non-toxic doses (for example , at a cumulative dose of SN-38 equivalent, less than or equal to 3.2 mg / kg). Trop-2 is widely expressed in many types of epithelial cancer, but also in some normal tissues; therefore, in order to assess the clinical safety of this conjugate, a dose escalation study was conducted on cynomolgus monkeys. Monkeys tolerated 24 mg SN-38 / kg equivalents with only negligible and reversible toxicity. Given the ability to target tumors and the safety profile of satsituzumab govitecan, it provides a significant improvement in the management of solid tumors that respond to irinotecan.</span>
  </p>
  <p num="290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Materials and methods</span>
  </p>
  <p num="291" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0223]  ,     -     ,    ,      .    Calu-3 (  ), SK-MES-1 (  ), COLO 205 (  ), -1  -3 (  ),  -3 (  ).  IgG- RS7      CD20 (IgG hA20, )   CD22 (hLL2 IgG, )   Immunomedics, Inc.  (20 /)   Hospira, Inc.</span>[0223] Cell lines, antibodies and chemotherapeutic agents - All human cancer cell lines used in this study were acquired from the American Type Culture Collection. These lines include Calu-3 (non-small cell lung carcinoma), SK-MES-1 (squamous cell carcinoma of the lung), COLO 205 (colon adenocarcinoma), Sarap-1 and BhRS-3 (pancreatic adenocarcinoma), and PC-3 (adenocarcinoma prostate gland). Humanized RS7 IgG antibodies and control anti-CD20 antibodies (IgG hA20, veltuzumab) and anti-CD22 (hLL2 IgG, epratuzumab) were obtained from Immunomedics, Inc. Irinotecan (20 mg / ml) was obtained from Hospira, Inc.</span>
  </p>
  <p num="292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0224] ADC  SN-38   in vitro -  CL2-SN-38    (Moon et al., 2008, J Med Chem 51:6916-26).    IgG hRS7         (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61).    CL2A-SN-38 (  - 1480)     hRS7,   ,          .</span>[0224] ADC with SN-38 and in vitro aspects - The synthesis of CL2-SN-38 has been previously described (Moon et al., 2008, J Med Chem 51: 6916-26). His conjugation with hRS7 IgG and serum stability studies were performed as described (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al., 2009, Clin Chem Res 15: 6052-61). The preparation of formulations with CL2A-SN-38 (molecular weight 1480) and its conjugate with hRS7, and stability, binding and cytotoxicity studies were carried out as described in the examples section above.</span>
  </p>
  <p num="293" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0225]   in vivo -       ADC  SN-38      SN-38.     SN-38/IgG,  6,  500  ADC      20  (25 /)  0,4 / SN-38.       SN-38 (.. 40  /  24 / SN-38).</span>[0225] In vivo Therapeutic Studies - For all animal studies, doses of ADC with SN-38 and irinotecan are given in SN-38 equivalents. With an average SN-38 / IgG substitution rate of 6, a dose of 500 g ADC for a mouse weighing 20 g (25 mg / kg) contains 0.4 mg / kg SN-38. Dosages of irinotecan are also given in SN-38 equivalents (i.e. 40 mg irinotea / kg are equivalent to 24 mg / kg SN-38).</span>
  </p>
  <p num="294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0226]    NCr Nude (nu/nu)  4-8     Swiss-Webster  10    Taconic Farms.       ( fascicularis;       2,5-4 )  SNBL USA, Ltd.        .   () ,       2 ,  : L  w <sup class="style-scope patent-text">2</sup>/2,  L      , a w     .       0,10  0,47 <sup class="style-scope patent-text">3</sup>   .  ,           .      ADC           .     (0,1 ),   ,   .          ,    ADC   4             (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61).             in vitro,      ADC.</span>[0226] Female nude NCr Nude (nu / nu) mice 4-8 weeks old and Swiss-Webster <figure-callout id="10" label="male mice" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">male mice</a></figure-callout> 10 weeks old were purchased from Taconic Farms. Tolerance studies were performed on cynomolgus monkeys (Masas fascicularis; males and females weighing 2.5-4 kg) at SNBL USA, Ltd. Animals were implanted subcutaneously with cells of different human cancer lines. Tumor volume (PA) was determined by conducting measurements using calipers in two dimensions, as follows: L  w <sup class="style-scope patent-text">2/2,</sup> where L represents the largest linear dimension of the tumor, aw is the smallest linear dimension. Tumor size ranged from 0.10 to 0.47 cm <sup class="style-scope patent-text">3</sup> at the beginning of therapy. Treatment regimens, dosages and number of animals in each experiment are described in the results section. Lyophilized sacituzumab govitecan and control ADC were reconstituted and diluted as directed in sterile saline. All reagents were administered intraperitoneally (0.1 ml), with the exception of irinotecan, which was administered intravenously. The dosage regimen was influenced by previous studies of the authors of the present invention, in which ADC was administered every 4 days or twice a week for periods of time of varying duration (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al ., 2009, Clin Chem Res 15: 6052-61). The indicated dosing frequency was chosen taking into account the half-life of the conjugate in serum in vitro, in order to better ensure continuous exposure to ADC.</span>
  </p>
  <p num="295" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0227]  -          .           (AUC).         .             f-.             t-,     ,     t- (      0,05).   AUC     ,        .</span>[0227] Statistics - Growth curves reflect the percentage change in the initial TOE over time. Statistical analysis of tumor growth was based on the area under the curve (AUC). The growth profiles of individual tumors were obtained by modeling linear curves. To determine the equality of variance between groups before the statistical analysis of the growth curves used the f-test. To assess the statistical significance between the different treatment groups and controls, a two-sided t-test was used, except for the control saline solution, for which a one-sided t-test was used (significance at P is less than or equal to 0.05). Statistical comparisons of AUC were performed only until the time when the first animal from the group was euthanized due to progression.</span>
  </p>
  <p num="296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0228]    -    <sup class="style-scope patent-text">111</sup>In    IgG hRS7   Nude,  /  SK-MES-1 (~0,3 <sup class="style-scope patent-text">3</sup>).     20  (250  ) <sup class="style-scope patent-text">111</sup>In- ,      20  (250  ) <sup class="style-scope patent-text">111</sup>In-IgG hRS7.      (5   ) ,     ,   .     ,    -         (% /).    250      3    <sup class="style-scope patent-text">111</sup>In-      . 2- t-        IgG hRS7       f-.           WinNonLin (Parsight Corp.).</span>[0228] Pharmacokinetics and biodistribution - <sup class="style-scope patent-text">111</sup> In radiolabeled sacituzumab govitecan and IgG hRS7 were injected with Nude mice bearing SK-MES-1 tumor scores (~ 0.3 cm <sup class="style-scope patent-text">3</sup> ). One group was injected intravenously with 20 Ci (250 g protein) <sup class="style-scope patent-text">111</sup> In-sacituzumab govitecan, while the other group received 20 Ci (250 g protein) <sup class="style-scope patent-text">111</sup> In-IgG hRS7. At various time points, mice (5 per time point) were anesthetized, blood was taken by intracardiac puncture, and then sacrificed. Tumors and various tissues were removed, weighed, and -scintillation was recorded to determine the percentage of injected dose per gram of tissue (% ID / g). The third group was injected with 250 g of unlabeled sacituzumab govitecan 3 days before the administration of <sup class="style-scope patent-text">111</sup> In-sacituzumab govitecan and necropsy was performed in a similar manner. The 2-sided t-test was used to compare the absorption of sacituzumab govitecan and IgG hRS7 after determining the dispersion using the f-test. A pharmacokinetic analysis of blood elimination was performed using WinNonLin software (Parsight Corp.).</span>
  </p>
  <p num="297" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0229]    Swiss-Webster    - ,    4 ,   2  /    - ,  3     (4, 8  12 / SN-38)  0  3        ,     .   (3   3 ; 2,5-4,0 )  2    . ,     ,         ,        . </span>[0229] Tolerance in Swiss-Webster and Javanese Macaque Mice - Briefly, the mice were divided into 4 groups, each receiving 2 ml i.v. injections of either control sodium acetate buffer or 3 different doses of govitecan sacituzumab (4, 8 or 12 mg / kg SN-38) on <figure-callout id="0" label="days" filenames="00000052.png,00000053.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="3" label="days" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 0 and 3, followed by sampling of blood and serum, as described in the results section. Java monkeys (3 males and 3 females; 2.5-4.0 kg) were injected with 2 different doses of gavitecan sacituzumab. Dosages, time points and the number of monkeys who took blood to assess possible hematological toxicity, and serum biochemical analysis are described in the results section. results</span>
  </p>
  <p num="298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0230]    hRS7-SN-38 -       SN-38  IgG hRS7 ( ).   CL2-SN-38     (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61).    CL2A            CL2.    ,       (,  CL2-SN-38,  CL2A-SN-38  ~6 SN-38   IgG).         ,     in vitro.    ,     CL2        ,  .</span>[0230] Stability and Power hRS7-SN-38 - Two different bonds were used to conjugate SN-38 with hRS7 IgG (not shown). The former is called CL2-SN-38 and has been described previously (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al., 2009, Clin Chem Res 15: 6052-61). To obtain the CL2A linker, changes were used to remove the phenylalanine fragment in the linker in the synthesis of CL2. This change simplified the synthesis, but did not affect the outcome of conjugation (for example, both CL2-SN-38 and CL2A-SN-38 attached ~ 6 SN-38 per IgG molecule). Parallel comparisons did not show significant differences in serum stability, antigen binding, or in vitro cytotoxicity. This result was unexpected, since the phenylalanine residue in CL2 is part of the designed cathepsin B cleavage site, a lysosomal protease.</span>
  </p>
  <p num="299" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0231]   ,    SN-38   CL2  CL2A     in vivo,     hRS7-CL2-SN-38  ,   COLO 205 ( )  -1 ( ),   0,4   0,2 / SN-38      4 , ,     0,25 <sup class="style-scope patent-text">3</sup>   .   ,   CL2-SN-38          (AUC<sub class="style-scope patent-text">14 </sub>   0,002      COLO 205; AUC<sub class="style-scope patent-text">21 </sub>   0,001      Capan-1),    ADC  CD20, hA20-CL2A-SN-38 (AUC<sub class="style-scope patent-text">14 </sub>   0,003   COLO-205; AUC<sub class="style-scope patent-text">35 </sub>:   0,002   Capan-1).    (140 )   Capan-1  50% ,    ,  40% ,  hRS7-CL2-SN-38,   ,      hA20-ADC    20%    .  CL2A        CL2 ( ).</span>[0231] To confirm that changing the SN-38 linker with replacing CL2 with CL2A did not affect in vivo power, sacituzumab govitecan and hRS7-CL2-SN-38 were compared in <figure-callout id="205" label="mice bearing COLO" filenames="00000049.png,00000051.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">mice bearing COLO</a></figure-callout> 205 tumors (not shown) or Sarap- 1 (not shown), using 0.4 mg or 0.2 mg / kg SN-38 twice a week x 4 weeks, respectively, with a starting tumor size of 0.25 cm <sup class="style-scope patent-text">3</sup> in both studies. Both sacituzumab govitecan and CL2-SN-38 conjugates significantly inhibited tumor growth compared with no treatment (AUC <sub class="style-scope patent-text">14 days</sub> P less than 0.002 or saline in the <figure-callout id="205" label="COLO" filenames="00000049.png,00000051.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">COLO</a></figure-callout> 205 model; AUC <sub class="style-scope patent-text">21 days</sub> P less than 0.001 or saline in the Capan-1 model) and a non-targeting control ADC against CD20, hA20-CL2A-SN-38 (AUC <sub class="style-scope patent-text">14 days</sub> P less than 0.003 in the COLO-205 model; AUC <sub class="style-scope patent-text">35 days</sub> : P less than 0.002 in the Capan-1 model). At the end of the study (140 days), in the Capan-1 model, 50% of mice treated with sacituzumab govitecan and 40% of mice treated with hRS7-CL2-SN-38 showed no tumors, while only mice treated with hA20-<figure-callout id="20" label="ADC" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">ADC</a></figure-callout> 20% had no visible signs of the disease. Linker CL2A led to greater efficiency compared to CL2 (not shown).</span>
  </p>
  <p num="300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0232]   -   in vitro ,      IC<sub class="style-scope patent-text">50</sub>    (/)        ( 2). IC<sub class="style-scope patent-text">50</sub>   SN-38  ,   ,    .      -2      ,  IC<sub class="style-scope patent-text">50</sub> ADC   SN-38        Trop-2, ,  ,            .</span>[0232] Mechanism of Action - In vitro cytotoxicity studies have shown that sacituzumab govitecan differ in IC <sub class="style-scope patent-text">50</sub> values in the nanomolar range (nmol / L) with respect to several different lines of solid tumors (Table 2). IC <sub class="style-scope patent-text">50</sub> in free SN-38 was lower than in conjugate in all cell lines. Although there was no obvious correlation between Thor-2 expression and sacituzumab govitecan sensitivity, the ratio of IC <sub class="style-scope patent-text">50</sub> ADC and free SN-38 was lower in cells with high Trop-2 expression, which most likely reflects an increased ability to drug internalization at higher antigen levels.</span>
  </p>
  <p num="301" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0233] ,  SN-38      ,     (., , Cusack et al., 2001, Cancer Res 61:3535-40; Liu et al. 2009, Cancer Lett 274:47-53; Lagadec et al., 2008, Br J Cancer 98:335-44).         2 ,      (p21<sup class="style-scope patent-text">Wafl/Cip1</sup>  53)  1    [ (-)- (PARP)] in vitro ( ).   -3 SN-38  20-   p21<sup class="style-scope patent-text">Wafl/Cip1</sup> ( ),       10-  ( );         SN-38     ( 2).   ,  Calu-3   p21<sup class="style-scope patent-text">Wafl/Cip1</sup>      2      SN-38 ( ).</span>[0233] SN-38 is known to activate several signaling pathways in cells, leading to apoptosis (see, for example, Cusack et al., 2001, Cancer Res 61: 3535-40; Liu et al. 2009, Cancer Lett 274 : 47-53; Lagadec et al., 2008, Br J Cancer 98: 335-44). In initial studies, the authors of the present invention studied the expression of 2 proteins involved in early signaling events (p21 <sup class="style-scope patent-text">Wafl / Cip1</sup> and p53) and 1 late apoptotic event [cleavage of poly (ADP-ribose) polymerase (PARP)] in vitro (not shown). In BxRS-3 cells, SN-38 caused a 20-fold increase in p21 <sup class="style-scope patent-text">Wafl / Cip1 expression</sup> (not shown), while sacituzumab govitecan caused only a 10-fold increase (not shown); the indicated result is consistent with the higher activity of free SN-38 in the indicated cell line (table 2). However, in Calu-3, the increase in p21 <sup class="style-scope patent-text">Wafl / Cip1 expression by</sup> sacituzumab govitecan was more than 2 times higher than the results for free SN-38 (not shown).</span>
  </p>
  <p num="302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0234]          SN-38       53 ( ).  -3,  Calu-3   53  SN-38     48 ,      53   24  ( ).  ,  53  ,    ADC,          ,    SN-38 ( ). ,   IgG hRS7        p21<sup class="style-scope patent-text">Wafl/Cip1</sup> ,   ,    53   -3,   Calu-3,    48   ( ).     ,  PARP          SN-38,    ( ).  24   PARP       -3 ( ),      21     IC<sub class="style-scope patent-text">50</sub>.        SN-38,   ADC,     .</span>[0234] Even greater discrepancies between sacituzumab-mediated govitecan and free SN-38 signaling events were observed with respect to p53 expression (not shown). Yves BxRS-3, Yves Calu-3 upregulation of p53 with free SN-38 did not occur until 48 hours later, while sacituzumab govitecan stimulated p53 within 24 hours (not shown). In addition, p53 expression in cells exposed to ADC in both cell lines was higher compared to cells exposed to SN-38 (not shown). Interestingly, although IgG hRS7 had an undetectable effect on the expression of p21 <sup class="style-scope patent-text">Wafl / Cip1</sup> , it nonetheless induced upregulation of p53 in both BxRS-3 and Calu-3, but only after 48 hours of exposure (not shown). For late apoptotic events, PARP cleavage was evident in both cell lines upon incubation with either SN-38 or conjugate (not shown). After 24 hours, cleaved PARP was more present in BxRS-3 cells (not shown), which correlated with high expression of p21 and its lower IC <sub class="style-scope patent-text">50</sub> . A higher degree of cleavage when using free SN-38 rather than ADC is consistent with the results of a cytotoxicity study.</span>
  </p>
  <p num="303" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0235]  hRS7-SN-38 -  Trop-2      ,        ,     hRS7-CL2-SN-38,        CL2A-.   Calu-3  Nude,   0,04  SN-38/ hRS7-CL2-SN-38  4   4,        ,      hLL2-CL2-SN-38 (OO=0,140,22 <sup class="style-scope patent-text">3</sup>  0,800,91 <sup class="style-scope patent-text">3</sup>, ; AUC<sub class="style-scope patent-text">42 </sub>   0,026;  ).          0,4 / SN-38 ( ).         ,    hRS7,     28 ,        147 ,    ,    ADC,     ( ADC   ADC-AUC<sub class="style-scope patent-text">98 </sub>: =0,05).  ,   hRS7 IgG  SN-38,    4,5-  56  (=1,100,88 <sup class="style-scope patent-text">3</sup>; AUC<sub class="style-scope patent-text">56 </sub>   0,006    hRS7-CL2-SN-38) ( ).</span>[0235] Efficiency of hRS7-SN-38 - Since Trop-2 is widely expressed in a number of human carcinomas, studies have been carried out on several different models of human cancer, starting with the use of the hRS7-CL2-SN-38 link, but then moving on to using conjugates with CL2A -connection. Calu-3-bearing Nude mice that received 0.04 mg SN-38 / kg hRS7-CL2-SN-38 every 4 days  4 showed significantly improved responses compared to animals that were injected with an equivalent amount of non-targeting hLL2-CL2- SN-38 (OO = 0.14  0.22 cm <sup class="style-scope patent-text">3</sup> versus 0.80  0.91 cm <sup class="style-scope patent-text">3</sup> , respectively; AUC <sub class="style-scope patent-text">42 days</sub> P less than 0.026; not shown). The dose-response relationship was observed with increasing doses to 0.4 mg / kg SN-38 (not shown). At the indicated higher dose level, all mice treated with the specific hRS7 conjugate had a cure within 28 days and no tumors were present until the end of the study on day 147, while the animals treated with irrelevant ADC showed re-growth of the tumors (specific ADC or irrelevant ADC-AUC <sub class="style-scope patent-text">98 days</sub> : P = 0.05). In mice treated with a mixture of hRS7 IgG and SN-38, the tumors progressed more than 4.5-fold by 56 days (OO = 1.10  0.88 cm <sup class="style-scope patent-text">3</sup> ; AUC <sub class="style-scope patent-text">56 days</sub> P less than 0.006 for difference with hRS7-CL2-SN -38) (not shown).</span>
  </p>
  <p num="304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0236]         (COLO 205)    (Capan-1) .    COLO 205  ( ) hRS7-CL2-SN-38 (0,4 /,  4   8)      28-  ,          ADC  CD20 (hA20-CL2-SN-38)  IgG hRS7 (=0,160,09 <sup class="style-scope patent-text">3</sup>, 1,190,59 <sup class="style-scope patent-text">3</sup>,  1,770,93 <sup class="style-scope patent-text">3</sup>, ; AUC<sub class="style-scope patent-text">28 </sub>   0,016).</span>[0236] Efficacy was also investigated on xenografts of a colon tumor (COLO 205) and a human pancreas (Capan-1). In COLO-bearing tumors, 205 animals (not shown) hRS7-CL2-SN-38 (0.4 mg / kg, every 4 days  8) prevented tumor growth during the 28-day treatment period, providing significantly smaller tumors compared to control ADC against CD20 (hA20-CL2-SN-38) or IgG hRS7 (O = 0.16  0.09 cm <sup class="style-scope patent-text">3</sup> , 1.19  0.59 cm <sup class="style-scope patent-text">3</sup> , and 1.77  0.93 cm <sup class="style-scope patent-text">3</sup> , respectively; AUC <sub class="style-scope patent-text">28 days</sub> P less than 0.016).</span>
  </p>
  <p num="305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3e/6e/39/041c44b04780b3/00000022.png" class="style-scope patent-text"><img file="00000022.jpg" he="123" wi="160" img-format="jpg" img-content="undefined" width="640" height="492" alt="Figure 00000022" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3e/6e/39/041c44b04780b3/00000022.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3e/6e/39/041c44b04780b3/00000022.png" class="style-scope patent-text"><img file="00000022.jpg" he="123" wi="160" img-format="jpg" img-content="undefined" width="640" height="492" alt="Figure 00000022" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3e/6e/39/041c44b04780b3/00000022.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0237]   (24 / SN-38,  2   5)    ,   hRS7-CL2-SN-38   COLO 205,            SN-38 (Morton et al., 2000, Cancer Res 60:4206-10)     ,   SN-38   (  2,400 )   37,5  ,    (   64 ).</span>[0237] MPD of irinotecan (24 mg / kg SN-38, every 2 days  5) was as effective as hRS7-CL2-SN-38 in <figure-callout id="205" label="COLO" filenames="00000049.png,00000051.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">COLO</a></figure-callout> 205 cells, since mouse serum is capable of more efficient conversion of irinotecan to SN-38 (Morton et al., 2000, Cancer Res 60: 4206-10) compared with human serum, however, the dose of SN-38 in irinotecan (cumulative dose of 2,400 g) was 37.5 times higher than in the conjugate ( a total of 64 mcg).</span>
  </p>
  <p num="307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0238]  ,  -1 ( ),           ,  SN-38   hRS7-CL2-SN-38 (,  35      0,040,05 <sup class="style-scope patent-text">3</sup>  ,  0,4 / SN-38  hRS7-SN-38  1,780,62 <sup class="style-scope patent-text">3</sup>     ,   0,4 / SN-38; AUC <sub class="style-scope patent-text"> 35</sub>   0,001;  ).  10-     4 / SN-38  ,       ,        SN-38 0,4 / (=0,170,18 <sup class="style-scope patent-text">3</sup>  1,690,47 <sup class="style-scope patent-text">3</sup>, AUC<sub class="style-scope patent-text"> 49</sub>   0,001) ( ).    hA20-CL2-SN-38              ,    hRS7    ,   ADC (OO=0,170,18 <sup class="style-scope patent-text">3</sup>  0,800,68 <sup class="style-scope patent-text">3</sup>, AUC<sub class="style-scope patent-text"> 49</sub> P  0,018) ( ).</span>[0238] In animals carrying Sarap-1 (not shown), there was no significant response to irinotecan individually when a dose equivalent to SN-38 was administered in the hRS7-CL2-SN-38 conjugate (for example, on <figure-callout id="35" label="day" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 35, the average tumor size was 0.04  0.05 cm <sup class="style-scope patent-text">3</sup> in animals treated with 0.4 mg / kg SN-38 in hRS7-SN-38 versus 1.78  0.62 cm <sup class="style-scope patent-text">3</sup> in animals treated with irinotecan administered 0.4 mg / kg SN-38; AUC <sub class="style-scope patent-text">day 35</sub> P less than 0.001; not shown). With a 10-fold increase in the dose of irinotecan to 4 mg / kg SN-38, the response improved, but still was not as significant as when the conjugate was administered with a dose level of SN-38 of 0.4 mg / kg ( = 0.17  0 , 18 cm <sup class="style-scope patent-text">3</sup> versus 1.69  0.47 cm <sup class="style-scope patent-text">3</sup> , AUC <sub class="style-scope patent-text">days 49</sub> P less than 0.001) (not shown). An equal dose of the non-targeting hA20-CL2-SN-38 also had a significant antitumor effect compared to the results in animals treated with irinotecan, however, the specific hRS7 conjugate showed significantly better results than irrelevant ADC (OO = 0.17  0.18 cm <sup class="style-scope patent-text">3</sup> against 0.80  0.68 cm <sup class="style-scope patent-text">3</sup> , AUC <sub class="style-scope patent-text">day 49</sub> P less than 0.018) (not shown).</span>
  </p>
  <p num="308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0239]      ADC     2     .  ,      -3 ( ),            ,         hA20-CL2A-SN-38 (=0,240,11 <sup class="style-scope patent-text">3</sup>  1,170,45 <sup class="style-scope patent-text">3</sup>  1,050,73 <sup class="style-scope patent-text">3</sup>, ; AUQ<sub class="style-scope patent-text"> 21</sub>   0,001);     10-   SN-38 (=0,270,18 <sup class="style-scope patent-text">3</sup>  0,900,62 <sup class="style-scope patent-text">3</sup>, ; AUC<sub class="style-scope patent-text">day25</sub>P  0,004) ( ). ,   ,       SK-MES-1,   0,4 / ADC ( ),           IgG hRS7 (=0,360,25 <sup class="style-scope patent-text">3</sup>  1,020,70 <sup class="style-scope patent-text">3</sup>  1,301,08 <sup class="style-scope patent-text">3</sup>, ; AUC<sub class="style-scope patent-text">28 </sub>,   0,043),   hA20-CL2A-SN-38        ,     hRS7-SN-38 ( ).      ADC hRS7-SN-38  ,        ( ).</span>[0239] Studies with sacituzumab-containing govitecan ADC were then expanded to 2 other models of human epithelial cancer. In mice bearing human pancreatic tumors BxRS-3 (not shown), sacituzumab govitecan also significantly inhibited tumor growth compared to control mice treated with saline or an equivalent amount of non-targeting hA20-CL2A-SN-38 (O = 0.24  0.11 cm <sup class="style-scope patent-text">3</sup> versus 1.17  0.45 cm <sup class="style-scope patent-text">3</sup> and 1.05  0.73 cm <sup class="style-scope patent-text">3</sup> , respectively; AUQ <sub class="style-scope patent-text">day 21</sub> P less than 0.001); or irinotecan with the introduction of a 10-fold equivalent dose of SN-38 (OO = 0.27  0.18 cm <sup class="style-scope patent-text">3</sup> versus 0.90  0.62 cm <sup class="style-scope patent-text">3</sup> , respectively; AUC <sub class="style-scope patent-text">day25</sub> P less than 0.004) (not shown). Interestingly, in mice bearing SK-MES-1 human lung flat cell tumors treated with 0.4 mg / kg ADC (not shown), tumor growth inhibition was superior to saline or unconjugated hRS7 IgG (OO = 0.36  0.25 cm <sup class="style-scope patent-text">3</sup> versus 1.02  0.70 cm <sup class="style-scope patent-text">3</sup> and 1.30  1.08 cm <sup class="style-scope patent-text">3</sup> , respectively; AUC <sub class="style-scope patent-text">28 days</sub> , P less than 0.043), however non-targeting hA20-CL2A-SN-38 or MTD irinotecan provided the same antitumor effects as the specific hRS7-SN-38 conjugate (not shown). In all studies in mice, ADC hRS7-SN-38 was well tolerated based on estimates of weight loss (not shown).</span>
  </p>
  <p num="309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0240]    -      IgG hRS7   ,       SK-MES-1 ( ),    <sup class="style-scope patent-text">111</sup>In- .         hRS7    ( ). ADC      hRS7,   ADC           40%.   ,        ( ).          24   48 ,  72  ( )       .             ( ).  24            2    IgG hRS7 ( ).  ,     IgG hRS7    (   48 )  3      ( ).      ,  ,      ( ).</span>[0240] Biodistribution of satsituzumab govitecan - biodistribution of satsituzumab govitecan or unconjugated IgG hRS7 was compared in mice bearing SK-MES-1 human lung squamous cell carcinoma xenografts (not shown) using the appropriate <sup class="style-scope patent-text">111</sup> In-labeled substrates. For a comparative study of the elimination of sacituzumab govitecan and unconjugated hRS7, a pharmacokinetic analysis (not shown) was performed. ADC was excreted faster than the equivalent amount of unconjugated hRS7, with ADC showing a reduction in half-life and average retention time of approximately 40%. However, this had a minimal effect on tumor uptake (not shown). Despite the presence of significant differences in time points after 24 hours and 48 hours, by 72 hours (peak absorption) the amounts of both agents in the tumor were similar. In normal tissues, differences for liver and spleen tissues (not shown) were most pronounced. 24 hours after the injection, the amount of sacituzumab govitecan in the liver was more than 2 times the amount of hRS7 IgG (not shown). Conversely, in the spleen, the amount of the original hRS7 IgG upon peak absorption (time point after 48 hours) was 3 times higher than the amount of gavitecan sacituzumab (not shown). Absorption and excretion in other tissues, as a rule, reflected differences in blood concentration (not shown).</span>
  </p>
  <p num="310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0241]         ,      ,     0,2 / (250  ) ADC  hRS7  3    <sup class="style-scope patent-text">111</sup>In- .   <sup class="style-scope patent-text">111</sup>In-                  ,     (,  72         12,5%3,8% /  25,4%8,1% /  ,    ; =0,0123;   http://clincancerres.aaciioumals.org/contenty/I 7/10/3157.long - F4).               ( ).   ,     ,          () (), , , ,          ADC       .</span>[0241] Since the therapy was dosed twice a week, tumor uptake was examined in a group of animals that first received a preliminary dose of 0.2 mg / kg (250 g protein) ADC with <figure-callout id="3" label="hRS7" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">hRS7</a></figure-callout> 3 days before injection of <sup class="style-scope patent-text">111</sup> In-labeled antibody. Tumor uptake of <sup class="style-scope patent-text">111</sup> In-satsituzumab govitecan by a preliminary dose of mice was substantially reduced at each time point compared with animals that did not receive a preliminary dose (for example, after 72 hours, tumor uptake in the pre-dose group was 12.5%  3.8 % ID / g vs. 25.4%  8.1% ID / g in animals not receiving a preliminary dose; P = 0.0123; not shown http://clincancerres.aaciioumals.org/contenty/I 7/10 / 3157.long - F4). Pre-dosing did not have an measurable effect on excretion from the blood or tissue uptake (not shown). These studies suggest that in some tumor models, the accumulation of a specific antibody in the tumor may decrease due to the previous dose (s), which probably explains why the specificity of the therapeutic response may decrease with increasing doses of ADC and why further dose escalation does not shown.</span>
  </p>
  <p num="311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0242]      Swiss-Webster   </span>[0242] Tolerance of satsituzumab govitecan in Swiss-Webster mice and Javanese macaques</span>
  </p>
  <p num="312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> Swiss-Webster   2    3 ,      4, 8,  12  SN-38/  ,       ( ).             (ACT,  )   (,  ).       ACT     ( 298 /)   3   ( ),         28 / .   15            .         ( 77 /)   7   ( )      15 .             ( ).    ,           .   28 /   5  7       ( 273-320 /,    - 263 /),     15   .  ,     ,    116  127 / (    - 115 /)  2     ( 57%    28 /   100%    212 /),     15   .        ,         ;           -     ( ).</span>Swiss-Webster mice tolerated 2 doses for 3 days, each containing 4, 8, and 12 mg of SN-38 / kg of satsituzumab govitecan, with minimal temporary weight loss (not shown). Hematopoietic toxicity was absent and serum biochemical analysis showed only elevated levels of aspartate transaminase (ACT, not shown) and alanine transaminase (ALT, not shown). Seven days after treatment, the ACT level rose above normal levels (greater than 298 U / L) in all 3 treatment groups (not shown), with the maximum proportion of mice belonging to the 2  8 mg / kg group. However, by <figure-callout id="15" label="day" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 15 after treatment, the values in most animals were within the normal range. ALT levels were also higher than the normal range (greater than 77 U / L) for 7 days of treatment (not shown) and showed signs of normalization by <figure-callout id="15" label="day" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 15. In the liver of all these mice, no histological signs of tissue damage were observed (not shown). Regarding renal function, only glucose and chloride levels were slightly increased in the treatment groups. In the 2  8 mg / kg group, 5 out of 7 mice showed slightly increased glucose levels (range 273320 mg / dl, upper normal range 263 mg / dl), returning to normal by <figure-callout id="15" label="day" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 15 after injection. Similarly, chloride levels were slightly increased, ranging from 116 to 127 mmol / L (the upper limit of the normal range is 115 mmol / L) in 2 groups receiving the maximum dosage (57% of mice in the 2  8 mg / kg group and 100% of the mice in the 2  12 mg / kg group), and remained elevated up to 15 days after injection. This may also indicate toxicity to the gastrointestinal tract, since most of the chloride is formed as a result of absorption by the intestines; however, by the time the study was terminated, histological signs of tissue damage were absent in any studied organ system (not shown).</span>
  </p>
  <p num="313" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0243]  Trop-2,   hRS7,       ,         hRS7   .            ,      ( , , - , , , ,  ,  ,  ,  ,  , ,  ,  , , ,    ;  ).          .</span>[0243] Since Trop-2, the target hRS7 antigen, is not expressed in normal tissues in mice, a more suitable model was required to determine the potential of the hRS7 conjugate for clinical use. In immunohistological studies, binding was found in several tissues in both humans and Javanese macaques (mammary gland, eyes, gastrointestinal tract, kidneys, lungs, ovaries, fallopian tubes, pancreas, parathyroid gland, prostate gland, salivary gland, skin, thymus, thyroid, tonsils, ureter, bladder and uterus; not shown). Based on this cross-reactivity, monkey tolerance studies were performed.</span>
  </p>
  <p num="314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0244]  ,  20,96  / SN-38               .      7,3%,      15 .           ( ),        .         .        11  ( 8    )       ( ,     ,    ),  -  (,  ,  ,  ,  ,     ),    (,   ),    .       ,         (32 )   ,      - ,             ( ).</span>[0244] In the group receiving 2  0.96 mg / kg SN-38 in the form of govitecan sacituzumab, no significant clinical events were observed after the infusion and until the end of the study. The decrease in body weight did not exceed 7.3%, the values returned to acclimatization by <figure-callout id="15" label="day" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">day</a></figure-callout> 15. There was a temporary decrease in indicators for most of the formed blood elements (not shown), but the values did not fall below the boundaries of normal ranges. No abnormal values were found in serum biochemical analysis. Histopathological examination of animals after necropsy on day 11 (8 days after the last injection) revealed microscopic changes in the hematopoietic organs (thymus, mandibular and mesenteric lymph nodes, spleen and bone marrow), organs of the gastrointestinal tract (stomach, duodenum, jejunum, ileum, cecum, colon and rectum), female reproductive organs (ovary, uterus and vagina), and at the injection site. These changes ranged from minimal to moderate, and showed complete reversibility at the end of the recovery period (32 days) in all tissues, with the exception of the thymus and gastrointestinal tract, for which a trend toward complete recovery was observed at the indicated late point in time (not shown) .</span>
  </p>
  <p num="315" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0245]     21,92  / SN-38  1 ,          ,         ,          20,96 /  ( ).   ,         ,  ,    . ,         20,96  1,92 / SN-38,       20,3 - 0,6 / SN-38.</span>[0245] At the dose level of the conjugate 2x1.92 mg / kg SN-38, 1 death was observed due to complications from the gastrointestinal tract and suppression of bone marrow function, while other animals in this group showed similar, but more serious adverse events compared with the treated 2  0.96 mg / kg group (not shown). These data show that the indicators of dose-limiting toxicity were identical to those for irinotecan, namely, intestinal and hematological indicators. Accordingly, the MTD for sacituzumab govitecan is in the range from 2  0.96 to 1.92 mg / kg SN-38, which corresponds to the equivalent human dose of 2  0.3 - 0.6 mg / kg SN-38.</span>
  </p>
  <p num="316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Discussion</span>
  </p>
  <p num="317" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0246] Trop-2   ,     ,      ,  ,    ,  ,    ,           (Ohmachi et al., 2006, Clin Cancer Res 12:3057-63; Fong et al., 2008, Br J Cancer 99:1290-95; Cubas et al., 2009, Biochim Biophys Acta 1796:309-14).  RS7     Trop-2 (Shih et al., 1995, Cancer Res 55:5857s-63s),        .</span>[0246] Trop-2 is a protein expressed on many epithelial tumors, including cancer of the lung, breast, colon and rectum, pancreas, prostate and ovaries, making it a potentially important target for the delivery of cytotoxic agents ( Ohmachi et al., 2006, Clin Cancer Res 12: 3057-63; Fong et al., 2008, Br J Cancer 99: 1290-95; Cubas et al., 2009, Biochim Biophys Acta 1796: 309-14). The RS7 antibody is internalized upon binding to Trop-2 (Shih et al., 1995, Cancer Res 55: 5857s-63s), which allows direct intracellular delivery of cytotoxic agents.</span>
  </p>
  <p num="318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0247] SN-38     -I,   IC<sub class="style-scope patent-text">50</sub>       .      , ,         ,      ,     .    ,    SN-38   ADC         -11  ,      -11            SN-38 (Mathijssen et al., 2001, Clin Cancer Res 7:2182-94).</span>[0247] SN-38 is a potent topoisomerase-I inhibitor, with IC <sub class="style-scope patent-text">50</sub> values in the nanomolar range for several cell lines. It is an active form of the prodrug, irinotecan, which is used to treat cancer of the colon and rectum, also active against cancer of the lung, breast and brain. The authors of the present invention reasoned that directly targeted SN-38 in the form of ADC would be a significantly improved therapeutic agent compared to CPT-11, by overcoming the characteristic low CPT-11 bioconversion to active SN-38, which varies from patient to patient (Mathijssen et al., 2001, Clin Cancer Res 7: 2182-94).</span>
  </p>
  <p num="319" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0248]  Phe-Lys,     CL2,     .       CL2A  , , ,      . ,             ,   CL2 ( ), ,   ,         ,  ,  ,       .</span>[0248] The Phe-Lys peptide, integrated into the derivative of the original CL2, provided the possibility of cleavage with cathepsin B. To simplify the synthesis of phenylalanine in CL2A, it was eliminated and, accordingly, the site of cleavage with cathepsin B. was deleted. Interestingly, this product had a more distinct chromatographic profile compared to the wide profile obtained for CL2 (not shown), however, more importantly, this change did not affect the binding or stability of the conjugate, and, unexpectedly, provided a slight increase in power during parallel testing.</span>
  </p>
  <p num="320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0249]  ADC  hRS7 in vitro          IC<sub class="style-scope patent-text">50</sub>    (/).       SN-38  IC<sub class="style-scope patent-text">50</sub>  ,   ADC.       SN-38     ENZ-2208 (Sapra et al., 2008, Clin Cancer Res 14:1888-96, Zhao et al., 2008, Bioconjug Chem 19:849-59)  NK012 (Koizumi et al., 2006, Cancer Res 66:10048-56).  ENZ-2208   ,        3,5-4  SN-38,   NK012    ,  20% SN-38  .       ADC   (..      SN-38)       Trop-2   ,         .      in vitro,  CL2-,  CL2A-SN-38  hRS7-SN-38    </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png" class="style-scope patent-text"><img file="00000023.jpg" he="5" wi="6" img-format="jpg" img-content="undefined" width="24" height="20" alt="Figure 00000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png"></a></div> ~20 ,       <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png" class="style-scope patent-text"><img file="00000023.jpg" he="5" wi="6" img-format="jpg" img-content="undefined" width="24" height="20" alt="Figure 00000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png"></a></div>,  12,3 ,   ENZ-2208 (Zhao et al., 2008, Bioconjug Chem 19:849-59),   57%  SN-38  NK012     24  (Koizumi et al., 2006, Cancer Res 66:10048-56).     hRS7-SN-38 ( CL2-SN-38,  CL2A-SN-38)      5   .  4     ,    Calu-3      hRS7-SN-38       .    ,          SN-38   ,  50%,           (Morton et al., 2000, Cancer Res 60:4206-10; Furman et al., 1999, J Clin Oncol 17:1815-24).  hRS7-SN-38             10-     SN-38 .     , 24 /,  2   5 ( 37,5   SN-38)     hRS7-SN-38.     ,             -     .[0249] The cytotoxicity of ADC with hRS7 in vitro against the range of solid tumor cell lines was characterized by stable IC <sub class="style-scope patent-text">50</sub> values in the nanomolar range (nmol / L). However, when exposed to cells with free SN-38, the IC <sub class="style-scope patent-text">50</sub> value was lower than for ADC. The indicated discrepancy between free and conjugated SN-38 was also recorded for ENZ-2208 (Sapra et al., 2008, Clin Cancer Res 14: 1888-96, Zhao et al., 2008, Bioconjug Chem 19: 849-59) and NK012 (Koizumi et al., 2006, Cancer Res 66: 10048-56). ENZ-2208 uses a branched PEG, with about 3.5-4 SN-38 molecules attached to each PEG molecule, while NK012 is a micellar nanoparticle containing 20% SN-38 by weight. When applying the ADC proposed by the inventors of the present invention, the indicated discrepancy (i.e., the ratio of the power of free and conjugated SN-38) decreased with increasing levels of Trop-2 expression in tumor cells, which indicates an advantage for targeted drug delivery. Regarding in vitro serum stability, both CL2- and CL2A-SN-38 hRS7-SN-38 forms showed half-lives <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png" class="style-scope patent-text"><img file="00000023.jpg" he="5" wi="6" img-format="jpg" img-content="undefined" width="24" height="20" alt="Figure 00000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png"></a></div> ~ 20 hours, which differs from a short half-life <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png" class="style-scope patent-text"><img file="00000023.jpg" he="5" wi="6" img-format="jpg" img-content="undefined" width="24" height="20" alt="Figure 00000023" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a4/15/c4/73446e8c323b7c/00000023.png"></a></div> equal to 12.3 minutes recorded for ENZ-2208 (Zhao et al., 2008, Bioconjug Chem 19: 849-59), however, similar to 57% release of SN-38 from NK012 under physiological conditions after 24 hours (Koizumi et al. 2006 Cancer Res 66: 10048-56). Treatment of tumor-bearing hRS7-SN-38 mice (either CL2-SN-38 or CL2A-SN-38) significantly inhibited tumor growth in 5 different tumor models. In 4 of them, tumor regression was observed, and when Calu-3 was used, all mice receiving the maximum dose of hRS7-SN-38 showed no tumors at the end of the study. Unlike humans, mouse plasma esterase provides a very effective conversion of irinotecan to SN-38 with a conversion rate in excess of 50%, providing higher efficacy in mice than humans (Morton et al., 2000, Cancer Res 60: 4206-10 ; Furman et al., 1999, J Clin Oncol 17: 1815-24). The administration of hRS7-SN-38 provided significantly better control of tumor growth compared with the administration of irinotecan at 10-fold higher or equivalent doses of SN-38. Only with the introduction of MPD irinotecan, 24 mg / kg, every 2 days  5 (37.5 times more than SN-38), its effectiveness reached the effectiveness of hRS7-SN-38. According to the expectations of the authors of the present invention, in patients the indicated advantage of sacituzumab govitecan should have been even more pronounced due to the significantly lower rate of bioconversion.
  <p class="style-scope patent-text"></p>
  <p num="321" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0250]           ,   SK-MES-1,    ADC            .       . ,   SN-38,  ,       ,  ,   IgG-SN-38     .     ,    ,    ,       ,     (Jain, 1994, Sci Am 271:58-61).        50% SN-38   ~13 ,      ,    (,  5,3  37;   ),             2 . ,                SN-38.  ,            ,        .                ,          .     SK-MES-1  ,             ,    ,     .</span>[0250] The authors of the present invention also showed on some antigen expressing cell lines, such as SK-MES-1, that the use of antigen-binding ADC does not guarantee the achievement of better therapeutic responses compared to non-binding, irrelevant conjugate. The indicated result is not unusual or unexpected. Thus, the non-binding SN-38 conjugates mentioned earlier enhance therapeutic activity compared to irinotecan, so the irrelevant IgG-SN-38 conjugate is expected to have some activity. This is due to the fact that the tumors contain immature vessels, characterized by increased permeability, which allows macromolecules to penetrate into them more easily than into normal tissues (Jain, 1994, Sci Am 271: 58-61). When using the conjugate proposed by the present inventors, 50% SN-38 is released in ~ 13 hours if the pH drops to a level resembling lysosomal levels (for example, pH 5.3 at 37  C; data not shown), while at neutral values serum pH, the rate of release is reduced by almost 2 times. It is expected that when an irrelevant conjugate enters the acidic microenvironment of the tumor, it will locally release some SN-38. Other factors, such as the physiology of the tumor and the intrinsic sensitivity of the drug to the tumor, also play a role in determining this base activity. However, a specific conjugate with a longer retention time should have increased power relative to the specified base response, provided that there is a sufficient amount of antigen to capture a specific antibody. Biodistribution studies in the SK-MES-1 model also showed that when a tumor antigen was saturated due to successful dosing, the tumor uptake of a specific conjugate decreased, giving therapeutic results similar to those observed for an irrelevant conjugate.</span>
  </p>
  <p num="322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0251]           ADC          SN-38,      .            0,4 / SN-38.   Calu-3    4      1,6 / SN-38,  32  SN-38      20 .      ENZ-2208,   ,  10 /  5 (Sapra et al., 2008, Clin Cancer Res 14:1888-96; Pastorini et al., 2010, Clin Cancer Res 16:4809-21);    NK012    NK012,  30 /  3 (Koizumi et al., 2006, Cancer Res 66:10048-56).  ,   hRS7-SN-38       30-  55-    SN-38      ENZ-2208  NK012, .        10-   ADC  hRS7 (0,04 /),     ENZ-2208   ,   4-   NK012  7,5 /   (Koizumi et al., 2006, Cancer Res 66:10048-56).         1-   24 / SN-38 (1,500 / ),      . ,         7,5-15-    SN-38.</span>[0251] Despite the difficulty of making direct comparisons of the ADC proposed by the present inventors and other SN-38 delivery agents described in published reports, some general observations may be made. In the therapeutic studies conducted by the inventors of the present invention, the maximum individual dose was 0.4 mg / kg SN-38. In the Calu-3 model, only 4 injections were introduced with a total cumulative dose of 1.6 mg / kg SN-38, or 32 g SN-38 per mouse with a body weight of 20 g. Several studies were conducted with ENZ-2208, using MTD component of 10 mg / kg  5 (Sapra et al., 2008, Clin Cancer Res 14: 1888-96; Pastorini et al., 2010, Clin Cancer Res 16: 4809-21); preclinical studies with NK012 included the use of a NK012 MTD of 30 mg / kg  3 (Koizumi et al., 2006, Cancer Res 66: 10048-56). Thus, with the introduction of hRS7-SN-38, significant antitumor effects were obtained for 30-fold and 55-fold fewer SN-38 equivalents compared to the recorded doses of ENZ-2208 and NK012, respectively. Significant antitumor effects were observed even with 10-fold lower amounts of ADC with hRS7 (0.04 mg / kg), while lower doses of ENZ-2208 were not presented, and with a 4-fold reduction in the dose of NK012 to 7.5 mg / kg there was no efficacy (Koizumi et al., 2006, Cancer Res 66: 10048-56). In healthy mice, acute toxicity was not observed at a 1-week cumulative dose of 24 mg / kg SN-38 (1,500 mg / kg conjugate), indicating a higher MTD. Accordingly, the treatment of tumor-bearing animals was effective with 7.5-15 fold fewer SN-38 equivalents.</span>
  </p>
  <p num="323" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0252]     ,          IgG hRS7,      ,  2-    ,      SN-38.  ADC   , ,         .         ,       ,         ,    . ,      .      ,    ,   -   .</span>[0252] In biodistribution studies, it was found that the tumor uptake of govitecan sacituzumab by the tumor was similar to that of the original hRS7 IgG, but excretion was substantially faster with 2-fold higher liver uptake, which may be due to the hydrophobicity of SN-38. Since ADC is excreted through the liver, toxicity to the liver and gastrointestinal tract is expected to be dose-limiting. Although mice showed signs of elevated levels of liver transaminases, only mild gastrointestinal toxicity was observed, with an exceptionally temporary decrease in body weight and the absence of abnormalities noticeable in histopathological examination. Interestingly, no hematologic toxicity was noted. However, the monkeys showed a toxicity profile identical to that expected for irinotecan, with dose-limiting gastrointestinal tract and hematological toxicity.</span>
  </p>
  <p num="324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0253]  Trop-2,  hRS7,    ,       ,      Trop-2.  ,      ,  0,96 // (~12 /<sup class="style-scope patent-text">2</sup>),      ~0,3 //   (~11 /<sup class="style-scope patent-text">2</sup>).    NK012 I        28 /<sup class="style-scope patent-text">2</sup> SN-38  3         4  (; Hamaguchi et al., 2010, Clin Cancer Res 16:5058-66).  ,    I   ENZ-2208        10 /<sup class="style-scope patent-text">2</sup>  3 ,  16 /<sup class="style-scope patent-text">2</sup>    - (Kurzrock et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA; Poster No C216; Patnaik et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA; Poster No C221).      ,   22 /<sup class="style-scope patent-text">2</sup>  , ,    ,  hRS7     ,     ADC  hRS7       SN-38-. ,    Trop-2, -,      ,       .   ,   ,            ,    ,    ,    ,   0,03 //  SN-38,        .</span>[0253] Since Trop-2 recognized by hRS7 is not expressed in mice, it was important to conduct toxicity studies in monkeys that differed in human tissue expression of Trop-2. The monkeys transferred, with the occurrence of mild and reversible toxicity, the introduction of 0.96 mg / kg / dose (~ 12 mg / m <sup class="style-scope patent-text">2</sup> ), which can be extrapolated to the amount of ~ 0.3 mg / kg / dose for humans (~ 11 mg / m <sup class="style-scope patent-text">2</sup> ). In a clinical trial of phase I NK012, patients with solid tumors underwent administration of 28 mg / m <sup class="style-scope patent-text">2</sup> SN-38 every 3 weeks with the occurrence of dose-limiting toxicity in the form of <figure-callout id="4" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 4 neutropenia (DLT; Hamaguchi et al., 2010, Clin Cancer Res 16: 5058-66 ) Similarly, in phase I clinical trials with ENZ-2208, dose-limiting febrile neutropenia was detected and administration of 10 mg / m <sup class="style-scope patent-text">2</sup> every 3 weeks, or 16 mg / m <sup class="style-scope patent-text">2</sup> when administered to patients with G-CSF (Kurzrock et al., AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA; Poster No C216; Patnaik et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston , MA; Poster No C221). Since the monkeys tolerated a cumulative dose equivalent to a dose of 22 mg / m <sup class="style-scope patent-text">2</sup> for humans, presumably even though hRS7 binds to some normal tissues, MTD for single administration of ADC with hRS7 may be similar to that of other non-targeting SN-38 agents . Indeed, the specificity of the anti-Trop-2 antibody did not seem to play a role in the determination of DLT, since the toxicity profile was similar to that of irinotecan. More importantly, if a person can achieve antitumor activity under the same conditions as in mice that respond to a dose equivalent to a dose to humans of only 0.03 mg / kg / dose of SN-38 equivalents , clinical implementation is possible with the achievement of significant antitumor responses.</span>
  </p>
  <p num="325" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0254]  ,  ,     ,            in vivo, ,     Trop-2 ADC            .</span>[0254] In summary, toxicological studies in monkeys, in combination with studies in human cancer xenograft models in mice in vivo, have shown that this Trop-2-targeted ADC is an effective therapeutic agent for treating a number of tumors of various epithelial origin.</span>
  </p>
  <p num="326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 5.       Trop-2</span>Example 5. Analysis of the binding of cells to antibodies against Trop-2</span>
  </p>
  <p num="327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0255]    ADC        Trop-2 .  , 162-46.2,    (, -187),    .  , 650,   R&amp;D Systems (, ).        Trop-2-     NCI-N87.  (1,510<sup class="style-scope patent-text">5</sup>/)   96-    .           162-46.2, 650,  RS7  (0,03-66 ).         1,5   4.      1   4          (HRP)    .   ,     .     - Envision   ,     .</span>[0255] Two different mouse monoclonal antibodies against human Trop-2 were prepared for conjugation with ADC. The first antibody, 162-46.2, was purified from a hybridoma (ATCC, HB-187) cultured in roller bottles. The second antibody, MAB650, was purchased from R&amp;D Systems (Minneapolis, Minnesota). To compare binding, Trop-2 positive human gastric carcinoma cells NCI-N87 were used as targets. Cells (1.5  10 <sup class="style-scope patent-text">5</sup> / well) were seeded in 96-well plates on the eve of the binding assay. The next morning, a dose-response curve was constructed for 162-46.2, MAB650, and RS7 mice (0.03-66 nM). These primary antibodies were incubated with cells for 1.5 hours at 4  C. Wells were washed and secondary horseradish peroxidase conjugated antibody (HRP) conjugated to all wells for 1 hour at 4  C. The wells were re-washed, after which a luminescent substrate was added. Plates were read using an Envision plate reader and values expressed in relative luminescence units were recorded.</span>
  </p>
  <p num="328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0256]       K<sub class="style-scope patent-text">D</sub>, 0,57   RS7, 0,52   162-46.2  0,49   650.       (B<sub class="style-scope patent-text">max</sub>) 162-46.2  650  RS7     25%  50%,  (B<sub class="style-scope patent-text">Max</sub>=11,250  RS7, 8,471  162-46.2;  6,018  650),      RS7  .</span>[0256] All three antibodies had similar K <sub class="style-scope patent-text">D</sub> values, 0.57 nM for RS7, 0.52 nM for 162-46.2, and 0.49 nM for MAB650. However, when comparing the maximum binding values (B <sub class="style-scope patent-text">max</sub> ) of 162-46.2 and MAB650 with RS7, they were 25% and 50% lower, respectively (B <sub class="style-scope patent-text">Max</sub> = 11,250 for RS7, 8,471 for 162-46.2; and 6,018 for MAB650), which indicates binding properties differing from RS7.</span>
  </p>
  <p num="329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 6.  ADC  Trop-2 (MAB650-SN-38)</span>Example 6. Cytotoxicity of ADC against Trop-2 (MAB650-SN-38)</span>
  </p>
  <p num="330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0257]   ADC  Trop-2  SN-38  650,    ,  6,89     .     ADC MAB650-SN-38  ADC              (-3  Capan-1)            (MDA-MB-468)   .</span>[0257] Received a new anti-Trop-2 ADC with SN-38 and MAB650, with an average substitution rate of 6.89 drug molecules per antibody. Cytotoxicity analyzes for comparing ADC MAB650-SN-38 and ADC sacituzumab govitecan were performed using two different human pancreatic adenocarcinoma cell lines (BxRS-3 and Capan-1) and a triple negative phenotype human breast carcinoma cell line (MDA-MB- 468) as targets.</span>
  </p>
  <p num="331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0258]      ADC         96- .        , MAB650-SN-38   SN-38       3,8410<sup class="style-scope patent-text">-12</sup>  2,510<sup class="style-scope patent-text">-7</sup> .  650      ,    MAB650-SN-38.    37   96 .           MTS  ,         OD<sub class="style-scope patent-text">492</sub>  1,0    .         ,    Microsoft Excel  Prism (             IC<sub class="style-scope patent-text">50</sub>).</span>[0258] The day before the addition of these ADCs, cells were harvested from tissue culture and plated on 96-well plates. The next day, the cells were exposed to sacituzumab govitecan, MAB650-SN-38 and free SN-38 in the drug concentration range from 3.84  10 <sup class="style-scope patent-text">-12</sup> to 2.5  10 <sup class="style-scope patent-text">-7</sup> M. The unconjugated MAB650 was used as a dose control corresponding to the protein equivalent of MAB650-SN-38. The plates were incubated at 37  C for 96 hours. After the indicated incubation period, an MTS substrate was added to all plates and read, recording color development at half-hour intervals until an OD of <sub class="style-scope patent-text">492nm reached</sub> approximately 1.0 for untreated control cells. Growth inhibition was measured as the percentage of growth relative to untreated cells using Microsoft Excel and Prism software (non-linear regression to obtain sigmoidal dose-response curves for determining IC <sub class="style-scope patent-text">50</sub> values).</span>
  </p>
  <p num="332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0259]    MAB650-SN-38        IC<sub class="style-scope patent-text">50</sub>     ,    SN-38-ADC     ( ).        Capan-1 ( ) IC<sub class="style-scope patent-text">50</sub> ADC    3,5 ,   IC<sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38  4,1 ,  IC<sub class="style-scope patent-text">50</sub>  SN-38  1,0 .        -3 ( ) IC<sub class="style-scope patent-text">50</sub> ADC    2,6 ,   IC<sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38  3,0 , a IC<sub class="style-scope patent-text">50</sub>  SN-38  1,0 .       NCI-N87 ( ) IC<sub class="style-scope patent-text">50</sub> ADC    3,6 ,   IC<sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38  4,1 ,  IC<sub class="style-scope patent-text">50</sub>  SN-38  4,3 .</span>[0259] Sacituzumab govitecan and MAB650-SN-38 exhibited similar growth inhibitory effects with IC <sub class="style-scope patent-text">50</sub> values in the lower nanomolar range, which is typical of SN-38-ADC in these cell lines (not shown). In the human pancreatic adenocarcinoma cell line Capan-1 (not shown), the IC <sub class="style-scope patent-text">50</sub> ADC of sacituzumab govitecan was 3.5 nM, while the IC <sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38 was 4.1 nM and the IC <sub class="style-scope patent-text">50 of</sub> free SN-38 was 1 , 0 nM. In the human pancreatic adenocarcinoma cell line BxRS-3 (not shown), IC <sub class="style-scope patent-text">50</sub> ADC of sacituzumab govitecan was 2.6 nM, while IC <sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38 was 3.0 nM and IC <sub class="style-scope patent-text">50 of</sub> free SN-38 was 1 , 0 nM. In the human gastric adenocarcinoma cell line NCI-N87 (not shown), the IC <sub class="style-scope patent-text">50</sub> ADC of sacituzumab govitecan was 3.6 nM, while the IC <sub class="style-scope patent-text">50</sub> ADC MAB650-SN-38 was 4.1 nM and the IC <sub class="style-scope patent-text">50 of</sub> free SN-38 was 4. 3 nM.</span>
  </p>
  <p num="333" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0260]  ,    in vitro  SN-38     Trop-2, hRS7  650,        ,    SN-38. ,      Trop-2    in vivo    ,  in vitro,   ,  ADC  Trop-2  SN-38       in vivo  ADC,         .</span>[0260] Summarizing the above, in these in vitro assays, conjugates of SN-38 with two anti-Trop-2 antibodies, hRS7 and MAB650, show the same efficacy against several tumor cell lines, similar to that of free SN-38. Considering that the targeting function of anti-Trop-2 antibodies should be a much more important factor in vivo than in vitro, these data confirm that anti-Trop-2 ADCs with SN-38 should be a highly effective class of ADC when used in vivo, which demonstrated in the above examples for satsituzumab govitecan.</span>
  </p>
  <p num="334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 7.  ADC  Trop-2 (162-46.2-SN-38)</span>Example 7. Cytotoxicity of ADC against Trop-2 (162-46.2-SN-38)</span>
  </p>
  <p num="335" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0261]   ADC  Trop-2  SN-38  162-46.2,   ,  6,14     .     ADC 162-46.2-SN-38  ADC hRS7-SN-38      Trop-2-     ,     -3          MDA-MB-468.</span>[0261] Received a new ADC against Trop-2 with SN-38 and 162-46.2, with a replacement coefficient of 6.14 molecules of the drug per antibody. Cytotoxicity analyzes for comparing ADC 162-46.2-SN-38 and ADC hRS7-SN-38 were performed using two different Trop-2-positive cell lines as targets, human pancreatic adenocarcinoma BxRS-3 and human triple negative breast carcinoma phenotype MDA-MB-468.</span>
  </p>
  <p num="336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0262]     ADC         96-    2000   .        , 162-46.2-SN-38   SN-38       3,8410<sup class="style-scope patent-text">-12</sup>  2,510<sup class="style-scope patent-text">-7</sup> .  162-46.2  hRS7      ,    162-46.2-SN-38   , .    37   96 .           MTS  ,         OD<sub class="style-scope patent-text">492</sub>  1,0    .             Microsoft Excel  Prism (             IC<sub class="style-scope patent-text">50</sub>).</span>[0262] The day before ADC addition, cells were harvested from tissue culture and plated in 96-well plates at a density of 2000 cells per well. The next day, the cells were exposed to satsituzumab govitecan, 162-46.2-SN-38 or free SN-38 in the range of drug concentrations from 3.84  10 <sup class="style-scope patent-text">-12</sup> to 2.5  10 <sup class="style-scope patent-text">-7</sup> M. Unconjugated 162-46.2 and hRS7 used as a control in doses corresponding to the protein equivalents of 162-46.2-SN-38 and gavitecan sacituzumab, respectively. The plates were incubated at 37  C for 96 hours. After the indicated incubation period, an MTS substrate was added to all plates and read, recording color development at half-hour intervals until an OD of <sub class="style-scope patent-text">492nm reached</sub> approximately 1.0 for untreated control wells. Growth inhibition was measured as a percentage of growth relative to untreated cells using Microsoft Excel and Prism software (non-linear regression to obtain sigmoidal dose-response curves for determining IC <sub class="style-scope patent-text">50</sub> values).</span>
  </p>
  <p num="337" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0263]  IC<sub class="style-scope patent-text">50</sub> ADC 162-46.2-SN-38    IC<sub class="style-scope patent-text">50 </sub>  ( ).          -3 ( ) IC<sub class="style-scope patent-text">50</sub>    5,8 ,   IC<sub class="style-scope patent-text">50</sub> 162-46.2-SN-38  10,6 ,  IC<sub class="style-scope patent-text">50</sub>  SN-38  1,6 .          MDA-MB-468 ( ) IC<sub class="style-scope patent-text">50</sub>      3,9 ,   IC<sub class="style-scope patent-text">50</sub> 162-46.2-SN-38  6,1 ,  IC<sub class="style-scope patent-text">50</sub>  SN-38  0,8 .           Trop-2-    .</span>[0263] The IC <sub class="style-scope patent-text">50</sub> values of ADC 162-46.2-SN-38 were similar to the IC <sub class="style-scope patent-text">50</sub> values of gavitecan sacituzumab (not shown). When tested on human pancreatic adenocarcinoma cell line BxRS-3 (not shown), IC <sub class="style-scope patent-text">50 of</sub> sacituzumab govitecan was 5.8 nM, while IC <sub class="style-scope patent-text">50</sub> 162-46.2-SN-38 was 10.6 nM and IC <sub class="style-scope patent-text">50 was</sub> free SN-38 was 1.6 nM. When tested on a human mammary adenocarcinoma cell line MDA-MB-468 (not shown), IC <sub class="style-scope patent-text">50 of</sub> sacituzumab govitecan was 3.9 nM sacituzumab govitecan, while IC <sub class="style-scope patent-text">50</sub> 162-46.2-SN-38 was 6.1 nM and IC <sub class="style-scope patent-text">50</sub> free SN-38 was 0.8 nM. When used alone, free antibodies against all Trop-2 positive cancer cell lines showed slight cytotoxicity.</span>
  </p>
  <p num="338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0264]  ,    in vitro     Trop-2,         ,   ADC    ,      Trop-2- .   ,     Trop-2,   ADC-   ,          Trop-2  .</span>[0264] Summarizing the above, when comparing the in vitro efficacy of three different anti-Trop-2 antibodies conjugated to the same cytotoxic drug, all three ADCs showed equivalent cytotoxic effects directed against different Trop-2-positive cancer cell lines. These data confirm that the class of anti-Trop-2 antibodies included in the ADC drug conjugates is an effective anti-cancer therapeutic agent for the treatment of Trop-2 expressing solid tumors.</span>
  </p>
  <p num="339" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 8.   ADC  IMMU-132 ( ),    Trop-2 hRS7,   SN-38</span>Example 8. Clinical trials of ADC with IMMU-132 (satsituzumab govitekan) containing anti-Trop-2 hRS7 antibody conjugated to SN-38</span>
  </p>
  <p num="340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Short description</span>
  </p>
  <p num="341" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0265]         I      II IMMU-132, ADC     hRS7  Trop-2,  -   SN-38 (        = 7,6). Trop-2     I ,   ,     (~110<sup class="style-scope patent-text">5</sup>),      ,      .     Nude,    Capan-1   , ,  IMMU-132      120   SN-38,      .</span>[0265] This example presents the results of a phase I clinical trial and an ongoing extended phase II trial of IMMU-132, ADC with an internalized humanized anti-Trop-2 hRS7 antibody, a conjugated pH-sensitive linker with SN-38 (average drug-to-drug ratio antibodies = 7.6). Trop-2 is a type I transmembrane protein, a calcium signal carrier, expressed with high density (~ 1  10 <sup class="style-scope patent-text">5</sup> ), frequency and specificity of many human carcinomas, with limited expression in normal tissues. Preclinical studies in Nude mice bearing xenografts of human pancreatic Capan-1 tumors showed that IMMU-132 is capable of delivering up to 120 times more SN-38 to the tumor than with maximum tolerated irinotecan therapy.</span>
  </p>
  <p num="342" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0266]        I  25 ,       (   -I/II  ),      II,        69 ,          (),      (, , ),        (),    (),     .</span>[0266] This example describes an initial Phase I trial with 25 patients undergoing unsuccessful prior therapy several times (sometimes including topoisomerase-I / II inhibiting drugs) and an ongoing extended Phase II trial, currently recording results for 69 patients including cancer of the colon and rectum (ROPK), small cell and non-small cell lung cancer (MRL, NSCLC, respectively), breast cancer with a triple negative phenotype (TNBC), pancreatic cancer (PCa), esophagus and other types of cancer .</span>
  </p>
  <p num="343" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0267]    , Trop-2     ,    (   2<sup class="style-scope patent-text">+</sup>   )    .     3+3 IMMU-132   1  8     21- ,    8 /,    12  18 /    .          II      8  10 / (n = 30  14, ).  49              3    28% (4   4%).             (55%;    G3=9%),  (53%;    G3=0%),  (47%;    G3=9%),  (40%)   (32%;    G3=2%);    .  UGT1A1 *28/*28    6 ,  2           .</span>[0267] According to the detailed discussion below, Trop-2 was not detected in serum, however, expression was expressed (greater than or equal to 2 <sup class="style-scope patent-text">+</sup> by immunohistochemical staining) in most archived tumors. In a trial with a 3 + 3 design, IMMU-132 was administered on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 for multiple 21-day cycles, starting at a dose of 8 mg / kg, followed by doses of 12 and 18 mg / kg until dose-limiting neutropenia occurred. To optimize cumulative treatment with minimal delays in phase II, the focus was on dosages of 8 and 10 mg / kg (n = 30 and 14, respectively). Of 49 patients with registered related AEs, at the indicated time, neutropenia greater than or equal to <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 occurred in 28% (<figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 4 in 4%). Generally, general non-hematologic toxicity in these patients was initially represented by fatigue (55%; greater than or equal to G3 = 9%), nausea (53%; greater than or equal to G3 = 0%), diarrhea (47%; greater than or equal to G3 = 9 %), alopecia (40%) and vomiting (32%; greater than or equal to G3 = 2%); alopecia often also occurred. Homozygous UGT1A1 * 28 / * 28 was found in 6 patients, 2 of whom had more severe hematological and gastrointestinal toxicity.</span>
  </p>
  <p num="344" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0268]   I         48  (  ),     RECIST/c     .   (15%)      (),        (N  1),  (N  2),  (N  2),  (N  1)    (N  1),    27  (56%)    ();  ,     38  (79%)     ;  8  13         (62%)  ,      () 12,7     8,0     .    48   12,6+  ( 6,0-51,4 ).    19-9              .      ,   hRS7   SN-38   .</span>[0268] In phase I and expansion phase, 48 patients are currently taking part (excluding prostate cancer) who are measurable on a RECIST / c scale by CT for the best response. Seven (15%) of the patients showed a partial response (PR), including patients with ROPK (N = 1), TNBC (N = 2), MRL (N = 2), NSCLC (N = 1) and cancer the esophagus (N is 1), and the remaining 27 patients (56%) had a stable disease (SZ); thus, a total of 38 patients (79%) had a disease response; 8 out of 13 CT-measurable patients with prostate cancer (62%) had CK, with a median time to progression (CAP) of 12.7 weeks compared with 8.0 weeks for the last previous treatment. VDP for the remaining 48 patients is 12.6+ weeks (range 6.0-51.4 weeks). Plasma levels of CEA and CA19-9 correlated with responses in patients with elevated titers of these antigens in the blood. Despite dosing for months, antibodies against hRS7 or against SN-38 were not detected.</span>
  </p>
  <p num="345" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0269]        3 ,       in vivo,      50% SN-38,   95% SN-38      IgG   ,  ,   SN-38,   ,  ,  100 .   ,         ,       .</span>[0269] The conjugate was removed from serum within a 3-day period, which is consistent with in vivo animal studies in which 50% SN-38 was released daily, with more than 95% SN-38 in serum being bound to IgG in a non-glucuronidated form, at concentrations exceeding the concentrations of SN-38, registered in patients receiving irinotecan, up to 100 times. These results indicate that sacituzumab govitecan is therapeutically active in metastatic solid cancer, with diarrhea and neutropenia being manageable.</span>
  </p>
  <p num="346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Pharmacokinetics</span>
  </p>
  <p num="347" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0270]    ELISA     IgG (    hRS7)    ( IgG  SN-38 /     hRS7). SN-38    .   IMMU-132 ( )   IgG ( ),       SN-38  .  SN-38    (  ) ,   95% SN-38       IgG.   SN-38G ,  SN-38,   IgG,   .    ELISA      SN-38 ,   , ,   ELISA          SN-38.</span>[0270] Two ELISA ELISA methods were used to measure IgG excretion (capture against anti-idiotype hRS7) and intact conjugate (capture IgG against SN-38 / probe with anti-idiotype hRS7). SN-38 was measured using HPLC. The total proportion of IMMU-132 (intact conjugate) was excreted faster than IgG (not shown), reflecting the known data on the gradual release of SN-38 from the conjugate. Determination of SN-38 by HPLC (unbound and total) showed that more than 95% of serum SN-38 was associated with the indicated IgG. Low concentrations of SN-38G suggest that SN-38 bound to IgG is protected against glucuronidation. A comparison of ELISA ELISA results for conjugate and HPLC for SN-38 showed that they overlap, suggesting that ELISA ELISA can be used as a surrogate analysis to monitor SN-38 excretion.</span>
  </p>
  <p num="348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0271]            3.</span>[0271] A summary of the dosing regimen and patient pools is given in table 3.</span>
  </p>
  <p num="349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/f2/e4/86125c43074475/00000024.png" class="style-scope patent-text"><img file="00000024.jpg" he="140" wi="160" img-format="jpg" img-content="undefined" width="640" height="560" alt="Figure 00000024" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/f2/e4/86125c43074475/00000024.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/08/f2/e4/86125c43074475/00000024.png" class="style-scope patent-text"><img file="00000024.jpg" he="140" wi="160" img-format="jpg" img-content="undefined" width="640" height="560" alt="Figure 00000024" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/08/f2/e4/86125c43074475/00000024.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/9c/bb/30/73523473e68797/00000025.png" class="style-scope patent-text"><img file="00000025.jpg" he="113" wi="160" img-format="jpg" img-content="undefined" width="640" height="452" alt="Figure 00000025" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/9c/bb/30/73523473e68797/00000025.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/9c/bb/30/73523473e68797/00000025.png" class="style-scope patent-text"><img file="00000025.jpg" he="113" wi="160" img-format="jpg" img-content="undefined" width="640" height="452" alt="Figure 00000025" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/9c/bb/30/73523473e68797/00000025.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Clinical trial status</span>
  </p>
  <p num="352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0272]    69  (   25    I)     ,   3     ( ).      ,         .   13          .   (  )      11,9  (  2  21,4 )      8     .</span>[0272] A total of 69 patients were registered (including 25 patients in phase I) with various types of metastatic cancer, on average 3 times undergoing previous therapy (median value). Eight patients showed clinical progression and were suspended for evaluation by CT. Individually recorded 13 measurable with the help of CT patients with pancreatic cancer. The median PAP (time to progression) in patients with prostate cancer was 11.9 weeks (range from 2 to 21.4 weeks) compared with the median PAP of 8 weeks for the last previous treatment.</span>
  </p>
  <p num="353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0273]  48          1    ,       ( )     (;  ).       8      (      ): 2  ( ), 4  ( )  2  ( ),    [ + ]=6/8 (75%).    (  )  4     2 , 0   2 ,    2/4 (50%).    (    )  18     1 , 11   6 ,    12/18 (67%).      4     1 , 2   1 ,    3/4 (75%).    (  )  5     1 , 3   1 ,    4/5 (80%).       48     7 , 27   14 ,    34/48 (71%).   ,  ADC  TROP-2 (hRS7-SN-38)           -.</span>[0273] A total of 48 patients with a variety of cancers underwent at least 1 CT scan, which determined the best response (not shown) and time to progression (IPD; not shown). Summarized data on the best responses in 8 measurable patients with MLCD (breast cancer with a triple negative phenotype): 2 PR (partial response), 4 SZ (stable disease) and 2 PZ (progressive disease), with a common response [PR + SZ ] = 6/8 (75%). In the case of MRL (small cell lung cancer) in 4 measurable patients, 2 PF, 0 SZ and 2 PZ were observed, with a total response of 2/4 (50%). In the case of ROPK (colorectal cancer) in 18 measurable patients, 1 PO, 11 SZ and 6 PZ were observed, with a total response of 12/18 (67%). In case of esophageal cancer, 4 measurable patients had 1 HO, 2 SZ and 1 PZ, with a general response of 3/4 (75%). In the case of NSCLC (non-small cell lung cancer) in 5 measurable patients, 1 CHO, 3 SZ and 1 PZ were observed, with a total response of 4/5 (80%). Of all the patients treated, 48 measurable patients had 7 PF, 27 SZ and 14 PZ, with a total response of 34/48 (71%). These results indicate that anti-TROP-2 ADC (hRS7-SN-38) showed significant clinical efficacy against a wide range of solid tumors in human patients.</span>
  </p>
  <p num="354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0274]     ( )    4.    ,    4,        ADC,       .</span>[0274] The reported side effects of the therapy (adverse events) are summarized in Table 4. As can be seen from the data in Table 4, the therapeutic efficacy of sacituzumab govitecan was achieved with dosages of ADC showing an acceptable low level of undesirable side effects.</span>
  </p>
  <p num="355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/86/d6/21/2129f5903a6d0c/00000026.png" class="style-scope patent-text"><img file="00000026.jpg" he="163" wi="160" img-format="jpg" img-content="undefined" width="640" height="652" alt="Figure 00000026" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/86/d6/21/2129f5903a6d0c/00000026.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/86/d6/21/2129f5903a6d0c/00000026.png" class="style-scope patent-text"><img file="00000026.jpg" he="163" wi="160" img-format="jpg" img-content="undefined" width="640" height="652" alt="Figure 00000026" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/86/d6/21/2129f5903a6d0c/00000026.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0275]    4   ,      261 .  ( ),  ,     4,         3      10%     .         3      10%.       ADC    ADC;           ADC  Trop-2,      ,      3   ,   10%     ,  .     ( )     421   121 ,            ,         hRS7   SN-38,      .</span>[0275] The study in Table 4 was continued, with 261 currently included. The results (not shown), as a rule, correspond to the description in table 4, and only for neutropenia the incidence of adverse events of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 or higher was more than 10% of the patients participating in the test. For all other adverse events, the frequency of responses of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 or higher was less than 10%. This distinguishes the ADCs proposed according to the present invention from the vast majority of ADCs; according to some embodiments, the claimed methods and compositions relate to anti-Trop-2 ADCs that demonstrate efficacy in a variety of solid tumors, with an incidence of adverse events of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 or higher, representing less than 10% of patients for all adverse events except neutropenia. In a prospective study (follow-up) in a total of 421 samples from 121 patients, including the base and at least one sample obtained after treatment, no response was detected in the form of antibodies against hRS7 or against SN-38, despite repeated treatment cycles.</span>
  </p>
  <p num="357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0276]     ADC  Trop-2      ( ).        62        .            ,    7      FOLFOX,    1   5FU.       ,     (  - 3+ Trop-2),             8 /   1     .   -   ,  37%     ( ).          65%  10   ( )      781 /  26,5 /),   3  .</span>[0276] Examples of partial responses to ADC against Trop-2 were confirmed based on CT data (not shown). In the example of CHO with ROPK, a woman aged 62 with the first diagnosed ROPK underwent primary hemicolectomy. Four months later, the patient underwent a liver resection for liver metastases, and for 7 months received treatment according to the FOLFOX regimen, and for 1 month received 5FU. The patient had several lesions, mainly in the liver (immunohistological score of 3+ Trop-2), and she was included in the test with satsituzumab govitecan at a starting dose of 8 mg / kg about 1 year after the initial diagnosis. At the first CT examination, the achievement of CHO was established, with a 37% decrease in the target lesions (not shown). Patient treatment was continued with a maximum reduction of 65% after 10 months of treatment (not shown) and a decrease in CEA from 781 ng / ml to 26.5 ng / ml), until 3 months later progressed.</span>
  </p>
  <p num="358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0277]         65       IIIB ().   / (3 )       (XRT)   7000     10 .         ,           IMMU-132,    .     IMMU-132  5   ,          5,6        .   ,     6 ,            3,2  ( ).</span>[0277] In the example of CH with NSCLC, a 65-year-old man was diagnosed with NSCLC in stage IIIB (squamous). Initial treatment with carboplatin / etoposide (3 months) in combination with external radiation therapy (XRT) at a dose of 7000 cGy provided a response lasting 10 months. Then the patient began to undergo maintenance therapy with Tarcevs drug, which continued until consideration of its inclusion in the IMMU-132 trial, in addition to lumbar laminectomy. The patient received the first dose of IMMU-132 after 5 months of using Tarcev, by which time he had a lesion of 5.6 cm in the right lung with a profuse pleural effusion. Two months later, immediately after the patient received 6 doses, the first CT scan revealed a decrease in the primary target lesion to 3.2 cm (not shown).</span>
  </p>
  <p num="359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0278]         65     .   / ( -II),   2    ,     ( -I),   2 ,    ,       (XRT, 3000 ),   1 .      .  IMMU-132      ( 12 /;   6,8 /;  Trop-2 = 3+),      IMMU-132  38%    ,           ( ).      3    12 .</span>[0278] In the example of HR with MRL in a <figure-callout id="65" label="woman" filenames="00000052.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">woman</a></figure-callout> 65 years old, a low-grade MRL was diagnosed. After the administration of carboplatin / etoposide (topoisomerase-II inhibitor), completed after 2 months in the absence of a response, followed by the administration of topotecan (topoisomerase-I inhibitor), completed after 2 months, also in the absence of a response, the patient received local external radiation therapy (XRT, 3000 cGy), completed in 1 month. However, next month, progression continued. The introduction of IMMU-132 to the patient began next month (dose 12 mg / kg; reduced to 6.8 mg / kg; Trop-2 expression = 3+), and after two months of IMMU-132 administration, a 38% decrease in the target lesions occurred. including a significant decrease in the main lesion in the lung (not shown). Progression in the patient began 3 months after receiving 12 doses.</span>
  </p>
  <p num="360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0279]    ,  ,  ADC  Trop-2     ,              .   ,           ,      3 .    IMMU-132 (   )  /         ,   ,   ,     ;   ,             -I.     ADC  Trop-2     ,     .</span>[0279] These results are significant because they demonstrate that anti-Trop-2 ADC was effective even in patients who underwent unsuccessful therapy or who experienced progression after repeated previous treatment. In conclusion, we note that for all dosages used, primary toxicity was represented by controlled neutropenia, with only a few cases of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 toxicity. Signs of IMMU-132 activity (CHO and persistent SZ) were observed in recurrent / refractory patients with breast cancer with a triple negative phenotype, small cell lung cancer, non-small cell lung cancer, colorectal cancer; and esophageal cancer, including in patients with a previous history of relapse after treatment with topoisomerase-I inhibitors. These results demonstrate the effectiveness of ADC against Trop-2 in a wide range of cancers that are resistant to existing therapies.</span>
  </p>
  <p num="361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 9.    ADC  Trop-2</span>Example 9. Comparative effectiveness of different ADC against Trop-2</span>
  </p>
  <p num="362" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0280]        Trop-2 (162-46.2),   SN-38,       (ADC)  ,  ,      (NCI-N87).  NCI-N87         /.    Nude  / 200    NCI-N87,      1:1,  ,     110<sup class="style-scope patent-text">7</sup> .        0,25 <sup class="style-scope patent-text">3</sup> ( 6 ),       ,     .   ADC  SN-38   /   500         .        ADC hA20-SN-38    /   .               .         .     ,     1,0 <sup class="style-scope patent-text">3</sup>.</span>[0280] The therapeutic efficacy of the mouse anti-Trop-2 monoclonal antibody (162-46.2) conjugated to SN-38 and the antibody-drug conjugate (ADC) of satsituzumab govitecan was compared in mice bearing human gastric carcinoma xenografts (NCI-N87) . NCI-N87 cells were propagated in tissue culture and harvested using trypsin / EDTA. Female Nude athymic mice were injected sc with 200 l of a suspension of NCI-N87 cells mixed with matrigel in a 1: 1 ratio, so that each mouse received 1  10 <sup class="style-scope patent-text">7</sup> cells. After the tumors reached a size of approximately 0.25 cm <sup class="style-scope patent-text">3</sup> (after 6 days), the animals were divided into seven different treatment groups, nine mice each. When using ADC with SN-38, mice were given iv 500 mg once daily for two weeks. Control mice received the same tumor-free ADC hA20-SN-38 at the same dose / in the same manner. The last group of mice received only saline and served as untreated controls. Tumors were measured and mice were weighed twice a week. Mice were euthanized due to disease progression if the tumor volume exceeded 1.0 cm <sup class="style-scope patent-text">3</sup> .</span>
  </p>
  <p num="363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0281]    SN-38-ADC      ( ).        (AUC)   ,   162-46.2-SN-38           ,     hA20-SN-38 (  0,001).         7  9        () 18,43,3 .  ,   162-46.2-SN-38,     6  9 ,   3    .    24,26,0 ,   ,        (=0,0382).</span>[0281] In the mice treated with SN-38-ADC, the average tumor volume was determined (not shown). Based on the area under the curve (AUC), both sacituzumab govitecan and 162-46.2-SN-38 significantly inhibited tumor growth compared to control mice treated with saline and hA20-SN-38 (P less than 0.001). When treated with sacituzumab govitecan, stable disease was achieved in 7 of 9 mice with an average time to tumor progression (TDS) of 18.4  3.3 days. Among mice treated with 162-46.2-SN-38, a positive response was achieved in 6 of 9 mice, and in the remaining 3, a stable disease was achieved. The mean VDV was 24.2  6.0 days, which is significantly more than in animals treated with satsituzumab govitecan (P = 0.0382).</span>
  </p>
  <p num="364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    in vivo  ADC  Trop-2     .</span>These results confirm the in vivo efficacy of various ADCs against Trop-2 for the treatment of human gastric carcinoma.</span>
  </p>
  <p num="365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 10.         ADC  Trop-2</span>Example 10. Treatment of patients with advanced metastatic pancreatic cancer ADC against Trop-2</span>
  </p>
  <p num="366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Short description</span>
  </p>
  <p num="367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0282] IMMU-132 ( )   ADC  Trop-2,       hRS7  Trop-2,  -   SN-38,   ,         ,  7,6. Trop-2     ,   I ,    ,        ,       ,      .  29        Trop-2-    ,         ,   ,  115-891 .  Trop-2.</span>[0282] IMMU-132 (satsituzumab govitecan) is an anti-Trop-2 ADC containing cancer cell-internalized humanized anti-Trop-2 hRS7 antibody conjugated with a pH-sensitive linker with SN-38, an active metabolite of irinotecan, with an average drug molecule ratio to antibody molecules equal to 7.6. Trop-2 is a calcium signal carrier, type I transmembrane protein expressed with high density, frequency and specificity in many types of epithelial cancer, including pancreatic duct adenocarcinoma, with limited expression in normal tissues. All 29 tested samples of pancreatic tumor microarrays were Trop-2 positive according to the results of an immunohistochemical study, and it was found that 115-891 thousand copies of Trop-2 were expressed on the cell membrane of the human pancreatic cancer line.</span>
  </p>
  <p num="368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0283]        IMMU-132 I    3+3,       13   .  I      .    80%  24          ,    ( RECIST)         (),       (),      (, ),    ().       IMMU-132 I/II       .   ,       2  ( ; : 1-5 ),  IMMU-132  1  8     21- .</span>[0283] The authors of the present invention described above the results of an IMMU-132 I phase study with a 3 + 3 design, which included patients with 13 different types of tumors. In phase I, dose-limiting toxicity was represented by neutropenia. More than 80% of the 24 measurable patients in this study had a long-term stable disease, with partial responses (according to RECIST) in patients with colorectal cancer (ROPC), breast with a triple negative phenotype (TNBC), small cell and non-small cell lung cancer (MRL, NSCLC), and esophageal cancer (AKP). This example describes the results of a study of IMMU-132 I / II phase in a cohort of patients with metastatic prostate cancer. Patients with PCa who underwent unsuccessful previous therapy on average 2 times (median value; range: 1-5 times) received IMMU-132 on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 during multiple 21-day cycles.</span>
  </p>
  <p num="369" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0284]      (N  15) 14         .        9    [ 3  9    G3, 33%; 1     G4),         .      3 ;           3-4 .  (1-2 )   5  9 .      13  14 ,  8     8-21,4  ( - 12,7 ; 11,9    14 ).  ,   ,     -.         RECIST; 1       1        .  19-9     3      23  72%.    ,             IMMU-132   SN-38.          ,  IMMU-132   IgG -  ,        SN-38   .      IgG SN-38        ,  12 / IMMU-132,  ~4000 /,   40    SN-38,   ,   .</span>[0284] In a subgroup of patients with prostate cancer (N is 15), 14 patients received pre-treatment as part of a regimen involving gemcitabine. Based on initial toxicity data, neutropenia was detected in 9 patients [3 out of 9 have G3, 33% greater or equal; 1 case of grade G4 febrile neutropenia), which led to delays in dose administration or dose reduction. Two patients had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 diarrhea; none of the patients experienced nausea or vomiting of grades 3-4. Alopecia (grades 1-2) occurred in 5 of 9 patients. The best response was measurable in 13 of 14 patients, with 8 cases of stable disease lasting 8-21.4 weeks (median - 12.7 weeks; 11.9 weeks for all 14 patients). One patient, whose treatment is ongoing, has not yet passed the first CT scan. Five patients had progressive disease according to the RECIST criteria; 1 patient was suspended after administration of only 1 dose due to clinical progression and could not be evaluated. Serum CA19-9 titers decreased in 3 patients with stable disease from 23 to 72%. Despite repeated administration, none of the patients developed an antibody response to IMMU-132 or to SN-38. The analysis of serum samples with a peak and with a minimum concentration showed that IMMU-132 was excreted faster than IgG - the expected result, taking into account the known data on the local release of SN-38 inside the tumor cell. The observed concentration levels of IgG-associated SN-38 in samples with a peak concentration from one patient receiving 12 mg / kg IMMU-132 were ~ 4000 ng / ml, which is 40 times higher than the titers of SN-38 recorded in patients receiving therapy irinotecan.</span>
  </p>
  <p num="370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0285]    ,  IMMU-132  (  )  62% (8/13)   ,      ,         .           ( 6)   8-10 / IMMU-132  1  8  21- ,               .     ,      , , , , ,          IMMU-132.  ,  IMMU-132         ,      ,         .</span>[0285] The authors of the present invention conclude that IMMU-132 is active (long-term stable disease) in 62% (8/13) of patients with prostate cancer who have undergone several previous treatment failures, with controlled neutropenia and low gastrointestinal toxicity. In patients with advanced prostate cancer, multiple treatment cycles (greater than 6) can be carried out with the introduction of 8-10 mg / kg IMMU-132 on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of the 21-day cycle, with certain dose adjustments or auxiliary introduction of growth factors for neutropenia in subsequent treatment cycles . These results are consistent with data obtained for patients with advanced ROPK, TNRM, MRL, NSCLC, AKP, who showed partial responses and long-term stable disease with the introduction of IMMU-132. Summarizing the above, IMMU-132 monotherapy is a new effective treatment regimen for patients with prostate cancer, including patients with tumors that previously demonstrated resistance to other therapeutic regimens in prostate cancer.</span>
  </p>
  <p num="371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Methods and Results</span>
  </p>
  <p num="372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0286]  Trop-2 -  Trop-2                -  QUANTBRITE.      Trop-2        :    -3 (891 000);   NCI-N87 (383 000);    MDA-MB-468 (341 000);    SK-MES-1 (27000);    Capan-1 (115000);   AGS (78 000)    COLO 205 (52 000).  Trop-2    29  29 (100%)      ( ).</span>[0286] Trop-2 Expression - The expression of Trop-2 on the surface of cancer cells of different cancer cell lines was determined by flow cytometry using FE-conjugated QUANTBRITE granules. When counting the number of detected Trop-2 molecules in different cell lines, the following results were obtained: pancreatic cancer BxRS-3 (891,000); gastric cancer NCI-N87 (383,000); breast cancer MDA-MB-468 (341,000); squamous lung cancer SK-MES-1 (27000); pancreatic cancer Capan-1 (115000); gastric cancer AGS (78,000) colon cancer COLO 205 (52,000). Trop-2 expression was also observed in 29 of 29 (100%) microarrays of pancreatic adenocarcinoma tissue (not shown).</span>
  </p>
  <p num="373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0287]  SN-38-  SN-38    Nude,  Capan-1      (~0,06-0,27 ).   / 40 /  (773 ;    448   SN-38).       .     = 3,25 /  ~126 /<sup class="style-scope patent-text">2</sup>.  ,   / 1,0  IMMU-132 ( SN-38: = 7,6; 20   SN-38).       .     ~4 / IMMU-132 (~80 /  SN-38).      3 ,        5 , 1, 2, 6  24 ,      IMMU-132   1, 6, 24, 48  72 .             SN-38, SN-38G  .     IMMU-132       SN-38   (..  [] SN-38).  ,  ADC IMMU-132       120   SN-38         22     SN-38   ADC ( ).</span>[0287] SN-38 Accumulation - SN-38 accumulation was determined in Nude mice bearing Capan-1 human pancreatic cancer xenografts (~ 0.06-0.27 g). Mice were injected iv with 40 mg / kg of irinotecan (773 g; a total of 448 g SN-38 equivalents). The indicated dose is MTD for mice. Equivalent doses for humans = 3.25 mg / kg or ~ 126 mg / m <sup class="style-scope patent-text">2</sup> . Alternatively, mice were injected with iv 1.0 mg IMMU-132 (SN-38: antibody ratio = 7.6; 20 g SN-38 equivalents). The indicated dose is significantly lower than the MTD for mice. The equivalent dose for humans is ~ 4 mg / kg IMMU-132 (~ 80 g / kg SN-38 equivalents). In each interval, 3 animals were necropsy, from the group of mice receiving injections of irinotecan after 5 min, 1, 2, 6 and 24 hours, or from the group of injections of IMMU-132 mice after 1, 6, 24, 48 and 72 hours. Tissues were extracted and analyzed by reverse phase HPLC analysis on SN-38, SN-38G and irinotecan. Tissue extracts of animals treated with IMMU-132 were also hydrolyzed with acid to release SN-38 from the conjugate (ie, [total] SN-38 scores). The results demonstrate that IMC ADMU-132 is potentially capable of delivering 120 times more SN-38 to the tumor compared to irinotecan even when 22 times less SN-38 equivalents with the indicated ADC are introduced (not shown).</span>
  </p>
  <p num="374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0288]   IMMU-132 - ,     I/II      5.</span>[0288] Clinical Protocol IMMU-132 - The protocol used in the Phase I / II study was in accordance with Table 5 below.</span>
  </p>
  <p num="375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/66/c5/48/abef93a4e20856/00000027.png" class="style-scope patent-text"><img file="00000027.jpg" he="191" wi="160" img-format="jpg" img-content="undefined" width="640" height="764" alt="Figure 00000027" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/66/c5/48/abef93a4e20856/00000027.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/66/c5/48/abef93a4e20856/00000027.png" class="style-scope patent-text"><img file="00000027.jpg" he="191" wi="160" img-format="jpg" img-content="undefined" width="640" height="764" alt="Figure 00000027" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/66/c5/48/abef93a4e20856/00000027.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="376" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3d/a3/de/dd327fd8336db7/00000028.png" class="style-scope patent-text"><img file="00000028.jpg" he="162" wi="160" img-format="jpg" img-content="undefined" width="640" height="648" alt="Figure 00000028" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3d/a3/de/dd327fd8336db7/00000028.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/3d/a3/de/dd327fd8336db7/00000028.png" class="style-scope patent-text"><img file="00000028.jpg" he="162" wi="160" img-format="jpg" img-content="undefined" width="640" height="648" alt="Figure 00000028" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/3d/a3/de/dd327fd8336db7/00000028.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0289]   IMMU-132    ,  .      .      34 ,        ()        ,    //FG-3019,  FOLFIRINOX  GTX,   IMMU-132 ( 8 /,   1  8  21- ).        4 ,    ,  , 72%    19-9 ( 15885 U/  4418 U/)        /  RECIST     .         ;   ~6  ,  6    .</span>[0289] Patients were administered IMMU-132 in accordance with the protocol summarized above. The following is a practical example of a clinical case. A 34-year-old white male, with initially diagnosed metastatic pancreatic (liver) cancer, showed progression during the application of several chemotherapy regimens, including gemcitabine / erlotinib / FG-3019, FOLFIRINOX and GTX modes, before administration of IMMU-132 (<figure-callout id="8" label="dose" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dose</a></figure-callout> 8 mg / kg, administration on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of the 21-day cycle). The patient received the indicated drug for 4 months, with good symptomatic tolerance, pain relief, 72% maximum decline in CA 19-9 (from 15885 U / ml to 4418 U / ml) and a stable disease as assessed using CT / RECIST criteria along with with signs of tumor necrosis. Therapy was suspended due to a liver abscess; the patient died ~ 6 weeks later, 6 months after the start of therapy.</span>
  </p>
  <p num="378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>conclusions</span>
  </p>
  <p num="379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0290]   ,  IMMU-132   120-   SN-38      ,    .               IMMU-132   2     8  10 /,          .            SN-38,     .</span>[0290] Preclinical studies have shown that IMMU-132 delivers 120-fold more SN-38 to the xenograft of a human pancreatic tumor than with irinotecan. When including patients with various types of metastatic solid cancer in a larger study, the dose of IMMU-132 for <figure-callout id="2" label="phase" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">phase</a></figure-callout> 2 was determined to be from 8 to 10 mg / kg, based on controlled neutropenia and diarrhea as the main side effects. To date, no antibodies against antibodies or against SN-38 have been detected, even with multiple therapeutic cycles.</span>
  </p>
  <p num="380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0291]   14    ,        ( )     ,  8/13  (62%)   .     13        12,7      8,0     .  ADC    ,     ,    ,   Trop-2,       ,   ,     ,            ADC.           ,  ,  ,       ,           ,       .</span>[0291] A study in 14 patients with advanced prostate cancer who recurred on average after a double previous treatment (median value) showed confirmed CT antitumor activity, corresponding to 8/13 patients (62%) with stable disease. The median duration of UDT in 13 CT-measurable patients was 12.7 weeks compared with the calculated 8.0 weeks for the last previous treatment. Specified ADC with a known drug with toxicity in the nanomolar range, which is conjugated to an antibody targeting Trop-2, which is widespread in many epithelial cancers, using a linker that provides cleavage at the tumor site, is a new effective strategy for the treatment of pancreatic cancer glands using ADC. An increase in the period of time before progression in patients with pancreatic cancer, in particular in patients who are resistant to several previous therapy, compared with existing standards for the treatment of patients with pancreatic cancer, was unexpected and could not be predicted.</span>
  </p>
  <p num="381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 11.     ()  -Trop-2-SN-38 ADC     </span>Example 11. The combination of antibody-targeted radiation (radioimmunotherapy) with anti-Trop-2-SN-38 ADC improves the treatment of pancreatic cancer</span>
  </p>
  <p num="382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0292]           Nude,     , <sup class="style-scope patent-text">90</sup>Y- IgG PAM4 (hPAM4; <sup class="style-scope patent-text">90</sup>Y- ),       (GEM) (Gold et al., Int J. Cancer 109:618-26, 2004; Clin Cancer Res 9:3929S-37S, 2003).        <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG    GEM,    .  ,  GEM   ,                ,      ,      <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG.</span>[0292] The inventors previously reported effective antitumor activity in Nude mice bearing human pancreatic tumors, <sup class="style-scope patent-text">90</sup> Y-humanized IgG PAM4 (hPAM4; <sup class="style-scope patent-text">90</sup> Y-clivatuzumab tetraxetan), which was enhanced in combination with gemcitabine (GEM) (Gold et al ., Int J. Cancer 109: 618-26, 2004; Clin Cancer Res 9: 3929S-37S, 2003). These studies have led to clinical testing of fractional <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG in combination with GEM, demonstrating encouraging objective responses. Although GEM is known to have a radiosensitizing ability, when used alone, it is not a very effective therapeutic agent for treating pancreatic cancer, and its dosage is limited by hematological toxicity, which is also limiting for <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG.</span>
  </p>
  <p num="383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0293]      , ADC  Trop-2,   IgG hRS7,   SN-38,       .  ADC      (,    60 ),    4,0  (0,5 ,      4)    . Trop-2        .</span>[0293] As described in the examples section above, an anti-Trop-2 ADC consisting of hRS7 IgG coupled to SN-38 exhibits antitumor activity in various solid tumors. The indicated ADC was very well tolerated in mice (for example, greater than or equal to 60 mg), and already a dose of 4.0 mg (0.5 mg, twice a week  4) has significant therapeutic value. Trop-2 is also expressed in most pancreatic cancers.</span>
  </p>
  <p num="384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0294]      <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG      Nude,     0,35 <sup class="style-scope patent-text">3</sup>      , Capan-1.  (N  10)       <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG   (130 , ..    (),  75 ),     (  ),    2      <sup class="style-scope patent-text">90</sup>Y-hPAM4,     ADC     ,   <sup class="style-scope patent-text">90</sup>Y-hPAM4.     ,        15%.      ,              ,     .     ,  0,13  <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG +  ,       4 ,          .      ,     ADC      .</span>[0294] In the present study, combinations of <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG with sacituzumab govitecan were studied in Nude mice bearing 0.35 cm <sup class="style-scope patent-text">3</sup> subcutaneous xenografts of human pancreatic cancer cell line, Capan-1. Mice (N = 10) were treated as a single dose of <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG alone (130 Ci, i.e., maximum tolerated dose (MTD), or 75 Ci), of govitecan sacituzumab individually (as described above), or a combination of these 2 agents at two dose levels of <sup class="style-scope patent-text">90</sup> Y-hPAM4, with the first injection of ADC being performed on the same day as <sup class="style-scope patent-text">90</sup> Y-hPAM4. All treatment options were tolerable, with a decrease in body weight of less than or equal to 15%. Objective responses occurred in most animals, however, they were more stable in both groups receiving the combination compared to groups receiving any agent individually. In all animals in the group receiving 0.13 mCi <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG + sacituzumab govitecan, the absence of tumors was achieved within a period of 4 weeks, while in other animals signs of persistent disease continued to be observed. These studies provide primary evidence that a combination of radioimmunotherapy and ADC enhances efficacy when using safe doses.</span>
  </p>
  <p num="385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0295]      4     .  1     <sup class="style-scope patent-text">111</sup>In-hPAM4,       2    .  2, 3  4     <sup class="style-scope patent-text">90</sup>Y-hPAM4,       2    (200 /<sup class="style-scope patent-text">2</sup>).    36,5 /<sup class="style-scope patent-text">2</sup>.               315 /<sup class="style-scope patent-text">2</sup> (   ).  22          (++)  68%,     5  (23%)    10  (45%)       RECIST.</span>[0295] As part of ongoing clinical trials of RAM4, a four-week cycle of clinical treatment is conducted. At 1 week, subjects received a dose of <sup class="style-scope patent-text">111</sup> In-hPAM4, followed by a dose of gemcitabine at least 2 days later. At 2, 3, and 4 weeks, subjects were dosed with <sup class="style-scope patent-text">90</sup> Y-hPAM4, after which gemcitabine (200 mg / m <sup class="style-scope patent-text">2</sup> ) was administered at least 2 days later. Escalation began with 3  6.5 mCi / m <sup class="style-scope patent-text">2</sup> . The maximum tolerated dose in patients with first-line therapy for pancreatic cancer was 3  15 mCi / m <sup class="style-scope patent-text">2</sup> (hematological toxicity is dose-limiting). In 22 CT-measurable patients, the disease control rate (PO + CHO + SZ) was 68%, with partial responses in 5 patients (23%) and stabilization in 10 patients (45%) as the best response according to the RECIST criteria.</span>
  </p>
  <p num="386" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">      (ADC)</span>Obtaining a conjugate of an antibody with a drug (ADC)</span>
  </p>
  <p num="387" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0296] SN-38,    hRS7,            (Moon et al. J Med Chem 2008, 51:6916-6926; Govindan et al., Clin Cancer Res 2009. 15:6052-6061).     SN-38 (CL2A-SN-38).  CL2A-SN-38 - (-[]-Lys--20-O-SN-38,     -,     ).       (2-) ()   CL2A-SN-38      SN-38,   RS7.</span>[0296] SN-38 conjugated to the hRS7 antibody was prepared as described above and in accordance with the previously presented protocols (Moon et al. J Med Chem 2008, 51: 6916-6926; Govindan et al., Clin Cancer Res 2009. 15 : 6052-6061). Received a reactive bifunctional derivative SN-38 (CL2A-SN-38). Formula CL2A-SN-38 is (maleimido- [x] -Lys-RAVOSO-20-O-SN-38, where RAV is p-aminobenzyl and x contains a short PEG). After disulfide bonds were reduced in the antibody, tris (2-carboxyethyl) phosphine (TCEP) was reacted with CL2A-SN-38 with reduced antibody to produce SN-38 conjugated to RS7.</span>
  </p>
  <p num="388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0297] <sup class="style-scope patent-text">90</sup>Y-hPAM4     (Gold et al., Clin Cancer Res 2003, 9:3929S-37S; Gold et al., Int J Cancer 2004, 109:618-26).</span>[0297] <sup class="style-scope patent-text">90</sup> Y-hPAM4 is prepared as described (Gold et al., Clin Cancer Res 2003, 9: 3929S-37S; Gold et al., Int J Cancer 2004, 109: 618-26).</span>
  </p>
  <p num="389" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> RAIT + ADC</span>RAIT + ADC Combination</span>
  </p>
  <p num="390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0298]  Trop-2       (,  ,  , ,    ,  ),              .    <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG     GEM   ,        .         .    ,  ,      .  ,     ,       (RAIT) <sup class="style-scope patent-text">90</sup>Y-hPAM4 IgG.</span>[0298] The Trop-2 antigen is expressed in most types of epithelial cancer (lung, breast, prostate, ovary, colon and rectum, pancreas), and conjugates of satsituzumab govitecan are examined in various models of human cancer xenografts in mice. Initial clinical trials of <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG supplemented with radiosensitizing amounts of GEM give encouraging results, showing signs of tumor reduction or disease stabilization. However, pancreatic cancer therapy is associated with significant difficulties. Therefore, combination therapy was examined to determine if it would induce a better response. In particular, the administration of sacituzumab govitecan in effective but non-toxic doses was combined with radioimmunotherapy (RAIT) <sup class="style-scope patent-text">90</sup> Y-hPAM4 IgG.</span>
  </p>
  <p num="391" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0299]  ,      <sup class="style-scope patent-text">90</sup>Y-hPAM4   ,     ,      ( ).   75  <sup class="style-scope patent-text">90</sup>Y-hPAM4   1  10      20   ( ):   ,         ( ).      <sup class="style-scope patent-text">90</sup>Y-hPAM4     4  10   20  ( ),                ( ).   130  <sup class="style-scope patent-text">90</sup>Y-hPAM4      :    9  10        5  10     RAIT  ( ).          <sup class="style-scope patent-text">90</sup>Y-hPAM4.  RAIT + ADC              .  ADC     RAIT <sup class="style-scope patent-text">90</sup>Y-hPAM4    ,    %         ( ).</span>[0299] The results showed that the combination of satsituzumab govitecan with <sup class="style-scope patent-text">90</sup> Y-hPAM4 was more effective than any single treatment, or the sum of individual treatment options (not shown). At a dosage of 75 Ci <sup class="style-scope patent-text">90</sup> Y-hPAM4, only 1 out of 10 mice showed no tumors after 20 weeks of therapy (not shown): the same result as that observed individually for govitecan sacituzumab (not shown). However, the combination of sacituzumab govitecan with <sup class="style-scope patent-text">90</sup> Y-hPAM4 ensured the absence of tumors in 4 out of 10 mice after 20 weeks (not shown), while the rest showed a significant decrease in tumor volume compared to any treatment alone (not shown). At a dose of 130 Ci <sup class="style-scope patent-text">90</sup> Y-hPAM4, the difference was even more pronounced: tumors were absent in 9 out of 10 animals in the combination therapy group and in 5 out of 10 animals in the RAIT-only group (not shown). These data demonstrate the synergistic effect of the combination of satsituzumab govitecan with <sup class="style-scope patent-text">90</sup> Y-hPAM4. The combination of RAIT + ADC significantly improved the rate of progression and increased the frequency of achieving absence of tumors during treatment. The combination of sacituzumab govitecan ADC and MPD RAIT <sup class="style-scope patent-text">90</sup> Y-hPAM4 showed minimal additional toxicity, as indicated by% reduction in animal body weight in response to treatment (not shown).</span>
  </p>
  <p num="392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0300]          ,        RAIT    ADC ( ).  ,    ADC    RAIT     ,     ( ).      hPAM4  hRS7         ( ).</span>[0300] An analysis of the effects of different treatment sequences on tumor survival showed that the optimal effect is achieved by first performing RAIT followed by the introduction of ADC (not shown). Conversely, with the introduction of ADC first followed by RAIT, a decrease in the incidence of animals with no tumors is observed (not shown). None of the unconjugated hPAM4 and hRS7 antibodies had antitumor activity when administered separately (not shown).</span>
  </p>
  <p num="393" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 12.    (IMMU-132)         </span>Example 12. The use of satsituzumab govitecan (IMMU-132) for the treatment of metastatic breast cancer refractory to therapy</span>
  </p>
  <p num="394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0301]  -   57   IV         (ER/PR-, HER-neu-),    2005 .        2005         ACT       2005 .     ,   .              ()     2012 .,        (, , 5-).       ,         .      +     ,      .        ,      6 .    . -- 09/26/12            .     .</span>[0301] The patient is a 57-year-old woman with stage IV breast cancer with a triple negative phenotype (ER / PR-negative, HER-neu-negative), first diagnosed in 2005. The patient underwent a lumpectomy of the left mammary gland in 2005, followed by a consolidated therapy according to the ACT scheme as adjuvant therapy in September 2005. Then the patient underwent radiation therapy, which ended in November. Local recurrence of the disease was identified after the patient detected palpation of a seal in the contralateral (right) mammary gland in early 2012, after which the patient underwent chemotherapy treatment with CMF (cyclophosphamide, methotrexate, 5-fluorouracil). The disease recurred during the same year, with the appearance of metastatic lesions in the skin of the chest wall. After that, the patient received carboplatin + TAXOL as part of a chemotherapeutic regimen, the use of which led to the development of thrombocytopenia. The disease progressed and the patient began to take doxorubicin weekly, the introduction of which was continued until 6 doses were received. Skin disease also progressed. FDG-PET scan 09/26/12 showed the progression of the disease in the chest wall and enlarged solid axillary nodes. The patient received oxycodone for pain relief.</span>
  </p>
  <p num="395" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0302]       2012    2013  (   2    4 ),             .    ,    ,     ,   .     ,      IMMU-132    .          ,      (       ).          ()         4,4   2,0 .            ,               .</span>[0302] The patient received ICSEMPRA from October 2012 to February 2013 (once every 2 weeks for 4 months) when an autopsy from the lesion in the chest wall and bleeding occurred. The patient was prescribed the drug XELODA, the intake of which was poorly tolerated, accompanied by neuropathy of the palms of the hands and feet, as well as constipation. The lesions in the skin progressed, and the patient was included in the IMMU-132 trial after obtaining informed consent. The patient also had a history of hyperthyroidism and visual disturbances, with a high risk of central nervous system disease (however, an MRI scan of the brain showed no central nervous system disease). At the time of inclusion in the indicated test, the skin lesions (target) in the patient's right mammary gland reached a maximum diameter of 4.4 cm and 2.0 cm. Also, another non-target lesion was present in the patients right mammary gland, and there was one enlarged axillary lymphatic node on the right and left side of the body.</span>
  </p>
  <p num="396" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0303]   IMMU-132 (12 /),   ,  12  2013 .      -     ()   3  (0,9)      ,  1 .    1          IMMU-132    25% , 9 /.     IMMU-132    ,       2 ,     .     17  2013 ,  3  ,          43%,       RECIST.       9 /.              IMMU-132.</span>[0303] The first infusion of IMMU-132 (12 mg / kg), well tolerated by the patient, was performed on March 12, 2013. The second infusion was delayed due to a decrease in the absolute number of neutrophils (AKN) to <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 values (0.9) on the day of the infusion according to the scheme, after 1 week. After a delay of 1 week and the administration of the drug NEULASTA, the patient was administered IMMU-132 for a second time in a dose reduced by 25%, 9 mg / kg. After that, she received IMMU-132 according to the protocol, once a week for 2 weeks, followed by one week of rest. At the first assessment of the response on May 17, 2013, after 3 cycles of therapy, a decrease in the sum of the maximum diameters of the target lesions was observed by 43%, which is a partial response according to the RECIST criteria. The patient continues treatment at a dose level of 9 mg / kg. Her general health and clinical symptoms have improved significantly since the start of IMMU-132 treatment.</span>
  </p>
  <p num="397" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 13.    (IMMU-132)       </span>Example 13. The use of satsituzumab govitecan (IMMU-132) for the treatment of refractory metastatic small cell lung cancer</span>
  </p>
  <p num="398" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0304]  -   65      ,       ,             .    ,   ,    .        . ,    IMMU-132   18 /     ;      5 .           2 ,     .  5  -  13%        .      10%   .     IMMU-132   3     3 ;       ,  25%        21%     .</span>[0304] The patient is a 65-year-old woman with diagnosed small cell lung cancer, affecting the left lung and mediastinal lymph nodes, with signs of metastasis revealed in the left parietal lobe of the brain using MRI. Previous chemotherapy included carboplatin, etoposide, and topotecan, but no responses were noted. Radiation therapy to control the disease has also been unsuccessful. Accordingly, the patient began to receive IMMU-132 at a dose of 18 mg / kg once every three weeks; a total of 5 infusions were performed. After the introduction of the second dose, the patient developed hypotension and <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 neutropenia, improvement occurred until the next infusion. After 5 infusions, a CT scan showed a 13% reduction in the size of the target tumor mass in the left lung. Brain MRI also showed a 10% decrease in this metastasis. The patient continues to receive doses of IMMU-132 once every 3 weeks for another 3 months; Objective and subjective improvement of the state continues to be observed, with a 25% decrease in tumor mass in the left lung and a 21% decrease in brain metastasis.</span>
  </p>
  <p num="399" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 14.    (IMMU-132)       IV   </span>Example 14. Therapy with satsituzumab govitecan (IMMU-132) in a patient with gastric cancer at the IV stage of metastatic disease</span>
  </p>
  <p num="400" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0305]   -   60            40 .      ,      ,    ,      ,          .     ,               ,   ,    .    (  -)          ,  ,      (2      1   ,     2  4 ).    ,       ,   5-.  4 ,    6 ,     ,       ,   ,             .</span>[0305] The indicated patient is a 60-year-old male with smoking and a history of alcohol abuse of over 40 years. He experienced a decrease in body weight, discomfort when eating food and pain not relieved by taking antacids, frequent pains in the abdomen and lower back, and recently discovered palpable axillary nodes on both sides of the body. The patient sought medical help, and after the examination, he was found to have an adenocarcinoma of the gastroesophageal compound with some signs of squamous cell carcinoma, based on a biopsy performed using a gastroscope. Radiological studies (CT and FDG-PET) also revealed metastatic disease in the right and left axillary region, mediastinal region, lumbar spine and liver (2 tumors in the right lobe and 1 in the left lobe, all tumors with a diameter of 2 to 4 cm) . The gastric tumor was removed, after which the patient was prescribed a course of chemotherapy with epirubicin, cisplatin and 5-fluorouracil. After 4 months, after a rest period of 6 weeks, the patient was transferred to docetaxel chemotherapy, which was also unsuccessful for disease control, judging by the progression confirmed by measuring metastatic tumors during CT and some general worsening of the condition.</span>
  </p>
  <p num="401" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0306] ,    IMMU-132 (hRS7-SN-38)   10 /,      6      ,    -    .    ,      ,     .  - ,         28%,          5  . -            35%   RECIST      IMMU-132;    , -, ,         ,   .</span>[0306] Accordingly, the patient received IMMU-132 therapy (hRS7-SN-38) at a dose of 10 mg / kg, by infusion of a total of 6 doses once every two weeks, after which CT examinations were performed to assess the status of the disease. The indicated infusions were well tolerated, with some mild nausea and diarrhea controlled with symptomatic medication. During CT examinations, it was found that the sum of index metastatic lesions decreased by 28%, therefore, the indicated therapy in the patient was continued with 5 additional courses. CT examinations as part of a prospective study indicate continued relief of the disease by approximately 35% according to the RECIST criteria for baseline measurements prior to IMMU-132 therapy; the general condition of the patient also seems to have improved, and an optimistic attitude towards the disease under control is returned to the patient.</span>
  </p>
  <p num="402" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 15.   IMMU-132    Trop-2- </span>Example 15. Clinical trials of IMMU-132 for various types of Trop-2-positive cancer</span>
  </p>
  <p num="403" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Summary</span>
  </p>
  <p num="404" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0307]   (IMMU-132,    hRS7-CL2A-SN-38)        (ADC),   Trop-2,  ,     ,   SN-38,   .     ADC,       ,  IMMU-132            SN-38  .        ,  Trop-2      ,      ,  ,        (),   ,    .            IMMU-132    hRS7,        5-  Trop-2    IMMU-132   hRS7  .         ,    60%        hRS7.</span>[0307] Sacituzumab govitecan (IMMU-132, also known as hRS7-CL2A-SN-38) is a drug-conjugated antibody (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for SN delivery -38, an active metabolite of irinotecan. Unlike most ADCs involving ultra-toxic drugs and stable linkers, the IMMU-132 uses a moderately toxic drug and a moderately stable carbonate bond between SN-38 and the linker. Using flow cytometry and immunohistochemical studies, it was found that Trop-2 is expressed in a wide range of tumor types, including cancer of the stomach, pancreas, breast cancer with a triple negative phenotype (TNBC), cancer of the colon, prostate and lung. Although no significant differences were found between the IMMU-132 and the original hRS7 antibody in cell binding experiments, surface plasma resonance analysis using a CM5 chip with Trop-2 shows a significant advantage of IMMU-132 over hRS7 binding. The indicated conjugate retained the ability to bind to the neonatal receptor, however, it lost more than 60% of the activity of antibody-dependent cell-mediated cytotoxicity compared to hRS7.</span>
  </p>
  <p num="405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0308]        SN-38,  IMMU-132        ,    pJNK1/2  p21WAF1/Cip1     9, 7  3,        (-)-    .   ADC        (MRT) 15,4 ,   - hRS7   ,    (MRT = ~300 ).  ,     ,   IMMU-132 (17,5 /;      4 )        ,    .     IMMU-132       ,        -      .</span>[0308] When tumor cells were exposed to either free SN-38 or IMMU-132, the participation of the same signaling pathways was demonstrated with upregulation of pJNK1 / 2 and p21WAF1 / Cip1 and subsequent cleavage of <figure-callout id="9" label="caspases" filenames="00000046.png,00000052.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="7" label="caspases" filenames="00000045.png,00000050.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="3" label="caspases" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">caspases</a></figure-callout></a></figure-callout></a></figure-callout> 9, 7 and 3, which ultimately as a result, it cleaves the poly (ADP-ribose) polymerase and breaks the double-stranded DNA. The pharmacokinetics of intact ADC in mice indicated an average retention time (MRT) of 15.4 hours, while the hRS7 carrier antibody was excreted at a rate similar to an unconjugated antibody (MRT = ~ 300 hours). Treatment of mice bearing human gastric cancer xenografts with IMMU-132 (17.5 mg / kg; twice weekly  4 weeks) provided significant antitumor effects compared to mice treated with nonspecific control. Clinically relevant dosing regimens for IMMU-132 included once every two weeks, weekly, or twice weekly administration in mice bearing human pancreatic or gastric cancer.</span>
  </p>
  <p num="406" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0309]     I    ADC                 .            ,        , ,    ,  ,   SN-38 ,       .      ,     .</span>[0309] In this Phase I trial, the indicated ADC was evaluated as a potential therapeutic agent for use in prior treatment patients with various types of metastatic solid cancer. According to specific embodiments, said therapy is suitable for use in treating patients who have previously found resistance to standard types of anti-cancer treatments, including, but not limited to, treatment with irinotecan, the original compound for SN-38, or who have recurred after using these treatments. The indicated results were unexpected and unforeseen, and could not be predicted.</span>
  </p>
  <p num="407" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0310]     1  8  21- ,         .       3+3  4          . 25  ( 52-60 ,   3    ())      8 (N  7), 10 (N  6), 12 (N  9)  18 (N  3) /.     ,        1  12 /,         .        ,       4 ,    3 ,   (N  3),  (N  2),  (N  1)   (N  1).       RECIST 1.1  3     (      ,   ,   ),    15       ;  12             16-36 .       Trop-2    .</span>[0310] Sacituzumab govitecan was administered on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of the 21-day cycles, with cycles repeated until dose-limiting toxicity or progression occurred. Dose escalation was carried out according to the standard 3 + 3 scheme with 4 planned dose levels with permitted delays in administration or dose reductions. 25 patients (aged 52-60 years, on average 3 previous chemotherapeutic regimens (median)) received treatment at dose levels of 8 (N is 7), 10 (N is 6), 12 (N is 9) and 18 (N is 3 ) mg / kg. Dose-limiting toxicity was represented by neutropenia, while the maximum tolerated dose for <figure-callout id="1" label="cycle" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">cycle</a></figure-callout> 1 was 12 mg / kg, however, with repeated cycles, the indicated dose was too toxic. Lower doses were acceptable with extended treatment, without the occurrence of treatment-related toxicity of <figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 4, and with toxicity of <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3, limited fatigue (N is 3), neutropenia (N is 2), diarrhea (N is 1) and leukopenia (N is 1). According to the CTIST-based RECIST 1.1 criteria, a partial response was achieved in 3 patients (breast cancer with a triple negative phenotype, small cell lung cancer, colon cancer), and another 15 showed a stable disease as the best response; 12 of these patients retained control of the disease with continued treatment for 16-36 weeks. Preliminary selection of patients based on the expression of Trop-2 in tumors was not performed.</span>
  </p>
  <p num="408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0311]   ,        ADC             .  8  10 /      II .</span>[0311] It was concluded that satsituzumab govitecan is a promising ADC conjugate with acceptable toxicity and promising therapeutic activity in patients with intractable cancers. Doses of 8 and 10 mg / kg were selected for phase II studies.</span>
  </p>
  <p num="409" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Introduction</span>
  </p>
  <p num="410" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0312]          (ADC),    (   )  ,       ADC    ,         (Younes et al., 2011, Nat Rev Drug Discov 11:19-20; Sievers &amp; Senter, 2013, Ann Rev Med 64:15-29; Krop &amp; Winer, 2014, Clin Cancer Res 20:15-20).  Moon   (Moon et al., 2008, J Med Chem 51:6916-26)  Govindan   (Govindan et al., 2009, Clin Cancer Res 15:6052-61), ,  SN-38,   I,     ,      ,     (Mathijssen et al., 2001, Clin Cancer Res 7:2182-94).         SN-38,       IgG   ,      (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Cancer Res 15:6052-61; Cardillo et al., 2011, Clin Cancer Res 17:3157-69).   ,  CL2A,      ,        SN-38;                   ;       ,   (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).   SN-38         SN-38,     , , ,  ,     , ,  ,    .</span>[0312] Two new drug-antibody conjugates (ADCs) were approved, including different ultra-toxic (picomolar activity) drugs, leading to further development of other ADCs based on similar principles, including using ultra-toxic drugs (Younes et al., 2011, Nat Rev Drug Discov 11: 19-20; Sievers &amp; Senter, 2013, Ann Rev Med 64: 15-29; Krop &amp; Winer, 2014, Clin Cancer Res 20: 15-20). However, Moon et al. (Moon et al., 2008, J Med Chem 51: 6916-26) and Govindan et al. (Govindan et al., 2009, Clin Cancer Res 15: 6052-61), in contrast, chose SN-38. topoisomerase I inhibitor, which is an active metabolite of irinotecan, an approved drug with well-known but complex pharmacological characteristics (Mathijssen et al., 2001, Clin Cancer Res 7: 2182-94). Several linkers for conjugation with SN-38 have been evaluated to release it upon disconnection from IgG at various rates, from several hours to days (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al., 2009, Clin Cancer Res 15: 6052-61; Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). The selected optimal linker, designated CL2A, providing intermediate serum conjugate stability, was attached to the hydroxyl group on the SN-38 lactone ring; thus, said ring, while maintaining communication with the linker, was protected from opening to form a less toxic carboxylate form; said linker also contained a short fragment of polyethylene glycol that improves solubility (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). The active form of SN-38 was released upon cleavage of the carbonate bond between the linker and SN-38, either at low pH values, such as in lysosomes, as well as in the tumor microenvironment, or, as an option, due to enzymatic decomposition.</span>
  </p>
  <p num="411" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0313] ,      ADC,     Trop-2 (   ) (Cardillo et al., 2011, Clin Cancer Res 17:3157-69)    ,    ,    RS7 (Stein et al., 1993, Int J Cancer 55:938-46). Trop-2     ADC,       ,  ,    (Ambrogi et al., 2014, PLoS One 9:e96993; Cubas et al., 2009, Biochim Biophys Act 1796:309-14; Trerotola et al., 2013, Oncogene 32:222-33). Trop-2      ,      ,     ,     ADC      ,        Trop-2   (Cardillo et al., 2011, Clin Cancer Res 17:3157-69). ,    ,              (Cardillo et al., 2011, Clin Cancer Res 17:3157-69),     I           ADC          /   .     - ClinicalTrials.gov (  NCT01631552).</span>[0313] An antibody selected for use in said ADC targets a tumor-associated Trop-2 antigen (surface trophoblast cell antigen) (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69) and is internalized as previously shown, the humanized monoclonal antibody RS7 (Stein et al., 1993, Int J Cancer 55: 938-46). Trop-2 is an important ADC tumor target because it is overexpressed on many epithelial tumors, in particular the more aggressive type (Ambrogi et al., 2014, PLoS One 9: e96993; Cubas et al., 2009, Biochim Biophys Act 1796: 309 -14; Trerotola et al., 2013, Oncogene 32: 222-33). Trop-2 is also present in some normal tissues, however, in preclinical studies on monkeys expressing the indicated antigen, using the indicated new ADC, only dose-limiting neutropenia and diarrhea were observed, with no evidence of toxicity for Trop-2 expressing normal tissues (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). Accordingly, based on preclinical data that demonstrated activity in several models of human tumor xenografts and a wide therapeutic window (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69), a phase I clinical trial was initiated to determine the maximum tolerated and optimal doses of the indicated new ADC in previously undergoing serious treatment patients with various types of recurrent / refractory metastatic epithelial tumors. This test is registered on the website ClinicalTrials.gov (under the number NCT01631552).</span>
  </p>
  <p num="412" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  </span>Materials and methods</span>
  </p>
  <p num="413" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0314]   -           (IMMU-132)   .       3+3  I,    8 /  ,      2   3-  .</span>[0314] Selection Criteria - The primary goal was to determine the safety and tolerability of govitecan sacituzumab (IMMU-132) as a separate agent. The test design was a standard 3 + 3 phase I design, with a starting dose of 8 mg / kg per injection, with weekly dosing for 2 weeks in a 3-week treatment cycle.</span>
  </p>
  <p num="414" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0315]      ,         18         13  .       Trop-2  , ,   Trop-2        75%        . ,        (       5 ),                   .      (   1 )  ,     ,               3            -1.              .    ,            .</span>[0315] For inclusion, men and non-pregnant, non-breastfeeding women aged more than or equal to 18 years old with a diagnosed epithelial tumor of one of 13 different types were suitable. Although pre-selection based on Trop-2 expression was not required, it is expected that Trop-2 expression in these tumors is present in more than 75% of cases based on the results of immunohistological studies of archival samples. Patients were required to have a measurable metastatic disease (without single lesions greater than or equal to 5 cm), with relapse or refractoriness after applying at least one approved standard chemotherapeutic regimen for the disease. Other key criteria included adequate (less than or equal to class 1) hematological parameters, liver and kidney function indicators, and the absence in the history of known anaphylactic reactions to irinotecan or toxicity greater than or equal to <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 in relation to the gastrointestinal tract with previous treatment with irinotecan or other topoisomerase-1 inhibitors . Due to the admission of patients with such a variety of diseases, prior irinotecan therapy was not a prerequisite. Patients with Gilbert's disease, intolerance to irinotecan with previous administration or with a known metastatic disease of the central nervous system were excluded.</span>
  </p>
  <p num="415" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0316]   -       4    ,      ,   ,       .         SN-38     ELISA,              .  -   6-8    ,     8-12-   .        -     .       CTCAE NCI  4.0;      RECIST 1.1.</span>[0316] Study Design  Baseline assessments were performed within 4 weeks of starting treatment, regularly monitoring the number of blood elements, serum biochemical parameters, key vital signs, and any adverse events. The response in the form of antibodies to antibodies and to SN-38 was measured using ELISA ELISA, sampling was carried out at the base moment and then before the start of each even treatment cycle. The first CT examination was performed 6-8 weeks after the start of treatment, and then repeated at 8-12-week intervals until progression. Additional follow-up was required only to monitor any ongoing treatment-related toxicity. The toxicity class was determined using CTCAE NCI criteria version 4.0; efficacy was evaluated using RECIST 1.1 criteria.</span>
  </p>
  <p num="416" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0317]    ELISA   Trop-2     2 /,    12       Trop-2    .         Trop-2       Trop-2 ,       (R&amp;D Systems, , ),  ,   ADC, hRS7,           (Stein et al., 1993, Int J Cancer 55:938-46).      .</span>[0317] An ELISA ELISA was developed to detect Trop-2 in serum with a sensitivity of 2 ng / ml, but after testing 12 patients and detecting no signs of circulating Trop-2, no further screening was performed. Samples of previously archived tumors were requested for immunohistological evaluation of Trop-2 using a polyclonal goat anti-human Trop-2 antibody, although this was not an inclusion criterion (R&amp;D Systems, Minneapolis, Minnesota) because the epitope recognized by the ADC antibody, hRS7, is not stored in fixed formalin and paraffin embedded sections (Stein et al., 1993, Int J Cancer 55: 938-46). Staining was performed as described below.</span>
  </p>
  <p num="417" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0318]   -            2-3  ( 100    ~1,6  SN-38,      :  [DAR] = 7,6:1).        ,   ( H1  2)  .        .    2    1  8  3-  ,         8  (.. 16  ),       . ,         8 ,   .</span>[0318] Therapeutic regimen - Lyophilized satsituzumab govitecan was reconstituted in saline and infused for 23 hours (~ 1.6 mg SN-38 was contained in 100 mg of antibody, with an average drug: antibody [DAR] = 7.6 :1). Prior to each infusion, most patients received acetaminophen, antihistamines (H1 and H2 blockers), and dexamethasone. Prophylactic use of antiemetic or antidiarrheal drugs was prohibited. The therapy included the administration of 2 consecutive doses on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of the 3-week treatment cycle, with the proposed continued treatment of patients with up to 8 cycles (i.e. 16 treatment procedures), provided that there was no unacceptable toxicity or progression. Patients with stabilization of the disease or response after 8 cycles could continue treatment.</span>
  </p>
  <p num="418" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0319]    ()         3 ,  3        4    5 , -  ,    3 ,     48 ,     ,  ,     4 ()  ,         3 ,        ,    -     3 .</span>[0319] Dose-limiting toxicity (DLT) was considered febrile neutropenia of any duration greater than or equal to <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3, thrombocytopenia of <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 with significant bleeding or <figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 4 thrombocytopenia of greater than or equal to 5 days, any of <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 nausea, vomiting or diarrhea persisting on for more than 48 hours, despite optimal medical management, or nausea, vomiting or diarrhea of class 4 (life threatening) of any duration, or any other non-hematological toxicity greater than or equal to 3 classes, at least probably due to the investigational medicinal product, as well as the occurrence of or an infusion-related reaction of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3.</span>
  </p>
  <p num="419" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0320]    ()        .                 2 ,   ,      2 .           1 .          (25%     1 , 50%     2 ),        ,          .    ,        3   ,  .  ,         ; ,    ,      . , ,   ,    /      ,    ,   .</span>[0320] The maximum tolerated dose (MTD) was determined based on patient tolerance of the first treatment cycle. On the day of planned treatment, treatment of any patient with observed treatment-related toxicity greater than or equal to <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2, with the exception of alopecia, was delayed at weekly intervals of up to 2 weeks. Treatment was resumed after toxicity decreased to a level less than or equal to <figure-callout id="1" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 1. The protocol initially also required a reduction in all subsequent doses of treatment (25% when recovering within 1 week, 50% when recovering within 2 weeks), but this requirement was mitigated later during the trial, when the protocol was changed to provide supportive treatment after the first cycle. However, if toxicity did not decrease within a period of 3 weeks or increase, treatment was discontinued. What is important, delayed administration with a dose reduction was not equal to DLT; accordingly, treatment could be continued, however with a lower dose. Accordingly, it was believed that in a patient who required a delay in administration / dose reduction and who could continue treatment, DLT was not subject to evaluation, therefore, it was replaced.</span>
  </p>
  <p num="420" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0321]         ,       ,         ,       .        ; ,                 ,        .</span>[0321] Since the occurrence of DLT led to the cessation of any further treatment, the secondary goal was to assess the dose level that could be tolerated over several treatment cycles, with minimal delay in administration or dose reduction. The indicated dose level was designated as the maximum acceptable dose; it was required that patients tolerate a given dose level in the first cycle without delay or decrease during the indicated cycle, which would ensure the transition to the beginning of the second cycle.</span>
  </p>
  <p num="421" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0322]    -        ~30     (,     )       (,     ).          IgG       ELISA.    SN-38      ,   ( SN-38,   IgG,  ),     SN-38 (..  SN-38).</span>[0322] Pharmacokinetics and immunogenicity - Blood sampling was carried out within a period of ~ 30 min from the end of the infusion (for example, taking samples with a peak concentration) and then before each subsequent injection (for example, taking samples with a minimum concentration). Samples were separated and the serum was frozen to determine the total concentrations of IgG and gacitezan sacituzumab using an ELISA ELISA. We also analyzed the content of SN-38 in serum samples from seven patients, both total (corresponding to SN-38 associated with IgG and free), and the content of free SN-38 (i.e., unbound SN-38).</span>
  </p>
  <p num="422" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>results</span>
  </p>
  <p num="423" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0323]   -       ( 6).     52  60 ,   76%      ECOG,  1,  - ECOG 0.        () (N  7),            () (N  4),      () (N  3),    () (N  2)    () (N  2),      (), -    (),    (),    (),  ,     ().</span>[0323] Patient Characteristics - Twenty-five patients were included in the study (Table 6). The median age ranged from 52 to 60 years, with 76% of patients having ECOG status of 1, the rest of <figure-callout id="0" label="ECOG" filenames="00000052.png,00000053.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">ECOG</a></figure-callout> 0. Most patients had metastatic pancreatic cancer (PCa) (N = 7), followed by breast cancer glands with a triple negative phenotype (TNBC) (N = 4), colorectal cancer (ROPK) (N = 3), small cell lung cancer (MRL) (N = 2) and stomach cancer (RG) (N = 2) , with single cases of esophageal adenocarcinoma (AKP), hormonal-refractory prostate cancer (HGRP), non-small cell lung cancer (NSCLC), epithelial cancer of the ovaries (EPR), cancer of the kidneys, tonsils and bladder (RMP).</span>
  </p>
  <p num="424" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0324]       17 ,    13 (76,4%)        2+  3+     10%  ; 3  (17,6%)   .     .</span>[0324] An immunohistological analysis of archival tissues from 17 patients was performed, with membrane and cytoplasmic staining from 2+ to 3+ levels in more than 10% of tumor cells observed in 13 (76.4%) samples; 3 samples (17.6%) gave a negative result. A number of representative cases are described below.</span>
  </p>
  <p num="425" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0325]            ,      .     ,           9,7  ( = 2,9-29,8 ),    14   3      (    = 4,  = 1-10  ),    2    ( = 0-7  ),    .       3 ,   7  (2   ,  1   , ,  )     ,  7  -    ; 11     .     I    ,   2  3   , 4  7     1     ,  2  2     ;     ( 2        )      1 . ,   23  ( 2    )         ,  3  (: 1-11 ).</span>[0325] All enrolled patients suffered from metastatic disease with metastases at sites typical of the corresponding type of primary cancer. Using CT, it was determined that the median of the sum of the maximum tumor diameters for all patients was 9.7 cm (range = 2.9-29.8 cm), while 14 patients had 3 or more target lesions (median for all patients = 4, range = 1-10 lesions), and on average 2 non-target lesions (range = 0-7 lesions) identified in the baseline studies. The previous systemic therapy was performed on average 3 times, while 7 patients (2 prostate cancer and pancreatic cancer, 1 patient with ROPK, TNRM, tonsil cancer) underwent previous therapy once, and 7 patients five or more times; 11 patients underwent previous radiation therapy. Prior therapy with a topoisomerase I inhibitor was carried out in nine patients, with 2 out of 3 patients with ROPK, 4 out of 7 patients with prostate cancer and 1 patient with AKP receiving irinotecan, and 2 of 2 patients with MRI received topotecan; in three of them (in 2 patients with MPD and one patient with ROPK) there was no response to therapy with <figure-callout id="1" label="topoisomerase" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">topoisomerase</a></figure-callout> 1 inhibitor. Further, seven out of 23 patients (data not determined for 2 patients) responded to the last previous therapy with a median response duration of 3 months (range: 1-11 months).</span>
  </p>
  <p num="426" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0326]          ( = 10 )        -   RECIST 1.1;       ,   1                   .</span>[0326] Almost all patients received sacituzumab govitecan treatment several times (median = 10 doses) until the disease progression was finally confirmed using a CT scan according to RECIST 1.1 criteria; one patient was removed due to systematic deterioration, and in 1 patient the target lesion was not measured at the first visit as part of a follow-up when a new lesion was detected.</span>
  </p>
  <p num="427" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/de/a2/b1/1085f9ef4e97f1/00000029.png" class="style-scope patent-text"><img file="00000029.jpg" he="177" wi="160" img-format="jpg" img-content="undefined" width="640" height="708" alt="Figure 00000029" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/de/a2/b1/1085f9ef4e97f1/00000029.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/de/a2/b1/1085f9ef4e97f1/00000029.png" class="style-scope patent-text"><img file="00000029.jpg" he="177" wi="160" img-format="jpg" img-content="undefined" width="640" height="708" alt="Figure 00000029" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/de/a2/b1/1085f9ef4e97f1/00000029.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="428" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ec/8e/80/27a9901dce9934/00000030.png" class="style-scope patent-text"><img file="00000030.jpg" he="235" wi="160" img-format="jpg" img-content="undefined" width="640" height="940" alt="Figure 00000030" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ec/8e/80/27a9901dce9934/00000030.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ec/8e/80/27a9901dce9934/00000030.png" class="style-scope patent-text"><img file="00000030.jpg" he="235" wi="160" img-format="jpg" img-content="undefined" width="640" height="940" alt="Figure 00000030" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ec/8e/80/27a9901dce9934/00000030.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="429" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ff/d1/0b/5a6290e3828bf6/00000031.png" class="style-scope patent-text"><img file="00000031.jpg" he="237" wi="160" img-format="jpg" img-content="undefined" width="640" height="948" alt="Figure 00000031" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ff/d1/0b/5a6290e3828bf6/00000031.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ff/d1/0b/5a6290e3828bf6/00000031.png" class="style-scope patent-text"><img file="00000031.jpg" he="237" wi="160" img-format="jpg" img-content="undefined" width="640" height="948" alt="Figure 00000031" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ff/d1/0b/5a6290e3828bf6/00000031.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="430" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/15/a0/405de0eecac746/00000032.png" class="style-scope patent-text"><img file="00000032.jpg" he="54" wi="160" img-format="jpg" img-content="undefined" width="640" height="216" alt="Figure 00000032" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/15/a0/405de0eecac746/00000032.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/15/a0/405de0eecac746/00000032.png" class="style-scope patent-text"><img file="00000032.jpg" he="54" wi="160" img-format="jpg" img-content="undefined" width="640" height="216" alt="Figure 00000032" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/15/a0/405de0eecac746/00000032.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="431" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0327]   -      ,      3  (1 , 2 ),      8,0 /.      , 12 /,             .          ( 4    1 ,   2      ,   1        2 ).   ,    12 /    .         12 /  ,     ,    9 /,       1    3 .      /,      9          (,  1         3     ; 2 ,     3     ,    ,  1    3     ,    ,  2   3     ,  2    2       ,   1     ); ,       18 /.                ,   1      18 /.       4 ,      ,       18 /,             2 . ,       12 /        0/9   .</span>[0327] Dose Assessment - There were no delays in the administration or dose reduction, as well as the phenomenon of DLT in 3 patients (1 ROPC, 2 PCa) included with an initial dose level of 8.0 mg / kg. Nine patients were included in the study with the next dose level, 12 mg / kg, due to the protocol-specific delay requirement for the second dose. For five patients, the delay requirement arose in the first cycle (in 4 patients the delay was 1 week, while 2 patients received auxiliary myeloid growth factor, and in 1 patient the delay before the second dose was 2 weeks). All of these patients except one received 12 mg / kg as a second dose. In four of nine patients with a dose level of 12 mg / kg, the third dose, administered at the beginning of the third cycle, was reduced to 9 mg / kg, and the second cycle was delayed by 1 additional week in 3 patients. Despite the indicated delays / reductions due to the protocol, none of the indicated 9 patients showed dose-limiting effects during the first cycle (for example, 1 patient had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 hemoglobin levels after the first dose; 2 patients who had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 neutropenia after the first dose, myeloid growth factors were obtained, 1 patient had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 neutropenia after the first dose, resolved without adjuvants, <figure-callout id="2" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 neutropenia was observed after the second dose, 2 patients had <figure-callout id="2" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 neutropenia after the introduction the first or second dose, and in 1 patient there were no adverse events); accordingly, an increase in dose level to 18 mg / kg was allowed. At this stage, in all three patients, dose administration was delayed after the first treatment dose was administered, and only 1 patient received a second treatment dose of 18 mg / kg. Two patients had <figure-callout id="4" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 4 dose-limiting neutropenia, one after the first dose, the other after the second dose of 18 mg / kg, and the last patient also had <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 diarrhea after the indicated dose. Accordingly, in the first cycle with a dose level of 12 mg / kg, the indicated level was indicated as MTD in 0/9 patients with DLT.</span>
  </p>
  <p num="432" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0328]           ,            /. ,      4     8 /,       10 /.   ,    8 /,          8 /,      31  11  ,         8 /     6 /    2     ,     3      ,       .  4    3  9  8 /     .       1       6 /    2    2 .</span>[0328] Additional dose-selection studies were continued to refine the dose level, which would allow for several cycles with minimal delays between treatment procedures / cycles. Accordingly, 4 more patients were included in the study at a dose level of 8 mg / kg, and a new intermediate level of 10 mg / kg was established. Of the three patients included at a dose of 8 mg / kg, in two patients with ROSC, treatment was continued at a dose of 8 mg / kg, with a total of 31 and 11 treatment procedures, while a patient with prostate cancer received three doses of 8 mg / kg to dose reduction to 6 mg / kg due to the occurrence of <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 neutropenia with the introduction of the fourth dose, and then underwent another 3 treatment procedures at the indicated dose level, after which it was suspended due to the progression of the disease. Another 4 patients received from 3 to 9 doses of 8 mg / kg to suspension with the progression of the disease. Two of these patients received only 1 dose to the reduction required by the protocol to 6 mg / kg due to the occurrence of a <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 rash and <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 neutropenia.</span>
  </p>
  <p num="433" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0329]    ,    10 /,   6  30        .      (#9)    3 ,      4    1 .        ,       ,            4      .   ,    ,     4     .</span>[0329] Five out of six patients, included at a dose of 10 mg / kg, received from 6 to 30 doses without reduction to suspension due to disease progression. One patient with RJ (# 9) developed <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 febrile neutropenia, as well as <figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 4 hemoglobin levels after receiving 1 dose. Febrile neutropenia was considered to be presumably related to treatment because it occurred shortly after the first dose, while perforation of the lining of the stomach was considered to be presumably partially conditional on <figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 4 hemoglobin levels and not related to treatment. In the end, the patient's condition quickly worsened, and he died 4 weeks after receiving the first dose.</span>
  </p>
  <p num="434" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0330] ,       ,  12 /   ,   8-10 /            ,   II     2   .</span>[0330] Accordingly, although cumulative results suggest that 12 mg / kg is MTD, since doses of 8-10 mg / kg were better tolerated in the first cycle and allowed cycles to be repeated with minimal toxicity, phase II clinical studies to evaluate these 2 dose levels are ongoing.</span>
  </p>
  <p num="435" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0331]   - 297      2-3 ,           .      .        , , ,   ,            ;       1  2  ( ).     3  4     (N  8),            12  18 /.     2 ,        #9,      10 /,       (#19),   4  12 /.      :    (12%)    3 .       12 /,  -   4 ,      ,      6  12 /,       2 .         ,   .    ,    , ,        2 ,   3    1 .</span>[0331] Adverse events  297 infusions of sacituzumab govitecan were administered in 23 hours, with most researchers preferring to use medication before each infusion. There were no adverse events associated with infusion. Although more than half of the patients experienced fatigue, nausea, alopecia, diarrhea and neutropenia, which were considered to be at least presumably related to treatment with sacituzumab govitecan; basically, these phenomena belonged to <figure-callout id="1" label="classes" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">classes</a></figure-callout> 1 and 2 (not shown). Basically, registered toxicity of <figure-callout id="3" label="classes" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="4" label="classes" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">classes</a></figure-callout></a></figure-callout> 3 or 4 was represented by neutropenia (N is 8), but six of these patients received initial treatment at doses of 12 and 18 mg / kg. Febrile neutropenia occurred in 2 patients, in the already mentioned patient with <figure-callout id="9" label="RJ #" filenames="00000046.png,00000052.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">RJ #</a></figure-callout> 9, who received only one dose of 10 mg / kg, and in the second patient with PCa (# 19), who received 4 doses of 12 mg / kg. Diarrhea in most patients was mild: only three (12%) patients had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 diarrhea. Two cases were observed for a dose level of 12 mg / kg, one after receiving 4 doses, and the other after receiving the first dose, however, the indicated patient received another 6 doses of 12 mg / kg, while only <figure-callout id="2" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 2 diarrhea was recorded. After that, both patients were prescribed an over-the-counter antidiarrheal drug, and treatment was continued. There were no other types of significant toxicity associated with satsituzumab govitecan, however, two patients had a <figure-callout id="2" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 2 rash, and <figure-callout id="1" label="class" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 1 prurite was observed in 3 patients.</span>
  </p>
  <p num="436" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0332]  -                  ,      -        ( ).  ,    ,    ,    -     (N = 1),        , ,        (N  3).  ,  3     30%     ( , ).     (#3  #15)   -    ,      (# 22)     -,  12  .  15        (),  7  -  (),    RECIST 1.1.         24  (  1 ,     1     )  3,6  [: 1-12,8 ]; 4,1  (: 2,6-12,8 )        (N  18).   ,    ,   -I,         (28%  38%),  5   ,     2   -     (4,1  6,9 , ),    2      .</span>[0332] Efficiency - The best response was determined based on data on changes in the target lesions and time to progression in patients who underwent at least one CT examination after treatment to measure the target lesions (not shown). Four patients whose diseases progressed are not shown in the graph, since they did not undergo a CT examination as part of the follow-up (N = 1), or due to the appearance of new lesions and, accordingly, progression regardless of the status of the target lesions (N is 3). In general, 3 patients showed a more than 30% decrease in target lesions (partial response, CH). Two of these patients (# 3 and # 15) underwent confirmatory CT examinations as part of the follow-up, while the third patient (# 22) experienced progression at the <figure-callout id="12" label="next CT exam" filenames="00000045.png,00000047.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">next CT exam</a></figure-callout> 12 weeks later. In 15 patients, the best response was represented by stable disease (SZ), in 7 patients - progression (PZ), according to the criteria of the RECIST 1.1 scale. The median time to progression from the start of treatment for 24 patients (with the exception of 1 patient who underwent only 1 treatment procedure and was suspended) was 3.6 months [range: 1-12.8 months]; 4.1 months (range: 2.6-12.8 months) for all patients with SZ or CHO (N is 18). Of the nine patients who underwent previous therapy, including a topoisomerase-I inhibitor, two showed a significant decrease in the target lesions (28% and 38%), 5 had a stable disease, including 2 of them over long periods ( 4.1 and 6.9 months, respectively), while 2 patients showed progression at the first assessment.</span>
  </p>
  <p num="437" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0333]        ,   16    15-20     ,        40 ( 15 ()  3 (),      (2  , 1  , 1  ) ( ).     2 ,   30%     () ( ).</span>[0333] Comparison of SAR and survival in these patients shows that for 16 patients, survival was 1520 months from the start of therapy, including two patients with 40 (patients 15 (TNBC) and 3 (ROPC), and four others with SZ (2 with ROPK, 1 with GRGR, 1 with TNBC) (not shown). Radiological responses were observed in 2 patients, with a more than 30% decrease in target lesions (FN) (not shown).</span>
  </p>
  <p num="438" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0334]  3    ,  40,        .    50    ( 18;    Trop-2 = 3+)  13%     3 ,          19%   16  (   (SLD)   7,5  6,1 ),    45       26 .    63    ( 10;   2+), 7    ,     3    ,  ,   23%  5      5  10 /  ,    28%    18 .        1,6 /    38,5 /.   25  (27 )      20%  SLD   .  ,            4,5 /.    68    ( 20;    )  5    (13,3 )  5    (3   ).   34      12,7   ,           .      -   52     ( 25;   3+) 6    ,     6-    FOLFIRI   3  .       18 /,     13,5 / - .         30 ,     15 .   60    (#11),    ,    10 /.   19-9       5880  2840 /   8 ,     ( : 12%  )     15  (11 )     .   ,   19-9   (2814 /),    8   (  3 )   10 /         .</span>[0334] In addition to the 3 patients with the best response, represented by 40, a number of notable cases of prolonged stable disease were noted. A patient aged 50 years with TNBC (<figure-callout id="18" label="patient" filenames="00000049.png,00000053.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient</a></figure-callout> 18; immunohistological evaluation of Trop-2 expression = 3+) showed a 13% decrease after receiving only 3 doses, with a maximum reduction of four target lesions by 19% after receiving 16 doses (the sum of the largest diameters (SLD) decreased from 7.5 to 6.1 cm), to <figure-callout id="45" label="progression" filenames="00000046.png,00000047.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">progression</a></figure-callout> 45 weeks after starting treatment and receiving 26 doses. A patient aged 63 years with ROPK (<figure-callout id="10" label="patient" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient</a></figure-callout> 10; <figure-callout id="2" label="immunohistological assessment" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">immunohistological assessment</a></figure-callout> 2+) who underwent <figure-callout id="7" label="previous treatment" filenames="00000045.png,00000050.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">previous treatment</a></figure-callout> 7 times, including after 3 separate courses with regimens that included irinotecan, showed a cumulative 23% reduction in 5 target lesions after 5 doses of 10 mg / kg of satsituzumab govitecan, with a maximum of 28% reduction after 18 doses. The patient's plasma CEA levels decreased to 1.6 ng / ml at a baseline of 38.5 ng / ml. After receiving 25 doses (27 weeks), the patient experienced PZ with a 20% increase in SLD relative to the minimum values. It is interesting to note that the level of CEA in plasma at the time of the end of treatment was only 4.5 ng / ml. In a patient aged 68 years with HGRP (<figure-callout id="20" label="patient" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient</a></figure-callout> 20; no immunohistological evaluation was performed), 5 target lesions (13.3 cm) and 5 non-target lesions (3 bone metastases) were present. He received 34 treatments over a period of 12.7 months prior to progression, with PSA levels gradually increasing over a specified period of time. In another noteworthy case, a patient - a 52-year-old man with esophageal cancer (<figure-callout id="25" label="patient" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient</a></figure-callout> 25; <figure-callout id="3" label="immunohistological rating" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">immunohistological rating</a></figure-callout> 3+) underwent <figure-callout id="6" label="previous therapy" filenames="00000045.png,00000049.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">previous therapy</a></figure-callout> 6 times, including 6-month therapy according to the FOLFIRI regimen as a 3-course treatment. The treatment was started with a dose of 18 mg / kg satsituzumab govitecan, which was reduced to 13.5 mg / kg due to neutropenia. The patient had SZ for a period of 30 weeks, before progression he received 15 doses. A 60-year-old patient with prostate cancer (# 11), with liver metastases, received treatment with doses of 10 mg / kg. The patients baseline serum CA19-9 titer decreased from 5880 to 2840 units / ml after receiving 8 doses, and the disease stabilized (best response: 12% reduction in size) over a period of 15 weeks (11 doses) until a new lesion was detected . However, since CA19-9 levels remained low (2814 units / ml), the patient received another 8 treatment procedures (within 3 months) at a dose of 10 mg / kg before leaving the study with progression of the target lesions.</span>
  </p>
  <p num="439" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0335]        Trop-2        16          ,            .</span>[0335] To date, the potential usefulness of testing Trop-2 expression in archival samples of this small sample of 16 patients with various types of cancer is insufficient to make final estimates, which is mainly associated with increased levels of expression in most of them.</span>
  </p>
  <p num="440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0336]    -     IgG   30-     7,         .       (#15)   ,    12 /,         .  IgG     30-     ,     ELISA,       ( ),    .   IgG     ,       (   ),      ( ).</span>[0336] FC and immunogenicity - The concentrations of sacituzumab govitecan and IgG in a 30-minute serum sample are shown in Table 7, showing the general trend of increasing values as the dose increases. In a representative case, a patient with TNBC (# 15) received several doses, starting with a dose of 12 mg / kg, followed by a decrease several times during the course of treatment. The concentrations of IgG and sacituzumab govitecan in a 30-minute serum with multiple doses, determined using ELISA ELISA, were similar over a period of time (not shown), dropping with a decrease in dose. Residual IgG concentrations could be detected in serum taken immediately before the next dose (with a minimum concentration of samples), however, satsituzumab govitecan was not detected (not shown).</span>
  </p>
  <p num="441" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0337]   SN-38   30-   15  3,930 /       1 (C1D1),         9,0 /      (C1D2)     2,947 / ( ).    2,381 /   6 ,      6,0 /.   SN-38      88  102 / ( 2,4%  3,6%   SN-38),   ,   96% SN-38           IgG.   28  30-   7    ,     SN-38       2,910,91%   SN-38.   SN-38G,   4 ,      SN-38, ,  ,     . ,   #25     30-   12    8  .    18 /         5,089 / SN-38 ( SN-38);      155,2 / ( SN-38; 3,0%).   SN-38G ( )     26,2 /,   14,4%     SN-38 + SN-38G   .      13,5 /,    SN-38    3309,8601,8 /  11       ,    SN-38    105,447,7 / (.. 96,8%    IgG),    SN-38G    13,94,1 / (11,6%    SN-38 + SN-38G).  ,       SN-38G        ,  ,  SN-38,   ,   .</span>[0337] The total concentration of SN-38 in the 30-minute serum sample of <figure-callout id="15" label="patient" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient</a></figure-callout> 15 was 3.930 ng / ml after the first dose in cycle 1 (C1D1) was administered, however, after the therapeutic doses of govitecan sacituzumab were reduced to 9.0 mg / kg for the second dose of the first cycle (C1D2) the indicated level was reduced to 2.947 ng / ml (not shown). A further decrease to 2.381 ng / ml was observed in the 6th cycle, after an additional dose reduction to 6.0 mg / kg. The amount of free SN-38 in these samples ranged from 88 to 102 ng / ml (2.4% to 3.6% of total SN-38), illustrating the fact that more than 96% of SN-38 in these serum samples was peak concentration was associated with IgG. We analyzed 28 samples of 30-minute serum from 7 patients using HPLC, while the concentrations of free SN-38 in these samples averaged 2.91  0.91% of the total SN-38. Concentrations of free SN-38G, measured in 4 patients, never exceeded the levels of SN-38, and, as a rule, were several times lower. For example, in <figure-callout id="25" label="patient #" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">patient #</a></figure-callout> 25, the results of the determination were evaluated in a 30-minute sample for 12 injections over 8 treatment cycles. At a starting dose of 18 mg / kg, an acid hydrolyzed sample from said patient contained 5.089 ng / ml SN-38 (total SN-38); the unhydrolyzed sample contained only 155.2 ng / ml (free SN-38; 3.0%). The content of free SN-38G (glucuronidated form) in the specified sample was 26.2 ng / ml, or only 14.4% of the total content of unbound SN-38 + SN-38G in the specified sample. Treatment of the patient was continued with a dose of 13.5 mg / kg, with an average SN-38 content of 3309.8  601.8 ng / ml in the remaining 11 acid-hydrolyzed samples with a peak concentration, with an average SN-38 content of 105.4  47.7 ng / ml (i.e., 96.8% was associated with IgG), and the content of free SN-38G averaged 13.9  4.1 ng / ml (11.6% of total content of SN-38 + SN-38G). It is important to note that in almost all patients, the concentrations of SN-38G in acid-hydrolyzed and non-hydrolyzed samples were similar, which indicates that the SN-38 associated with the conjugate was completely non-glucuronidated.</span>
  </p>
  <p num="442" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/91/2e/49/0e0a2a7434b075/00000033.png" class="style-scope patent-text"><img file="00000033.jpg" he="100" wi="160" img-format="jpg" img-content="undefined" width="640" height="400" alt="Figure 00000033" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/91/2e/49/0e0a2a7434b075/00000033.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/91/2e/49/0e0a2a7434b075/00000033.png" class="style-scope patent-text"><img file="00000033.jpg" he="100" wi="160" img-format="jpg" img-content="undefined" width="640" height="400" alt="Figure 00000033" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/91/2e/49/0e0a2a7434b075/00000033.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0338]            (..  50 /)        IgG   SN-38    .</span>[0338] None of these patients showed a positive baseline (ie, greater than 50 ng / ml) or a positive antibody response against IgG or against SN-38 throughout the course of treatment.</span>
  </p>
  <p num="444" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Discussion</span>
  </p>
  <p num="445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0339] Trop-2        ,           (Cubas et al., 2009, Biochim Biophys Acta 1796:309-14), ,  ,           (Cardillo et al., 2011, Clin Cancer Res 17:3157-69; Ambrogi et al., 2014, PLoS One 9:e96993; Cubas et al., 2009, Biochim Biophys Acta 1796:309-14; Trerotola et al., 2013, Oncogene 32:222-33).   ,              , EpCam,     ,     ,   Trop-2 (Trerotola et al., 2009, Biochim Biophys Acta 1805:119-20),        ,    Trop-2      , ,            , ~40 / (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).          ,   ,   SN-38   ,        Trop-2    (Cardillo et al., 2011, Clin Cancer Res 17:3157-69). ,        , ,                        ,     I  ,            .</span>[0339] Trop-2 is expressed in large numbers in many epithelial tumors, for this reason being an antigen of interest for targeted therapy (Cubas et al., 2009, Biochim Biophys Acta 1796: 309-14), since, in particular, it is considered a prognostic marker and oncogen for certain types of cancer (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69; Ambrogi et al., 2014, PLoS One 9: e96993; Cubas et al., 2009, Biochim Biophys Acta 1796: 309-14; Trerotola et al., 2013, Oncogene 32: 222-33). Although its expression in normal tissues and its relationship with another well-studied tumor-associated antigen, EpCam, has raised concerns about the safety of developing immunotherapeutic agents targeting Trop-2 (Trerotola et al., 2009, Biochim Biophys Acta 1805 : 119-20) studies conducted by the authors of the present invention on cynomolgus monkeys, in which the expression of Trop-2 in tissues is similar to that in humans, showed that sacituzumab govitecan was very well tolerated with a human dose equivalent of ~ 40 mg / kg (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). At higher doses in animals, neutropenia and diarrhea were observed, known side effects associated with SN-38 during irinotecan therapy, however, there were no signs of significant histopathological changes in normal tissues expressing Trop-2 (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). Accordingly, based on the results of these and other preclinical studies showing that sacituzumab govitecan was active at concentrations in the lower region of the nanomolar range and was effective against xenografts of various human epithelial tumors in non-toxic doses, a phase I test was started on patients, one or more times undergoing unsuccessful standard therapy for a variety of metastatic epithelial tumors.</span>
  </p>
  <p num="446" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0340]  ,     ,   , ,       ,     ( ,    ;   SN-38        ),     -Trop-2-SN-38             ,      , ,  ,   .      297    25   ; 4    25 .  ,       IgG hRS7  SN-38   ,   ,       12 .  Trop-2         (Cardillo et al., 2011, Clin Cancer Res 17:3157-69),      ,   2 ,     12 /  ,     ,        ,       .    12 /        8,0  10,0 /,                ,      .   2  13  (15,4%)       3 .    3  4    ,       3         ,  14-26% ( -    ,  (  ,   ), Pfizer, 2012).       1     10 /   3 .    ,   31%  ,   4  ,      3  4  ( -    ,  (  ,   ), Pfizer, 2012).    ,    ,  ,   ,    -1  2 ,   .    10  12 /             3 .  UGT1A1       , , ,            .</span>[0340] The main discovery made during this study was that, despite the use of a more standard drug, not considered ultra-toxic (drugs active in the picomolar range; whereas SN-38 is active at concentrations in the lower region nanomolar range), for the conjugate of sacituzumab govitecan anti-Trop-2-SN-38 clinically confirmed therapeutic activity against a wide range of types of solid cancer in doses leading to moderate and controlled toxicity, thus demonstrating a high therapeutic index. In total, 297 doses of sacituzumab govitecan were administered to 25 patients without incident; 4 patients received more than 25 injections. It is important to note that the response in the form of antibodies against IgG hRS7 or SN-38 was not detected, even in patients who underwent several treatment cycles lasting up to 12 months. Although Trop-2 is expressed in small amounts in various normal tissues (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69), neutropenia was the only type of dose-limiting toxicity, with 2 patients receiving more than or equal to 12 mg / kg Sacituzumab govitecan, ancillary myeloid growth factor was administered to accelerate recovery and allow continued treatment of patients when all other therapeutic options were exhausted. With an established MTD of 12 mg / kg, dose levels of 8.0 and 10.0 mg / kg were chosen for further expansion, due to the more likely tolerance of additional cycles in patients using these levels with minimal supportive therapy, and responses were observed at these levels. Only 2 out of 13 patients (15.4%) had <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 neutropenia at the indicated dose levels. The incidence of <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="4" label="grade" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout></a></figure-callout> 3 and 4 neutropenia with irinotecan monotherapy given weekly or once every 3 weeks as first-line or second-line therapy was 14-26% (camptosar-irinotecan hydrochloride for injection, solution (information for use, package insert ), Pfizer, 2012). With the introduction of satsituzumab govitecan in only 1 patient at a dose level of 10 mg / kg, <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 diarrhea was observed. The indicated frequency of occurrence is lower than the frequency of 31% in patients who received weekly  4 doses of irinotecan, who had late diarrhea of <figure-callout id="3" label="grades" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grades</a></figure-callout> 3 and 4 (Kaptosar - irinotecan hydrochloride for injection, solution (information for use, package insert), Pfizer, 2012 ) Other common types of toxicity attributed to the use of satsituzumab govitecan include fatigue, nausea and vomiting, in most cases, <figure-callout id="1" label="grades" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="2" label="grades" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grades</a></figure-callout></a></figure-callout> 1 and 2, as well as alopecia. At dose levels of 10 and 12 mg / kg, two cases of febrile neutropenia and one case of <figure-callout id="3" label="grade" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">grade</a></figure-callout> 3 deep vein thrombosis were also observed. Monitoring of UGT1A1 did not begin until the exploratory dose analysis was completed, and accordingly, an assessment of its contribution to toxicity cannot currently be indicated.</span>
  </p>
  <p num="447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0341] ,    ,       Trop-2,   ,         (    ,  ,  ,    ,   ) ,       90%  ( ).  , Trop-2      12      , ,   , ,         .     ,       ,    ,     ,      ,    ,   ,        Trop-2  .</span>[0341] Patients included in this test were not pre-selected based on the expression of Trop-2, mainly insofar as immunohistological evaluations of tissue microarrays of various types of cancer (such as cancer of the prostate, breast, pancreas, colon and rectum, and lung cancer) showed that this antigen was present in more than 90% of the samples (not shown). In addition, Trop-2 was not found in the serum of 12 patients with various types of metastatic cancer, which, in turn, suggests that serum analysis may not be suitable for the selection of patients. Although the inventors have made efforts to obtain archived samples of the patients tumors included in this test, there are currently insufficient data to suggest that there is a correlation between the selection of patients based on immunohistological staining and antitumor activity, therefore enrichment of the patient sample based on Trop- <figure-callout id="2" label="expression" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">expression</a></figure-callout> 2 was not carried out.</span>
  </p>
  <p num="448" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0342]                , /,  ,              RECIST1.1,       .   (12%)  25  ( 1    [    ],     )   30%        2,9, 4,3  7,1 , ,   .  15  (60%)  ,    9       4    .        7  9 ,        I    .            I (  ),   ,             :  13%         38%   ,  . ,        ,             I,      II    .</span>[0342] When used as a monotherapy, satsituzumab govitecan has good antitumor activity in patients with a variety of metastatic, recurrent / refractory, epithelial tumors, demonstrating a measurable decrease in target lesions according to CT results and application of RECIST1.1 criteria, including ensuring long-term stabilization diseases. Three (12%) of 25 patients (1 patient each with sclerosis cancer [after progression with topotecan], TNBC and colon cancer) showed a more than 30% reduction in the target lesions before progression through 2.9, 4.3 and 7, 1 month, respectively, after initiation of therapy. 15 patients (60%) had C3, while 9 of them began to progress more than 4 months after the start of treatment. Responses or stabilization of the disease occurred in 7 out of 9 patients who underwent previous therapy with a topoisomerase I inhibitor drug or regimen. Three of them did not have a response to previous therapy with a topoisomerase I inhibitor (irinotecan or topotecan), and it turned out that sacituzumab govitecan was able to induce a reduction in tumor size in two of them: by 13% in a patient with colon cancer and by 38% in another patient with MRL. Accordingly, satsituzumab govitecan can be therapeutically active in patients who have failed treatment or who have recurred after a previous regimen with a topoisomerase I inhibitor, which will be investigated later in phase II of the extension study.</span>
  </p>
  <p num="449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0343]                  (N  7;     2,9 ]; : 1,0-4,0 ),              19-9  ,   (Picozzi et al., 2014,      AACR Pancreatic Cancer: Innovations in Research and Treatment (  :      ),  , -, , . 99).           ,         . ,        (Goldenberg et al., 2014,         AACR, -, )   (Goldenberg et al., 2014, Sci Transl Med),       , ,        ,         , ,   . ,     ,       17   ,    ,     () 29%,     46% ( +     6 ).   (15-20 )    25% (6/25)  ,   2   40  4   ,       (N  2),  (N  3)   (N  1).</span>[0343] Although among the patients included in this trial, there were the largest number of patients with advanced pancreatic duct cancer (N = 7; median time to progression 2.9 months]; range: 1.0-4.0 months), even with the indicated intractable disease, there was an encouraging decrease in target lesions and serum CA19-9 concentrations suggesting activity (Picozzi et al., 2014, data presented at the AACR special conference Pancreatic Cancer: Innovations in Research and Treatment (Pancreatic cancer: new approaches in research and therapy ), New Orleans, Los Angeles, USA, p. B99). However, the responses in patients with TNBC and MRL are of particular interest, given the need for the targeted therapy shown in these cases. Thus, additional partial responses in patients with DLCM (Goldenberg et al., 2014, data presented at the AACR Breast Cancer Symposium, San Antonio, Texas) and MRL (Goldenberg et al., 2014, Sci Transl Med), observed in the ongoing expansion phase of this test suggests that these cancers should be given extra attention, although there are also observations of encouraging responses in NSCLC, AKP, RMP and ROPK. So, according to recently received new information, in the ongoing test of satsituzumab govitecan in 17 patients with TNBC, studied to date, an overall response rate (PR) of 29% was observed, with a clinical benefit level of 46% (PR + 3 or more than 6 months) . Long-term survival (1520 months) was observed in almost 25% (6/25) of the studied patients, and included 2 patients with 40 and 4 patients with SZ, including patients with transient breast cancer (N = 2), ROPK (N = 3 ) and GRGR (N is 1).</span>
  </p>
  <p num="450" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0344]     30     ,   96% SN-38    IgG.         II  .            SN-38G,      AUC    SN-38G  4,5  ,   SN-38 (Xie et al., 2002, J Clin Oncol 20:3293-301).   SN-38    ,      , ,    IgG SN-38 ,    ,   ,  50%  SN-38    (Goldenberg et al., 2014, J Clin Oncol 32: Abstract 3107).   ,  ,       SN-38       Capan-1    135  ,     (Goldenberg et al., 2014, Sci Transl Med). ,             -I: (i)       ( Trop-2)  (ii) ,    SN-38 (..   ),  ,  SN-38,         ,        ,   ,     .   ,          , SN-38,           ADC,    .      ADC,     ,       :  (7,6:1), SN-38           ,     SN-38    ,      SN-38,   .</span>[0344] Analysis of <figure-callout id="30" label="serum samples" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">serum samples</a></figure-callout> 30 minutes after the end of the infusion showed that more than 96% of SN-38 was associated with IgG. More detailed pharmacokinetic data will be available after the completion of phase II trials. Only trace amounts of free SN-38G were also detected in serum HPLC analysis, while AUC for irrelevant SN-38G was more than 4.5 times higher than for SN-38 (Xie et al., 2002, J Clin Oncol 20: 3293-301). Comparison of SN-38 delivery in tumor-bearing animals that received govitecan and irinotecan sacituzumab showed that IgG-associated SN-38 is non-glucuronidated, while in animals that received irinotecan, more than 50% of total serum SN-38 is glucuronidated (Goldenberg et al., 2014, J Clin Oncol 32: Abstract 3107). More importantly, the analysis showed that when Sacituzumab govitecan was administered, the concentrations of SN-38 in xenografts of human pancreatic cancer Capan-1 were approximately 135 times higher than when irinotecan was administered (Goldenberg et al., 2014, Sci Transl Med). Accordingly, satsituzumab govitecan has several distinct advantages over non-targeting forms of topoisomerase-I inhibitors: (i) the mechanism of selective retention of conjugate in the tumor (Trop-2 binding) and (ii) presumably complete protection of targeted SN-38 (i.e. non-glucuronidated lactone form), therefore, all SN-38 accumulated by tumor cells either by direct internalization of the conjugate or by release into the microenvironment of the tumor from the conjugate associated with the tumor is in the most active form. These results indicate that a moderately toxic and yet well-studied cytotoxic agent, SN-38, can be effective when used in tumor-targeted ADCs such as sacituzumab govitecan. Moreover, due to the introduction of ADC containing a moderately toxic drug conjugated with a high drug: antibody (7.6: 1) ratio, SN-38 can be delivered to target cancers in higher concentrations, as indicated by the concentration of SN- 38 when using satsituzumab govitekan, increased compared with the concentration of SN-38 released from irinotecan.</span>
  </p>
  <p num="451" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0345]  ,   I  ,         ,     SN-38,     , ,   ,  Trop-2.  ,             ,       -I. ,    ,            ,          I, ,   .          8  10 /    ,     Trop-2<sup class="style-scope patent-text">+</sup> .</span>[0345] Summing up, the indicated phase I results showed that sacituzumab govitecan was tolerated with moderate and manageable toxicity, completely related to SN-38 activity, without evidence of damage to normal tissues, which reportedly contain Trop-2. It is important to note that sacituzumab govitecan was active in patients with various types of metastatic solid tumors, even after unsuccessful prior therapy with topoisomerase-I inhibitors. Accordingly, these initial results indicate that satsituzumab govitecan has a high therapeutic index even for patients with tumors for whom there are no data on responses to topoisomerase I inhibitors, for example, MRL and TNLC. The indicated clinical trial continues with a focus on starting doses of 8 and 10 mg / kg in patients with TNBC, MRL and other types of Trop-2 <sup class="style-scope patent-text">+</sup> cancer.</span>
  </p>
  <p num="452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 16.  IMMU-132         ()</span>Example 16. The use of IMMU-132 in breast cancer with a triple negative phenotype (TNBC)</span>
  </p>
  <p num="453" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0346]  Trop-2/TACSTD2   (Fornaro et al., 1995, Int J Cancer 62:610-18),   ,      <sup class="style-scope patent-text">++</sup>- (Basu et al., 1995, Int J Cancer 62:472-72; Ripani et al., 1998, Int J Cancer 76:671-76),          ,                ,      , , ,    ,  ,  ,  ,   ,   (Cardillo et al., 2011, Clin Cancer Res 17:3157-69; Stein et al., 1994; Int J Cancer Suppl 8:98-102; Cubas et al., 2009, Biochim Biophys Acta 196:309-14; Trerotola et al., 2013, Oncogene 32:222-33).   Trop-2,   ,        (Trerotola et al., 2013, Oncogene 32:222-33),      D1-Trop-2   (Guerra et al., 2008, Cancer Res 68:8113-21).  ,                 (Cubas et al., 2009, Biochim Biophys Acta 196:309-14; Guerra et al., 2008, Cancer Res 68:8113-21; Bignotti et al., 2010, Eur J Cancer 46:944-53; Fang et al., 2009, Int J Colorectal Dis 24:875-84; Muhlmann et al., 2009, J Clin Pathol 62:152-58),       (Ambrogi et al., 2014, PLoS One 9:e96993; Lin et al., 2013, Exp Mol Pathol 94:73-8).    Trop-2                   ;   - ,            Trop-2    (Lin et al., 2013, Exp Mol Pathol 94:73-8).</span>[0346] The Trop-2 / TACSTD2 gene was cloned (Fornaro et al., 1995, Int J Cancer 62: 610-18), and it has been found that it encodes a transmembrane carrier of a Ca <sup class="style-scope patent-text">++</sup> signal (Basu et al., 1995 , Int J Cancer 62: 472-72; Ripani et al., 1998, Int J Cancer 76: 671-76), functionally associated with cell migration and substrate-independent growth, with higher levels of expression compared to normal tissues at different types of human epithelial cancer, including carcinomas of the breast, lung, stomach, colon and rectum, pancreas, prostate, cervix, head and neck, and ovaries (Cardillo et al., 2011, Clin Cancer Res 17: 3157 -69; Stein et al., 1994; Int J Cancer Suppl 8: 98-102; Cubas et al., 2009, Biochim Biophys Acta 196: 309-14; Trerotola et al., 2013, Oncogene 32: 222-33) . The increased expression of Trop-2, as described, is necessary and sufficient to stimulate cancer growth (Trerotola et al., 2013, Oncogene 32: 222-33), and the bicistronic chimeric cyclin D1-Trop-2 mRNA is an oncogene (Guerra et al. 2008, Cancer Res 68: 8113-21). It is important to note that increased expression was associated with a more aggressive disease and poor prognosis for several types of cancer (Cubas et al., 2009, Biochim Biophys Acta 196: 309-14; Guerra et al., 2008, Cancer Res 68: 8113-21 ; Bignotti et al., 2010, Eur J Cancer 46: 944-53; Fang et al., 2009, Int J Colorectal Dis 24: 875-84; Muhlmann et al., 2009, J Clin Pathol 62: 152-58) , including breast cancer (Ambrogi et al., 2014, PLoS One 9: e96993; Lin et al., 2013, Exp Mol Pathol 94: 73-8). Elevated Trop-2 mRNA is a strong prognostic factor for poor survival and metastasis to lymph nodes in patients with invasive breast duct cancer; Kaplan-Mayer survival curves show that the survival time of patients with breast cancer with high Trop-2 expression was significantly shorter (Lin et al., 2013, Exp Mol Pathol 94: 73-8).</span>
  </p>
  <p num="454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Ways</span>
  </p>
  <p num="455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0347]  DAR   HIC -   IMMU-132       (HIC)  -  -NPR (Tosoh Bioscience, --, ).  IMMU-132 (100 )      2,25-1,5  NaCl  25   ,  7,4,   15    1 /   .</span>[0347] HIC DAR Determination  Clinical batches of IMMU-132 were analyzed using hydrophobic interaction chromatography (HIC) on a butyl NPR HPLC column (Tosoh Bioscience, King of Prussia, PA). Introduced IMMU-132 (100 g) was resolved in a linear gradient of a concentration of 2.25-1.5 M NaCl in 25 mM sodium phosphate, pH 7.4, for 15 minutes at a speed of 1 ml / min and room temperature.</span>
  </p>
  <p num="456" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0348]  DAR   - -              ( ),        -     ,   . IMMU-132         Agilent 1200     Aeris Widepore 4    (3,6 , 502,1 )             30-80%   0,1%     14 .   -      (ESI-TOF)   - Agilent 6210 ESI-TOF    ,     5000, 300  80, .   -,    -   ,    -.</span>[0348] Determination of DAR using LC-MS - Since the interchain disulfides are reduced and the sulfhydryl groups obtained are used to conjugate (or block) the heavy and light chains were resolved during LC-MS analysis without the addition of reducing agents, and analyzed independently. IMMU-132 from different lots was introduced into an Agilent 1200 series HPLC system with an Aeris Widepore C4 reverse phase HPLC column (3.6 M, 50  2.1 mm) and resolved using reverse phase HPLC in a linear concentration gradient of 30- 80% acetonitrile in 0.1% formic acid for 14 minutes. We performed time-of-flight mass spectrometric analysis with ionization in electrospray (ESI-TOF) on an Agilent 6210 ESI-TOF built-in mass spectrometer mounted on a capillary, fragmentator, and skimmer with voltage of 5000 V, 300 V, and 80 V, respectively. The full RP-HPLC peak corresponding to all products of kappa chains or heavy chains was used to deconvolute the mass spectra.</span>
  </p>
  <p num="457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0349]   -     ,    ,       (, ),    ;           (STR)  .</span>[0349] Cell lines  All human cancer cell lines used in this study were purchased from the American Type Culture Collection (Manassas, Virginia), unless otherwise indicated; they were all authenticated using short tandem repeat analysis (STR) from ATCC.</span>
  </p>
  <p num="458" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0350]   Trop-2         -   Trop-2       . ,          (Becton Dickinson (BD);  , -; . 561527)    Trop-2   -  QuantiBRITE (BD . 340495)  -   Trop-2 (eBiosciences, . 12-6024),   .      FACSCalibur (BD)    CellQuest Pro,       Flowjo (Tree Star; , ).</span>[0350] Surface expression of Trop-2 on various cell lines of human breast carcinoma cells - Analysis of the expression of Trop-2 on the surface of cells based on flow cytometry. Briefly, cells were harvested using a nekutase cell isolation solution (Becton Dickinson (BD); Franklin Leike, NJ; Cat. No. 561527) and Trop-2 expression was analyzed using QuantiBRITE PV-conjugated granules (BD Cat. No. 340495) and a PV-conjugated anti-Trop-2 antibody (eBiosciences, Cat. No. 12-6024), following the manufacturer's instructions. Data was recorded on a FACSCalibur flow cytometer (BD) in CellQuest Pro software by analysis using Flowjo software (Tree Star; Ashland, Oregon).</span>
  </p>
  <p num="459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0351]   in vitro -   SN-38       3-(4,5--2-)-5-(3-)-2-(4-)-2- (   MTS; Promega, , ). ,    96-      . SN-38,   ,       0,004  250 .        96   37/5% <sub class="style-scope patent-text">2</sub>,     MTS              1,0.         .              ,    IC<sub class="style-scope patent-text">50</sub>    Prism GraphPad.</span>[0351] In Vitro Cytotoxicity Testing  Sensitivity to SN-38 was determined using 3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H dye reduction assay -tetrazolium (MTS dye reduction analysis; Promega, Madison, Wisconsin). Briefly, cells were seeded in 96-well clear flat-bottomed plates as described above. SN-38, dissolved in DMSO, was diluted with the medium to a final concentration of from 0.004 to 250 nM. The plates were incubated in a humidified chamber for 96 hours at 37  C / 5% CO <sub class="style-scope patent-text">2</sub> , after which the MTS dye was added and returned to the incubator until the absorption index exceeded 1.0 of the untreated control cells. Growth inhibition was measured as a percentage of growth relative to untreated cells. Dose response curves were obtained using average values for the results of three measurements, and IC <sub class="style-scope patent-text">50</sub> values were calculated using Prism GraphPad software.</span>
  </p>
  <p num="460" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0352]   in vitro       rH2AX  -     ,    1806  1395   6-    510<sup class="style-scope patent-text">5</sup> /    37   .     10        IMMU-132,   hA20  CD20-SN38   ~20 / (  SN38     )   30   ,    ,     37  .    ,  ,   4%    15 ,      0,15% Triton-100      15 .    1%   /       rH2AX AF488 (EMD Millipore Corporation, , )   45   4.   rH2AX       BD FACSCalibur (BD Biosciences, -, ).</span>[0352] In vitro specificity testing by flow cytometry on rH2AX stained cells - For testing the activity of the drug, cells of the TNLM lines HCC1806 and HCC1395 were seeded in 6-well plates with a density of 5  10 <sup class="style-scope patent-text">5</sup> cells / well and kept at 37  C in overnight. After cooling for 10 min on ice, the cells were incubated with either IMMU-132 or anti-CD20-SN38 hA20 at a concentration of ~ 20 g / ml (an equal amount of SN38 per well for both agents) for 30 minutes on ice, washed three times with fresh Wednesday, and returned to the conditions of 37  C at night. The cells were briefly trypsinized, centrifuged, fixed in 4% formalin for 15 minutes, then washed and permeabilized in 0.15% Triton-X100 in PBS for another 15 minutes. After washing twice with 1% bovine serum albumin / FSB, the cells were incubated with anti-rH2AX AF488 mouse antibody (EMD Millipore Corporation, Temecula, Calif.) For 45 minutes at 4  C. RH2AX signal intensity was measured by flow cytometry on a BD FACSCalibur (BD Biosciences, San Jose, CA).</span>
  </p>
  <p num="461" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0353]   Trop-2        -           .          10%     ,    , 1+ ( ), 2+ ( ),  3+ ( ).</span>[0353] Immunohistochemical analysis of Trop-2 in tumor microarrays and patient samples - The analysis included the use of standard immunohistochemical methods for examining tissue sections and microarrays. Assessment of the level of staining was based on the staining intensity of more than 10% of tumor cells in the samples, and included a negative result, 1+ (weak staining), 2+ (moderate staining), and 3+ (intensive staining).</span>
  </p>
  <p num="462" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0354]   in vivo     -   250  ADC      20  (12,5 /)    SN-38,  0,2 / SN-38.    (-HCl  ; AREVA Pharmaceuticals, Inc., , ), 10 /   5,8 / SN-38    .</span>[0354] In vivo Therapeutic Studies in Xenograft Models  A dose of 250 g ADC for a mouse weighing 20 grams (12.5 mg / kg) contains SN-38 equivalents of 0.2 mg / kg SN-38. In the case of irinotecan (irinotecan-HCl for injection; AREVA Pharmaceuticals, Inc., Elizabethtown, Kentucky), 10 mg / kg of irinotecan correspond to 5.8 mg / kg SN-38 based on weight.</span>
  </p>
  <p num="463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0355]  -  (210<sup class="style-scope patent-text">6</sup>)   6-     .       SN-38,  IMMU-132    SN-38 0,4 / (1 )   24  48 .  hRS7      ADC.</span>[0355] Immunoblotting - Cells (2  10 <sup class="style-scope patent-text">6</sup> ) were seeded in 6-well plates and left overnight. The next day, they were treated with either SN-38 or IMMU-132 at a concentration of SN-38 equivalents of 0.4 g / ml (1 M) for 24 and 48 hours. The starting hRS7 was used as a control for ADC.</span>
  </p>
  <p num="464" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0356]   SN-38       -   ,     15 ,         ,   ,  IMMU-132.     5     3 .  Capan-1 (0,131  0,054 ; N  30)       () (1   + 10  -);     -.              (-).              ,     ,  IMMU-132,   2 ,            IgG SN-38,          .</span>[0356] Quantification of SN-38 in Mice with Xenografts of Human Tumors - In two groups, each of which included 15 animals carrying subcutaneous implants of human pancreatic carcinoma cells, either irinotecan or IMMU-132 was administered. In each group, 5 animals were killed at 5 different intervals. Capan-1 tumors (0.131  0.054 g; N is 30) were removed and homogenized in deionized water (DI) (1 part tissue + 10 parts DI water); serum was diluted with an equal amount of DI water. Serum and tissue homogenates were extracted and analyzed using reverse phase HPLC (RP-HPLC). To detect products in samples from animals treated with irinotecan, it was sufficient to extract the samples, while samples from animals treated with IMMU-132 were divided into 2 parts, one of which was hydrolyzed with acid to release all IgG-related SN-38, which otherwise could be detected in extracted samples.</span>
  </p>
  <p num="465" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0357]  -      GraphPad Prism  5.00  Windows, GraphPad Software, -, , .        .</span>[0357] Statistics - Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, La Hoya, California, USA. For each study, specific test parameters are determined.</span>
  </p>
  <p num="466" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>results</span>
  </p>
  <p num="467" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0358]    SN-18 -  IMMU-132    I, SN-38,       (7--10-[4-(1-)-1-]),        , ,     (Garcia-Carbonero et al., 2002, Clin Cancer Res 8:641061).     SN-38   ,       in vivo  .        SN-38,   2-3   ,        (Kawato et al., 1991, Cancer Res 51:4187-91).         ,         (10% )    (Burke &amp; Mi, 1994, J Med Chem 37:40-46).</span>[0358] Structure and properties of SN-18 - IMIU-132 utilizes a topoisomerase I, SN-38 inhibitor, a water-soluble metabolite of the anticancer camptothecin agent irinotecan (7-ethyl-10- [4- (1-piperidino) -1-piperidino] carbonyloxycamptothecin ), therapeutically active in cancer of the colon and rectum, lung, cervix and ovaries (Garcia-Carbonero et al., 2002, Clin Cancer Res 8: 641061). An important advantage when choosing SN-38 is that the pharmacological characteristics of the drug in vivo are well known. Irinotecan must be cleaved with esterases to form SN-38, which is 2-3 orders of magnitude more powerful than irinotecan, with activity in the lower region of the nanomolar range (Kawato et al., 1991, Cancer Res 51: 4187-91). At physiological pH values, camptothecins exist in equilibrium, including a more active lactone form and a less active (10% power) open carboxylic form (Burke &amp; Mi, 1994, J Med Chem 37: 40-46).</span>
  </p>
  <p num="468" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0359]   SN-38,   IMMU-132, CL2A-SN-38,    ,         ADC,    : (i)  -     ()         ; (ii)      -     ,     ,         ; (iii)     -         ;  (iv)  , -    SN-38  20--,                 (Giovanella et al., 2000, Ann NY Acad Sci 922:27-35).   SN-38   CL2A-SN-38    IgG hRS7   .               / ,     ,   8 -    .     CL2A-SN-38,  ,    .       ,     SN-38  IMMU-132,         1%  SN-38  .         37 SN-38       ~1  ( ).</span>[0359] The design of the SN-38 derivative involved in IMMU-132, CL2A-SN-38, resolved a number of problems arising from the use of the indicated drug in ADC format and included the following features: (i) a short link was placed in the cross-linker a fragment of polyethylene glycol (PEG) to impart water solubility to said extremely poorly soluble drug; (ii) a maleimide group was introduced for rapid thiol-maleimide conjugation with a mildly reduced antibody, using a specially developed synthesis procedure that provides highly efficient inclusion of maleimide in the context of the formation of a carbonate bond; (iii) the benzyl carbonate site provided a pH-mediated cleavage site to disconnect from the linker and release the drug; and (iv) importantly, the cross-linker was attached to SN-38 at the 20-hydroxy position, preventing the drug lactone ring from opening to form a less active carboxylic acid form under physiological conditions (Giovanella et al., 2000, Ann NY Acad Sci 922: 27-35). The synthesis of derivatives of SN-38 and the conjugation of CL2A-SN-38 with mildly reduced IgG hRS7 have been described above. In the limited reduction procedure, only interchain disulfide bridges break between the heavy and between the heavy / light chains, but not the disulfides within the domains, with 8 site-specific thiols per antibody molecule. It is then conjugated to CL2A-SN-38, purified by diafiltration, and lyophilized for storage. In the process of obtaining conditions are adjusted so as to minimize any loss of SN-38 from IMMU-132, so that the final lyophilized product stably contains less than 1% free SN-38 after recovery. However, when added to serum and kept at 37  C, SN-38 is released from the conjugate with a half-life of ~ 1 day (not shown).</span>
  </p>
  <p num="469" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0360]  SN-38, -,     IMMU-132,           ,     SN-38,    ,     SN-38,   SN-38    ~10    (Moon et al., 2008(30, 31).             ,  ~2 .          ,  CL2A,     (Cardillo et al., 2011, Clin Cancer Res 17:3157-64),         -   Trop-2 (CL2),      SN-38     (..       5,0).       Trop-2   CL2A          SN-38,  ,       ,    SN-38      ~1  (Govidan et al. 2013, Mol Cancer Ther 12:968-78).            ,         ,      1  (Sharkey et al., 1995, Cancer Res 55:5935s-45s),    SN-38           ,     ,     .</span>[0360] SN-38 release appears to be an important feature of IMMU-132, with the indicated linker type being selected based on performance studies that tested SN-38 conjugated to various linkers providing different SN release rates -38, from releasing SN-38s with a half-life of ~ 10 h to highly stable (Moon et al., 2008 (30, 31). Optimal therapeutic activity was found in the conjugate with an intermediate release rate in serum of ~ 2 days. Then, the authors of the present invention improved the method of manufacturing the indicated type of linker, designated CL2A, by removing the phenylalanine residue (Cardillo et al., 2011, Clin Cancer Res 17: 3157-64), and then compared the efficacy with the efficacy of another stably bound conjugate against Trop-2 (CL2), which was designed to release SN-38 exclusively under lysosome conditions (ie, in the presence of cathepsin B at pH 5.0). However, the anti-Trop-2 conjugate with the CL2A linker gave better therapeutic responses compared to stably bound SN-38, which shows that even rapidly internalizing antibodies gain an advantage if serum SN-38 is released over a half-life of ~ 1 day (Govidan et al. 2013, Mol Cancer Ther 12: 968-78). Since in clinical studies with radiolabeled antibodies, antibodies were found to localize in tumors within a few hours, reaching peak concentrations within 1 day (Sharkey et al., 1995, Cancer Res 55: 5935s-45s), selective local delivery SN-38 at elevated concentrations in the tumor occurs due to the internalization of the intact conjugate, extracellular release of the free drug, or both mechanisms together.</span>
  </p>
  <p num="470" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0361]         (DAR).    IMMU-132       (HIC-),   ,    DAR 6, 7  8,         DAR = 8 ( ).       IMMU-132   DAR (DAR<sub class="style-scope patent-text">AVE</sub>) 7,600,03     ( ). HIC-        - (-) ( ).   ,   99%  8       CL2A,  SN-38   .  (  N-)       . ,  DAR      SN-38     ,       .     IMMU-132      .</span>[0361] Determining the ratio of drug amount to antibody amount (DAR). Five clinical batches of IMMU-132 were evaluated using HPLC hydrophobic interactions (HIC-HPLC) yielding three peaks corresponding to products with <figure-callout id="6" label="DAR" filenames="00000045.png,00000049.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="7" label="DAR" filenames="00000045.png,00000050.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="DAR" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">DAR</a></figure-callout></a></figure-callout></a></figure-callout> 6, 7 and 8, with the largest fraction containing the product with DAR = 8 (not shown). The specified manufacturing method provided stable production of IMMU-132 with a total DAR (DAR <sub class="style-scope patent-text">AVE</sub> ) of 7.60  0.03 for five clinical lots (not shown). HIC-HPLC results were confirmed using liquid chromatography with mass spectrometry (LC-MS) (not shown). This analysis showed that more than 99% of the 8 available sulfhydryl groups were linked by a CL2A linker, with or without SN-38. Unsubstituted (or capped by N-ethyl maleimide) heavy or light chains were not detected. Accordingly, the difference in DAR among products is the result of disconnecting the SN-38 from the linker during production, rather than a lower initial substitution rate. After receiving and lyophilization IMMU-132 remained stable for several years.</span>
  </p>
  <p num="471" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0362]  DAR       . ,  Trop-2<sup class="style-scope patent-text">+</sup>     (NCI-N87), 2    7       (0,5 ) IMMU-132  DAR,  6,89, 3,28  1,64 ( ).  ,   ADC  DAR 6,89,       (MST)    ,   ADC  DAR 3,38  DAR 1,64 (MST = 39   25  21 , ;   0,0014).  ,     DAR 3,28  DAR 1,64,   ,   ,  .</span>[0362] Effect of DAR on pharmacokinetics and antitumor efficacy in mice. In mice carrying Trop-2 <sup class="style-scope patent-text">+</sup> human gastric carcinoma xenografts (NCI-N87), equal doses of protein equivalents (0.5 mg) of IMMU-132 with a DAR of 6.89, 3.28 or 1 were administered 2 times with an interval of 7 days , 64 (not shown). Animals treated with ADC with a DAR of 6.89 showed a significant increase in median survival time (MST) compared with mice that received ADC with a DAR of 3.38 or DAR of 1.64 (MST = 39 days versus 25 and 21 days, respectively; P less than 0.0014). There were no differences between the groups treated with conjugates with DAR 3.28 or DAR 1.64 and the control group treated with saline.</span>
  </p>
  <p num="472" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0363]       DAR, ,    NCI-N87,  0,5  IMMU-132  DAR 6,89         ( ).       (1 )  IMMU-132  DAR 3,28.           SN-38 (36 )    ,      DAR 6,89        ,     ,     DAR 3,28 ( = 0,0227; AUC).  ,      DAR       .  ,   ,     DAR    .</span>[0363] To further study the importance of higher DAR, mice bearing tumors of the stomach with NCI-N87 were injected with 0.5 mg IMMU-132 with a DAR of 6.89 twice a week for two weeks (not shown). The other group received a dose of protein (1 mg) of IMMU-132 conjugate with DAR 3.28 twice. Although both groups received the same total amount of SN-38 (36 g) in each dosing regimen, 6.89 animals treated with DAR conjugate showed significantly more pronounced inhibition of tumor growth than tumor-bearing animals treated with conjugate with DAR 3.28 (P = 0.0227; AUC). In addition, treatment with a conjugate with a lower DAR did not significantly differ from the control lack of treatment. Taken together, these studies indicate that lower DARs result in decreased efficacy.</span>
  </p>
  <p num="473" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0364]                ,   0,2   ,  IgG hRS7  IgG hRS7,     N-.     5- ,  0,5  168 ,      ELISA  IgG hRS7.        IgG  ( ). ,       , ,    ,    , -,   .</span>[0364] A study of the pharmacokinetic behavior of the resulting conjugates with the indicated different ratios was performed on tumor-free mice that received 0.2 mg of each conjugate, unconjugated IgG hRS7 or IgG hRS7, reduced and then capped with N-ethyl maleimide. Serum was taken at 5-minute intervals, from 0.5 to 168 hours, and analyzed using ELISA ELISA for IgG hRS7. Significant differences in the excretion of these conjugates and unconjugated IgG were absent (not shown). Accordingly, the level of substitution did not affect the pharmacokinetics of the conjugates, and, no less important, the restoration of interchain disulfide bonds, apparently, did not destabilize the antibody.</span>
  </p>
  <p num="474" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0365]  Trop-2      SN-38.  Trop-2     (IHC)        .   ,  31  ,   15  --  HER-2-   ,      95% ,    3+  65% .</span>[0365] Expression of Trop-2 in TNBC and sensitivity to SN-38. Trop-2 expression was determined by immunohistochemical study (IHC) in several micromassives of tissue from samples of human tumors. In one microarray containing 31 samples of TNBC, as well as 15 samples of hormone receptor-positive or HER-2-positive breast cancer, staining appeared in more than 95% of tumors, with a staining level of 3+ in 65% of cases.</span>
  </p>
  <p num="475" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0366]   8  6      ,     ,     Trop-2    SN-38.   Trop-2  5   6    90000   .  SN-38   2  6   5   6  ,   MCF-7    , 33 .  IMMU-132 in vitro  ,    SN-38,   IMMU-132,      4-  , , ,     SN-38. ,         SN-38   .</span>[0366] Table 8 <figure-callout id="6" label="lists" filenames="00000045.png,00000049.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">lists</a></figure-callout> 6 human breast cancer cell lines, including four TNBCs, describing surface expression of Trop-2 and sensitivity to SN-38. The surface expression of Trop-2 in 5 of these 6 cell lines exceeded 90,000 copies per cell. SN-38 power ranged from 2 to 6 nM in 5 of the indicated 6 cell lines, and MCF-7 cells had the lowest sensitivity, 33 nM. The in vitro power of IMMU-132 is not indicated, since almost all of the SN-38 associated with IMMU-132 is released on Wednesday during the 4-day incubation period, and, accordingly, the power is similar to that for SN-38. Accordingly, a different strategy was required to illustrate the importance of targeting the antibody as an SN-38 delivery mechanism.</span>
  </p>
  <p num="476" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/14/ad/ec/050967c024a6a8/00000034.png" class="style-scope patent-text"><img file="00000034.jpg" he="117" wi="160" img-format="jpg" img-content="undefined" width="640" height="468" alt="Figure 00000034" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/14/ad/ec/050967c024a6a8/00000034.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/14/ad/ec/050967c024a6a8/00000034.png" class="style-scope patent-text"><img file="00000034.jpg" he="117" wi="160" img-format="jpg" img-content="undefined" width="640" height="468" alt="Figure 00000034" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/14/ad/ec/050967c024a6a8/00000034.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="477" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0367]  - (1806)  - (1395)      4   30    IMMU-132,      CD20 SN-38.       ,        37.    ,         2.         (Bonner et al., 2008, Nat Rev Cancer 8:957-67) ( 9).    (MFI)  Trop-2<sup class="style-scope patent-text">+</sup>    , 1806,    IMMU-132   168 (   )  546,        ,   MFI  ,    ,    .  , MFI     Trop-2  , 1395,        IMMU-132,     . ,   IMMU-132     ADC         Trop-2- ,      Trop-2.</span>[0367] Cells of antigen-positive (HCC1806) or antigen-negative (HCC1395) THLM cell lines were incubated at 4  C for 30 minutes with either IMMU-132 or a non-binding conjugate against CD20 SN-38. Then the cells were washed to remove unbound conjugate, and then incubated overnight at 37  C. Cells were fixed and permeabilized, and then stained with a fluorescent antibody against phosphorylated histones H2A.X to detect dsDNA breaks using flow cytometry (Bonner et al., 2008, Nat Rev Cancer 8: 957-67) (table 9). The median fluorescence intensity (MFI) of Trop-2 <sup class="style-scope patent-text">+</sup> cells of the breast cancer line, HCC1806, when incubated with IMMU-132 increased from 168 (baseline without treatment) to 546, which indicates the presence of a larger number of dsDNA breaks, while MFI for cells incubated with a non-binding conjugate remained at baseline levels. Conversely, the MFI for the Trop-2 antigen negative cell line, HCC1395, remained at baseline levels after treatment with both IMMU-132 and the non-binding control conjugate. Accordingly, the specificity of IMMU-132 compared to irrelevant ADC is convincingly indicated by dsDNA breaks only in Trop-2-expressing cells incubated with an anti-Trop-2 binding conjugate.</span>
  </p>
  <p num="478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0f/88/01/27139985c9c878/00000035.png" class="style-scope patent-text"><img file="00000035.jpg" he="182" wi="160" img-format="jpg" img-content="undefined" width="640" height="728" alt="Figure 00000035" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0f/88/01/27139985c9c878/00000035.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/0f/88/01/27139985c9c878/00000035.png" class="style-scope patent-text"><img file="00000035.jpg" he="182" wi="160" img-format="jpg" img-content="undefined" width="640" height="728" alt="Figure 00000035" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/0f/88/01/27139985c9c878/00000035.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0368]    in vivo   .   IMMU-132   Nude,    MDA-MB-468 ( ). IMMU-132   0,12  0,20 /  SN-38 (0,15  0,25  IMMU-132/)         ,  (10 /; ~5,8 /  SN-38  )   ADC  CD20, hA20-CL2A-SN-38,      2   (  0,0017,   , AUC).       SN-38   ,    (38) (         ~25%, . ),      ~145-174  SN-38,     IMMU-132   9,6 .   ,  IMMU-132   SN-38  ,    .          (Cardillo et al., 2011, Clin Cancer Res 17:3157-69), ,      SN-38     IMMU-132   ,          IgG hRS7     SN-38 (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).   RS7,      1   ,   -   (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).    in vitro  ,  Trop-2,    mAb RS7      (Bignotti et al., 2010, Eur J Cancer 46:944-53; Raji et al., 2011, J Exp Clin Cancer Res 30:106; Varughese et al., 2011, Gynecol Oncol 122:171-7; Varughese et al., 2011, Am J Obstet Gyneol 205:567).     Fab-    Trop-2,   in vitro     .</span>[0368] In vivo efficacy of sacituzumab govitecan in xenografts of TNRM. The efficacy of IMMU-132 was evaluated in Nude mice bearing MDA-MB-468 TNLM tumors (not shown). IMMU-132 at a dose of 0.12 or 0.20 mg / kg SN-38 equivalents (0.15 and 0.25 mg IMMU-132 / dose) induced significant tumor regression compared with saline, irinotecan (10 mg / kg ; ~ 5.8 mg / kg SN-38 equivalents by weight) or control ADC against CD20, hA20-CL2A-SN-38, when administered at the same 2 dose levels (P less than 0.0017, area under the curve, AUC) . Since in mice, the conversion of irinotecan to SN-38 occurs more efficiently than in humans (38) (in the studies of the authors of the present invention, it averaged ~ 25%, see below), with the indicated dose of irinotecan, ~ 145-174 g SN- 38, while the administered dose of IMMU-132 contained only 9.6 g. However, since IMMU-132 selectively targeted SN-38 to tumors, it was more effective. These results confirm the data for other models of solid tumors (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69), showing that the specific targeting of a small amount of SN-38 into the tumor using IMMU-132 is much more effective than significantly a higher dose of irinotecan, or even a mixture of hRS7 IgG with an equal amount of free SN-38 (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). The unconjugated RS7 antibody, even with multiple doses of 1 mg per animal, did not show any antitumor effects (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). However, in vitro studies of gynecological cancer expressing Trop-2 demonstrated killing of RS7 mAb cells due to antibody-dependent cellular cytotoxicity (Bignotti et al., 2010, Eur J Cancer 46: 944-53; Raji et al., 2011, J Exp Clin Cancer Res 30: 106; Varughese et al., 2011, Gynecol Oncol 122: 171-7; Varughese et al., 2011, Am J Obstet Gyneol 205: 567). A monovalent Fab fragment of another anti-Trop-2 antibody, therapeutically active in vitro and in animal studies, has also been described.</span>
  </p>
  <p num="480" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0369]  56        ,  0,12 /  ADC hA20-CL2A-SN-38,      1,0 <sup class="style-scope patent-text">3</sup> ( ).        IMMU-132,      0,2 /,         .        ,     ,         (  [] = 0,140,14 <sup class="style-scope patent-text">3</sup>  0,740,41 <sup class="style-scope patent-text">3</sup>, ; =0,0031,  t-).  ,             ,   ~0,7 <sup class="style-scope patent-text">3</sup>,       ,   - IMMU-132 ( ).   2             23%,    ,       IMMU-132    60%  .   ,    ,      SN-38   ADC,           Trop-2- IMMU-132.     IMMU-132      MDA-MB-231 ( ).          Trop-2,       SN-38.</span>[0369] On day 56 of treatment, four of the seven tumors in mice treated with 0.12 mg / kg of control ADC hA20-CL2A-SN-38 already progressed to an endpoint of 1.0 cm <sup class="style-scope patent-text">3</sup> (not shown). At this point, these animals were treated with IMMU-132, with a higher dose of 0.2 mg / kg selected to try to influence the progression of these significantly enlarged tumors. Despite the significant tumor size in several animals, all mice showed a therapeutic response, with a significant decrease in tumor size after five weeks (total volume [OO] = 0.14  0.14 cm <sup class="style-scope patent-text">3</sup> versus 0.74  0.41 cm <sup class="style-scope patent-text">3</sup> , respectively; P = 0.0031, two-sided t-test). Similarly, the authors of the present invention selected two animals from the irinotecan-treated group with tumors progressing to ~ 0.7 cm <sup class="style-scope patent-text">3</sup> , and re-treated one mouse with irinotecan and the other IMMU-132 (not shown). Within 2 weeks after the end of treatment, the tumor in the animal treated with irinotecan decreased by 23% and then began to progress, while the tumor in the animal treated with IMMU-132 stabilized at a 60% reduction in size. These results demonstrate that even for tumors whose growth continued after exposure to SN-38 from non-specific ADC, a significantly improved therapeutic response could be achieved with Trop-2-specific IMMU-132. However, the specific therapeutic effects of IMMU-132 were not achieved with MDA-MB-231 (not shown). This cell line is not only the lowest levels of Trop-2, but also the lowest sensitivity to SN-38.</span>
  </p>
  <p num="481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0370]   IMMU-132   -  ,   IMMU-132,     , MDA-MB-468,    HER2<sup class="style-scope patent-text">+</sup>- SK-BR-3,   ,   ADC       SN-38 ( ). SN-38    IMMU-132    2-   p21<sup class="style-scope patent-text">WAF1/Cip1</sup>    24   MDA-MB-468,   48   p21<sup class="style-scope patent-text">WAF1/Cip1</sup>      (31%  43%  SN-38  IMMU-132, ). ,    HER2<sup class="style-scope patent-text">+</sup>- SK-BR-3  SN-38,  IMMU-132     p21<sup class="style-scope patent-text">WAF1/Cip1</sup>,   ,   24 , ,     MDA-MB-468,  48   SN-38  IMMU-132  p21<sup class="style-scope patent-text">WAF1/Cip1</sup>     57%.  SN-38,  IMMU-132   -3       24 ,           48 . ,      IMMU-132     -3,      48 ,    ,    SN-38. ,  SN-38,  IMMU-132   (-)- (PARP),   24 ,      48 .     ,    IMMU-132     SN-38   in vitro.</span>[0370] The mechanism of action of IMMU-132 in TNBC - The apoptotic pathway that employs IMMU-132 was examined in the TNBC cell line, MDA-MB-468, and in the HER2 <sup class="style-scope patent-text">+</sup> cell line SK-BR-3, to confirm that ADC function is based on its constituent SN-38 (not shown). Separately, SN-38 and IMMU-132 mediated more than 2-fold up-regulation of p21 <sup class="style-scope patent-text">WAF1 / Cip1</sup> within a period of 24 hours in MDA-MB-468, and after 48 hours the amount of p21 <sup class="style-scope patent-text">WAF1 / Cip1</sup> in these cells began to decrease (31% and 43% for SN-38 or IMMU-132, respectively). Interestingly, in the SK-BR-3 tumor HER2 <sup class="style-scope patent-text">+ line,</sup> neither SN-38 nor IMMU-132 mediated upregulation of p21 <sup class="style-scope patent-text">WAF1 / Cip1 up</sup> to constitutive levels in the first 24 hours, however, as in MDA-MB cells -468, after 48 hours of exposure to SN-38 or IMMU-132, the amount of p21 <sup class="style-scope patent-text">WAF1 / Cip1</sup> decreased by more than 57%. Both SN-38 and IMMU-132 ensured cleavage of pro-caspase-3 into active fragments within a 24 h period, however, a higher level of active fragments was observed after exposure for 48 h. It is noteworthy that in both cell lines IMMU-132 mediated a greater degree of cleavage procaspase-3, with a maximum observed level after 48 hours, compared with cells exposed to SN-38. Finally, both SN-38 and IMMU-132 mediated the cleavage of poly (ADP-ribose) polymerase (PARP), starting after 24 hours, with almost complete cleavage after 48 hours. Together, these results confirm that the mechanism of action of IMMU-132 similar to the mechanism of action of free SN-38 when administered in vitro.</span>
  </p>
  <p num="482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0371]  SN-38   IMMU-132        -  ,     IMMU-132,         /      (Capan-1),    (773 ; 448   SN-38)  IMMU-132 (1,0 ; 16   SN-38).</span>[0371] Delivery of SN-38 using IMMU-132 or irinotecan in a human tumor xenograft model - Component products derived from irinotecan or IMMU-132 were determined in the serum and tumors of mice with human pancreatic cancer implanted and / or xenograft (Capan- 1) to which irinotecan (773 g; 448 g SN-38 equivalents) and IMMU-132 (1.0 mg; 16 g SN-38 equivalents) were injected.</span>
  </p>
  <p num="483" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0372]      ,     5    SN-38  SN-38G.  24        .  AUC   6    21,0, 2,5  2,8 /  , SN-38  SN-38G,  (  SN-38   = [2,5+2,8)/21=25,2%]).  ,  IMMU-132,       SN-38  ,      48  ( ).  SN-38G     1  6 ,      3-7     SN-38.</span>[0372] Irinotecan was very rapidly excreted from serum, with conversion observed within 5 minutes to SN-38 and SN-38G. After 24 hours, none of these products were detected. AUC values over a 6-hour period were 21.0, 2.5, and 2.8 g / mlh for irinotecan, SN-38, and SN-38G, respectively (SN-38 conversion rate in mice = [2.5+ 2.8) / 21 = 25.2%]). Animals treated with IMMU-132 showed significantly lower serum free SN-38 concentrations, but were detected within 48 hours (not shown). Free SN-38G was detected only after 1 and 6 hours, and its concentration was 3-7 times lower than the concentration of free SN-38.</span>
  </p>
  <p num="484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0373]   Capan-1,       ,       6 ,     24  (AUC<sub class="style-scope patent-text">5  - 6 </sub> = 48,4 /).  SN-38        2  (.. AUC<sub class="style-scope patent-text">5  - 2 </sub> = 0,4 /),     SN-38G    3   (AUC = 1,1 /) ( ).  ,  IMMU-132,   -    SN-38  SN-38G,    SN-38  , ,   IMMU-132.  ,       SN-38G ,  SN-38,   IMMU-132,   . AUC    IMMU-132SN-38     54,3 /,   135    SN-38   ,   ,   2- ,  SN-38   ,   ,  ,   ,   28    SN-38,  ,   IMMU-132 (.. 448  16   SN-38, )</span>[0373] In Capan-1 tumors recovered from animals treated with irinotecan, irinotecan levels remained high for 6 hours, but became undetectable after 24 hours (AUC <sub class="style-scope patent-text">5 min - 6 h</sub> = 48.4 g / gh). The level of SN-38 was significantly lower and was detected only after 2 h (i.e., AUC <sub class="style-scope patent-text">5 min - 2 h</sub> = 0.4 g / gh), while the values for SN-38G were almost 3 times higher (AUC = 1.1 g / gh) (not shown). Tumors of animals treated with IMMU-132 do not contain any detectable levels of free SN-38 or SN-38G, while all of the SN-38 in the tumor, in contrast, is associated with IMMU-132. It is important to note that the absence of detectable SN-38G in these tumors suggests that SN-38 associated with IMMU-132 was not glucuronidated. The AUC for IMMU-132SN-38 bound in these tumors corresponded to 54.3 g / gh, which is 135 times the amount of SN-38 in tumors of animals treated with irinotecan over a 2-hour period when SN-38 could be detected despite the fact that mice injected with irinotecan received 28 times more SN-38 equivalents than mice injected IMMU-132 (i.e. 448 or 16 g SN-38 equivalents, respectively)</span>
  </p>
  <p num="485" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Discussion</span>
  </p>
  <p num="486" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0374]      ADC,   Trop-2,     ,           ,    Trop-2<sup class="style-scope patent-text">+</sup>   (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27).   IMMU-132     ADC  .  ,    4   ADC: (i)  /; (ii) , ,    ,   ADC; (iii)  ,  ,    ,  (iv)      .           ADC,          (        ). Trop-2, -,       ,        (Cubas et al., 2009, Biochim Biophys Acta 1796:309-14; Trerotola et al., 2013, Oncogene 32:222-33; Stepan et al., 2011, 59:701-10),      .     , -, ,    (Bignotti et al., 2010, Eur J Cancer 46:944-53),  Trop-2, ,    ,     ,            .           , ,     IMMU-132  ,     ,   ,    Trop-2    (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).    ,          ,   ,    ,  (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27),    IMMU-132   .</span>[0374] The inventors of the present invention described a new Trop-2-targeted ADC, and early clinical results suggest that it is well tolerated and effective in patients with DST and other Trop-2 <sup class="style-scope patent-text">+</sup> cancers (Bardia et al., 2014 , San Antonio Breast Cancer Symposium, P5-19-27). Due to the inherent features of IMMU-132, it is a second-generation ADC. Typically, the optimal performance of the 4 generalized ADC attributes is required: (i) targeting / activity selectivity; (ii) the binding, affinity, internalization, and immunogenicity of an antibody involved in ADC; (iii) the drug, its potency, metabolism and pharmacological distribution, and (iv) the nature of the binding of the drug to the antibody. Selectivity for the target is the most common requirement for all ADCs, as it plays a major role in determining the therapeutic index (ratio of toxicity for tumor to toxicity for normal cells). Trop-2 appears to be widespread in some types of epithelial cancer, but is also expressed in some normal tissues (Cubas et al., 2009, Biochim Biophys Acta 1796: 309-14; Trerotola et al., 2013, Oncogene 32: 222-33; Stepan et al., 2011, 59: 701-10), which could affect specificity. However, expression in normal tissues appears to be lower than in cancer (Bignotti et al., 2010, Eur J Cancer 46: 944-53), and Trop-2 is supposedly shielded by normal tissue architecture, which limits accessibility for antibodies whereas in cancer, these tissue barriers are weakened as a result of the introduction of the tumor. Supporting evidence was found during initial toxicological studies in monkeys, when, despite escalating doses of IMMU-132 to levels leading to neutropenia and diarrhea similar to those caused by irinotecan, there was no histopathological damage to Trop-2-expressing normal tissues (Cardillo et al., 2011 Clin Cancer Res 17: 3157-69). These results are clinically confirmed by the lack of specific organ toxicity in patients to date, with the exception of the toxicity known for the parent compound, irinotecan (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27), which when applied IMMU-132 is better manageable.</span>
  </p>
  <p num="487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0375]      ADC   ,      ,      .  IMMU-132 ,    ,     ADC,    SN-38, , ,        ,     ,        . ,          IgG    ,      .     -      ,         .      ,  SN-38        ,    ~10    ,                  (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61).        ,    SN-38    ,   CL2A,       (Govindan et al., 2013, Mol Cancer Ther 12:968-78).</span>[0375] A generally accepted important criterion for the treatment of ADC is the internalization of the antibody, which delivers the chemotherapeutic agent into the cell, where it is usually metabolized in lysosomes. Although IMMU-132 is internalized, the authors of the present invention believe that the linker in the specified ADC, allowing the local release of SN-38, which, presumably, can induce a "witness effect" in relation to cancer cells, is another feature that distinguishes the specified platform from the involved ultratoxic drugs. Thus, for compounds of this type, the stable binding of an ultratoxic agent to IgG is the only configuration that is capable of providing a suitable therapeutic window. However, the use of a more moderately toxic drug does not allow the use of a linker that would release the drug into the bloodstream too early. In our group, linkers were released that released SN-38 from a conjugate with different serum half-lives ranging from ~ 10 hours to a highly stable linker, however, the linker with intermediate stability provided the best therapeutic response in models of human tumor xenografts in mice (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al., 2009, Clin Chem Res 15: 6052-61). After this initial study, the authors of the present invention showed that the highly stable SN-38 bond was significantly less effective than the CL2A linker, which has more intermediate stability in serum (Govindan et al., 2013, Mol Cancer Ther 12: 968-78).</span>
  </p>
  <p num="488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0376]      ADC              ,  ,  0,003  0,08%      (Sharkey et al., 1995, Cancer Res 55:5935s-45s).         ,               4:1,                   (Hamblett et al., 2004, Clin Cancer Res 10:7063-70).   ADC-          IgG,  -           IgG,     8  .   CL2A-SN-38,     DAR,  7,6:1,    - ,    8     CL2A, , -,   SN-38     .   , 95%  CL2A  7-8  SN-38.     ,  ()       ,  (b)              ,      . ,    ,                   .</span>[0376] Another modern dogma in the design of ADC is the use of an ultra-toxic drug to compensate for low levels of antibody accumulation in tumors, typically from 0.003 to 0.08% of the injected dose per gram (Sharkey et al., 1995, Cancer Res 55 : 5935s-45s). For the modern generation of conjugates with ultra-toxic drugs, it has been established that the optimal substitution coefficient for drug molecules in the antibody is less than or equal to 4: 1, since higher ratios undesirably affected their pharmacokinetics and reduced the therapeutic index due to concomitant toxicity (Hamblett et al ., 2004, Clin Cancer Res 10: 7063-70). For this second-generation ADC platform, the inventors have chosen an IgG binding method comprising site-specific binding of a drug to interchain disulfides by mild IgG reduction, resulting in exposure of 8 binding sites. Using the CL2A-SN-38 linker, the authors of the present invention obtained a DAR reaching 7.6: 1, while LC-MS data show that each of the 8 connection sites carries a CL2A linker, however, apparently, some SN-38 lost during the receipt procedure. However, 95% of the CL2A linker contains 7-8 SN-38 molecules. Subsequently, the inventors of the present invention found that (a) the compound with the indicated sites did not destabilize the antibody, and (b) the preparation of conjugates with high levels of substitution at the indicated sites did not interfere with the binding to the antibody and did not affect the pharmacokinetic properties. Thus, the inventors of the present invention demonstrated that the conjugates obtained with the maximum level of substitution provided the best therapeutic response in models with xenografts of human tumors in mice.</span>
  </p>
  <p num="489" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0377]      IMMU-132      ,  SN-38,   IgG,  ,         .       SN-38        SN-38G.  AUC  SN-38G ,      4,5-32  ,   SN-38 (Gupta et al., 1994, Cancer Res 54:3723-25; Xie et al., 2002, J Clin Oncol 20:3293-301).  SN-38G      -,   ,    -  SN-38    ,     (Stein et al., 2010, Ther Adv Med Oncol 2:51-63).   IMMU-132  SN-38G               (,   ,  IMMU-132,  20-40%  SN-38    SN-38G),     ,  SN-38,   IgG,      ,     10-- SN-38.    ,    SN-38G,  IMMU-132,            ,   ADC,     .</span>[0377] One of the most notable features of IMMU-132 in terms of tolerability is that IgG-linked SN-38 is not glucuronidated, which is a critical step for detoxification of irinotecan. During irinotecan therapy, most of the resulting SN-38 is easily converted in the liver to the inactive form of SN-38G. Estimated AUCs for SN-38G show that its levels are often 4.5-32 times higher than SN-38 levels (Gupta et al., 1994, Cancer Res 54: 3723-25; Xie et al., 2002, J Clin Oncol 20: 3293-301). Secretion of SN-38G into bile followed by deconjugation with beta-glucuronidase produced by the intestinal flora is closely associated with enterohepatic recirculation of SN-38 and delayed severe diarrhea observed with irinotecan (Stein et al., 2010, Ther Adv Med Oncol 2: 51-63). Following the administration of IMMU-132, the concentrations of SN-38G were very low in animal studies and clinical trials by the authors of the present invention (for example, in the serum of patients receiving IMMU-132, only 20-40% of free SN-38 are in the form of SN-38G ), which is convincing evidence that SN-38 associated with IgG is significantly protected from glucuronidation, even though the 10-hydroxy position of SN-38 is available. The inventors of the present invention suggest that the low levels of SN-38G generated by IMMU-132 contribute to a lower incidence and rate of diarrhea in patients receiving this ADC compared to irinotecan therapy.</span>
  </p>
  <p num="490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0378]   SN-38,   ,         SN-38,   .     ,  ,    ,   10     SN-38  SN-38G.  ,  SN-38,    ,  IMMU-132,  SN-38,   IgG.    ,  ,   ,    ,     SN-38,   ,  SN-38     ;        ,       SN-38G,     .   ,       20-- SN-38, SN-38      (Zhao et al., 2000, J Org Chem 65:4601-6).  ,   ,  IMMU-132     SN-38  Trop-2<sup class="style-scope patent-text">+</sup>-  ,    SN-38,    ,  ,  SN-38,  IMMU-132,         .</span>[0378] Prevention of glucuronidation of SN-38 associated with the antibody may also contribute to the improved therapeutic effects of SN-38 delivered to the tumor. High levels of irinotecan and 10 times lower concentrations of SN-38 and SN-38G were found in tumor extracts from animals treated with irinotecan. In contrast, the only SN-38 found in animal tumors treated with IMMU-132 was IgG-linked SN-38. The authors of the present invention suggest that the conjugate retained in the tumor, as a result, will be internalized, thus releasing the SN-38 with which it is loaded, or SN-38 can be released outside the tumor cell; however, it will be released in a fully active form, with a lower probability of conversion to SN-38G, occurring mainly in the liver. It is also important to emphasize that by linking the linker to the 20-hydroxy position of SN-38, SN-38 remains in active lactone form (Zhao et al., 2000, J Org Chem 65: 4601-6). Together, these results show that IMMU-132 is capable of delivering and concentrating SN-38 in Trop-2 <sup class="style-scope patent-text">+</sup> tumors in a selective manner, in contrast to SN-38 originating from non-targeting irinotecan, and it is likely that SN-38 delivered by IMMU -132, is released in the tumor in a fully active non-glucuronidated lactone form.</span>
  </p>
  <p num="491" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0379]            .           ,      SN-38     .     , MDA-MB-468   HER2<sup class="style-scope patent-text">+</sup> SK-BR-3, IMMU-132     ,       ,   PARP.      ,  IMMU-132 (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27),       ADC  SN-38     SN-38   .   ,           ,    ,       (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27).  ,  IMMU-132       ,      ,    I,   (Starodub et al., 2015, Clin Cancer Res 21:3870-78).</span>[0379] Irinotecan is not a standard treatment for patients with breast cancer. However, the experiments described in this document on TNLM cell lines show that when the concentration of large amounts of SN-38 in the tumor is concentrated, its activity increases. In both tumor cell lines, MDA-MB-468 TNRM and HER2 <sup class="style-scope patent-text">+</sup> SK-BR-3, IMMU-132 mediated activation of the internal apoptotic pathway, with cleavage of procaspases into the corresponding active fragments, and cleavage of PARP. Demonstrated DNA strand breaks of cancer cells treated with IMMU-132 (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27) compared with the results for irrelevant ADC with SN-38 confirm the selective delivery of SN-38 to target cells. Most importantly, these laboratory studies are confirmed in the treatment of patients with metastatic TNBC who have undergone serious treatment and have persistent objective responses (Bardia et al., 2014, San Antonio Breast Cancer Symposium, P5-19-27). It also turned out that IMMU-132 is active in patients with other cancers in which the previous use of a therapeutic regimen including a topoisomerase I inhibitor was unsuccessful (Starodub et al., 2015, Clin Cancer Res 21: 3870-78).</span>
  </p>
  <p num="492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0380]  ,  SN-38,                ,     ,     ,    ADC  .      ,  Trop-2         Trop-2+,  ,  .</span>[0380] In conclusion, the use of SN-38, conjugated with a very high ratio of drug molecules to antibody molecules using a moderately stable linker, is effective in animal models as well as in clinical applications, representing the second generation ADC platform. The results obtained by the authors of the present invention show that Trop-2 is a clinically relevant new target in solid tumors of Trop-2 +, in particular with TNRM.</span>
  </p>
  <p num="493" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 17.    IMMU-132</span>Example 17. Studies of the mechanism of action of IMMU-132</span>
  </p>
  <p num="494" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0381]   (IMMU-132,    hRS7-CL2A-SN-38)        (ADC),   Trop-2,  ,     ,   SN-38,   .     ADC,         ,  IMMU-132            SN-38  .  -    ,  Trop-2      ,      ,  ,       (),  ,    .            IMMU-132    hRS7,        5-  Trop-2    IMMU-132   hRS7  .         ,    60%        hRS7.</span>[0381] Sacituzumab govitecan (IMMU-132, also known as hRS7-CL2A-SN-38) is a drug-conjugated antibody (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for SN delivery -38, an active metabolite of irinotecan. Unlike most ADCs that use ultra-toxic drugs and stable linkers, IMMU-132 uses a moderately toxic drug with a moderately stable carbonate bond between SN-38 and the linker. Flow-cytometric and immunohistochemical studies revealed that Trop-2 is expressed in a wide range of tumor types, including cancer of the stomach, pancreas, breast with a triple negative phenotype (TNBC), colon, prostate and lung. Although no significant differences were found between cell binding experiments between IMMU-132 and the original hRS7 antibody, surface plasmon resonance analysis using a CM5 chip with Trop-2 demonstrates a significant advantage of IMMU-132 over hRS7 binding. The indicated conjugate retained the ability to bind to the neonatal receptor, however, it lost more than 60% of the activity of antibody-dependent cell-mediated cytotoxicity compared to hRS7.</span>
  </p>
  <p num="495" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0382]        SN-38,  IMMU-132            pJNK1/2  p21WAF1/Cip1     9, 7  3,        (-)-    .</span>[0382] When tumor cells were exposed to either free SN-38 or IMMU-132, the participation of the same signaling pathways with upregulation of pJNK1 / 2 and p21WAF1 / Cip1 and subsequent cleavage of <figure-callout id="9" label="caspases" filenames="00000046.png,00000052.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="7" label="caspases" filenames="00000045.png,00000050.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="3" label="caspases" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">caspases</a></figure-callout></a></figure-callout></a></figure-callout> 9, 7 and 3 was demonstrated, which ultimately leads to cleavage of poly (ADP-ribose) -polymerase and rupture of double-stranded DNA.</span>
  </p>
  <p num="496" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0383]   ADC        (MRT) 15,4 ,   - hRS7   ,    (MRT=~300 ).  ,     ,   IMMU-132 (17,5 /;      4 )        ,    .      IMMU-132,       ,        ,        ,        .    I/II  (ClinlcalTrials.gov, NCT01631552)    IMMU-132  ,  Trop-2,           .</span>[0383] The pharmacokinetics of intact ADC in mice indicated an average retention time (MRT) of 15.4 hours, whereas the hRS7 carrier antibody was excreted at a rate similar to an unconjugated antibody (MRT = ~ 300 hours). Treatment of mice bearing human gastric cancer xenografts with IMMU-132 (17.5 mg / kg; twice weekly  4 weeks) provided significant antitumor effects compared to mice treated with nonspecific control. For clinically relevant IMMU-132 dosing regimens, including once every two weeks, weekly, or twice a week administration in mice bearing xenografts of human pancreatic or stomach cancer, similar significant antitumor effects were demonstrated in both models. Ongoing clinical trials of phase I / II (ClinlcalTrials.gov, NCT01631552) confirm the anti-cancer activity of IMMU-132 in cancer expressing Trop-2, including in patients with cancer of the stomach and pancreas.</span>
  </p>
  <p num="497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Introduction</span>
  </p>
  <p num="498" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0384]  ,         22220    ,   10990  ,    (Siegel et al., 2014,  Cancer J Clin 64:9-29).        5-  (    29%),               ,      ,      (65%, 90%  100%, ). ,   5-          , ,    .             ,   5- ,   6% (Siegel et al., 2014,  Cancer J Clin 64:9-29).                  .</span>[0384] It is estimated that 22220 new cases of stomach cancer will be diagnosed in the United States this year, followed by 10,990 deaths due to the disease (Siegel et al., 2014, CA Cancer J Clin 64: 9-29). Despite the emergence of a trend toward an increase in 5-year survival rates (currently 29%), these levels are still quite low compared to most other cancers, including colon, breast and prostate cancers (65 %, 90% and 100%, respectively). In fact, 5-year survival rates for all types of cancer are worse only for cancer of the esophagus, liver, lung, and pancreas. Pancreatic cancer remains the fourth leading cause of all cancer deaths in the United States, with a 5-year survival rate of only 6% (Siegel et al., 2014, CA Cancer J Clin 64: 9-29). Such bleak statistics for cancer of the stomach and pancreas clearly indicate the need for new therapeutic approaches.</span>
  </p>
  <p num="499" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0385] Trop-2     45 ,      TACSTD,  , TACSTD22.                . Trop-2            (Wang et al., 2008, Mol Cancer Ther 7:280-85; Trerotola et al., 2013, Oncogene 32:222-33).       ,      ,    12-14.   ,   Trop-2,  NF-,  D1  ERK (Guerra et al., 2013, Oncogene 32:1594-1600; Cubas et al., 2010, Mol Cancer 9:253).</span>[0385] Trop-2 is a 45 kDa glycoprotein that belongs to the TACSTD gene family, in particular, TACSTD22. Overexpression of the indicated transmembrane protein in various types of epithelial cancer was associated with an overall poor prognosis. Trop-2 is essential for substrate-independent cell growth and tumorigenesis (Wang et al., 2008, Mol Cancer Ther 7: 280-85; Trerotola et al., 2013, Oncogene 32: 222-33). It functions as a calcium signal carrier, which requires an intact cytoplasmic fragment that phosphorylates C12-14 protein kinase. Growth signaling factors associated with Trop-2 include NF-B, cyclin D1, and ERK (Guerra et al., 2013, Oncogene 32: 1594-1600; Cubas et al., 2010, Mol Cancer 9: 253).</span>
  </p>
  <p num="500" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0386]       Trop-2   55%  ,     ,          ,       (Fong et al., 2008, Br J Cancer 99:1290-95).  ,     56%     Trop-2  , -,                Trop-2-     (Muhlmann et al., 2009, J Clin Pathol 63:152-58).       ,  Trop-2      ,                (ADC).</span>[0386] In pancreatic cancer, overexpression of Trop-2 was observed in 55% of the studied patients, with a positive correlation with metastasis, tumor grade and poor progression-free survival in patients who underwent surgery to cure (Fong et al., 2008, Br J Cancer 99: 1290-95). Similarly, in 56% of patients with gastric cancer, over-expression of Trop-2 on tumors was observed, again correlating with shorter disease-free survival and a less satisfactory prognosis in patients with Trop-2-positive tumor cells lymph nodes (Muhlmann et al., 2009, J Clin Pathol 63: 152-58). Given these characteristics and the fact that Trop-2 is associated with many intractable cancers, it is an attractive target for therapeutic intervention using the antibody-drug conjugate (ADC).</span>
  </p>
  <p num="501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0387]              ,   , : ()      ,     , (b)        ;  ()        (Panowski et al., 2014, mAbs 6:34-45).   ,     ,  RS7-3G11 (RS7),    Trop-2     (Stein et al., 1993, Int J Cancer 55:938-46; Basu et al., 1995, Int J Cancer 62:472-79)    (Cardillo et al., 2011k, Clin Cancer Res 17:3157-69),     Trop-2   (Shih et al., 1995, Cancer Res 55:5857s-63s).</span>[0387] The general paradigm of using an antibody to target a drug to a tumor includes several key features, including the following: (a) the target antigen is predominantly expressed on the tumor, but not in normal tissue, (b) the antibody has good affinity and is internalized by the tumor a cell; and (c) an ultratoxic drug is stably coupled to an antibody (Panowski et al., 2014, mAbs 6: 34-45). Guided by these principles, the authors of the present invention have developed an antibody, designated RS7-3G11 (RS7), which binds to Trop-2 in a number of solid tumors (Stein et al., 1993, Int J Cancer 55: 938-46; Basu et al., 1995, Int J Cancer 62: 472-79) with nanomolar affinity (Cardillo et al., 2011k, Clin Cancer Res 17: 3157-69), and after binding to Trop-2 is internalized by the cell (Shih et al., 1995, Cancer Res 55: 5857s-63s).</span>
  </p>
  <p num="502" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0388]     Trop-2     , ,  ,         ,           (Trerotola et al., 2013, Oncogene 32:222-33).     RS7        , 7--10- (SN-38).  in vitro    ,   ,   IC<sub class="style-scope patent-text">50</sub>      SN-38,          ,      ADC (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).      ,     ,   ADC,   2-4    ,    ,      ,       ADC     (Junutula et al., 2010, Clin Cancer Res 16:4769-78).</span>[0388] According to the results of immunohistochemical studies, Trop-2 is expressed in some normal tissues, although, as a rule, with significantly lower intensity compared to neoplastic tissue, and is often present in areas of tissues with limited vascular access (Trerotola et al., 2013, Oncogene 32: 222-33). Based on these characteristics, RS7 was humanized and conjugated to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38). In vitro cytotoxicity in multiple cell lines has been found to be characterized by IC <sub class="style-scope patent-text">50</sub> values in the single-bit nanomolar range for SN-38, in contrast to the picomolar range for many ultra-toxic drugs currently used in ADC (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). Although the idea is predominant of using ultratoxic agents, such as auristatins or maytansines, to produce ADCs containing only 2-4 drugs per antibody, stably connected to it, such agents have a narrow therapeutic window, which leads to new attempts to reconstruct ADCs with an expanded therapeutic index (Junutula et al., 2010, Clin Cancer Res 16: 4769-78).</span>
  </p>
  <p num="503" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0389]              7-8 SN-38      ,   SN-38       ~1 .   ,       SN-38       ADC  ,        ,    ,      ADC.  ADC, hRS7-CL2A-SN-38 ( ,  IMMU-132),          (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).       IMMU-132            () (Goldenberg et al., 2014,          -, 9-13  2014 .,  5-19-08).   ,      I/II  IMMU-132      (Bardia et al., 2014,          -, 9-13  2014 .,  5-19-2), ,        ADC,        ,  SN-38   ,      ADC   .</span>[0389] As one way of avoiding this practice, the inventors conjugated 7-8 SN-38 molecules per antibody using a linker that releases SN-38 with a half-life in human serum of ~ 1 day. It has been suggested that the use of a less stable linker will allow SN-38 to be released at the tumor site after targeting the ADC to the cells, making the drug available to surrounding tumor cells, and not just the cells that the specified ADC directly targets. The resulting ADC, hRS7-CL2A-SN-38 (sacituzumab govitecan, or IMMU-132), showed antitumor activity against a wide range of tumor types (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). Significant antitumor activity of IMMU-132 has recently been demonstrated in relation to the preclinical triple negative phenotype cancer model (TNBC) (Goldenberg et al., 2014, poster presentation at the San Antonio Breast Cancer Symposium, December 9-13, 2014 ., abstract No. P5-19-08). Most importantly, in the current clinical trial of phase I / II, IMMU-132 showed activity in TNBC patients (Bardia et al., 2014, poster presentation at the Symposium on Breast Cancer in San Antonio, December 9-13, 2014, theses No.P5-19-2), respectively, confirming the effectiveness of the indicated paradigm shift in the chemistry of ADC, involving the use of a less toxic drug and a linker that releases SN-38 over time, instead of completely depending on the internalization of ADC to ensure activity.</span>
  </p>
  <p num="504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0390] SN-38     -I,      .       , 53  p21WAF1/Cip1,        (-)- (PARP).  p21WAF1/Cip1        G1 , ,       .     ,  IMMU-132           (53  p21WAF1/Cip1),     PARP     (Calu-3)    (-3),       (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).</span>[0390] SN-38 is a known topoisomerase-I inhibitor that induces significant damage to cell DNA. It mediates the upregulation of early proapoptotic proteins, p53 and p21WAF1 / Cip1, which leads to activation of caspases and cleavage of poly (ADP-ribose) polymerase (PARP). The expression of p21WAF1 / Cip1 is associated with cell cycle arrest in the G1 phase and, accordingly, is a hallmark of the internal apoptotic pathway. The authors of the present invention previously demonstrated that IMMU-132 is similarly able to mediate the upregulation of early proapoptotic signaling events (p53 and p21WAF1 / Cip1), which leads to cleavage of PARP in the cell lines of NSCLC (Calu-3) and pancreas (BxRS-3) , which corresponds to the internal pro-apoptotic signaling pathway (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69).</span>
  </p>
  <p num="505" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0391]         IMMU-132,      ,  ,      .     Trop-2          in vivo   .          ,  IMMU-132,           ()    . ,                ,       ,       ,  ,              .</span>[0391] In this document, the authors of the present invention further characterized IMMU-132, with particular attention to the treatment of solid cancer, in particular, tumors of the stomach and pancreas of a person. The surface expression of Trop-2 in a range of solid tumor types was investigated and compared with in vivo expression in tumor xenografts. Mechanistic studies provide additional information about internal pro-apoptotic signaling events mediated by IMMU-132, including data on an increase in double-stranded DNA breaks (dsRNAs) and subsequent activation of caspases. Finally, clinically relevant and non-toxic dosing regimens are compared in models of gastric carcinoma and pancreatic carcinoma diseases, testing dosing schedules twice a week, weekly and once every two weeks to determine which treatment cycle is best for clinical use without loss of effectiveness.</span>
  </p>
  <p num="506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Experimental procedures</span>
  </p>
  <p num="507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0392]      -             () (, ).              ;          (STR)  . IMMU-132 (hRS7-SN-38)   ADC (hA20-SN-38  CD20  hLL2-SN-38  CD22)         -20 (Cardillo et al., 2011, Clin Cancer Res 17:3157-69). SN-38  (Biddle Sawyer Pharma, LLC, -,  -)      1     -20.</span>[0392] Cell lines and chemotherapeutic agents - All used human cancer cell lines were purchased from the American Type Culture Collection (ATCC) (Manassas, Virginia). All lines were maintained in accordance with ATCC recommendations and routine mycoplasma testing was performed; all lines were authenticated using short tandem repeat (STR) analysis from ATCC. IMMU-132 (hRS7-SN-38) and control ADC (hA20-SN-38 against CD20 and hLL2-SN-38 against CD22) were prepared as described above and stored at -20  C (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). SN-38 was purchased (Biddle Sawyer Pharma, LLC, New York, NY) and stored in 1 mM aliquots in DMSO at -20  C.</span>
  </p>
  <p num="508" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0393]  ELISA  Trop-2 -  Trop-2   His- (Sino Biological, Inc., , ; . 10428-09)   Trop-2   His- (Sino Biological, Inc., . 50922-08)    Ni-NTA HisSorb (Qiagen GmbH, . 35023)   1    1    .  4-    -Tween (0,05%).    hRS7     1% -      0,1 /  10 /.      2       4-         (    ,    Fc-; Jackson Immunoresearch, . 109-036-098).  45            (- (OPD); Sigma, . 828).       15 ,     4  .    450   - Biotek ELX808.         Prism GraphPad Software (v4.03) (Advanced Graphics Software, Inc.; , ).</span>[0393] ELISA ELISA on Trop-2 - Recombinant human Trop-2 with His-tag (Sino Biological, Inc., Beijing, China; Cat. No. 10428-H09H) and recombinant mouse Trop-2 with His-tag (Sino Biological , Inc., Cat. No. 50922-M08H) was applied to HisSorb Ni-NTA strips (Qiagen GmbH, Cat. No. 35023) in an amount of 1 g for 1 hour at room temperature. The tablet was washed 4 times with FSB-Tween wash buffer (0.05%). Serial dilutions of hRS7 were obtained in a dilution buffer of 1% BSA-FSB in the range of test concentrations from 0.1 ng / ml to 10 g / ml. The plates were then incubated for 2 hours at room temperature, followed by 4-fold washing and addition of a peroxidase-conjugated secondary antibody (goat anti-human antibody specific for the Fc fragment; Jackson Immunoresearch, cat. No. 109-036-098). After 45 minutes of incubation, the plate was washed and a substrate solution (o-phenylenediamine dihydrochloride (OPD); Sigma, Cat. No. P828) was added to all wells. The plates were incubated in the dark for 15 minutes, after which the reaction was stopped with 4N sulfuric acid. Plates were read at 450 nm on a Biotek ELX808 plate reader. Data was analyzed and plotted using Prism GraphPad Software (v4.03) (Advanced Graphics Software, Inc .; Encinitas, CA).</span>
  </p>
  <p num="509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0394]   in vitro -           LumiGLO (KPL, , ). ,     96-         .    1:2     ,     0,03  66,7 .     1   4                     (Jackson Immunoresearch, -, )   1:20000   1   4.       LumiGLO.      - Envision (Perkin Elmer, , ).           (KD).    KD     Prism GraphPad Software (v4.03) (Advanced Graphics Software, Inc.; , )   F-      .        0,05.</span>[0394] In Vitro Cell Binding - The LumiGLO chemiluminescent substrate system (KPL, Gaithersburg, Maryland) was used to detect the binding of antibodies to cells. Briefly, cells were seeded in a black 96-well plate with a flat transparent bottom and left overnight. Antibodies were serially diluted 1: 2 and added in triplicate to obtain a concentration range from 0.03 to 66.7 nM. After incubation for 1 hour at 4  C, the medium was removed and the cells were washed with fresh cold medium, followed by the addition of horseradish peroxidase conjugated secondary goat anti-human antibodies (Jackson Immunoresearch, West Grove, PA) at a dilution of 1: 20,000 for 1 hour at 4  C. The plates were re-washed before adding LumiGLO reagent. The luminescence of the tablets was read using an Envision plate reader (Perkin Elmer, Boston, Massachusetts). Data were analyzed by nonlinear regression to determine the equilibrium dissociation constant (KD). Statistical comparisons of KD values were performed using Prism GraphPad Software (v4.03) (Advanced Graphics Software, Inc.; Encinitas, California) using the F test for best fit curves for data. For a significant level, a P value of less than 0.05 was taken.</span>
  </p>
  <p num="510" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0395]    () - 4-      -,  IMMU-132, IgG hRS7, hLL2-SN-38  IgG hLL2 (hLL2      CD22     ). ,   (MDA-MB-468, NIH:OVCAR-3,  -3)    110<sup class="style-scope patent-text">4</sup> /  96-        .         (),   ,         :=50:1.            (, ).           33,3 .             ,          TritonX100      .     4   37.  4             (Cyto Tox-One Homogenous Membrane Integrity Assay; Promega, . G7891).</span>[0395] Antibody-dependent cell-mediated cytotoxicity (ADCC) - A 4-hour LDH release assay was performed to evaluate ADCC activity induced by IMMU-132, IgG hRS7, hLL2-SN-38 and IgG hLL2 (hLL2 are non-binding anti-CD22 conjugates for cell lines solid tumors). Briefly, target cells (MDA-MB-468, NIH: OVCAR-3, or BxPC-3) were plated at a density of 1  10 <sup class="style-scope patent-text">4</sup> cells / well in a 96-well black flat-bottomed plate and incubated overnight. The next day, peripheral blood mononuclear effector cells (PBMCs), freshly isolated from the donor, are added to predetermined wells of the reaction plate with a ratio of E: T = 50: 1. The capture of the human IPC was carried out with the approval of the New England Institutional Supervisory Board (Newton, Massachusetts). Test reagents were added to predetermined wells at a final concentration of 33.3 nM. Separately, ADCC assay medium was added to one group of wells to control the background, and cells and TritonX100 were added separately to another group of wells to determine the control maximum cell lysis. The plate was incubated for 4 hours at 37  C. After 4 hours, target cell lysis was assessed using a homogeneous fluorometric LDH release assay (Cyto Tox-One Homogenous Membrane Integrity Assay; Promega, Cat. No. G7891).</span>
  </p>
  <p num="511" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0396]   (544  - 590 )   - Envision (PerkinElmer LAS, Inc.; , ).     Microsoft Excel.      :</span>[0396] Tablets were read (544 nm - 590 nm) using an Envision plate reader (PerkinElmer LAS, Inc .; Shelton, Connecticut). Data was analyzed using Microsoft Excel. The percentage of specific lysis was calculated as follows:</span>
  </p>
  <p num="512" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/48/ef/c0edecff0b614a/00000036.png" class="style-scope patent-text"><img file="00000036.jpg" he="19" wi="160" img-format="jpg" img-content="undefined" width="640" height="76" alt="Figure 00000036" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/48/ef/c0edecff0b614a/00000036.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/31/48/ef/c0edecff0b614a/00000036.png" class="style-scope patent-text"><img file="00000036.jpg" he="19" wi="160" img-format="jpg" img-content="undefined" width="640" height="76" alt="Figure 00000036" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/31/48/ef/c0edecff0b614a/00000036.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="513" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">:</span>Where:</span>
  </p>
  <p num="514" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7c/27/5b/6fc09352961835/00000037.png" class="style-scope patent-text"><img file="00000037.jpg" he="15" wi="160" img-format="jpg" img-content="undefined" width="640" height="60" alt="Figure 00000037" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7c/27/5b/6fc09352961835/00000037.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/7c/27/5b/6fc09352961835/00000037.png" class="style-scope patent-text"><img file="00000037.jpg" he="15" wi="160" img-format="jpg" img-content="undefined" width="640" height="60" alt="Figure 00000037" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/7c/27/5b/6fc09352961835/00000037.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="515" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1d/8d/2d/a3e759a25ad4c0/00000038.png" class="style-scope patent-text"><img file="00000038.jpg" he="28" wi="146" img-format="jpg" img-content="undefined" width="584" height="112" alt="Figure 00000038" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1d/8d/2d/a3e759a25ad4c0/00000038.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/1d/8d/2d/a3e759a25ad4c0/00000038.png" class="style-scope patent-text"><img file="00000038.jpg" he="28" wi="146" img-format="jpg" img-content="undefined" width="584" height="112" alt="Figure 00000038" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/1d/8d/2d/a3e759a25ad4c0/00000038.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="516" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0397]       (BIACORE) - , rhTrop-2/TACSTD2 (Sino Biological, Inc.)      (FcRn),    (Wang et al., 2011, Drug Metab Dispos 39:1469-77),         (GE Healthcare; . BR-1000-50)   5- (GE Healthcare; . BR-1000-12),       .      IgG hRS7  IMMU-132    (400 , 200 , 100 , 50   25 ).         BIACORE (BIACORE-X; Biacore Inc., , -)        BIAevaluation (Biacore Inc., v4.1).       1:1 ( )  ,          ,     (  <sup class="style-scope patent-text">2</sup>).  KD    KD=kd1/ka1,  kd1     , a ka1     .</span>[0397] Surface Plasma Resonance Binding Assay (BIACORE) - Briefly, rhTrop-2 / TACSTD2 (Sino Biological, Inc.) or recombinant human neonatal receptor (FcRn) prepared as described (Wang et al., 2011, Drug Metab Dispos 39: 1469-77), immobilized using an amino group kit (GE Healthcare; Cat. No. BR-1000-50) on a CM5 sensor chip (GE Healthcare; Cat. No. BR-1000-12), following the manufacturer's instructions for low density chip. Three separate dilution series of IgG hRS7 and IMMU-132 were prepared in a movable buffer (400 nM, 200 nM, 100 nM, 50 nM and 25 nM). Each series was used for a separate analysis in the BIACORE system (BIACORE-X; Biacore Inc., Piscataway, NJ) and data were analyzed using the BIAevaluation software (Biacore Inc., v4.1). The analysis was performed using a 1: 1 binding model (Langmuir model) and approximation, using all five concentration points for each analysis of the sample, to determine the best approximation (minimum value  <sup class="style-scope patent-text">2</sup> ). The KD value was calculated by the formula KD = kd1 / ka1, where kd1 is the dissociation rate constant, and ka1 is the binding rate constant.</span>
  </p>
  <p num="517" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0398]    Trop-2        -     ,   10%      .     5     Tris/ (DaKo Target Retrieval Solution, pH 9,0; , )  95   30    NxGen Decloaking Chamber (Biocare Medical, , ). Trop-2      Trop-2    10 / (R&amp;D Systems, , )          -  Vector VECTASTAINR ABC Kit (Vector Laboratories, Inc., , ).         (R&amp;D Systems, , ).      6 .</span>[0398] Immunohistological evaluation of the distribution of Trop-2 in fixed formalins paraffin embedded tissues - Tumor xenografts were removed from mice, fixed in 10% buffered formalin and embedded in paraffin. After dewaxing, a 5 m thick medium was incubated with Tris / EDTA buffer (DaKo Target Retrieval Solution, pH 9.0; Daco, Denmark) at 95   for 30 minutes in an NxGen Decloaking Chamber apparatus (Biocare Medical, Concord, California). Trop-2 was detected with goat anti-human Trop-2 polyclonal antibody at a concentration of 10 g / ml (R&amp;D Systems, Minneapolis, Minnesota) and stained using a staining kit with avidin-biotin complex from Vector VECTASTAINR ABC Kit (Vector Laboratories, Inc., Burlingame, CA). Normal goat antibody was used as a negative control (R&amp;D Systems, Minneapolis, Minnesota). Tissues were contrasted with hematoxylin for 6 seconds.</span>
  </p>
  <p num="518" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0399]   Trop-2      -  Trop-2       . ,          (Becton Dickinson (BD),  , -; . 561527)    Trop-2   - QuantiBRITE (BD . 340495)  -   Trop-2 (eBiosciences, . 12-6024),   .      FACSCalibur (BD)     CellQuest Pro.       Flowjo (Tree Star, , ).</span>[0399] Surface expression of Trop-2 on human carcinoma cell lines  Analysis of the expression of Trop-2 on cell surfaces based on flow cytometry. Briefly, cells were harvested using a nekutase cell disconnect solution (Becton Dickinson (BD), Franklin Leike, NJ; Cat. No. 561527) and Trop-2 expression was analyzed using QuantiBRITE PV pellets (BD Cat. No. 340495) and PV-conjugated anti-Trop-2 antibody (eBiosciences, Cat. No. 12-6024), following the manufacturer's instructions. Data was recorded on a FACSCalibur flow cytometer (BD) using CellQuest Pro software. Staining was analyzed using Flowjo software (Tree Star, Ashland, Oregon).</span>
  </p>
  <p num="519" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0400]  -    NCr Nude (nu/nu)  8-10    Taconic Farms (, -).  (N  5)  / 200  IMMU-132,  hRS7   hRS7-NEM (hRS7,      N-).         30 , 4, 24, 72  168   .       IgG hRS7   ELISA,        IgG hRS7   hRS7   .     IMMU-132      SN-38          IgG hRS7  .  ()            Phoenix WinNonlin ( 6.3; Pharsight Corp., -, ).</span>[0400] Pharmacokinetics - Unstimulated female NCr Nude mice (nu / nu) 8-10 weeks old were purchased from Taconic Farms (Germantown, New York). Mice (N = 5) were injected iv with 200 g IMMU-132, the original hRS7 or modified hRS7-NEM (hRS7 treated with TCEP and conjugated to N-ethyl maleimide). Animals collected blood through the <figure-callout id="30" label="retroorbital plexus" filenames="00000045.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">retroorbital plexus</a></figure-callout> 30 minutes, 4, 24, 72 and 168 hours after injection. ELISA ELISA was used to determine the serum concentrations of total IgG hRS7, analyzing the competition for the binding of the idiotypic anti-IgG hRS7 antibody to the hRS7 conjugate with horseradish peroxidase. Serum concentrations of intact IMMU-132 were determined using anti-SN-38 antibody to capture and horseradish peroxidase conjugated anti-IgG hRS7 antibody for detection. Pharmacokinetic (PK) values were calculated using a non-compartmental analysis method using Phoenix WinNonlin software (version 6.3; Pharsight Corp., Mountain View, CA).</span>
  </p>
  <p num="520" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0401]     In vitro -       -3   6-    5105 /    37   .       10     IMMU-132, hA20-SN-38  hRS7-IgG    20 /   30   ,    ,      37      .       , ,       (Fixable Viability Stain 450, BD Biosciences, -, ),  1% -,     4%    15 ,    0,15% Triton-100      15 .    1% -       H2AX-AF488 (EMD Millipore Corporation, , )   45   4.   2       BD FACSCanto (BD Biosciences, -, ).</span>[0401] In Vitro Double-Stranded DNA Rupture Assessment - To test drug activity, BxRS-3 cells were seeded in 6-well plates with a density of 5  105 cells / well and kept at 37  C. overnight. After cooling on ice for 10 min, the cells were incubated with IMMU-132, hA20-SN-38 or hRS7-IgG at a final concentration of 20 g / ml for 30 minutes on ice, washed three times with fresh medium, and then returned to 37  C to continue cultivation overnight. The next morning, the cells were briefly trypsinized, centrifuged, stained with fixed dye to assess viability (Fixable Viability Stain 450, BD Biosciences, San Jose, California), washed with 1% BSA-FSB, and then fixed in 4% formalin for 15 minutes , re-washed, permeabilized 0.15% Triton-X100 in FSB for another 15 minutes. After washing twice with 1% BSA-FSB, the cells were incubated with anti-H2AX-AF488 mouse antibody (EMD Millipore Corporation, Temecula, Calif.) For 45 minutes at 4  C. H2AX signal intensity was measured by flow cytometry on a BD FACSCanto (BD Biosciences, San Jose, California).</span>
  </p>
  <p num="521" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0402]   in vivo -    NCr Nude (nu/nu)  4-8    Taconic Farms (, -).    NCI-N87       ,       1:1   (BD Bioscience; -, )        110<sup class="style-scope patent-text">7</sup>  /   .   -3    1           (HBSS)   40% (/).      1:1          20% (/).    300   /.   () ,       2 ,  : Lw<sup class="style-scope patent-text">2</sup>/2,  L      , a w     .           0,5 <sup class="style-scope patent-text">3</sup>,    ,  ,       .            ,      0,25 <sup class="style-scope patent-text">3</sup>.  ,                .  IMMU-132   ADC (hA20-SN-38)   ,    ,    .</span>[0402] In vivo therapeutic studies of female nude mice NCr Nude (nu / nu) 4-8 weeks old were purchased from Taconic Farms (Germantown, NY). Gastric tumor xenografts NCI-N87 were obtained by collecting cells from tissue culture, preparing a final cell suspension of 1: 1 in Matrigel (BD Bioscience; San Jose, California) and introducing each mouse a total of 1  10 <sup class="style-scope patent-text">7</sup> cells sc in the right side. In the case of BxRS-3, 1 g xenografts were collected and a tumor suspension was obtained in Hanks balanced salt solution (HBSS) at a concentration of 40% (mass / volume). The specified suspension was mixed in a 1: 1 ratio with matrigel to obtain a final tumor suspension with a concentration of 20% (mass / volume). Then, mice were injected with 300 l sc suspension. Tumor volume (PA) was determined by conducting measurements using calipers in two dimensions, as follows: L  w <sup class="style-scope patent-text">2/2,</sup> where L represents the largest linear dimension of the tumor, aw is the smallest linear dimension. For immunohistochemical analysis, tumors were allowed to grow to a size of approximately 0.5 cm <sup class="style-scope patent-text">3</sup> , after which the mice were sacrificed, the tumors were removed, fixed in formalin and embedded in paraffin. For therapeutic studies, mice were randomized into treatment groups and therapy was started when the tumor volume was approximately 0.25 cm <sup class="style-scope patent-text">3</sup> . Treatment regimens, dosages and the number of animals in each experiment are given in the results section and on the captions to the drawings. Lyophilized IMMU-132 and control ADC (hA20-SN-38) were reconstituted and diluted, as directed, in sterile saline.</span>
  </p>
  <p num="522" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0403]     1,0 <sup class="style-scope patent-text">3</sup>  , ,    .       :   -      30%     ;   -        29%       20%     ;  -      20%      ,    .    ()              20%     .</span>[0403] When the tumors exceeded the size of 1.0 cm <sup class="style-scope patent-text">3</sup> mice were killed, believing that they succumbed to the disease. The best response to therapy was defined as: partial response - reduction in size by more than 30% compared with the initial size; stable disease - a reduction in the volume of tumors up to a reduction of 29% or an increase of no more than 20% compared with the initial size; progression - an increase in tumors greater than or equal to 20% compared with either the initial size or the minimum size. Time to progression (TDS) was defined as the period of time after the start of therapy to increase the tumor by more than 20% compared with the minimum size.</span>
  </p>
  <p num="523" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0404]           (AUC).         .             f-.             t-,     ,     t- (      0,05).        - (  ),     Prism GraphPad Software (v4.03) (Advanced Graphics Software, Inc., , ).</span>[0404] A statistical analysis of tumor growth was based on the area under the curve (AUC). The growth profiles of individual tumors were obtained by modeling linear curves. To determine the equality of variance between groups before the statistical analysis of the growth curves used the f-test. To assess the statistical significance between the different treatment groups and controls, a two-sided t-test was used, except for the control saline solution, for which a one-sided t-test was used (significance at P is less than or equal to 0.05). Survival results were analyzed using Kaplan-Mayer graphs (log rank analysis) using the Prism GraphPad Software (v4.03) software package (Advanced Graphics Software, Inc., Encinitas, California).</span>
  </p>
  <p num="524" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0405]  -  (210<sup class="style-scope patent-text">6</sup>)   6-     .        SN-38 (  ),  IMMU-132  ,  0,4 / SN-38 (1 ).  hRS7      ADC.    ,  10  Tris,  7,4; 150  NaCl,      (2  Na2PO4, 10  NaF).    20     4-20% - ,       5%    1 TBS-T ( Tris  , 0,1% Tween-20)   1    .       4  ,      1        (1:2500)   .  ,     (Supersignal West Dura, Thermo Scientific; , ),     Kodak Image Station 40000R.   p21Waf1/Cip1 (. 2947), -3 (. 9665), -7 (. 9492), -9 (. 9502), PARP (. 9542), - (. 4967), pJNK1/2 (. 4668), JNK (. 9258)     HRP      (. 7074)   Cell Signal Technology (, ).</span>[0405] Immunoblotting - Cells (2  10 <sup class="style-scope patent-text">6</sup> ) were seeded in 6-well plates and left overnight. The next day they were treated with either free SN-38 (dissolved in DMSO) or IMMU-132 with a concentration equivalent to 0.4 g / ml SN-38 (1 M). The original hRS7 was used as a control for ADC. Cells were lysed in buffer containing 10 mM Tris, pH 7.4; 150 mM NaCl, protease inhibitors and phosphatase inhibitors (2 mM Na2PO4, 10 mM NaF). A total of 20 g of protein was passed through a 4-20% SDS-polyacrylamide gel, transferred onto a nitrocellulose membrane and blocked with 5% skim milk in 1  TBS-T (Tris buffered saline, 0.1% Tween-20) for 1 hours at room temperature. The membranes were probed overnight at 4  C with primary antibodies, followed by incubation for 1 hour with a secondary antibody against rabbit antibodies (1: 2500) at room temperature. The signal was detected using a chemiluminescence kit (Supersignal West Dura, Thermo Scientific; Rockford, Illinois), with imaging membranes on a Kodak Image Station 40000R. Primary antibodies p21Waf1 / Cip1 (Cat. No. 2947), Caspase-3 (Cat. No. 9665), Caspase-7 (Cat. No. 9492), Caspase-9 (Cat. No. 9502), PARP (Cat. No. 9542), -actin (cat. No. 4967), pJNK1 / 2 (cat. No. 4668), JNK (cat. No. 9258) and a secondary HRP conjugated goat anti-rabbit antibody (cat. No. 7074) were obtained from Cell Signal Technology (Danvers , Massachusetts).</span>
  </p>
  <p num="525" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>results</span>
  </p>
  <p num="526" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0406]   Trop-2       -   Trop-2       ,     ,  ,  ,     ( 10).    ,     ,    ;          . ,     Trop-2     , 49419 (Hs 746)   , 246 85764 651 (NCI-N87)    .</span>[0406] Trop-2 Expression Levels in Several Solid Tumor Cell Lines - Surface expression of Trop-2 is manifested in various solid human tumor lines, including tumors of the stomach, pancreas, mammary gland, colon, and lung (Table 10). There is no type of tumor where expression is higher than in other types; within a single type of tumor cell, variability is observed. For example, in gastric adenocarcinomas, Trop-2 levels ranged from very low values, 494  19 (Hs 746T) to high values, 246 857  64 651 (NCI-N87) surface molecules per cell.</span>
  </p>
  <p num="527" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0407]        Trop-2   ,     ( ).          Trop-2,    FACS-.         ,    -3   2+  3+.     NCI-N87   ,    3+          .  COLO 205        1+  2+,    -29  ,   ,    1+.</span>[0407] When xenografts of gastrointestinal tumors were stained for Trop-2 expression, both cytoplasmic and membrane staining were observed (not shown). Staining intensity correlated well with the results for surface expression of Trop-2, determined using FACS analysis. For all three pancreatic adenocarcinomas, homogeneous staining was observed, where the staining level of BxRS-3 ranged from 2+ to 3+. The staining pattern of gastric adenocarcinoma NCI-N87 was more heterogeneous, with staining of the <figure-callout id="3" label="level" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">level</a></figure-callout> 3+ of the apical lining of the glands and less pronounced staining of the surrounding tumor cells. In <figure-callout id="205" label="COLO" filenames="00000049.png,00000051.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">COLO</a></figure-callout> 205, only individual foci of staining of the level from 1+ to 2+ were found, while in HT-29 it was extremely rare, for several cells, staining of <figure-callout id="1" label="level" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">level</a></figure-callout> 1+ was found.</span>
  </p>
  <p num="528" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/6c/0d/ce00b8a445a004/00000039.png" class="style-scope patent-text"><img file="00000039.jpg" he="167" wi="160" img-format="jpg" img-content="undefined" width="640" height="668" alt="Figure 00000039" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/6c/0d/ce00b8a445a004/00000039.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/72/6c/0d/ce00b8a445a004/00000039.png" class="style-scope patent-text"><img file="00000039.jpg" he="167" wi="160" img-format="jpg" img-content="undefined" width="640" height="668" alt="Figure 00000039" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/72/6c/0d/ce00b8a445a004/00000039.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="529" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5d/d2/84/91da6b773da59a/00000040.png" class="style-scope patent-text"><img file="00000040.jpg" he="134" wi="87" img-format="jpg" img-content="undefined" width="348" height="536" alt="Figure 00000040" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5d/d2/84/91da6b773da59a/00000040.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/5d/d2/84/91da6b773da59a/00000040.png" class="style-scope patent-text"><img file="00000040.jpg" he="134" wi="87" img-format="jpg" img-content="undefined" width="348" height="536" alt="Figure 00000040" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/5d/d2/84/91da6b773da59a/00000040.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="530" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    ,      .</span>a Three separate analyzes were performed, calculating the mean and standard deviation.</span>
  </p>
  <p num="531" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0408]   IMMU-132 -   ,  hRS7       Trop-2 ,   ELISA  ,    Trop-2 ,  Trop-2  ( ).  RS7     Trop-2  (KD=0,3 );    Trop-2  .      Trop-2    Trop-2             Trop-2 (  ).</span>[0408] Binding Characteristics of IMMU-132 - To further demonstrate that hRS7 does not cross-react with mouse Trop-2, ELISA ELISA was performed on plates coated with either recombinant mouse Trop-2 or human Trop-2 (not shown). Humanized RS7 specifically bind only to human Trop-2 (KD = 0.3 nM); no cross-reactivity with mouse Trop-2. Control rabbit polyclonal antibodies against mouse Trop-2 and human Trop-2 did not cross-react and did not bind to both forms of Trop-2 (data not shown).</span>
  </p>
  <p num="532" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0409]   IMMU-132    ,     hRS7,     hRS7, hRS7-NEM (hRS7,      N-) ( ).      KD    ,     hRS7, IMMU-132  hRS7-NEM    .</span>[0409] The binding of IMMU-132 to several cell lines was studied by comparison with the original hRS7 as well as with the modified hRS7, hRS7-NEM (hRS7 treated with TCEP and conjugated to N-ethyl maleimide) (not shown). In all cases, the calculated KD values fell into the subnanomolar range, without significant differences between hRS7, IMMU-132 and hRS7-NEM in a given cell line.</span>
  </p>
  <p num="533" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0410]   IMMU-132  hRS7          (BIACORE) ( ).   Trop-2-    ( = 1110 . .)   Trop-2 .        ,     SN-38    IMMU-132  ,         Trop-2,   hRS7 (0,260,14   0,510,04 , ; =0,0398).</span>[0410] Comparative binding of IMMU-132 and hRS7 was further investigated using surface plasmon resonance analysis (BIACORE) (not shown). We used a low density biosensor Trop-2 chip (density = 1110 rel. Units) with recombinant human Trop-2. The results of three independent binding assays not only indicate that the conjugation process with SN-38 did not undesirably affect IMMU-132, but also demonstrate a higher binding affinity for Trop-2 than for hRS7 (0.26  0.14 nM against 0.51  0.04 nM, respectively; P = 0.0398).</span>
  </p>
  <p num="534" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0411]  :       -  - IMMU-132  hRS7     ,  (MDAMB-468),  (NIH:OVCAR-3)    (-3) ( ).      hRS7    ,       ,    IMMU-132 (  0,0054).   IMMU-132          60%    hRS7. ,   MDA-MB-468,  ,  hRS7,  29,82,6%  8,62,6%  IMMU-132 ( ;   0,0001).   -     NIH:OVCAR-3  -3 ( ;   0,0001    0,0054; ).   -     ,    ,           hRS7-NEM,     CL2A-SN-38,      N- ( ). -,   hRS7  IMMU-132,  (  ).</span>[0411] Mechanism of action: ADCC and internal apoptosis signaling pathways - The ADCC activity of IMMU-132 and hRS7 in three different cell lines, TNRM (MDAMB-468), ovaries (NIH: OVCAR-3) and pancreas (BxRS-3) were compared. ) (not shown). In all three cell lines, hRS7 mediated significant cell lysis, unlike all other treatment options, including IMMU-132 (P less than 0.0054). When IMMU-132 was used to target cells, ADCC decreased by more than 60% compared to hRS7. For example, in MDA-MB-468 cells, the specific lysis mediated by hRS7 was 29.8  2.6% versus 8.6  2.6% for IMMU-132 (not shown; P less than 0.0001). A similar decrease in ADCC activity was also observed in NIH cells: OVCAR-3 and BxRS-3 (not shown; P less than 0.0001 and P less than 0.0054; respectively). The indicated attenuated ADCC activity is supposedly the result of antibody changes that occur during the conjugation process, since the exact same decrease in specific cell lysis was observed for hRS7-NEM, in which the CL2A-SN-38 linker is absent, and instead, cysteines are blocked by N-ethyl maleimide (not shown). SCC activity associated with hRS7 or IMMU-132 is absent (data not shown).</span>
  </p>
  <p num="535" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0412]   ,  IMMU-132        (53  p21WAF1/Cip1),       PARP20.     ,  IMMU-132,       NCI-N87      -3  1   SN-38    IMMU-132 ( ).   SN-38,  IMMU-132    p21WAF1/Cip1,       NCI-N87,     SN-38  IMMU-132    48  ( ),       -3    24  ( ).   SN-38,   IMMU-132    -9  -7   48   . -3            48 . ,   SN-38,  IMMU-132   PARP.      24 ,    48 .     ,  SN-38,    IMMU-132,    ,    SN-38.</span>[0412] It was previously shown that IMMU-132 mediates upregulation of early proapoptotic signaling events (p53 and p21WAF1 / Cip1), ultimately leading to PARP20 cleavage. For a better understanding of the apoptotic pathway used by IMMU-132, the human gastric carcinoma cell line NCI-N87 and human pancreatic adenocarcinoma BxRS-3 were exposed to 1 M free SN-38 or an equivalent amount of IMMU-132 (not shown). Both free SN-38 and IMMU-132 mediate up-regulation of p21WAF1 / Cip1, although the same up-regulation in NCI-N87 cells, which were exposed to free SN-38 or IMMU-132, is observed only after 48 hours (not shown), whereas maximum positive regulation for BxRS-3 appears within 24 hours (not shown). Both free SN-38 and IMMU-132 show cleavage of pro-caspases-9 and -7 within 48 hours of exposure. Procaspase-3 cleaves in both cell lines with a maximum observed degree of cleavage after 48 hours. Finally, both free SN-38 and IMMU-132 mediated PARP cleavage. This cleavage first appears after 24 hours, with an increase after 48 hours. Together, these data confirm that SN-38, which is part of IMMU-132, has the same activity as free SN-38.</span>
  </p>
  <p num="536" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0413]       ,   -3,       SN-38,  IMMU-132,    hRS7 ( ),     ,    ,  ,  JNK (pJNK).   pJNK   4 ,       6 .  ,     SN-38,         ,    IMMU-132,       .         IMMU-132      -3.  IMMU-132  -3    30         2      ADC ( 11).  70%       2   20%   hRS7,  ADC, hA20-SN-38     (  0,0002).</span>[0413] In addition to these later signaling events of apoptosis, in BxRS-3 cells, which were briefly exposed to either free SN-38 or IMMU-132, but not naked hRS7 (not shown), an earlier event associated with the indicated by, namely, phosphorylation of JNK (pJNK). An increase in pJNK appears after 4 hours, with undetectable changes after 6 hours. Cells exposed to free SN-38 show a higher phosphorylation rate compared to cells exposed to IMMU-132, but both are essentially above control. As an endpoint for assessing the mechanism of action of IMMU-132, dsDNA breaks in BxRS-3 cells were measured. The effect of IMMU-132 on BxRS-3 for a total of 30 min led to a more than twofold increase in the induction of H2AX compared to the non-targeting control ADC (Table 11). About 70% of the cells were positive for H2AX staining, relatively less than 20% for naked hRS7, irrelevant ADC, hA20-SN-38, and untreated control (P less than 0.0002).</span>
  </p>
  <p num="537" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a0/ea/f0/7b13e276baab00/00000041.png" class="style-scope patent-text"><img file="00000041.jpg" he="90" wi="160" img-format="jpg" img-content="undefined" width="640" height="360" alt="Figure 00000041" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a0/ea/f0/7b13e276baab00/00000041.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/a0/ea/f0/7b13e276baab00/00000041.png" class="style-scope patent-text"><img file="00000041.jpg" he="90" wi="160" img-format="jpg" img-content="undefined" width="640" height="360" alt="Figure 00000041" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/a0/ea/f0/7b13e276baab00/00000041.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p num="538" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">  IMMU-132   3   ,   0,0002 ( t-; N  3).</span>a Comparison of IMMU-132 and all 3 control processing options, P less than 0.0002 (one-sided t-test; N is 3).</span>
  </p>
  <p num="539" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0414]  IMMU-132 -      (FcRn)     BIACORE ( ).    FcRn-   ( = 1302 . .)          (400-25 )   .  ,  hRS7,  IMMU-132   KD    (92,45,7   191,947,6 , ),   .   IMMU-132,    IMMU-132  IgG hRS7     hRS7,     ELISA ( ).  ,   hRS7,     ( ),     hRS7  IMMU-132 ( ),  -  -   3  200 , .  ,     IMMU-132    11      (MRT) 15,4  ( ).</span>[0414] Pharmacokinetics IMMU-132 - Binding to the human neonatal receptor (FcRn) was determined using a BIACORE assay (not shown). Using a low density biosensor FcRn chip (density = 1302 rel. Units), three independent binding assays were performed with five different concentrations (400-25 nM) for each agent. In general, both hRS7 and IMMU-132 show KD values in the nanomolar range (92.4  5.7 nM and 191.9  47.6 nM, respectively), without significant differences. Mice were injected with IMMU-132, and the excretion of IMMU-132 or IgG hRS7 compared to the original hRS7 was compared using two ELISA ELISA (not shown). In mice injected with hRS7, a two-phase elimination pattern (not shown) was observed similar to that observed for the hRS7 targeting part of IMMU-132 (not shown), with alpha and beta half-lives of approximately 3 and 200 hours, respectively. Conversely, fast excretion of intact IMMU-132 was observed with a half-life of 11 hours and an average retention time (MRT) of 15.4 hours (not shown).</span>
  </p>
  <p num="540" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0415]    ,          ,   hRS7     hRS7 (hRS7-NEM).    -     , Cmax, AUC,   MRT    ( ).</span>[0415] To further confirm that the destruction of the interchain disulfide bonds does not alter the targeting antibody FC, the parent hRS7 FC was compared with the modified hRS7 FC (hRS7-NEM). Significant differences between any agents with respect to half-life, Cmax, AUC, excretion, or MRT were not noted (not shown).</span>
  </p>
  <p num="541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0416]  IMMU-132       -  IMMU-132          ,   ,      (Cardillo et al., 2011, Clin Cancer Res 17:3157-69; Goldenberg et al.,  ,         -, 9-13 ,  5-19-08).           IMMU-132   ,     , NCI-N87 ( ).   IMMU-132           ,     ADC ( CD20) hA20-SN-38 ( ;   0,001).  ,      18       ,   6  7    IMMU-132.        (),  41,74,2 ,         ADC,    4,12,0  (  0,0001).  ,    (MST)    IMMU-132   66   24     ADC  14        ( ;   0,0001).</span>[0416] The efficacy of IMMU-132 against xenografts of human gastric carcinoma - The efficacy of IMMU-132 was previously demonstrated in models with xenografts of non-small cell lung cancer, colon cancer, TNBC, and pancreatic carcinoma (Cardillo et al., 2011, 17 Clincer Res : 3157-69; Goldenberg et al., Poster presentation presented at the Symposium on Breast Cancer in San Antonio, December 913, Abstracts No. P5-19-08). To further expand this finding to other gastrointestinal cancers, IMMU-132 was tested in mice bearing a human gastric carcinoma xenograft, NCI-N87 (not shown). When treating IMMU-132, significant regression of the tumors was achieved compared to that observed with controls, saline and non-targeting ADC (anti-CD20) hA20-SN-38 (not shown; P less than 0.001). A partial response lasting more than 18 days after the last therapeutic dose was administered to animals was observed in 6 of 7 mice in the IMMU-132 group. The specified response provided an average time to progression (VDP) of 41.7  4.2 days, which differs from the lack of response in the control ADC group, where the VDP was 4.1  2.0 days (P less than 0.0001). Overall, the median survival time (MST) in mice treated with IMMU-132 was 66 days versus 24 days for control ADC and 14 days for saline control animals (not shown; P less than 0.0001).</span>
  </p>
  <p num="542" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0417]     -    IMMU-132   ,     ,  8  10 /    1  8  21- .  8 /        98,4 /,   2       20 .        2  IMMU-132          (-3).             :      IMMU-132  1  (  1  15 ),      0,5  (  1, 8, 22  29 )        0,25  (  1, 4, 8, 11, 22, 25, 29  32 ).                ,      ,     ( ;   0,0009    0,0001, ).     -      ,    22,410,1     1   31,714,5     0,25  (       = 5,02,3 ).</span>[0417] Clinically Relevant Dosing Schemes - The maximum tolerated doses of IMMU-132 when administered repeatedly, clinically tested to date, are 8 and 10 mg / kg when given on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout"><figure-callout id="8" label="days" filenames="00000046.png,00000056.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout></a></figure-callout> 1 and 8 of 21-day cycles. A dose of 8 mg / kg for humans is converted to a dose for mice of 98.4 mg / kg, or approximately 2 mg per mouse, with a body weight of 20 g. Three different dosing regimens divided into parts of 2 mg IMMU-132 were investigated in a pancreatic adenocarcinoma xenograft model human glands (BxRS-3). The indicated total dose was divided into parts according to one of three different dosing regimens: one group received two doses of 1 mg IMMU-132 (therapy on <figure-callout id="1" label="days" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">days</a></figure-callout> 1 and 15), one received four doses of 0.5 mg (therapy on 1, 8, 22 and 29 days) and the last group received eight doses of 0.25 mg (therapy at 1, 4, 8, 11, 22, 25, 29 and 32 days). All three dosing regimens provided a significant antitumor effect compared to control untreated animals, both in terms of inhibition of tumor growth and overall survival (not shown; P less than 0.0009 and P less than 0.0001, respectively). There are no significant differences in VDT between any of the three different treatment groups; VDV ranged from 22.4  10.1 days for the <figure-callout id="1" label="dosing group" filenames="00000044.png,00000045.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">dosing group</a></figure-callout> 1 mg to 31.7  14.5 days for the dosing group 0.25 mg (VDP in treated with the control group = 5.0  2.3 days).</span>
  </p>
  <p num="543" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0418]        ,      NCI-N87 ( ).               ,      (AUC;   0,0001).    ,  ,  ,                  (  0,0001),   -      .</span>[0418] A similar experiment with dosing regimens was performed on mice bearing xenografts of the human stomach tumor NCI-N87 (not shown). All three dosing regimens provided a significant antitumor effect compared to control untreated mice, but did not differ from each other (AUC; P less than 0.0001). With regard to overall survival, similarly, while all three dosing regimens provided a significant advantage in terms of survival compared to the untreated control (P less than 0.0001), there were no differences between any of the three different treatment groups.</span>
  </p>
  <p num="544" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0419]       ,   NCI-N87,    IMMU-132,       0,5  IMMU-132                  ( ),     .       4  .</span>[0419] To further differentiate possible dosing regimens, mice bearing NCI-N87 tumors were subjected to chronic dosing of IMMU-132, in which mice were injected with 0.5 mg IMMU-132 once a week for two weeks, followed by one week of rest before the start of the next cycle (not shown), according to the current clinical trial schedule. In total, 4 treatment cycles were performed in animals.</span>
  </p>
  <p num="545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0420]         15,711,1   4,72,2      ADC  (  0,0122).  ,    19-    3 ,  21      ADC   63   ,   IMMU-132 (  0,0001).  ,                ,        (  ).</span>[0420] The dosing schedule indicated slowed tumor growth with VDT 15.7  11.1 days versus 4.7  2.2 days in mice treated with control ADC mice (P = 0.0122). In general, chronic dosing increased the 19-month median survival by 3 times, from 21 days for treated mice with ADC control mice to 63 days for animals treated with IMMU-132 (P = 0.0001). It is important to note that when evaluating all of these different dosing regimens in mice, treatment-related toxicity was not observed, as demonstrated by the absence of a significant reduction in body weight (data not shown).</span>
  </p>
  <p num="546" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"></span>Discussion</span>
  </p>
  <p num="547" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0421]     I/II  (ClinicalTrials.gov, NCT01631552),   IMMU-132 ( )           (Starodub et al., 2015, Clin Cancer Res 21:3870-78).       I/II       IMMU-132     Trop-2-  .  ,             IMMU-132,       ADC,      .</span>[0421] In the current clinical trial of phase I / II (ClinicalTrials.gov, NCT01631552), when using IMMU-132 (Sacituzumab Govitecan), objective responses are observed in patients with a wide range of solid tumors (Starodub et al., 2015, Clin Cancer Res 21 : 3870-78). As this clinical trial of phase I / II continues, the effectiveness of IMMU-132 for the treatment of an expanded list of Trop-2-positive cancers should be further investigated. In addition, as clinical development advances, more research is needed to elucidate the uniqueness of IMMU-132, which distinguishes it from other clinically relevant ADCs that use ultra-toxic drugs.</span>
  </p>
  <p num="548" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0422]       IMMU-132  ,                .  ,   ADC   ,  ,           ,         (Panowski et al., 2014, mAbs 6:34-45).      ADC     (IC50   ),     ,     (2-4     ). IMMU-132        : (i)      SN-38,     ( IC<sub class="style-scope patent-text">50</sub>); (ii) SN-38 -    8   ,     = 7,6     ;  (iii)   ,     ,           ~24  (Cardillo et al., 2011, Clin Cancer Res 17:3157-69). IMMU-132   ,      ,     ,   Trop-2 ,          ,  ,    ,      (Shih et al., 1995, Cancer Res 55:5857s-63s).    ,     Trop-2   , , ,    Trop-2   ,            ,       ,  ,       -  ,              (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).</span>[0422] In the work presented in this document, IMMU-132 is further characterized and demonstrated to be effective against gastric and pancreatic adenocarcinomas using clinically relevant dosing regimens. The prevailing view is that an effective ADC should include an antibody that recognizes an antigen that is characterized by high levels of expression in the tumor compared to normal tissues, and is preferably internalized upon binding to tumor cells (Panowski et al., 2014, mAbs 6: 34-45). All currently approved ADCs include an ultratoxic drug (IC50 in the picomolar range) coupled to the antibody by a highly stable linker with low substitution ratios (2-4 drug molecules per antibody). IMMU-132 diverges from this paradigm in three main aspects: (i) SN-38, a moderately cytotoxic drug (nM IC <sub class="style-scope patent-text">50</sub> ), is used as a chemotherapeutic agent; (ii) SN-38 is site-specific conjugated with 8 interchain thiols of the antibody, which gives a substitution coefficient = 7.6 drug molecules per antibody; and (iii) a carbonate linker is used that breaks down at low pH, but also releases a drug with a serum half-life of ~ 24 hours (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). IMMU-132 consists of an antibody that internalizes after binding to an epitope, as shown by the inventors, specific for human Trop-2, which is expressed at high levels in various types of epithelial tumors, as well as at lower concentrations, in their normal tissues (Shih et al., 1995, Cancer Res 55: 5857s-63s). Previous studies on monkeys that also expressed Trop-2 in similar tissues showed that, despite the presence of Trop-2 in normal tissues, the histopathological changes were relatively mild and reversible even at very high doses at which dose-limiting neutropenia and diarrhea occurred , which suggests that the indicated antigen in normal tissues was somehow sequestered, or that the use of a less toxic drug prevented serious damage to these normal tissues (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69).</span>
  </p>
  <p num="549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0423]          Trop-2      ,   in vitro      ,     ,  ,  ,       Trop-2     (, NCIN87)    (, COLO 205).  ,    Trop-2,  in vitro,      - .  ,  ,     ,  COLO 205,          Trop-2 , IMMU-132        ,           SN-38  ,     (Cardillo et al., 2011, Clin Cancer Res 17:3157-69). , SN-38     , , ,             ,     .  ,  SN-38,   ,   ;               (Sharkey et al., 2015, Clin Cancer Res, 21:5131-8).    ,   IMMU-132         SN-38      SN-38      ,    .</span>[0423] In this document, the inventors presented an extended assessment of Trop-2 expression in several lines of solid human tumors, examining in vitro expression with a greater emphasis on quantitative approach than in earlier reports, but also, importantly, the evaluation in xenografts with illustrative expression of Trop-2 ranging from homogeneous (e.g., NCIN87) to markedly focal (e.g., COLO 205). In general, Trop-2 surface expression levels determined in vitro correlated with staining intensity in the IHC analysis of xenografts. In particular, it is interesting to note that even in a tumor such as <figure-callout id="205" label="COLO" filenames="00000049.png,00000051.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">COLO</a></figure-callout> 205, where immunohistological analysis revealed exclusively focal clusters of Trop-2 expressing cells, IMMU-132 was still able to cause a specific tumor regression, indicating a possible witness effect "As a result of the release of SN-38 from the conjugate bound to antigen-presenting cells (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69). So, SN-38 easily penetrates through cell membranes, and, accordingly, local release within the tumor microenvironment provides another mechanism for its entry into cells, which does not require internalization of the intact conjugate. It is important to note that the SN-38 associated with the conjugate remains fully active; that is, it is not glucuronidated and is in the form of a lactone ring at the time of release (Sharkey et al., 2015, Clin Cancer Res, 21: 5131-8). This property is unique, providing the distinctive IMMU-132 ability to more selectively localize the fully active form of SN-38 compared to any other slow-release SN-38 or irinotecan agents studied to date.</span>
  </p>
  <p num="550" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0424]    I    IMMU-132  8  10 /,       21- ,     II  (Starodub et al., 2015, Clin Cancer Res 21:3870-78).        ,        ,     ,  ,        (Starodub et al., 2015, Clin Cancer Res 21:3870-78; Starodub et al., 2014, J Clin Oncol 32:5s (Suppl Abstr 3032)).                .    ,   8 /   (   98,4 /)        ,       ; ;        21- .         -         ;        . ,             ,       .</span>[0424] In a phase I clinical trial, dosages of IMMU-132 from 8 to 10 mg / kg, administered weekly for two weeks on a 21-day cycle, were identified for further study in phase II (Starodub et al., 2015, Clin Cancer Res 21 : 3870-78). Patients with a wide range of metastatic solid tumors, including pancreatic and gastric cancer, had prolonged periods of stabilization of the disease after relapses that occurred after several previous treatments (Starodub et al., 2015, Clin Cancer Res 21: 3870-78 ; Starodub et al., 2014, J Clin Oncol 32: 5s (Suppl Abstr 3032)). Additional studies have been conducted in xenograft models to determine the possible greater efficacy of other dosing regimens. For this purpose, a dose equivalent to a dose of 8 mg / kg in humans (mouse dose 98.4 mg / kg) was divided into parts according to three different dosage regimens, including administration once every two weeks; weekly; or twice a week during a 21-day cycle. In models of tumors of the pancreas and stomach between any of the three regimens, there was no significant difference in therapeutic responses; while the tumors progressed only after discontinuation of therapy. Accordingly, these data support the continued use of the dosing regimen with a weekly single administration currently used in a clinical trial.</span>
  </p>
  <p num="551" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0425]           IMMU-132  8  10 / (Starodub et al., 2015, Clin Cancer Res 21:3870-78),   ,          IMMU-132.           Nude   IgG hRS7   (,     25  50 /),      (Cardillo et al., 2011, Clin Cancer Res 17:3157-69);          . - hRS7 in vitro    Trop-2-     (Raji et al., 2011, J Exp Clin Cancer Res 30:106; Bignotti et al., 2011, Int J Gynecol Cnacer 21:1613-21; Varughese et al., 2011, Am J Obstet Gynecol 205:567; Varughese et al., 2011, Cancer 117:3163-72).     -  hRS7     ,  ,  IMMU-132  60-70%  .  /NEM- IgG    -,   CL2A-SN-38   , ,     .</span>[0425] Based on the recommended clinical trial dose of IMMU-132 from 8 to 10 mg / kg (Starodub et al., 2015, Clin Cancer Res 21: 3870-78), it was important to examine whether the antibody alone contribute to the activity of IMMU-132. Previous studies in human tumor xenograft models in Nude mice included individually unconjugated hRS7 IgG (e.g. multiple doses of 25 to 50 mg / kg) that did not show therapeutic activity (Cardillo et al., 2011, Clin Cancer Res 17: 3157-69); however, studies in mice do not always predict immunological functionality. The ADCC activity of hRS7 in vitro has been described for Trop-2 positive ovarian and uterine carcinomas (Raji et al., 2011, J Exp Clin Cancer Res 30: 106; Bignotti et al., 2011, Int J Gynecol Cnacer 21: 1613- 21; Varughese et al., 2011, Am J Obstet Gynecol 205: 567; Varughese et al., 2011, Cancer 117: 3163-72). The authors of the present invention confirmed the ADCC activity of unconjugated hRS7 in three different cell lines, but found that IMMU-132 lost 60-70% of effector function. Since reduced / NEM-blocked IgG was characterized by a similar decrease in ADCC activity, the attachment of the component CL2A-SN-38 in itself, presumably, was not related to this.</span>
  </p>
  <p num="552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0426]      ,      .       -        ,     ,  IMMU-132      SN-38 .     JNK1/2,     p21WAF1/Cip1,    -9, -7  -3,      PARP     ,         2 (2)41.   ,     IMMU-132   SN-38.</span>[0426] Antibodies can also cause cell death by acting on various apoptotic signaling pathways. However, the authors of the present invention did not observe any effects of unconjugated antibodies on a number of apoptotic signaling pathways, but it was noted that IMMU-132 stimulated internal apoptotic phenomena in a similar way to SN-38. Early events include phosphorylation of JNK1 / 2, as well as upregulation of p21WAF1 / Cip1, leading to activation of caspase-9, -7, and -3, the end result of which is the cleavage of PARP and significant levels of dsDNA breaks, estimated based on an increase in the amount of phosphorylated histone H2AX (H2AX) 41. These data suggest that the primary mechanism of action of IMMU-132 is associated with SN-38.</span>
  </p>
  <p num="553" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0427]       (BIACORE)    IMMU-132     (FcRn)   ,   ,      IMMU-132   2  .   FcRn       IgG   (Junghans &amp; Anderson, 1996, Proc Natl Acad Sci USA 93:5512-16), ,     FcRn in vitro      in vivo (Datta-Mannan et al., 2007, J Biol Chem 282:1709-17),     .          <sup class="style-scope patent-text">111</sup>In-DTPA-IMMU-132 ,          ,   <sup class="style-scope patent-text">111</sup>In-DTPA-hRS7,       (Cardillo et al., 2011, Clin Cancer Res 17:3157-69).       ELISA,    IgG-,  ,    IMMU-132    NEM- IgG      hRS7,  ,        .   ,    ELISA      (     SN-38       ),    ,     IgG-.       SN-38      ~1 .             ,    ELISA,         (Goldenberg et al., 2015, Oncotarget 8:22496-512).  ,   ,       -                 IgG  ,      IMMU-132       SN-38 .</span>[0427] When surface plasmon resonance analysis (BIACORE) analysis showed no significant difference in binding between IMMU-132 and human neonatal receptor (FcRn), despite the fact that the average binding levels for IMMU-132 are about 2 times lower. FcRn binding has been associated with an increase in serum IgG half-life (Junghans &amp; Anderson, 1996, Proc Natl Acad Sci USA 93: 5512-16), however, since the affinity of the anti-FcRn antibody in vitro does not necessarily correlate with the in vivo excretion rate (Datta- Mannan et al., 2007, J Biol Chem 282: 1709-17), the final importance of this binding is unknown. In previous experiments on tumor-bearing mice using <sup class="style-scope patent-text">111</sup> In-DTPA-IMMU-132, it was found that the excretion rate of the indicated conjugate from serum was slightly higher than that of <sup class="style-scope patent-text">111</sup> In-DTPA-hRS7, although both showed similar tumor uptake (Cardillo et al. 2011, Clin Cancer Res 17: 3157-69). In ongoing studies with ELISA ELISA, also measuring the excretion of the IgG component, it was found that the excretion rates of IMMU-132 and restored and NEM-blocked IgG were similar to the rates for unconjugated hRS7, which suggests that the compound with interchain disulfides does not destabilize the antibody. As expected, when ELISA ELISA was used to monitor excretion of an intact conjugate (capture using an anti-SN-38 antibody and a probe with an anti-idiotypic antibody antibody), the excretion rate was higher than when monitoring only the IgG component. The indicated difference merely reflects the release of SN-38 from the conjugate with a half-life of ~ 1 day. The inventors also investigated the excretion rates of govitecan sacituzumab conjugates with different levels of substitution using ELISA ELISA, and also did not find significant differences in excretion rates (Goldenberg et al., 2015, Oncotarget 8: 22496-512). In general, these data suggest that mild antibody recovery followed by site-specific modification of some or all of the interchain disulfides has minimal or no effect on serum IgG excretion, with the overall release rate of IMMU-132 being largely determined by the release rate SN-38 linker.</span>
  </p>
  <p num="554" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0428]  ,            IMMU-132,    NEM- ,  ,  -        . ,    BIACORE,        ,   , IMMU-132   2-    KD   Trop-2     hRS7.</span>[0428] In addition, extensive cell binding experiments have shown no significant differences in the binding of IMMU-132, unconjugated antibody, or NEM-modified antibody, suggesting that site-specific attachment to interchain disulfides retains antigen-binding properties of the antibody. Interestingly, in the BIACORE assay, which allows more accurate measurement of binding and dissociation rates, in addition to overall affinity, IMMU-132 showed a significant 2-fold increase in the calculated KD values for Trop-2 binding compared to bare hRS7.</span>
  </p>
  <p num="555" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0429]    ,           SN-38  .  ,        ,   ,      (Park et al., 2000, Nat Biotechnol 18:194-98; Berezov et al., 2001, J Med Chem 44:2565-74; Young et al., 2007, Proc Natl Acad Sci USA 104:808013).        - ,      ,      (Li et al., 2005, Structure 13:297-307).       SN-38       (CDR) hRS7,    ,  SN-38          ,        IMMU-132   hRS7.</span>[0429] The authors of the present invention suggest that this increase may be the result of increased hydrophobicity when conjugating SN-38 with an antibody. The hydrophobic residues, as well as the hydrophobicity of the closed regions of the protein binding sites, have been shown to enhance the affinity for the epitope (Park et al., 2000, Nat Biotechnol 18: 194-98; Berezov et al., 2001, J Med Chem 44: 2565 74; Young et al., 2007, Proc Natl Acad Sci USA 104: 808013). These regions do not have to be located on the protein-protein interaction interface, and can be located on surrounding residues that provide energetically less favorable contacts (Li et al., 2005, Structure 13: 297-307). Although none of the SN-38 conjugation sites is located in the complementarity determining regions (CDR) of hRS7, it cannot be ruled out that SN-38 on the antibody can replace a certain number of water molecules around the epitope, which leads to an observed increase in the binding affinity of IMMU-132 relatively naked hRS7.</span>
  </p>
  <p num="556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0430]   ADC             ;           (Panowski et al., 2014, mAbs 6:34-45; Phillips et al., 2008, Cancer Res 68:9280-90). ,   T-DM1  ,   , T-SSPDM1, ,   T-SSP-DM1    2  ,  T-DM-1,      (Phillips et al., 2008, Cancer Res 68:9280-90; Erickson et al., 2012, Mol Cancer Ther 11:1133-42),  1,5-    T-DM1    T-SSPDM1  .        ,                 ADC (Erickson et al., 2012, Mol Cancer Ther 11:1133-42).</span>[0430] In developing ADC, efforts have focused mainly on the use of a stable linker and an ultra-toxic drug; preclinical studies indicated specific optimal requirements for these conjugates (Panowski et al., 2014, mAbs 6: 34-45; Phillips et al., 2008, Cancer Res 68: 9280-90). For example, when comparing T-DM1 with another, less stable derivative, T-SSPDM1, it was found that intact T-SSP-DM1 was excreted approximately 2 times faster than T-DM-1 in non-tumor-bearing mice (Phillips et al ., 2008, Cancer Res 68: 9280-90; Erickson et al., 2012, Mol Cancer Ther 11: 1133-42), with 1.5-fold higher levels of T-DM1 compared to T-SSPDM1 in tumors. An unexpected and extremely interesting discovery was that the amount of free active maytansinoid metabolites in the target tumors was significantly similar for the two ADCs (Erickson et al., 2012, Mol Cancer Ther 11: 1133-42).</span>
  </p>
  <p num="557" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0431]  , T-SSP-DM1         ,                    T-DM1.  ,         ADC           .      T-DM1    ,           (Phillips et al., 2008, Cancer Res 68:9280-90).  SN-38        log-  ,   , ,     ADC     .        SN-38,         ,  136       ,    ,     20    SN-38 (Sharkey et al., 2015, Clin Cancer Res, 21:5131-8).           IMMU-132              IMMU-132 (Govindan et al., 2013, Mol Cancer Ther 12:968-78).</span>[0431] In other words, T-SSP-DM1 was able to compensate for the lack of stability of the linker due to the fact that lower stability led to a more efficient release of the drug in the tumor compared with the release of more stable T-DM1. Naturally, the indicated equivalence of the active catabolites of the drug from two ADCs in tumors led to similar antitumor effects in tumor-bearing animals. Ultimately, T-DM1 was chosen, taking into account the toxicity problems associated with the use of an ultra-toxic drug and less stable linkers (Phillips et al., 2008, Cancer Res 68: 9280-90). Since SN-38 is at least one order on the log scale less toxic than these maytansines, it is expected that its release from ADC will result in less toxicity. However, even when released in serum, the amount of SN-38 localized in xenografts of a human stomach or pancreas tumor was up to 136 times higher than the number of tumor-bearing mice injected with doses of irinotecan containing more than 20 times the equivalent of SN-38 (Sharkey et al., 2015, Clin Cancer Res, 21: 5131-8). When the inventors tested more stable linkers when developing IMMU-132, they were significantly less effective in tumor xenograft models compared to IMMU-132 (Govindan et al., 2013, Mol Cancer Ther 12: 968-78).</span>
  </p>
  <p num="558" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0432]  , ,  SN-38  (,      ~10 )         (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61),      SN-38,   . ,      ,  IMMU-132            ,  .</span>[0432] Similarly, linkers that released SN-38 faster (for example, with a serum half-life of ~ 10 hours) were also less effective in xenograft models (Moon et al., 2008, J Med Chem 51: 6916-26; Govindan et al., 2009, Clin Chem Res 15: 6052-61), suggesting an optimal SN-38 release window providing improved efficacy. Accordingly, current data demonstrate that IMMU-132 is a more effective method for targeting and releasing a drug in a tumor than irinotecan.</span>
  </p>
  <p num="559" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0433]           , ,   ,   ,           (Starodub et al., 2015, Clin Cancer Res 21:3870-78).</span>[0433] Early clinical studies showed promising objective responses in various solid tumors, and, importantly, a better safety profile with a lower incidence of diarrhea compared to irinotecan therapy (Starodub et al., 2015, Clin Cancer Res 21: 3870- 78).</span>
  </p>
  <p num="560" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0434]  , IMMU-132 ( )       ADC.    -    7-8      , SN-38,    Trop-2.           ADC,   ,  IMMU-132      Trop-2-         .     I/II      ,     , , ,     , IMMU-132           ,        IgG,    SN-38,      (Starodub et al., 2015, Clin Cancer Res 21:3870-78).    Trop-2      ,    IMMU-132,  ,   ,      .</span>[0434] Summarizing the above, IMMU-132 (satsituzumab govitekan) represents a paradigm shift in the development of ADC. It uses a moderately stable linker to conjugate 7-8 molecules of the best-tolerated active metabolite of irinotecan, SN-38, with an anti-Trop-2 antibody. Despite these seemingly contradictory characteristics compared to ultra-toxic ADCs, non-clinical studies have shown that IMMU-132 provides very effective targeting of Trop-2-expressing tumors with significant efficacy in the absence of measurable toxicity. In early clinical trials of phase I / II against a wide range of solid tumors, including pancreas, stomach, TNBC, small cell and non-small cell lung carcinomas, IMMU-132 similarly showed antitumor effects in controlled toxicity in these patients, in the absence of a detected immune response both on IgG and on SN-38, even after many months of dosing (Starodub et al., 2015, Clin Cancer Res 21: 3870-78). In view of the increased expression of Trop-2 on such a wide range of solid tumors, clinical studies of IMMU-132 are ongoing, in particular with advanced cancer refractory to most current treatment strategies.</span>
  </p>
  <p num="561" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> 18.     I/II </span>Example 18. Additional results of clinical trials of I / II phase</span>
  </p>
  <p num="562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">       ()</span>Triple negative phenotype breast cancer (TNBC)</span>
  </p>
  <p num="563" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0435]   I/II  (NCT01631552),     ,  ,   56   ,    10 /.   ,    IMMU-132,   ,     2   ,   .    , , , , , , , , ,   .             IMMU-132,    2     (),  13 -   (),   25 -   (),    ,  29% (15/52) ( ).     ++,      71%       IMMU-132  ( ).                9,4 ,    2,9  14,2    .  72%      .</span>[0435] The clinical trial of phase I / II (NCT01631552) described in the examples section above was continued, involving 56 patients with TNBC who were treated with 10 mg / kg. The patient population, prior to the start of IMMU-132 therapy, received extensive treatment involving at least 2 previous lines of therapy, including taxane treatment. Previous treatments included cyclophosphamide, doxorubicin, carboplatin, gemcitabine, capecitabine, eribulin, cisplatin, anastrozole, vinorelbine, bevacizumab and tamoxifen. Despite the history of extensive treatment, patients with TNBC responded well to IMMU-132, with 2 patients showing a complete response (PO), 13 - a partial response (PR), and 25 - a stable disease (SZ), with an objective response equal to 29% (15/52) (not shown). Based on the addition of the frequency of PO + CHO + SZ, treatment with TNBC resulted in a 71% favorable response rate for IMMU-132 treated patients (not shown). The median time to progression in the previously indicated serious treatment population of patients with TNBC was 9.4 months, with a range of 2.9 to 14.2 months to date. However, 72% of patients in the study continued to receive treatment.</span>
  </p>
  <p num="564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Metastatic NSCLC</span>
  </p>
  <p num="565" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0436]            (),       29   ,    8  10 / IMMU-132.       RESIST 1.1 ( ).  29   8  40   13 - .        ,   21/33 (64%)     40   ( ).      9/4 ,    1,8  15,5+ ,   47%    .        ,   8  10 / IMMU-132 ( ).    3,4    8 /  3,8    10 /.    ,      , ,  .</span>[0436] A clinical trial is also ongoing for patients with metastatic non-small cell lung cancer (NSCLC), with 29 evaluable patients currently receiving treatment with 8 or 10 mg / kg IMMU-132. The best answers were determined according to the criteria of the RESIST 1.1 scale (not shown). Of 29 patients, 8 had 40 and 13 had SZ. The time to progression for patients with NSCLC showed that in 21/33 (64%) patients with NSCLC there were 40 or SZ (not shown). The median time to progression was 9/4 months, with a range of 1.8 to 15.5+ months, with 47% of patients continuing to receive treatment. Progression-free survival was determined in patients with NSCLC treated with 8 or 10 mg / kg IMMU-132 (not shown). Median PFS was 3.4 months at a dose of 8 mg / kg and 3.8 months at a dose of 10 mg / kg. However, research is still ongoing, and progression-free median survival rates are likely to improve.</span>
  </p>
  <p num="566" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Metastatic scr</span>
  </p>
  <p num="567" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0437]         ( ).      ( )  4,9 ,    1,8  15,7+ ,   7     IMMU-132.    (  ) ( )  2,0    8 /  3,6    10 /.   ( )  8,1    8 /,        10 /.</span>[0437] Comparable results were observed in patients with metastatic MPD (not shown). The observed median time to progression (not shown) was 4.9 months, with a range of 1.8 to 15.7+ months, with 7 patients continuing to receive IMMU-132 treatment. The observed median PFS (progression-free survival) (not shown) was 2.0 months at a dose of 8 mg / kg and 3.6 months at a dose of 10 mg / kg. The median OS (overall survival) was 8.1 months at a dose of 8 mg / kg, and so far cannot be determined for 10 mg / kg.</span>
  </p>
  <p num="568" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> </span>Urothelial cancer</span>
  </p>
  <p num="569" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0438]        ,   8  10 / IMMU-132.     11     6   2  ( ).      ( )  8,1 ,    3,6  9,7+ .</span>[0438] Similar results were obtained for patients with urothelial cancer treated with 8 or 10 mg / kg IMMU-132. The best observed response for 11 measurable patients corresponded to 6 HO and 2 SZ (not shown). The observed median time to progression (not shown) was 8.1 months, with a range of 3.6 to 9.7+ months.</span>
  </p>
  <p num="570" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0439]  ,    I/II     IMMU-132   ADC   ,     , ,    .                  ,     . IMMU-132               ,      2-5  ( ).         3     20%  .    ,   IMMU-132    -,   ,        IMMU-132.       IMMU-132    Trop-2-    -.</span>[0439] Summarizing the above, an ongoing Phase I / II clinical trial has demonstrated superior efficacy of IMMU-132 in administering ADCs at the indicated dosages, at least for TNLC, NSCLC, MRL and urothelial cancer. The superior therapeutic effect of these previously severely treated and persistent metastatic cancers was not accompanied by serious toxicity, which may impede clinical use. IMMU-132 showed an acceptable safety profile in patients undergoing serious treatment with various types of solid cancer who, on average, underwent previous therapy 2-5 times (median value). Only in the case of neutropenia, the incidence of adverse reactions of <figure-callout id="3" label="class" filenames="00000044.png,00000046.png" class="style-scope patent-text"><a title="Show image containing callout" class="style-scope figure-callout">class</a></figure-callout> 3 or higher exceeded 20% of the patient population. This study also demonstrates that doses of IMMU-132 can be repeatedly administered to human patients at therapeutic dosages without causing interaction with the host antibodies against IMMU-132. These results demonstrate the safety and usefulness of IMMU-132 for the treatment of a variety of Trop-2-positive cancers in human patients.</span>
  </p>
  <p num="571" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">* * *</span>* * *</span>
  </p>
  <p num="572" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0440]                  ,        ,                 ,     .  ,    ,    ,     .</span>[0440] Based on the above description, a person skilled in the art can easily establish the essential characteristics of the present invention and, without departing from the essence and scope of the present invention, will be able to make various changes and modifications according to the present invention to adapt to various applications and conditions, not resorting to excessive experimentation. All patents, patent applications, and publications cited herein are incorporated by reference.</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(25)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Russian</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM264450425" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1.   Trop-2- ,   -  Trop-2-   -  (ADC),  SN-38,    ,     Trop-2    ,  ,                   , </span>1. A method of treating Trop-2-positive cancer, comprising administering to a human patient with Trop-2-positive cancer an antibody-drug conjugate (ADC) comprising SN-38 conjugated to a linker moiety attached to an anti-Trop-2 antibody or its antigen-binding fragment, characterized in that the said patient has relapsed after treatment with a control point inhibitor or refractory to treatment with a control point inhibitor,</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    Trop-2    hRS7,   CDR   CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2);  CDR3 (QQHYITPLT, SEQ ID NO:3),   CDR   CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5)  CDR3 (GGFGSSYWYFDV, SEQ ID NO:6);</span>wherein said anti-Trop-2 antibody is an hRS7 antibody comprising CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO: 1); CDR2 (SASYRYT, SEQ ID NO: 2); and CDR3 (QQHYITPLT, SEQ ID NO: 3), and CDR1 heavy chain CDR sequences (NYGMN, SEQ ID NO: 4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6);</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">    CL2A,  ADC   MAb-CL2A-SN-38</span>said linker is CL2A, and ADC has the structure MAb-CL2A-SN-38</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text">
        <span class="google-src-text style-scope patent-text">
          <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/00/3b/10/cf089594915aaa/00000042.png" class="style-scope patent-text"><img file="00000042.jpg" he="49" wi="160" img-format="jpg" img-content="undefined" width="640" height="196" alt="Figure 00000042" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/00/3b/10/cf089594915aaa/00000042.png"></a></div>
        </span>
        <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/00/3b/10/cf089594915aaa/00000042.png" class="style-scope patent-text"><img file="00000042.jpg" he="49" wi="160" img-format="jpg" img-content="undefined" width="640" height="196" alt="Figure 00000042" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/00/3b/10/cf089594915aaa/00000042.png"></a></div>
      </span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MAb-CL2A-SN-38.</span>MAb-CL2A-SN-38.</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2.   . 1,  ,         PD-1, PD-L1  CTLA-4.</span>2. The method of claim 1, wherein said checkpoint inhibitor is a PD-1, PD-L1, or CTLA-4 inhibitor.</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3.   . 1,  ,        ,   MPDL3280A, , , , , MDX-1105, , BMS-936559  .</span>3. The method according to p. 1, characterized in that said control point inhibitor is selected from the group consisting of MPDL3280A, pembrolizumab, nivolumab, ipilimumab, pidilizumab, MDX-1105, durvalumab, BMS-936559 and trelimumumab.</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4.   . 1,  ,        MPDL3280A.</span>4. The method according to p. 1, characterized in that said control point inhibitor is MPDL3280A.</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5.   . 1,  ,      ,       , , ,  , ,  ,  , , ,    .</span>5. The method according to p. 1, characterized in that said cancer is selected from the group consisting of cancer of the colon and rectum, lung, stomach, bladder, kidney, pancreas, breast, ovary, uterus, esophagus and prostate.</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6.   . 1,  ,            .</span>6. The method according to p. 1, characterized in that said cancer is breast cancer with a triple negative phenotype.</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7.   . 1,  ,      ,         , HER+, ER+, -   ,    ,    ,   ,        .</span>7. The method according to claim 1, characterized in that said cancer is selected from the group consisting of breast cancer with a triple negative phenotype, HER +, ER +, progesterone-positive breast cancer, metastatic non-small cell lung cancer, metastatic small cell lung cancer, metastatic endometrial cancer, metastatic urothelial cancer, and metastatic pancreatic cancer.</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8.   . 1,  ,   ADC     3 /  18 /.</span>8. The method according to p. 1, characterized in that the specified ADC is administered in a dosage of from 3 mg / kg to 18 mg / kg</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9.   . 8,  ,      ,   3 /, 4 /, 6 /, 7 /, 8 /, 9 /, 10 /, 11 /, 12 /, 16 /  18 /.</span>9. The method according to p. 8, characterized in that the dosage is selected from the group consisting of 3 mg / kg, 4 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 16 mg / kg and 18 mg / kg.</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10.   . 1,  ,   ADC     8 /  12 /.</span>10. The method according to p. 1, characterized in that the specified ADC is administered in a dosage of from 8 mg / kg to 12 mg / kg</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11.   . 1,  ,   ADC     8 /  10 /.</span>11. The method according to p. 1, characterized in that the specified ADC is administered in a dosage of from 8 mg / kg to 10 mg / kg</span>
    </claim-text>
  </claim>
  <claim num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12.   . 1,  ,   ADC    10 /.</span>12. The method according to p. 1, characterized in that the specified ADC is administered in a dosage of 10 mg / kg</span>
    </claim-text>
  </claim>
  <claim num="17" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13.   . 1,  ,       ,     15%,    20%,    30%     40%.</span>13. The method according to p. 1, characterized in that the treatment leads to a decrease in tumor size of at least 15%, at least 20%, at least 30%, or at least 40%.</span>
    </claim-text>
  </claim>
  <claim num="18" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14.   . 1,  ,     .</span>14. The method according to p. 1, characterized in that the cancer is metastatic.</span>
    </claim-text>
  </claim>
  <claim num="19" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15.   . 14,       .</span>15. The method according to p. 14, further comprising reducing the size or elimination of metastases.</span>
    </claim-text>
  </claim>
  <claim num="20" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16.   . 1,              ,   ,    ,  , , , ,  ,    -,      .</span>16. The method according to claim 1, further comprising using at least one other type of anticancer therapy in said patient selected from the group consisting of surgery, external radiation, radioimmunotherapy, immunotherapy, chemotherapy, antisense therapy, RNA interference therapy , treatment with a therapeutic agent and gene therapy.</span>
    </claim-text>
  </claim>
  <claim num="21" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17.   . 16,  ,        , , ,  ,    ,  , , , , ,  , , -,  , , ,   .</span>17. The method according to p. 16, characterized in that said therapeutic agent is a drug, toxin, immunomodulator, second antibody, antigen-binding fragment of the second antibody, proapoptotic agent, toxin, RNase, hormone, radionuclide, antiangiogenic agent, siRNA, RNA- interference, chemotherapeutic agent, cytokine, chemokine, prodrug or enzyme.</span>
    </claim-text>
  </claim>
  <claim num="22" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18.   . 17,  ,       ,   5-, , , , , , , AVL-101, AVL-291, , , , , -1, , , , , 10-, , , , ,  Cox-2,  (CPT-11), SN-38, , , , , , , , , , , , , , 2- (2P-DOX), -,  ,  , , , , , ,    ,  (VP16),  ,  , , ,  (FUdR), 3',5'-O--FudR (FUdR-dO), , ,  -, , , , GDC-0834, GS-1101, , , , , , , , , L-, , , , LFM-A13, , , , , 6-, , , , , , , , , , , , , , PCI-32765, , PSI-341, , , , , SU11248, , ,  (   (DTIC)), , , , , , , , , , , ,    ZD1839.</span>18. The method according to p. 17, characterized in that said drug is selected from the group consisting of 5-fluorouracil, afatinib, aplidine, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib , bozutinib, bryostatin-1, busulfan, calicheamicin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, cisplatin, inhibitors of Cox-2, irinotecan (CPT-11), SN-38, carboplatin, cladatin, cladatin , cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinacyclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicin, eceptorofinurofluorofinuricurofinuricinurofinuricurinuricinurofinuricin dicurofinuricinuricinurofinuricin dicarubinurotinuricinurofinuricin dicarubinurofinuricin estrogen agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, phloxuridine (FUdR), 3 ', 5'-O-dioleoyl-FudR (FU dR-dO), fludarabine, flutamide, farnesyl protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, aspirin aminibiside, ibrutinibibamide, laribacibinide, labidibicinibide, ibidebisinibide, lenalidomide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mitramycin, mitomycin, mitotan, navelbin, neratinib, nilotinib, plylazinozaminazaricaminazaricinazaricaminase pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temozolomide (an aqueous form of dacarbazine (DTIC)), transplatinum, thalidomide, thioguanine, thiotepin, vinibanotinum, vinotanibanum, topinabinol, vinotanabinotinobinotanotanabinotinobin vincristine, vinca alkaloids and ZD1839.</span>
    </claim-text>
  </claim>
  <claim num="23" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19.   . 17,  ,      ,   , , ,    , ,  ,   (),  (),  , , , , , ,   (),   (),   (),   , ,   , ,  ,  OB,    (), -, -,    (), , ,    (), -, -,   , -  , , ,    , ,  (),    (-), -   (-), -, -, -,  S1, -1, -1-cc, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -12, -13, -14, -15, -16, -17, -18 -21, -23, -25, -  (), Kit-, FLT-3, ,   .</span>19. The method according to p. 17, characterized in that said immunomodulator is selected from the group consisting of cytokines, lymphokines, monokines, stem cell growth factors, lymphotoxins, hematopoietic factors, colony stimulating factors (CSF), interferons (IFN), parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle-stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, prostaglandin, fibroblast growth factor, prolactin, growth factor, placental lactogen, transient protein, lactogen, TGF), TGF-, TGF-, insulin-like growth factor (IGF), erythropoietin, thrombopoietin, tumor necrosis factor (TNF), TNF-, TNF-, muller inhibitory substance, gonadotropin-associated peptide of mice, inhibin, activin , vascular endothelial growth factor, integrin, interleukin (IL), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulus factor (GM-CSF), interferon-, interferon-, interferon-, factor S1, IL-1, IL-1-cc, IL-2, IL-3, IL-4, IL-5, IL -6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 IL-21, IL-23, IL-25, leukemia inhibiting factor (LIF), Kit ligand, FLT-3, angiostatin, thrombospondin and endostatin.</span>
    </claim-text>
  </claim>
  <claim num="24" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20.   . 17,  ,      ,   <sup class="style-scope patent-text">11</sup>C, <sup class="style-scope patent-text">13</sup>N, <sup class="style-scope patent-text">15</sup>O, <sup class="style-scope patent-text">32</sup>P, <sup class="style-scope patent-text">33</sup>P, <sup class="style-scope patent-text">47</sup>Sc, <sup class="style-scope patent-text">51</sup>Cr, <sup class="style-scope patent-text">57</sup>Co, <sup class="style-scope patent-text">58</sup>Co, <sup class="style-scope patent-text">59</sup>Fe, <sup class="style-scope patent-text">62</sup>Cu, <sup class="style-scope patent-text">67</sup>Cu, <sup class="style-scope patent-text">67</sup>Ga, <sup class="style-scope patent-text">67</sup>Ga, <sup class="style-scope patent-text">75</sup>Br, <sup class="style-scope patent-text">75</sup>Se, <sup class="style-scope patent-text">75</sup>Se, <sup class="style-scope patent-text">76</sup>Br, <sup class="style-scope patent-text">77</sup>As, <sup class="style-scope patent-text">77</sup>Br, <sup class="style-scope patent-text">80m</sup>Br, <sup class="style-scope patent-text">89</sup>Sr, <sup class="style-scope patent-text">90</sup>Y, <sup class="style-scope patent-text">95</sup>Ru, <sup class="style-scope patent-text">97</sup>Ru, <sup class="style-scope patent-text">99</sup>Mo, <sup class="style-scope patent-text">99m</sup>Tc, <sup class="style-scope patent-text">103m</sup>Rh, <sup class="style-scope patent-text">103</sup>Ru, <sup class="style-scope patent-text">105</sup>Rh, <sup class="style-scope patent-text">105</sup>Ru, <sup class="style-scope patent-text">107</sup>Hg, <sup class="style-scope patent-text">109</sup>Pd, <sup class="style-scope patent-text">109</sup>Pt, <sup class="style-scope patent-text">111</sup>Ag, <sup class="style-scope patent-text">111</sup>In, <sup class="style-scope patent-text">113m</sup>In, <sup class="style-scope patent-text">119</sup>Sb, <sup class="style-scope patent-text">121m</sup>Te, <sup class="style-scope patent-text">122m</sup>Te, <sup class="style-scope patent-text">125</sup>I, <sup class="style-scope patent-text">125m</sup>Te, <sup class="style-scope patent-text">126</sup>I, <sup class="style-scope patent-text">131</sup>I, <sup class="style-scope patent-text">133</sup>I, <sup class="style-scope patent-text">142</sup>Pr, <sup class="style-scope patent-text">143</sup>Pr, <sup class="style-scope patent-text">149</sup>Pm, <sup class="style-scope patent-text">152</sup>Dy, <sup class="style-scope patent-text">153</sup>Sm, <sup class="style-scope patent-text">161</sup>Ho, <sup class="style-scope patent-text">161</sup>Tb, <sup class="style-scope patent-text">165</sup>Tm, <sup class="style-scope patent-text">166</sup>Dy, <sup class="style-scope patent-text">166</sup>Ho, <sup class="style-scope patent-text">167</sup>Tm, <sup class="style-scope patent-text">168</sup>Tm, <sup class="style-scope patent-text">169</sup>Er, <sup class="style-scope patent-text">169</sup>Yb, <sup class="style-scope patent-text">177</sup>Lu, <sup class="style-scope patent-text">186</sup>Re, <sup class="style-scope patent-text">188</sup>Re, <sup class="style-scope patent-text">189m</sup>Os, <sup class="style-scope patent-text">189</sup>Re, <sup class="style-scope patent-text">192</sup>Ir, <sup class="style-scope patent-text">194</sup>Ir, <sup class="style-scope patent-text">197</sup>Pt, <sup class="style-scope patent-text">198</sup>Au, <sup class="style-scope patent-text">199</sup>Au, <sup class="style-scope patent-text">199</sup>Au, <sup class="style-scope patent-text">201</sup>Tl, <sup class="style-scope patent-text">203</sup>Hg, <sup class="style-scope patent-text">211</sup>At, <sup class="style-scope patent-text">211</sup>Bi, <sup class="style-scope patent-text">211</sup>Pb, <sup class="style-scope patent-text">212</sup>Bi, <sup class="style-scope patent-text">212</sup>Pb, <sup class="style-scope patent-text">213</sup>Bi, <sup class="style-scope patent-text">215</sup>Po, <sup class="style-scope patent-text">217</sup>At, <sup class="style-scope patent-text">219</sup>Rn, <sup class="style-scope patent-text">221</sup>Fr, <sup class="style-scope patent-text">223</sup>Ra, <sup class="style-scope patent-text">225</sup>Ac, <sup class="style-scope patent-text">227</sup>Th  <sup class="style-scope patent-text">255</sup>Fm. </span>20. The method according to p. 17, characterized in that said radionuclide is selected from the group consisting of <sup class="style-scope patent-text">11</sup> C, <sup class="style-scope patent-text">13</sup> N, <sup class="style-scope patent-text">15</sup> O, <sup class="style-scope patent-text">32</sup> P, <sup class="style-scope patent-text">33</sup> P, <sup class="style-scope patent-text">47</sup> Sc, <sup class="style-scope patent-text">51</sup> Cr, <sup class="style-scope patent-text">57</sup> Co, <sup class="style-scope patent-text">58</sup> Co, <sup class="style-scope patent-text">59</sup> Fe, <sup class="style-scope patent-text">62</sup> Cu, <sup class="style-scope patent-text">67</sup> Cu, <sup class="style-scope patent-text">67</sup> Ga, <sup class="style-scope patent-text">67</sup> Ga, <sup class="style-scope patent-text">75</sup> Br, <sup class="style-scope patent-text">75</sup> Se, <sup class="style-scope patent-text">75</sup> Se, <sup class="style-scope patent-text">76</sup> Br, <sup class="style-scope patent-text">77</sup> As, <sup class="style-scope patent-text">77</sup> Br, <sup class="style-scope patent-text">80m</sup> Br, <sup class="style-scope patent-text">89</sup> Sr, <sup class="style-scope patent-text">90</sup> Y, <sup class="style-scope patent-text">95</sup> Ru, <sup class="style-scope patent-text">97</sup> Ru, <sup class="style-scope patent-text">99</sup> Mo, <sup class="style-scope patent-text">99m</sup> Tc , <sup class="style-scope patent-text">103m</sup> Rh, <sup class="style-scope patent-text">103</sup> Ru, <sup class="style-scope patent-text">105</sup> Rh, <sup class="style-scope patent-text">105</sup> Ru, <sup class="style-scope patent-text">107</sup> Hg, <sup class="style-scope patent-text">109</sup> Pd, <sup class="style-scope patent-text">109</sup> Pt, <sup class="style-scope patent-text">111</sup> Ag, <sup class="style-scope patent-text">111</sup> In, <sup class="style-scope patent-text">113m</sup> In, <sup class="style-scope patent-text">119</sup> Sb, <sup class="style-scope patent-text">121m</sup> Te, <sup class="style-scope patent-text">122m</sup> Te, <sup class="style-scope patent-text">125</sup> I, <sup class="style-scope patent-text">125m</sup> Te, <sup class="style-scope patent-text">126</sup> I, <sup class="style-scope patent-text">131</sup> I, <sup class="style-scope patent-text">133</sup> I, <sup class="style-scope patent-text">142</sup> Pr, <sup class="style-scope patent-text">143</sup> Pr, <sup class="style-scope patent-text">149</sup> Pm, <sup class="style-scope patent-text">152</sup> Dy, <sup class="style-scope patent-text">153</sup> Sm, <sup class="style-scope patent-text">161</sup> Ho, <sup class="style-scope patent-text">161</sup> Tb, <sup class="style-scope patent-text">165</sup> Tm, <sup class="style-scope patent-text">166</sup> Dy, <sup class="style-scope patent-text">166</sup> Ho, <sup class="style-scope patent-text">167</sup> Tm, <sup class="style-scope patent-text">168</sup> Tm, <sup class="style-scope patent-text">169</sup> Er, <sup class="style-scope patent-text">169</sup> Yb, <sup class="style-scope patent-text">177</sup> Lu, <sup class="style-scope patent-text">186</sup> Re, <sup class="style-scope patent-text">188</sup> Re, <sup class="style-scope patent-text">189m</sup> Os, <sup class="style-scope patent-text">189</sup> Re, <sup class="style-scope patent-text">192</sup> Ir, <sup class="style-scope patent-text">194</sup> Ir, <sup class="style-scope patent-text">197</sup> Pt, <sup class="style-scope patent-text">198</sup> Au, <sup class="style-scope patent-text">199</sup> Au, <sup class="style-scope patent-text">199</sup> Au, <sup class="style-scope patent-text">201</sup> Tl, <sup class="style-scope patent-text">203</sup> Hg, <sup class="style-scope patent-text">211</sup> At, <sup class="style-scope patent-text">211</sup> Bi, <sup class="style-scope patent-text">211</sup> Pb, <sup class="style-scope patent-text">212</sup> Bi, <sup class="style-scope patent-text">212</sup> Pb , <sup class="style-scope patent-text">213</sup> Bi, <sup class="style-scope patent-text">215</sup> Po, <sup class="style-scope patent-text">217</sup> At, <sup class="style-scope patent-text">219</sup> Rn, <sup class="style-scope patent-text">221</sup> Fr, <sup class="style-scope patent-text">223</sup> Ra, <sup class="style-scope patent-text">225</sup> Ac, <sup class="style-scope patent-text">227</sup> Th and <sup class="style-scope patent-text">255</sup> Fm.</span>
    </claim-text>
  </claim>
  <claim num="25" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21.   . 17,  ,      ,   , ,  (),  I,   ,   , ,  ,  Pseudomonas   Pseudomonas.</span>21. The method according to p. 17, characterized in that the toxin is selected from the group consisting of ricin, abrin, ribonuclease (RNase), DNase I, staphylococcal enterotoxin A, antiviral protein lacunas, gelonin, diphtheria toxin, exotoxin Pseudomonas and endotoxin Pseudomonas and endotoxin Pseudomonas and endotoxin Pseudomonas and endotoxin Pseudomonas .</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (125)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150132217A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150132217A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-14</span>
                    <span class="td style-scope patent-result">2015-05-14</span>
                    <span class="td style-scope patent-result">Ibc Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Disease therapy by inducing immune response to trop-2 expressing cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20150366988A1/en"><a id="link" href="#" class="style-scope state-modifier">US20150366988A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2015-12-24</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB1541435A/en"><a id="link" href="#" class="style-scope state-modifier">GB1541435A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1975-02-04</span>
                    <span class="td style-scope patent-result">1979-02-28</span>
                    <span class="td style-scope patent-result">Searle &amp; Co</span>
                    <span class="td style-scope patent-result">Immunological materials 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4036945A/en"><a id="link" href="#" class="style-scope state-modifier">US4036945A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1976-05-03</span>
                    <span class="td style-scope patent-result">1977-07-19</span>
                    <span class="td style-scope patent-result">The Massachusetts General Hospital</span>
                    <span class="td style-scope patent-result">Composition and method for determining the size and location of myocardial infarcts 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4200690A/en"><a id="link" href="#" class="style-scope state-modifier">US4200690A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1976-12-16</span>
                    <span class="td style-scope patent-result">1980-04-29</span>
                    <span class="td style-scope patent-result">Millipore Corporation</span>
                    <span class="td style-scope patent-result">Immunoassay with membrane immobilized antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4331647A/en"><a id="link" href="#" class="style-scope state-modifier">US4331647A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-03-03</span>
                    <span class="td style-scope patent-result">1982-05-25</span>
                    <span class="td style-scope patent-result">Goldenberg Milton David</span>
                    <span class="td style-scope patent-result">Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5204095A/en"><a id="link" href="#" class="style-scope state-modifier">US5204095A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-04-09</span>
                    <span class="td style-scope patent-result">1993-04-20</span>
                    <span class="td style-scope patent-result">National Research Development Corporation</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies against hepatitis B virus 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4359457A/en"><a id="link" href="#" class="style-scope state-modifier">US4359457A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1980-09-30</span>
                    <span class="td style-scope patent-result">1982-11-16</span>
                    <span class="td style-scope patent-result">Neville Jr David M</span>
                    <span class="td style-scope patent-result">Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4925922A/en"><a id="link" href="#" class="style-scope state-modifier">US4925922A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-02-22</span>
                    <span class="td style-scope patent-result">1990-05-15</span>
                    <span class="td style-scope patent-result">Xoma Corporation</span>
                    <span class="td style-scope patent-result">Potentiation of cytotoxic conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4916213A/en"><a id="link" href="#" class="style-scope state-modifier">US4916213A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-02-22</span>
                    <span class="td style-scope patent-result">1990-04-10</span>
                    <span class="td style-scope patent-result">Xoma Corporation</span>
                    <span class="td style-scope patent-result">Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4816567A/en"><a id="link" href="#" class="style-scope state-modifier">US4816567A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1983-04-08</span>
                    <span class="td style-scope patent-result">1989-03-28</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Recombinant immunoglobin preparations 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5672347A/en"><a id="link" href="#" class="style-scope state-modifier">US5672347A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1984-07-05</span>
                    <span class="td style-scope patent-result">1997-09-30</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Tumor necrosis factor antagonists and their use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4824659A/en"><a id="link" href="#" class="style-scope state-modifier">US4824659A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-06-07</span>
                    <span class="td style-scope patent-result">1989-04-25</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5776093A/en"><a id="link" href="#" class="style-scope state-modifier">US5776093A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-07-05</span>
                    <span class="td style-scope patent-result">1998-07-07</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Method for imaging and treating organs and tissues 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5525338A/en"><a id="link" href="#" class="style-scope state-modifier">US5525338A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-08-21</span>
                    <span class="td style-scope patent-result">1996-06-11</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Detection and therapy of lesions with biotin/avidin conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4918163A/en"><a id="link" href="#" class="style-scope state-modifier">US4918163A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-09-27</span>
                    <span class="td style-scope patent-result">1990-04-17</span>
                    <span class="td style-scope patent-result">Pfizer Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5618920A/en"><a id="link" href="#" class="style-scope state-modifier">US5618920A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1985-11-01</span>
                    <span class="td style-scope patent-result">1997-04-08</span>
                    <span class="td style-scope patent-result">Xoma Corporation</span>
                    <span class="td style-scope patent-result">Modular assembly of antibody genes, antibodies prepared thereby and use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4699784A/en"><a id="link" href="#" class="style-scope state-modifier">US4699784A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-02-25</span>
                    <span class="td style-scope patent-result">1987-10-13</span>
                    <span class="td style-scope patent-result">Center For Molecular Medicine &amp; Immunology</span>
                    <span class="td style-scope patent-result">Tumoricidal methotrexate-antibody conjugate 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5057313A/en"><a id="link" href="#" class="style-scope state-modifier">US5057313A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-02-25</span>
                    <span class="td style-scope patent-result">1991-10-15</span>
                    <span class="td style-scope patent-result">The Center For Molecular Medicine And Immunology</span>
                    <span class="td style-scope patent-result">Diagnostic and therapeutic antibody conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4997913A/en"><a id="link" href="#" class="style-scope state-modifier">US4997913A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-06-30</span>
                    <span class="td style-scope patent-result">1991-03-05</span>
                    <span class="td style-scope patent-result">Oncogen</span>
                    <span class="td style-scope patent-result">pH-sensitive immunoconjugates and methods for their use in tumor therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4946778A/en"><a id="link" href="#" class="style-scope state-modifier">US4946778A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-09-21</span>
                    <span class="td style-scope patent-result">1990-08-07</span>
                    <span class="td style-scope patent-result">Genex Corporation</span>
                    <span class="td style-scope patent-result">Single polypeptide chain binding molecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4704692A/en"><a id="link" href="#" class="style-scope state-modifier">US4704692A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-09-02</span>
                    <span class="td style-scope patent-result">1987-11-03</span>
                    <span class="td style-scope patent-result">Ladner Robert C</span>
                    <span class="td style-scope patent-result">Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5567610A/en"><a id="link" href="#" class="style-scope state-modifier">US5567610A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-09-04</span>
                    <span class="td style-scope patent-result">1996-10-22</span>
                    <span class="td style-scope patent-result">Bioinvent International Ab</span>
                    <span class="td style-scope patent-result">Method of producing human monoclonal antibodies and kit therefor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA1320905C/en"><a id="link" href="#" class="style-scope state-modifier">CA1320905C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-11-06</span>
                    <span class="td style-scope patent-result">1993-08-03</span>
                    <span class="td style-scope patent-result">Joseph M. Cummins</span>
                    <span class="td style-scope patent-result">Treatment of immuno-resistant disease 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4932412A/en"><a id="link" href="#" class="style-scope state-modifier">US4932412A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1986-12-18</span>
                    <span class="td style-scope patent-result">1990-06-12</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Intraoperative and endoscopic tumor detection and therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1988007553A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1988007553A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-03-26</span>
                    <span class="td style-scope patent-result">1988-10-06</span>
                    <span class="td style-scope patent-result">Teijin Limited</span>
                    <span class="td style-scope patent-result">Process for preparing antibody complex 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4981979A/en"><a id="link" href="#" class="style-scope state-modifier">US4981979A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1987-09-10</span>
                    <span class="td style-scope patent-result">1991-01-01</span>
                    <span class="td style-scope patent-result">Neorx Corporation</span>
                    <span class="td style-scope patent-result">Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IL89220A/en"><a id="link" href="#" class="style-scope state-modifier">IL89220A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-02-11</span>
                    <span class="td style-scope patent-result">1994-02-27</span>
                    <span class="td style-scope patent-result">Bristol Myers Squibb Co</span>
                    <span class="td style-scope patent-result">Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5112954A/en"><a id="link" href="#" class="style-scope state-modifier">US5112954A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-02-26</span>
                    <span class="td style-scope patent-result">1992-05-12</span>
                    <span class="td style-scope patent-result">Neorx Corporation</span>
                    <span class="td style-scope patent-result">Method of enhancing the effect of cytotoxic agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US4861579A/en"><a id="link" href="#" class="style-scope state-modifier">US4861579A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-03-17</span>
                    <span class="td style-scope patent-result">1989-08-29</span>
                    <span class="td style-scope patent-result">American Cyanamid Company</span>
                    <span class="td style-scope patent-result">Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5530101A/en"><a id="link" href="#" class="style-scope state-modifier">US5530101A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1988-12-28</span>
                    <span class="td style-scope patent-result">1996-06-25</span>
                    <span class="td style-scope patent-result">Protein Design Labs, Inc.</span>
                    <span class="td style-scope patent-result">Humanized immunoglobulins 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB8903021D0/en"><a id="link" href="#" class="style-scope state-modifier">GB8903021D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-02-10</span>
                    <span class="td style-scope patent-result">1989-03-30</span>
                    <span class="td style-scope patent-result">Celltech Ltd</span>
                    <span class="td style-scope patent-result">Chemical compounds 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5134075A/en"><a id="link" href="#" class="style-scope state-modifier">US5134075A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-02-17</span>
                    <span class="td style-scope patent-result">1992-07-28</span>
                    <span class="td style-scope patent-result">Oncogen Limited Partnership</span>
                    <span class="td style-scope patent-result">Monoclonal antibody to novel antigen associated with human tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5171665A/en"><a id="link" href="#" class="style-scope state-modifier">US5171665A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-04-17</span>
                    <span class="td style-scope patent-result">1992-12-15</span>
                    <span class="td style-scope patent-result">Oncogen</span>
                    <span class="td style-scope patent-result">Monoclonal antibody to novel antigen associated with human tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPH02283294A/en"><a id="link" href="#" class="style-scope state-modifier">JPH02283294A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1989-04-24</span>
                    <span class="td style-scope patent-result">1990-11-20</span>
                    <span class="td style-scope patent-result">Sumitomo Chem Co Ltd</span>
                    <span class="td style-scope patent-result">Human monoclonal antibody 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG46445A1/en"><a id="link" href="#" class="style-scope state-modifier">SG46445A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-01-26</span>
                    <span class="td style-scope patent-result">1998-02-20</span>
                    <span class="td style-scope patent-result">Immunomedics Inc</span>
                    <span class="td style-scope patent-result">Vaccines against cancer and infectious diseases 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU7566991A/en"><a id="link" href="#" class="style-scope state-modifier">AU7566991A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-03-14</span>
                    <span class="td style-scope patent-result">1991-10-10</span>
                    <span class="td style-scope patent-result">Biomembrane Institute, The</span>
                    <span class="td style-scope patent-result">Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5229275A/en"><a id="link" href="#" class="style-scope state-modifier">US5229275A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-04-26</span>
                    <span class="td style-scope patent-result">1993-07-20</span>
                    <span class="td style-scope patent-result">Akzo N.V.</span>
                    <span class="td style-scope patent-result">In-vitro method for producing antigen-specific human monoclonal antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5633425A/en"><a id="link" href="#" class="style-scope state-modifier">US5633425A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-08-29</span>
                    <span class="td style-scope patent-result">1997-05-27</span>
                    <span class="td style-scope patent-result">Genpharm International, Inc.</span>
                    <span class="td style-scope patent-result">Transgenic non-human animals capable of producing heterologous antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB9020075D0/en"><a id="link" href="#" class="style-scope state-modifier">GB9020075D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1990-09-14</span>
                    <span class="td style-scope patent-result">1990-10-24</span>
                    <span class="td style-scope patent-result">Filler Aaron G</span>
                    <span class="td style-scope patent-result">Contrast agents for magnetic resonance imaging of axonal transport 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5679640A/en"><a id="link" href="#" class="style-scope state-modifier">US5679640A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-02-12</span>
                    <span class="td style-scope patent-result">1997-10-21</span>
                    <span class="td style-scope patent-result">Cytel Corporation</span>
                    <span class="td style-scope patent-result">Immunosuppressant peptides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP3105629B2/en"><a id="link" href="#" class="style-scope state-modifier">JP3105629B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-04-23</span>
                    <span class="td style-scope patent-result">2000-11-06</span>
                    <span class="td style-scope patent-result">    </span>
                    <span class="td style-scope patent-result">
  Cell activity regulating conjugates of members of specific binding pairs
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IE922437A1/en"><a id="link" href="#" class="style-scope state-modifier">IE922437A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-07-25</span>
                    <span class="td style-scope patent-result">1993-01-27</span>
                    <span class="td style-scope patent-result">Idec Pharma Corp</span>
                    <span class="td style-scope patent-result">Recombinant antibodies for human therapy 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1993006217A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1993006217A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1991-09-19</span>
                    <span class="td style-scope patent-result">1993-04-01</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5622929A/en"><a id="link" href="#" class="style-scope state-modifier">US5622929A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-01-23</span>
                    <span class="td style-scope patent-result">1997-04-22</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Company</span>
                    <span class="td style-scope patent-result">Thioether conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5965132A/en"><a id="link" href="#" class="style-scope state-modifier">US5965132A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-03-05</span>
                    <span class="td style-scope patent-result">1999-10-12</span>
                    <span class="td style-scope patent-result">Board Of Regents, The University Of Texas System</span>
                    <span class="td style-scope patent-result">Methods and compositions for targeting the vasculature of solid tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6096289A/en"><a id="link" href="#" class="style-scope state-modifier">US6096289A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-05-06</span>
                    <span class="td style-scope patent-result">2000-08-01</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0643583B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0643583B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-05-06</span>
                    <span class="td style-scope patent-result">2000-07-26</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5686072A/en"><a id="link" href="#" class="style-scope state-modifier">US5686072A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-06-17</span>
                    <span class="td style-scope patent-result">1997-11-11</span>
                    <span class="td style-scope patent-result">Board Of Regents, The University Of Texas</span>
                    <span class="td style-scope patent-result">Epitope-specific monoclonal antibodies and immunotoxins and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ATE196606T1/en"><a id="link" href="#" class="style-scope state-modifier">ATE196606T1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1992-11-13</span>
                    <span class="td style-scope patent-result">2000-10-15</span>
                    <span class="td style-scope patent-result">Idec Pharma Corp</span>
                    <span class="td style-scope patent-result">
  THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0684814B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0684814B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-02-22</span>
                    <span class="td style-scope patent-result">1998-06-17</span>
                    <span class="td style-scope patent-result">Alza Corporation</span>
                    <span class="td style-scope patent-result">Compositions for oral delivery of active agents 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6214345B1/en"><a id="link" href="#" class="style-scope state-modifier">US6214345B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-14</span>
                    <span class="td style-scope patent-result">2001-04-10</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Co.</span>
                    <span class="td style-scope patent-result">Lysosomal enzyme-cleavable antitumor drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU683893B2/en"><a id="link" href="#" class="style-scope state-modifier">AU683893B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-17</span>
                    <span class="td style-scope patent-result">1997-11-27</span>
                    <span class="td style-scope patent-result">Immunomedics Inc.</span>
                    <span class="td style-scope patent-result">Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5484892A/en"><a id="link" href="#" class="style-scope state-modifier">US5484892A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-05-21</span>
                    <span class="td style-scope patent-result">1996-01-16</span>
                    <span class="td style-scope patent-result">Dana-Farber Cancer Institute, Inc.</span>
                    <span class="td style-scope patent-result">Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5565215A/en"><a id="link" href="#" class="style-scope state-modifier">US5565215A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-07-23</span>
                    <span class="td style-scope patent-result">1996-10-15</span>
                    <span class="td style-scope patent-result">Massachusettes Institute Of Technology</span>
                    <span class="td style-scope patent-result">Biodegradable injectable particles for imaging 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5417972A/en"><a id="link" href="#" class="style-scope state-modifier">US5417972A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-08-02</span>
                    <span class="td style-scope patent-result">1995-05-23</span>
                    <span class="td style-scope patent-result">The Board Of Trustees Of The Leland Stanford Junior University</span>
                    <span class="td style-scope patent-result">Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO1995009917A1/en"><a id="link" href="#" class="style-scope state-modifier">WO1995009917A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-10-07</span>
                    <span class="td style-scope patent-result">1995-04-13</span>
                    <span class="td style-scope patent-result">The Regents Of The University Of California</span>
                    <span class="td style-scope patent-result">Genetically engineered bispecific tetravalent antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5824701A/en"><a id="link" href="#" class="style-scope state-modifier">US5824701A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-10-20</span>
                    <span class="td style-scope patent-result">1998-10-20</span>
                    <span class="td style-scope patent-result">Enzon, Inc.</span>
                    <span class="td style-scope patent-result">Taxane-based prodrugs 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5443953A/en"><a id="link" href="#" class="style-scope state-modifier">US5443953A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1993-12-08</span>
                    <span class="td style-scope patent-result">1995-08-22</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Preparation and use of immunoconjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5639725A/en"><a id="link" href="#" class="style-scope state-modifier">US5639725A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-04-26</span>
                    <span class="td style-scope patent-result">1997-06-17</span>
                    <span class="td style-scope patent-result">Children's Hospital Medical Center Corp.</span>
                    <span class="td style-scope patent-result">Angiostatin protein 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5686578A/en"><a id="link" href="#" class="style-scope state-modifier">US5686578A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-08-05</span>
                    <span class="td style-scope patent-result">1997-11-11</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU3272695A/en"><a id="link" href="#" class="style-scope state-modifier">AU3272695A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-08-12</span>
                    <span class="td style-scope patent-result">1996-03-07</span>
                    <span class="td style-scope patent-result">Immunomedics Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8771694B2/en"><a id="link" href="#" class="style-scope state-modifier">US8771694B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-08-12</span>
                    <span class="td style-scope patent-result">2014-07-08</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5874540A/en"><a id="link" href="#" class="style-scope state-modifier">US5874540A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1994-10-05</span>
                    <span class="td style-scope patent-result">1999-02-23</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US5798554A/en"><a id="link" href="#" class="style-scope state-modifier">US5798554A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1995-02-24</span>
                    <span class="td style-scope patent-result">1998-08-25</span>
                    <span class="td style-scope patent-result">Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno</span>
                    <span class="td style-scope patent-result">MOS-technology power device integrated structure and manufacturing process thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AUPO591797A0/en"><a id="link" href="#" class="style-scope state-modifier">AUPO591797A0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-03-27</span>
                    <span class="td style-scope patent-result">1997-04-24</span>
                    <span class="td style-scope patent-result">Commonwealth Scientific And Industrial Research Organisation</span>
                    <span class="td style-scope patent-result">High avidity polyvalent and polyspecific reagents 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6441025B2/en"><a id="link" href="#" class="style-scope state-modifier">US6441025B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-12</span>
                    <span class="td style-scope patent-result">2002-08-27</span>
                    <span class="td style-scope patent-result">Pg-Txl Company, L.P.</span>
                    <span class="td style-scope patent-result">Water soluble paclitaxel derivatives 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0888125B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0888125B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-03-20</span>
                    <span class="td style-scope patent-result">2004-05-26</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">GLYCOSYLATED IgG ANTIBODIES 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2253904A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2253904A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-05-03</span>
                    <span class="td style-scope patent-result">1997-11-13</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Targeted combination immunotherapy of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2000516594A/en"><a id="link" href="#" class="style-scope state-modifier">JP2000516594A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-07-26</span>
                    <span class="td style-scope patent-result">2000-12-12</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Improved treatment of immune cell-mediated systemic diseases
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE19640207A1/en"><a id="link" href="#" class="style-scope state-modifier">DE19640207A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-09-30</span>
                    <span class="td style-scope patent-result">1998-04-02</span>
                    <span class="td style-scope patent-result">Bayer Ag</span>
                    <span class="td style-scope patent-result">
  Glycoconjugates of modified camptothecin derivatives (A or B ring linkage)
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6056973A/en"><a id="link" href="#" class="style-scope state-modifier">US6056973A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-10-11</span>
                    <span class="td style-scope patent-result">2000-05-02</span>
                    <span class="td style-scope patent-result">Sequus Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Therapeutic liposome composition and method of preparation 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6653104B2/en"><a id="link" href="#" class="style-scope state-modifier">US6653104B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1996-10-17</span>
                    <span class="td style-scope patent-result">2003-11-25</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7122636B1/en"><a id="link" href="#" class="style-scope state-modifier">US7122636B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-02-21</span>
                    <span class="td style-scope patent-result">2006-10-17</span>
                    <span class="td style-scope patent-result">Genentech, Inc.</span>
                    <span class="td style-scope patent-result">Antibody fragment-polymer conjugates and uses of same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6306393B1/en"><a id="link" href="#" class="style-scope state-modifier">US6306393B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-03-24</span>
                    <span class="td style-scope patent-result">2001-10-23</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotherapy of B-cell malignancies using anti-CD22 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6183744B1/en"><a id="link" href="#" class="style-scope state-modifier">US6183744B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-03-24</span>
                    <span class="td style-scope patent-result">2001-02-06</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotherapy of B-cell malignancies using anti-CD22 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP0975674B1/en"><a id="link" href="#" class="style-scope state-modifier">EP0975674B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-05-02</span>
                    <span class="td style-scope patent-result">2005-08-17</span>
                    <span class="td style-scope patent-result">THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services</span>
                    <span class="td style-scope patent-result">Immunotoxins, comprising an onc protein, directed against malignant cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6368596B1/en"><a id="link" href="#" class="style-scope state-modifier">US6368596B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-07-08</span>
                    <span class="td style-scope patent-result">2002-04-09</span>
                    <span class="td style-scope patent-result">Board Of Regents, The University Of Texas System</span>
                    <span class="td style-scope patent-result">Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6165440A/en"><a id="link" href="#" class="style-scope state-modifier">US6165440A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1997-07-09</span>
                    <span class="td style-scope patent-result">2000-12-26</span>
                    <span class="td style-scope patent-result">Board Of Regents, The University Of Texas System</span>
                    <span class="td style-scope patent-result">Radiation and nanoparticles for enhancement of drug delivery in solid tumors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6051228A/en"><a id="link" href="#" class="style-scope state-modifier">US6051228A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-02-19</span>
                    <span class="td style-scope patent-result">2000-04-18</span>
                    <span class="td style-scope patent-result">Bristol-Myers Squibb Co.</span>
                    <span class="td style-scope patent-result">Antibodies against human CD40 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR100508289B1/en"><a id="link" href="#" class="style-scope state-modifier">KR100508289B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-04-21</span>
                    <span class="td style-scope patent-result">2005-08-17</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">Cd19cd3 specific polypeptides and uses thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP2002530081A/en"><a id="link" href="#" class="style-scope state-modifier">JP2002530081A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-11-18</span>
                    <span class="td style-scope patent-result">2002-09-17</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Antibody variants with higher binding affinity than the parent antibody
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6201104B1/en"><a id="link" href="#" class="style-scope state-modifier">US6201104B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1998-12-04</span>
                    <span class="td style-scope patent-result">2001-03-13</span>
                    <span class="td style-scope patent-result">Entremed, Inc.</span>
                    <span class="td style-scope patent-result">Angiogenesisinhibiting protein binding peptides and proteins and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6379698B1/en"><a id="link" href="#" class="style-scope state-modifier">US6379698B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-04-06</span>
                    <span class="td style-scope patent-result">2002-04-30</span>
                    <span class="td style-scope patent-result">Isis Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Fusogenic lipids and vesicles 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU777970C/en"><a id="link" href="#" class="style-scope state-modifier">AU777970C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-07</span>
                    <span class="td style-scope patent-result">2006-08-17</span>
                    <span class="td style-scope patent-result">F. Hoffman-La Roche Ag</span>
                    <span class="td style-scope patent-result">Treatment of autoimmune diseases with antagonists which bind to B cell surface markers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8119101B2/en"><a id="link" href="#" class="style-scope state-modifier">US8119101B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-05-10</span>
                    <span class="td style-scope patent-result">2012-02-21</span>
                    <span class="td style-scope patent-result">The Ohio State University</span>
                    <span class="td style-scope patent-result">Anti-CD74 immunoconjugates and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1194167B1/en"><a id="link" href="#" class="style-scope state-modifier">EP1194167B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-09</span>
                    <span class="td style-scope patent-result">2009-08-19</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunotherapy of autoimmune disorders using antibodies which target b-cells 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DE19926154A1/en"><a id="link" href="#" class="style-scope state-modifier">DE19926154A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-06-09</span>
                    <span class="td style-scope patent-result">2000-12-14</span>
                    <span class="td style-scope patent-result">Ktb Tumorforschungs Gmbh</span>
                    <span class="td style-scope patent-result">
  Process for the preparation of an injectable pharmaceutical preparation
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2266607A3/en"><a id="link" href="#" class="style-scope state-modifier">EP2266607A3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1999-10-01</span>
                    <span class="td style-scope patent-result">2011-04-20</span>
                    <span class="td style-scope patent-result">Immunogen, Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates for treating cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6530944B2/en"><a id="link" href="#" class="style-scope state-modifier">US6530944B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-02-08</span>
                    <span class="td style-scope patent-result">2003-03-11</span>
                    <span class="td style-scope patent-result">Rice University</span>
                    <span class="td style-scope patent-result">Optically-active nanoparticles for use in therapeutic and diagnostic methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20030133972A1/en"><a id="link" href="#" class="style-scope state-modifier">US20030133972A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-10-11</span>
                    <span class="td style-scope patent-result">2003-07-17</span>
                    <span class="td style-scope patent-result">Targesome, Inc.</span>
                    <span class="td style-scope patent-result">Targeted multivalent macromolecules 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0028361D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0028361D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2000-11-21</span>
                    <span class="td style-scope patent-result">2001-01-03</span>
                    <span class="td style-scope patent-result">Glaxo Group Ltd</span>
                    <span class="td style-scope patent-result">Method of separating extra chromosomal dna from other cellular components 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US6716821B2/en"><a id="link" href="#" class="style-scope state-modifier">US6716821B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-21</span>
                    <span class="td style-scope patent-result">2004-04-06</span>
                    <span class="td style-scope patent-result">Immunogen Inc.</span>
                    <span class="td style-scope patent-result">Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SE0104462D0/en"><a id="link" href="#" class="style-scope state-modifier">SE0104462D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-12-29</span>
                    <span class="td style-scope patent-result">2001-12-29</span>
                    <span class="td style-scope patent-result">Carlbiotech Ltd As</span>
                    <span class="td style-scope patent-result">
  Peptide Purifcation
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2476166C/en"><a id="link" href="#" class="style-scope state-modifier">CA2476166C</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-02-14</span>
                    <span class="td style-scope patent-result">2011-11-15</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-cd20 antibodies and fusion proteins thereof and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7591994B2/en"><a id="link" href="#" class="style-scope state-modifier">US7591994B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-13</span>
                    <span class="td style-scope patent-result">2009-09-22</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Camptothecin-binding moiety conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8877901B2/en"><a id="link" href="#" class="style-scope state-modifier">US8877901B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-13</span>
                    <span class="td style-scope patent-result">2014-11-04</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Camptothecin-binding moiety conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1483295B1/en"><a id="link" href="#" class="style-scope state-modifier">EP1483295B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2008-12-10</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Rs7 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9770517B2/en"><a id="link" href="#" class="style-scope state-modifier">US9770517B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2017-09-26</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-Trop-2 antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN1649902B/en"><a id="link" href="#" class="style-scope state-modifier">CN1649902B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2011-04-13</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Internalizing anti-CD74 antibodies and methods of use 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/FR2840532B1/en"><a id="link" href="#" class="style-scope state-modifier">FR2840532B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-06-11</span>
                    <span class="td style-scope patent-result">2005-05-06</span>
                    <span class="td style-scope patent-result">Ethypharm Sa</span>
                    <span class="td style-scope patent-result">
  FURENT LIPID NANOCAPSULES, PROCESS FOR THEIR PREPARATION AND USE AS VECTOR OF ACTIVE (S) PRINCIPLES
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP4790413B2/en"><a id="link" href="#" class="style-scope state-modifier">JP4790413B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-10-08</span>
                    <span class="td style-scope patent-result">2011-10-12</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">
  Antibody therapy
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8420086B2/en"><a id="link" href="#" class="style-scope state-modifier">US8420086B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-13</span>
                    <span class="td style-scope patent-result">2013-04-16</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1572242B1/en"><a id="link" href="#" class="style-scope state-modifier">EP1572242B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-12-13</span>
                    <span class="td style-scope patent-result">2014-04-16</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Immunoconjugates with an intracellularly-cleavable linkage 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8551480B2/en"><a id="link" href="#" class="style-scope state-modifier">US8551480B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-02-13</span>
                    <span class="td style-scope patent-result">2013-10-08</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP1797109B1/en"><a id="link" href="#" class="style-scope state-modifier">EP1797109B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-09-09</span>
                    <span class="td style-scope patent-result">2016-02-24</span>
                    <span class="td style-scope patent-result">Yeda Research And Development Co., Ltd.</span>
                    <span class="td style-scope patent-result">Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7612153B2/en"><a id="link" href="#" class="style-scope state-modifier">US7612153B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2004-10-25</span>
                    <span class="td style-scope patent-result">2009-11-03</span>
                    <span class="td style-scope patent-result">Intezyne Technologies, Inc.</span>
                    <span class="td style-scope patent-result">Heterobifunctional poly(ethylene glycol) and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US7612180B2/en"><a id="link" href="#" class="style-scope state-modifier">US7612180B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-03-03</span>
                    <span class="td style-scope patent-result">2009-11-03</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Humanized L243 antibodies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8349332B2/en"><a id="link" href="#" class="style-scope state-modifier">US8349332B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2005-04-06</span>
                    <span class="td style-scope patent-result">2013-01-08</span>
                    <span class="td style-scope patent-result">Ibc Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2007386B1/en"><a id="link" href="#" class="style-scope state-modifier">EP2007386B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2006-04-19</span>
                    <span class="td style-scope patent-result">2012-08-22</span>
                    <span class="td style-scope patent-result">Bionumerik Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Camptothecin-analog with a novel,  flipped  lactone-stable, e-ring and methods for making and using same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3470087A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3470087A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-02-13</span>
                    <span class="td style-scope patent-result">2019-04-17</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2774015A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2774015A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-15</span>
                    <span class="td style-scope patent-result">2011-03-24</span>
                    <span class="td style-scope patent-result">Cerulean Pharma Inc.</span>
                    <span class="td style-scope patent-result">A cdp-camptothecin conjugate, particle or composition and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2011100131A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2011100131A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2010-01-28</span>
                    <span class="td style-scope patent-result">2011-08-18</span>
                    <span class="td style-scope patent-result">Alnylam Pharmacuticals, Inc.</span>
                    <span class="td style-scope patent-result">Monomers and oligonucleotides comprising cycloaddition adduct(s) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP5989668B2/en"><a id="link" href="#" class="style-scope state-modifier">JP5989668B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-01-11</span>
                    <span class="td style-scope patent-result">2016-09-07</span>
                    <span class="td style-scope patent-result">       </span>
                    <span class="td style-scope patent-result">
  Protein detection method
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2012151199A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2012151199A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-05-02</span>
                    <span class="td style-scope patent-result">2012-11-08</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Ultrafiltration concentration of allotype selected antibodies for small-volume administration 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9682143B2/en"><a id="link" href="#" class="style-scope state-modifier">US9682143B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-08-14</span>
                    <span class="td style-scope patent-result">2017-06-20</span>
                    <span class="td style-scope patent-result">Ibc Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Combination therapy for inducing immune response to disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10413539B2/en"><a id="link" href="#" class="style-scope state-modifier">US10413539B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2019-09-17</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20230078823A/en"><a id="link" href="#" class="style-scope state-modifier">KR20230078823A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2023-06-02</span>
                    <span class="td style-scope patent-result">, </span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2819573T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2819573T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2021-04-16</span>
                    <span class="td style-scope patent-result">Immunomedics Inc</span>
                    <span class="td style-scope patent-result">
  Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US8877202B2/en"><a id="link" href="#" class="style-scope state-modifier">US8877202B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-07</span>
                    <span class="td style-scope patent-result">2014-11-04</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2014163684A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2014163684A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-03</span>
                    <span class="td style-scope patent-result">2014-10-09</span>
                    <span class="td style-scope patent-result">Ibc Pharmaceuticals, Inc.</span>
                    <span class="td style-scope patent-result">Combination therapy for inducing immune response to disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3049443A4/en"><a id="link" href="#" class="style-scope state-modifier">EP3049443A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-09-27</span>
                    <span class="td style-scope patent-result">2017-04-05</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-trop-2 antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/DK3309174T3/en"><a id="link" href="#" class="style-scope state-modifier">DK3309174T3</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-07-11</span>
                    <span class="td style-scope patent-result">2022-06-07</span>
                    <span class="td style-scope patent-result">Ventana Med Syst Inc</span>
                    <span class="td style-scope patent-result">
  ANTI-PD-L1 antibodies and diagnostic uses thereof
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10195175B2/en"><a id="link" href="#" class="style-scope state-modifier">US10195175B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-25</span>
                    <span class="td style-scope patent-result">2019-02-05</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2017257254B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2017257254B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-04-27</span>
                    <span class="td style-scope patent-result">2022-02-24</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="nplCitations" class="scroll-target style-scope patent-result">
              Non-Patent Citations (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      BARDIA A. et al., Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552), DOI: 10.1158/1538-7445.SABCS14-P5-19-27
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      BARDIA A. et al., Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552), DOI: 10.1158/1538-7445.SABCS14-P5-19-27. GOLDENBERG D. M. et al., Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC), Oncotarget, 2015,Vol. 6, No. 26, P. 22496-22512.
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      GOLDENBERG D. M. et al., Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC), Oncotarget, 2015,Vol. 6, No. 26, P. 22496-22512.
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (26)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11052081B2/en"><a id="link" href="#" class="style-scope state-modifier">US11052081B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2021-07-06</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3470087A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3470087A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-02-13</span>
                    <span class="td style-scope patent-result">2019-04-17</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Lyophilised compositions of immunoconjugates with an intracellularly-cleavable linkage 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210393617A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210393617A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2021-12-23</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (immu-132) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9492566B2/en"><a id="link" href="#" class="style-scope state-modifier">US9492566B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2016-11-15</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10744129B2/en"><a id="link" href="#" class="style-scope state-modifier">US10744129B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2020-08-18</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016057398A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016057398A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-07</span>
                    <span class="td style-scope patent-result">2016-04-14</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Neoadjuvant use of antibody-drug conjugates 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10195175B2/en"><a id="link" href="#" class="style-scope state-modifier">US10195175B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-25</span>
                    <span class="td style-scope patent-result">2019-02-05</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2017257254B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2017257254B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-04-27</span>
                    <span class="td style-scope patent-result">2022-02-24</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20200110377A/en"><a id="link" href="#" class="style-scope state-modifier">KR20200110377A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-01-12</span>
                    <span class="td style-scope patent-result">2020-09-23</span>
                    <span class="td style-scope patent-result"> </span>
                    <span class="td style-scope patent-result">
  Protocol for minimizing the toxicity of combination doses and contrast agents for validation
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN111542324B/en"><a id="link" href="#" class="style-scope state-modifier">CN111542324B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-02-11</span>
                    <span class="td style-scope patent-result">2023-09-12</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Cytotoxic agent and conjugate thereof, preparation method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202016148A/en"><a id="link" href="#" class="style-scope state-modifier">TW202016148A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-07-09</span>
                    <span class="td style-scope patent-result">2020-05-01</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Antibodies specific to trophoblast antigen 2 (trop2) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11219689B2/en"><a id="link" href="#" class="style-scope state-modifier">US11219689B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-16</span>
                    <span class="td style-scope patent-result">2022-01-11</span>
                    <span class="td style-scope patent-result">Tae Life Sciences, Llc</span>
                    <span class="td style-scope patent-result">Boron enriched linker (BEL) compositions for boron neutron capture therapy and methods thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN111001012A/en"><a id="link" href="#" class="style-scope state-modifier">CN111001012A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-19</span>
                    <span class="td style-scope patent-result">2020-04-14</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Hydrophilic carbonate type antibody coupling drug 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210393791A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210393791A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-10-31</span>
                    <span class="td style-scope patent-result">2021-12-23</span>
                    <span class="td style-scope patent-result">Health Research, Inc.</span>
                    <span class="td style-scope patent-result">Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2021015802A/en"><a id="link" href="#" class="style-scope state-modifier">MX2021015802A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-06-27</span>
                    <span class="td style-scope patent-result">2022-04-01</span>
                    <span class="td style-scope patent-result">Etherna Immunotherapies Nv</span>
                    <span class="td style-scope patent-result">Combination therapy. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2705257C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2705257C2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-07-12</span>
                    <span class="td style-scope patent-result">2019-11-06</span>
                    <span class="td style-scope patent-result">    "    "     ( " "  )</span>
                    <span class="td style-scope patent-result">Method for assessing the effectiveness of the neoadjuvant chemoradiotherapy in patients suffering rectal cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN110639025B/en"><a id="link" href="#" class="style-scope state-modifier">CN110639025B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-10-15</span>
                    <span class="td style-scope patent-result">2021-11-09</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Polyamide-imide drug-loaded nanoparticle and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2020395181A1/en"><a id="link" href="#" class="style-scope state-modifier">AU2020395181A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-05</span>
                    <span class="td style-scope patent-result">2022-06-30</span>
                    <span class="td style-scope patent-result">Imaginab, Inc.</span>
                    <span class="td style-scope patent-result">Methods of imaging using multiple imaging agents 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN114901694A/en"><a id="link" href="#" class="style-scope state-modifier">CN114901694A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-12-31</span>
                    <span class="td style-scope patent-result">2022-08-12</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">anti-TROP 2 antibodies, antibody-drug conjugates, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021143741A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2021143741A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-01-15</span>
                    <span class="td style-scope patent-result">2021-07-22</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Targeting polypeptide-drug conjugate and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210316003A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210316003A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-03-20</span>
                    <span class="td style-scope patent-result">2021-10-14</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Biomarkers for sacituzumab govitecan therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN115667290A/en"><a id="link" href="#" class="style-scope state-modifier">CN115667290A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-05-12</span>
                    <span class="td style-scope patent-result">2023-01-31</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Novel IL10 agonists and methods of use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/IT202000031838A1/en"><a id="link" href="#" class="style-scope state-modifier">IT202000031838A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-12-22</span>
                    <span class="td style-scope patent-result">2022-06-22</span>
                    <span class="td style-scope patent-result">Saverio Alberti</span>
                    <span class="td style-scope patent-result">
  PLATFORM FOR OBTAINING MONOCLONAL ANTIBODIES DIRECTED AGAINST TUMOR-SPECIFIC PROCESSED ANTIGENS
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023060283A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2023060283A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-08</span>
                    <span class="td style-scope patent-result">2023-04-13</span>
                    <span class="td style-scope patent-result">Board Of Regents, The University Of Texas System</span>
                    <span class="td style-scope patent-result">Anti-trop2 antibody combination therapies and methods of use thereof 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023232745A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2023232745A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-05-30</span>
                    <span class="td style-scope patent-result">2023-12-07</span>
                    <span class="td style-scope patent-result">Mediterranea Theranostic S.R.L.</span>
                    <span class="td style-scope patent-result">Anti-idiotype antibodies and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116621927B/en"><a id="link" href="#" class="style-scope state-modifier">CN116621927B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-01-09</span>
                    <span class="td style-scope patent-result">2024-03-26</span>
                    <span class="td style-scope patent-result"></span>
                    <span class="td style-scope patent-result">Antibody coupling intermediate with irinotecan and C-lock fixed-point coupling group, coupling method and antibody coupling drug 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner,  Cited by third party,  Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2725292C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2725292C2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-30</span>
                    <span class="td style-scope patent-result">Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10954305B2/en"><a id="link" href="#" class="style-scope state-modifier">US10954305B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-03-23</span>
                    <span class="td style-scope patent-result">Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10918734B2/en"><a id="link" href="#" class="style-scope state-modifier">US10918734B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-16</span>
                    <span class="td style-scope patent-result">Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210046185A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210046185A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-18</span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2953441T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2953441T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-11-13</span>
                    <span class="td style-scope patent-result">
  Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10744129B2/en"><a id="link" href="#" class="style-scope state-modifier">US10744129B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-08-18</span>
                    <span class="td style-scope patent-result">Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9707302B2/en"><a id="link" href="#" class="style-scope state-modifier">US9707302B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-07-18</span>
                    <span class="td style-scope patent-result">Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP7188837B2/en"><a id="link" href="#" class="style-scope state-modifier">JP7188837B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-12-13</span>
                    <span class="td style-scope patent-result">
  Therapy of small cell lung cancer (SCLC) with a topoisomerase-I inhibitory antibody-drug conjugate (ADC) targeting TROP-2
 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20240148873A1/en"><a id="link" href="#" class="style-scope state-modifier">US20240148873A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-05-09</span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11253606B2/en"><a id="link" href="#" class="style-scope state-modifier">US11253606B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-02-22</span>
                    <span class="td style-scope patent-result">Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US201662328289P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2016-04-27</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US62/328,289<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2016-04-27</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2017189279A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2017/028137</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-04-18</span>
                    <span class="td style-scope patent-result">Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3998854552" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.3998854552" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=412674892" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>